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ABSTRACT 
 
The pharmaceutical business is driven by innovation and new technologies. In order to improve 
the overall efficiency, the modern R&D organisations nowadays have integrated problem-solving 
techniques in their innovation process. This thesis aims to explore and analyse the application of 
TRIZ technique in the problem-solving process in the medical device sector of the pharmaceutical 
industry. 
The findings of the literature review indicate that TRIZ can effectively guide the problem-finding 
process with a tool kit that can recognise patterns and regularities based on the past solutions in a 
knowledgebase. The results suggest that such systematic approach is more effective than the 
conventional methods of trial-and-error. 
This study conducted a survey amongst the innovative medical device departments of various 
pharmaceutical companies in the Rhine-Main region in Germany and provided contemporary data 
on the application of problem-solving tools, especially TRIZ, in those institutions. As a result, the 
survey data also delivered some possible criteria for technical solutions of medical devices which 
were subsequently discussed and finalised with a group of experienced experts (expert panel). 
The next step of the study was organised as a 2x2 experiment. During the experiments, two groups 
of experienced practitioners were asked to improve the design of two sample medical devices, 
alternatively using TRIZ and brainstorming. The efficacy of TRIZ application was analysed both 
in terms of the quality of the technical solutions and that of the group work. The SYMLOG 
Adjective Rating Form method initiated by Bales was used for the assessment of the group work. 
The results of the experiment indicate that the impact of the problem-solving tools is influenced 
by the type of innovation problem. For the analysis of such influences, this research makes a 
contribution to knowledge by proposing a 2-dimensional framework to capture the problem types. 
In addition, a TRIZ procedure for the technical innovations of medical devices was developed 
based on the model of Su et al.  
Due to the sensitive protection of intellectual property in the pharmaceutical industry, field studies 
of R&D processes in large pharmaceutical firms are limited in the public literature. This work 
provides valuable insights into this business sector, especially in respect of application of 
problem-solving tools and how those tools may potentially improve the outcomes of the R&D 
activities in the pharmaceutical industry.  
Keywords: TRIZ, pharmaceutical industry, innovation, medical device, group work, SYMLOG  
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ABREVIATIONS 
 
AAI  Adrenaline Auto-Injector 
API  Active pharmaceutical ingredient 
ARIZ  aлгоритм решения изобретательских задач [Russian: algorithm of 
inventive problems solving] 
B  Backward (dimension in SYMLOG Adjective Rating Form) 
BECM  Being, Engaging, Contextualizing and Managing 
BLA  Biologics License Application 
bn   Billion 
BSRI  Bem Sex Role Inventory 
C  Control 
CAD  Computer-Aided Design 
CEO  Chief Executive Officer 
COCB  Company-Sponsored Online Co-Creation Brainstorming 
D  Downward (dimension in SYMLOG Adjective Rating Form) 
DMAIC Define Measure Analyse Improve Control 
EMA  European Medicines Agency 
ER  External Rater 
F  Forward (dimension in SYMLOG Adjective Rating Form) 
FDA   Food and Drug Administration 
GCMS  Gas Chromatography Mass Spectrometry 
IP  Intellectual Property 
IR  Internal Rater 
LCMS  Liquid Chromatography Mass Spectrometry 
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NFC  Near Field Communication 
OTC  Over the counter 
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QR  Quick Response  
R  Rater 
R&D  Research and Development 
RQ  Research Question 
SME  Small and Medium-sized Enterprises 
SYMLOG System for the Multiple Level Observation of Groups 
T  Test 
TRIZ  теория решения изобретательских задач [Russian: Theory of inventive 
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1. Introduction    
1.1 Research background 
In late 1990s and early 2000s, the trend in the pharmaceutical market was the shift from 
small molecules to biological drugs with the development of erythropoietin and 
monoclonal antibodies. Monoclonal antibodies were a new class of biological medicines, 
manufactured from living organisms. These liquids monoclonal antibodies are often 
designed to be self-administered by the patients (Fox, 2010).  
 
A new type of products, the combination of a drug and a single-use disposable medical 
device “auto-injector” supported the development of a new market for the pharmaceutical 
industry (Datamonitor, 2010). One of the best sold auto-injectors in the world with 
Humira (Adalimumab) monoclonal antibody as combination products made a turnover of 
US$9.3 bn. in 2012 (King, 2013). In early 2000s, the market researchers found the new 
drug Lantus (insulin glargine) for the treatment of diabetes Types I and II less promising. 
After the drug was launched as a combination product with the new Solostar injection 
system, the added patient convenience facilitates the steady sales growth of Lantus year 
by year. Richter estimated that more than 30% of all submissions to the FDA in the next 
years would be self-injected drugs via needle system (Richter, 2011). 
 
The development of auto-injectors is a complex task and depends on the knowledge of 
biochemistry and pre-filled syringes or cartridges with mechanical engineering-driven 
plastic components (Datamonitor, 2010). In addition, the successful design of an auto-
injector also requires a good understanding of patient psychology. Hamilton highlighted 
that 10% of all US patients had a congenital needle phobia. To bypass this phobia, needle-
safe or needle-protected devices were developed for administration of monoclonal 
antibodies (Hamilton, 1995). A further challenge is that the patients’ preference for the 
combination products is difficult to predict. In the case of Amgen, a pioneer for 
combination products, the patients’ reactions towards the following products were totally 
different, although the same auto-injector design with comparable drugs was utilized for 
those devices (Amgen, 2013): 
- Enbrel Sureclick [1998]: still on the market  
- Aransep Sureclick [2001]: withdrawn in US [2011], in EU still available 
- Neulasta Sureclick [2002]: withdrawn worldwide [2006]    
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The physicochemical behaviours of the fluid drug with interaction of primary (cartridges 
and pre-filled syringes) and secondary packages (auto-injector systems) are only one 
example of the challenges for the technical innovation. In addition, it needs intensive 
investigation of the combination of formulated drug substance, pre-filled syringe/ 
cartridge and plastic component-based auto-injectors. 
 
The mechanical injection makes up only a fraction of the costs of the overall drug 
development programme which is obliged to elaborate biocompatibility tests, clinical 
trials with thousands of participants, marketing approvals and toxicology tests. However, 
a malfunction of the injection may cause an under-dosing of the patient and therefore 
jeopardise the patient’s health outcome. This work intends to contribute to the 
development process of auto-injectors. 
 
1.2 Research focus 
The pharmaceutical business is driven by innovation and new technologies. Although 
TRIZ is a well-known technique for innovative problem-solving, studies on TRIZ 
application for pharmaceutical research and development seem rare in the peer-reviewed 
publications. Thus, this thesis aims to explore and analyse the application of TRIZ 
techniques for the problem-solving process in R&D of medical devices in the 
pharmaceutical industry. 
 
TRIZ is the Russian abbreviation for теория решения изобретательских задач - theory 
of innovative problem solving (Ilevbare, Probert & Phaal, 2013). It is a problem-solving 
approach developed during the Cold War by the Russian engineer Altshuller (Altshuller, 
1999). The TRIZ techniques were designed to overcome the uncertainty of a solution by 
directing feasible ideas in an appropriate channel and identifying patterns of previous 
problems solutions of comparable technical issues (Altshuller, 1999).  
 
Over time, TRIZ methodology evolved to be adapted in non-technological sectors (Su, 
Lin & Chiang, 2008). Nowadays, the application of TRIZ covers a wide range of fields 
including e-commerce, service quality, healthcare and automotive engineering design, etc. 
(Su, Lin & Chiang, 2008; Altuntas & Yener, 2012; Gadd, 2011). Previous studies suggest 
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that the TRIZ problem-solving tools could also improve the innovation process for R&D 
in the pharmaceutical industry, e.g. for medical devices (Gadd, 2011). 
 
This work is planned to explore and analyse, by means of a case study, the use of TRIZ 
for the development of a medical device: the auto-injector. The term “auto-injector” is 
used to describe the medical device for the self-administered application of a drug. The 
idea of auto-injector was developed during the Cold War by the US Armed Forces. The 
first auto-injectors were designed as devices to administer antidotes against chemical 
weapons, especially against nerve gas (Landauer, 1977).  
 
During the case study, the participants made attempts to improve the design of two types 
of the well-known Epinephrine auto-injector (EpiPen) (Gallagher, Worth, Cunningham-
Burley & Sheikh, 2011) which was commonly used for drug delivery to allergy patients. 
Both the outputs and the process of the group work were traced and subsequently analysed 
to assess the contribution of the problem-solving tools to the technical innovations. 
1.3 Research aim 
The research aim of this research may be transformed into the following research 
questions and research objectives: 
 
Research questions 
RQ1: Which problem-solving tools are currently used for R&D of medical devices in 
the pharmaceutical industry? 
RQ2: How can TRIZ techniques be applied for medical device innovation?  
RQ3: How and why do TRIZ techniques differentiate themselves from other problem-
solving methods, from a theoretical perspective? 
 
Research objectives 
RO1: To capture the current status of the application of problem-solving tools used 
for R&D of medical devices in the pharmaceutical industry in the German Rhine-
Main region. 
RO2: To develop a TRIZ methodology for the practical use in the medical device 
innovation. 
RO3: To develop a theoretical understanding of how and why TRIZ influences 
problem-solving in groups. 
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To achieve the research objectives involves the following steps. 
 A survey of the current status of the application of problem-solving tools in the 
pharmaceutical medical device industry in the German Rhine-Main region; 
 To develop a TRIZ methodology for the practical use in the medical device 
innovation based on the results of a literature review; and 
 To conduct a field study on group work with problem-solving techniques 
including TRIZ. 
 
The field study in this research concentrates on the innovative design improvements of 
auto-injectors. The researcher does not raise the claim of developing an overall 
methodology for the innovation of all medical devices in class I, II and III according to 
the FDA classification. 
 
1.4 Organisation of the thesis 
This thesis is structured into eight parts.  
 
The first chapter consists of an introduction of the thesis, covering the research 
background and the research aim including the research questions and the research 
objectives.  
 
The second chapter focuses on a systematic literature review on application of problem-
solving techniques for innovative group work in the pharmaceutical industry, especially 
for the development of auto-injectors. The literature review delivers background 
information on the key concepts of this thesis, especially on how TRIZ may be tailored 
to guide the problem-finding process and how it can be applied to the present problems, 
as well as how group work and group behaviours are evaluated in the literature. 
 
Chapter 3 is dedicated to the methodology and methods of this research. This includes 
the philosophical perspective considered in this research, the research methodology, the 
methods for data collection and data assessment, the quality of the research design, the 
role of researcher and the ethical considerations and finally, the research schedule. 
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Chapter 4 provides a documentation of the survey study on the application of problem-
solving tools especially TRIZ for R&D of medical devices in the pharmaceutical industry 
in the German Rhine-Main region. The survey data also suggest assessment criteria for 
the technical solutions of medical devices. Subsequently, the proposed criteria are 
discussed and finalised with a group of experienced practitioners (expert panel).  
Next, chapter 5 focuses on the group work experiment aiming at improvement of auto-
injector design with problem-solving techniques. During the experiment, two groups of 
experienced practitioners are asked to improve the design of two sample medical devices, 
alternatively using TRIZ and a conventional problem-solving approach. Subsequently, 
the efficacy of TRIZ application is analysed both in terms of the quality of the technical 
solutions (the outputs) and that of the group work (the process). The SYMLOG Adjective 
Rating Form method initiated by Bales is used for the assessment of the group work. 
 
Next, chapter 6 highlights the results of the experiments sessions, as well as the analysis 
and interpretation of the findings. 
 
Subsequently, chapter 7 discusses the findings of the literature review, the survey study 
and the experiment in the previous chapters. It depicts the current usage of problem-
solving tools and the influence of TRIZ techniques on R&D activities for medical devices 
in the pharmaceutical industry and the implications of this study. 
 
Finally, conclusions for this research are drawn in chapter 8. 
 
This research intends to make a contribution to knowledge by capturing the current status 
of the problem-solving process in R&D of medical devices in the pharmaceutical industry 
and developing a theoretical framework for the influence of problem-solving tools on 
technical innovations in group work. In addition, it proposes a new assessment approach 
of group work as a combination of technical solutions and group behaviours.  
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2. Literature Review 
The literature review intends to provide background information on application of 
problem-solving techniques for innovations, especially for development of auto-injectors 
in the pharmaceutical environment. The review is divided in seven sections. Since the 
literature review in this chapter is organised as a systematic literature review, the 
characteristics of this type of literature review is introduced in some details in section 2.1. 
Next, section 2.2 explores previous researches on development and application of 
problem-solving techniques of TRIZ, followed by section 2.3 which is dedicated to auto-
injector development and section 2.4, to the technical characteristics of EpiPen. While 
section 2.5 summarises the literature findings on concurrent studies on group work, 
section 2.6 highlights the assessment methods of group behaviours in the academic 
research. Finally, section 2.7 depicts the application of SYMLOG as an assessment 
method for group work. 
2.1 Concept of systematic literature review 
 
The systematic literature review is a result of the evidence-based movement in the 1990s. 
This style of literature review is intended to improve the quality of the literature review 
process by increasing its performance in transparency and selection of the appropriate 
literature (Wolf, Shea & Albanese, 2001; Cook, Mulrow & Haynes, 1997; Tranfield, 
Denyer & Smart, 2003).  
 
Systematic reviews are often used for double-blinded clinical trials with the positivist 
research tradition in the pharmaceutical branch (Macdonald, 1999). According to Mulrow 
and Tranfield et al., healthcare authorities recommended systematic literature review for 
healthcare-related topics. This recommendation was also supported by the Cochrane 
Collaboration, as well as the National Institute for Clinical Excellence (Mulrow, 1994; 
Tranfield, Denyer & Smart, 2003).  
 
Based on the research tradition in the field of research-based pharmaceutical industry, as 
well as the researcher’s philosophical position, the literature review in this thesis was 
conducted in the manner of a systematic literature review.    
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Tranfield, Denyer and Smart conducted an in-depth analysis of literature reviews in which 
they compared the management-driven narrative with the evidence-driven systematic 
literature review (Tranfield, Denyer & Smart, 2003). Traditionally, management reviews 
are conducted in the narrative style. However, the narrative methodology is criticized for 
supporting indirect bias of the active researcher (Fink, 1998). The new path of a 
systematic literature review, on the other hand, enables relevant evidence with a clear 
synthesis of an existing summary of the investigated topic (Kitchenham, Brereton, Owen, 
Butcher & Jefferies, 2008).  
 
The systematic approaches in literature reviews in the pharmaceutical industry are driven 
by evidence-based medicine. In the 1980s, researchers in healthcare and medical science 
recognised that misinterpretation of the research journals and papers were often the cause 
of wrong recommendation of medical therapies. Such findings had an impact on the 
whole pharmaceutical industry. From the 1990s – 2000s, researchers in the 
pharmaceutical industry and medical science improved the quality of review methods by 
creating transparent, reproducible and systematic research procedures. Such evidence-
based processes were also essential, in order to provide best-in-class clinical trial reports 
by analysing the different population groups within API and placebo-armed studies. Since 
then, government-supported agencies like EMA and FDA demand to establish a more 
sophisticated systematic and scientific basis for literature reviews regarding clinical study 
evaluation. Nowadays, the systematic approach has become common practice in medical 
devices innovations (Wolf, Shea and Albanese, 2001; Becker Witkin, 1998; Tranfield, 
Denyer & Smart, 2003). 
 
The systematic review tool developed by Tranfield and his colleagues Denyer and Smart 
in the 2000s’ is a result of the evidence-based movement (Cook, Mulrow and Haynes, 
1997, Tranfield, Denyer & Smart, 2003). The key features of their approach may be 
described in three stages of the procedure: development of the search strategy, inclusion 
and exclusion criteria of studies, and finally, quality and synthesis appraisals.  
 
The systematic review in this thesis is conducted in the style as proposed by Tranfield, 
Denyer & Smart (2003). In order to increase the quality of the studies and outcomes, 
Tranfield, Denyer and Smart recommend a wider approach of management research 
which is similar as in biological medical science (Tranfield, Denyer & Smart, 2003). In 
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their opinion, this approach could help to minimize the biases of comments and reviews 
for sophisticated management research. The following is a comparison of the evidence-
based process for the biological medicine to the traditions of management research 
according to Tranfield, Denyer & Smart (2003) (see table 2-1). 
 
 Biological medicine Management 
Nature of study Convergent Divergent 
 
Aims of study Generally reducing illness and 
death; improving health 
Multiple and competing, while the 
balance between the competing goals 
may change over time 
 
Style of literature 
reviews 
Systematic review and meta-
analysis 
 
Largely narrative reviews 
Reporting and 
dissemination 
Standardised reporting structures 
used. No explanatory style 
adopted. Short scripts are made 
widely available through 
internationally recognized 
institutions. 
Comprehensive to experts. 
Non-standardised reporting structures. 
Interpretive long scripts. The explanatory 
power improved by using analogy, 
metaphor and homology. Process of 
knowledge generation omitted. 
Sometimes incomprehensive to experts 
due to lack of links between different 
literature sources. 
Evidence into 
practice 
Collaborative process and 
practice-oriented. 
Implementation of evidence is often an 
afterthought. 
Table 2-1:  Biological medical research vs. management research  
(according to Tranfield et al., 2003) 
 
By applying inclusion and exclusion criteria during data selection, Tranfield and his 
colleagues narrow down the available information to a feasible amount. However, this 
strategy also has weaknesses, as the applied inclusion /exclusion criteria have to be 
defined by the researcher as a subjective individual.  To improve this, Kitchenham et al. 
proposed the use of structured abstracts (Kitchenham, Brereton, Owen, Butcher & 
Jefferies, 2008). However, the length of abstracts is limited at certain publication agencies, 
therefore the use of structured abstracts is not always possible. Another weakness of the 
systematic literature review is the synthesis and quality standard of heterogeneous 
findings, when cause-and-effect relationships are to be established based on the data 
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findings (Sandelowski, Docherty & Emden, 1997; Popay, Rogers & Williams, 1998). 
Popay et al. proposed a qualitative assessment of the systematic reviews (Popay, Rogers 
& Williams, 1998). 
 
2.2 TRIZ 
In my practical experience as a coordinator in the R&D of medical devices, nowadays 
problem-solving tools are finding increasingly applications in the development of medical 
devices in the pharmaceutical industry. Among such techniques for the solution of 
inventive problems, TRIZ appears to be a unique instrument. While the traditional 
problem-solving techniques follow the trial-and-error path and are rather products of 
accidental circumstances, TRIZ takes a systematic approach and searches for solutions 
for present problems in the solutions of past problems by analysing the patterns of those 
solutions (Savranksy, 2000; Eversheim, 2009).  
 
The knowledge-based and systematic TRIZ methodology was reported to be effective in 
various business sectors in previous literature (Savranksy, 2000; Domb, Miller, MacGran 
& Slocum, 1998). However, literature on TRIZ application in the pharmaceutical industry 
still seems rare. Thus this thesis intends to explore how TRIZ influences the problem-
solving process for design improvement of medical devices in the pharmaceutical 
industry and subsequently, analyse the effects in depth. 
 
2.2.1 Research findings 
In their study on TRIZ, Ilevbare, Probert & Phaal described in detail the benefits and 
challenges of TRIZ applications in practice (Ilevbare, Probert & Phaal, 2013). This 
journal provided a deep overview about TRIZ in terms of its general theory, as well as its 
instruments.  
 
TRIZ is the Russian abbreviation for теория решения изобретательских задач - theory 
of innovative problem solving (Ilevbare, Probert & Phaal, 2013). In the 1940s, the 
Russian scientist and patent specialist Altshuller and his colleagues created TRIZ to speed 
up the development of solutions to technical problems. The idea behind TRIZ was to 
analyse and interpret 400.000 patents for technology issues, in order to identify patterns 
and regularities among those solutions and in a next step, so as to use this knowledge to 
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develop new ideas and innovations in a tighter timeframe than with brainstorming 
(Ilevbare, Probert & Phaal, 2013). 
 
TRIZ is a methodology based on tools and techniques to mitigate problems. It is 
knowledge-based and systematic (Savranksy, 2000; Domb, Miller, MacGran & Slocum, 
1998). While traditionally, inventive problems are solved based on the thoughts that 
inventions and technology development are products of accidental circumstances, 
Altshuller believes that there is a systematic approach to discover rules in solution-related 
thinking which may be utilized to solve contradictions and subsequently, to develop new 
ideas (Savranksy, 2000; Eversheim, 2009). 
 
While the conventional problem solving methods e.g. brainstorming, meta plan 
techniques and mind maps concentrate on the problems, TRIZ focuses on the root cause 
of the problem instead of the problem itself (Gadd, 2011). A central point in the TRIZ 
concept is the conceptual solution finding under application of inventive principles and 
general solutions (also known as standard solutions). The basic idea of TRIZ is to transfer 
a specific problem into a general problem. The general problem is to be solved with TRIZ 
tools and techniques (e.g. Nine Windows, 76 standard solution and contradiction matrix, 
etc.), in order to develop a standard solution. The standard solution can then be 
subsequently transferred into the specific solution. The following graphic demonstrates 
the different approaches of conventional problem-solving tools (e.g. brainstorming) and 
TRIZ (see Figure 2-1).  
 
 
Figure 2-1 Basic methodology of TRIZ (Ilevbare et al., 2013) 
 22 
 
With three concepts of parameters, Altshueller developed his TRIZ tools and techniques 
(Ilevbare, Probert & Phaal, 2013). Those concepts which distinguish TRIZ from other 
problem-solving tools are: 
 Contradiction 
 Ideality 
 Patterns of evolution of systems 
 
There are two different types of contradictions: a) technical contradictions and b) 
physical contradictions.  
A contradiction is related to the innovation process, when one system function which 
needs to be changed correlates with another. The following are some examples of such 
contradictions: 
- a) Improvement of speed (bigger engine  higher weight) 
- a) Sophisticated small device (more electronics  higher weight) 
- b) Size of umbrella (large protection volume  pocket size) 
- b) Handling of a small device (bigger device  pocket size)  
(Ilevbare, Probert & Phaal, 2013) 
Ideality derives from the term “the ideal machine” which is the target of the evolution 
steps (Altshuller, 1999). Altshuller defines ideality as the ideal final result if the system 
is guided into the direction which is considered ideal (Altshuller, 1999).  Mathematically, 
ideality is described as: 
 
𝐼𝑑𝑒𝑎𝑙 𝑓𝑖𝑛𝑎𝑙 𝑟𝑒𝑠𝑢𝑙𝑡 =
∑ 𝐵𝑒𝑛𝑒𝑓𝑖𝑡𝑠
∑ 𝐶𝑜𝑠𝑡𝑠 + ∑ 𝐻𝑎𝑟𝑚𝑠
 
 
  Benefit…..Useful system functions 
  Costs…….Input (e.g. design input requirements for medical devices) 
  Harms……Unwanted outputs, waste products (side products)  
(Ilevbare, Probert & Phaal, 2013).   
 
In Altshuller’s opinion, all inventions follow certain rules and the majority of all solutions 
the mankind is looking for already exist as world knowledge (Altshuller, 1999). The rules 
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may be translated into patterns of evolution (Altshuller, 1999). Later on, Gadd defined 8 
trends of development that were further divided into lines of evolution (Gadd, 2011). 
 
Furthermore, Altshullers developed specific TRIZ tools and techniques for his 3 concepts. 
Among all tools and techniques developed between 1946 and 2008, Ilevbare et al. regard 
the following ones as the most useful: 
- 40 Inventive principles 
- 76 Standard solutions 
- Separation Principles 
- Nine windows 
- Substance field analysis  
(Ilevbare, Probert & Phaal, 2013).   
 
However, some authors criticised Altshuller for not providing enough details for the TRIZ 
applications in practice, e.g. there was neither clear classification of the TRIZ tools, nor 
a specific sequence for the application of the tools (Eversheim, 2009). The explanations 
of the lists of improving and worsening features were too brief for a good understanding 
of the application of the contradiction matrix (Domb, Miller, MacGran & Slocum, 1998). 
To fill the above gaps, Zlotin et al. made efforts to categorise all TRIZ tools and 
subsequently divided them in 3 groups: analytical, knowledge-based and psychological 
tools (Zlotin et al., 2000). While analytical tools were used to describe the problem, 
knowledge-based tools could be selected for system transformation for the solution of the 
general problem. Psychological tools were defined as those which facilitate the overall 
process (Zlotin et al., 2000). 
 
Alternatively, Moehrle classified the tools according to the five fields of application in 
the problem solving process. Those were: current state, intended state, goals, 
transformation, resource analysis (Moehrle, 2005a). 
 
In spite of its popularity, TRIZ is not the only systematic problem solving methodology. 
In their essay, Kim & Cochran compared TRIZ with Axiomatic Design, another 
systematic problem solving approach developed by Suh and colleagues at Massachusetts 
Institute of Technology in the United States (Kim & Cochran, 2000). Although both 
concepts were developed independently from each other, Kim and Cochran discovered a 
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congruence relationship between some elements of both methodologies (Kim & Cochran, 
2000).  
 
In some business sectors, TRIZ application led to effective creation and improvement of 
new products in the past, successfully replacing the conventional trial-and-error method 
(Ishida, 2003; Su, Lin & Chiang, 2008). Below are some examples of such TRIZ 
implementations in the practice. 
   
Skakun et al. described how TRIZ improved the design of chemical pumps at minimal 
operating costs for a petroleum company (Skakun, Martsinkovskaya & Skirdachenko, 
2003). 
 
Moehrle & Lessing (2004) used the classical TRIZ applications as a support for the 
strategic management. Focusing on the profiling of technological competencies, they 
developed a 5-step TRIZ process, combining a patent database with 40 inventive 
principles approach (Moehrle & Lessing, 2004). The application of their TRIZ process in 
a leading German company led to positive results (Moehrle & Lessing, 2004). 
 
Sheu and Lee (2011) compared the systematic with the non-systematic approaches in 
innovation process. TRIZ was identified as a one of the leading systematic approaches. 
While the systematic approaches narrow down the path of solutions by using problem 
solving techniques and/or identifying opportunities, the conventional non-systematic 
tools (e.g. trial-and-error experiments or brainstorming) depend largely on coincidence 
(Sheu & Lee, 2011). Sheu & Lee described the advantages of TRIZ technique with 
practical examples and concluded that “…although innovation may be accidental, 
systematic innovation is destined” (Sheu & Lee, 2011). However, Sheu & Lee also 
pointed out that more efforts needed to be made for the application of systematic 
innovation tools like TRIZ, because the adaption required more training than 
brainstorming or other non-systematic approaches (Sheu & Lee, 2011). 
 
Liu, Wu & Hong illustrated the specific process of applying the contradiction matrix for 
the development of a balanced sailboat patent (Liu, Wu & Hong, 2010). 
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Sun & Tan vividly described a further story of successful TRIZ application in the 
disruptive innovation process (Sun & Tan, 2012). The disruptive innovation with TRIZ 
tools helped the company Sony in the design of a new type of video games. Their final 
result was the evolution of Play Station 2 (with control sticks) to an easy-to-use (with 
movement detection devices) and cost efficient game console: the Play Station 3 (Sun & 
Tan, 2012). 
 
Liou & Chen proposed a TRIZ approach for TeamSpirit, a web-based group decision 
supported tool (Liou & Chen, 2011). The authors found out that TRIZ had many 
advantages compared to the traditional creativity tools like brainstorming or mind maps 
(Liou & Chen, 2011). While the traditional techniques were restricted to the internal 
knowledge base of the company, the university or the internal think tank, TRIZ benefited 
additionally from the external knowledge base (Liou & Chen, 2011). That means, if a 
comparable problem to the described inventive problem was solved before, TRIZ would 
study the solution(s) to determine solution patterns (Liou & Chen, 2011). However, the 
translation process of the general or generic solution into the specific solution to the 
predefined problem still needed improvements (Liou & Chen, 2011). During the design 
process of TeamSpirit, TRIZ proved to be helpful in overcoming psychological barriers 
in the inventive product design (Liou & Chen, 2011). 
 
Also the company Rolls-Royce achieved substantial improvement of design process with 
TRIZ methodology (Knott, 2001). Knott demonstrated how TRIZ reduced time and costs 
in the design process. In addition, TRIZ helped the company to reduce fuel consumption, 
which in turn increased business opportunities in the Aero Engine industry (Knott, 2001). 
For his case study, Knott used the method of semi-structured interviews which led to 
interesting insights of TRIZ applications in practice (Knott, 2001). Therefore, this method 
is integrated in the case study of this thesis. 
 
Cascini & Rissone reported improved creativity and efficiency for plastic design by 
integrating TRIZ and semantic knowledge portals (Cascini & Rissone, 2004). However, 
they provided no measurements for the improvements. 
 
Moehrle & Wenzke demonstrated how TRIZ could be especially helpful at problem 
analysis, the starting point for R&D processes that were often neglected in practice 
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(Moehrle & Wenzke, 2006). In the experiments, Moehrle & Wenzke considered the 
important aspect of team management. However, their study focused alone on the 
outcomes of the group work and did not address the process itself (Moehrle & Wenzke, 
2006). 
 
Mao et al. discussed the critical phase of creativity to enhance the value of engineering. 
In a case study, they compared the outcomes of problem-solving process with TRIZ and 
the alternative brainstorming method. Their findings suggested that TRIZ led to better 
results in a more efficient way (Mao, Zhang & Abourizk, 2009). 
 
Hentschel found out, innovative ideas often did not lead to successful new products in the 
past, mainly due to the weak link between the new ideas and the practical requirements 
on new products. The systematic of TRIZ, on the contrary, helped the designers to become 
aware of the precise problem to solve and the available resources, therefore enhanced 
technical breakthroughs (Hentschel, 2009). 
Based on a survey study, Belski found out that TRIZ improved the students’ problem 
solving abilities (Belski, 2009). However, the survey study was based on self-assessment 
of the students. Such self-assessments are influenced by the subjective perceptions of the 
participants, causing biases in the statistics. This may be seen as a weakness of the study. 
 
Birdi et al. explored the impact of TRIZ creativity training in a field study (Birdi, Leach 
& Magadley, 2012). The authors analysed the effect of TRIZ trainings by a survey study 
among the participated employees. Their findings indicated that the motivation and the 
creativity in generating new ideas were higher among the employees after the 
participation at the TRIZ training (Birdi, Leach & Magadley, 2012). Like Belski (2009), 
Birdi et al. constructed their survey study based on the self-assessment of the employees, 
thus their research contained a similar weakness of biases of the participants. 
 
TRIZ methodology seems to be not only suitable for big-scale business, but also for small- 
and medium-sized enterprises (SMEs). Bianchi et al. illustrated how TRIZ methodology 
could be integrated in the innovation process of SMEs with limited resources (Bianchi, 
Campodall'Orto, Frattini & Paolo, 2010). 
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The previous literature suggests that each business sector has its specific requirements for 
TRIZ applications, e.g. the choice of TRIZ tools. As the pharmaceutical industry has 
already begun to focus on the combination production market, the improvement of 
engineering problem solving tools for such products is gaining more importance by the 
day. The design of the combination products involves the study of technical and 
biological influence parameters and the interplay of different forces. So far, the TRIZ 
applications for medical device design in the pharmaceutical industry have not yet been 
dealt with. Thus, one aim of this thesis is to develop a guideline for TRIZ application in 
this business sector.  
 
Based on a cluster analysis on more than 40 reported applications of TRIZ in practice, 
Moehrle recognized that while the 39x39 contradiction matrix and the 40 inventive 
principles were often used, engineers and natural scientists were less familiar with the 
other TRIZ tools (Moehrle, 2005b). He concluded that the whole set of TRIZ tools were 
not always necessary to solve the individual inventive problems. Moehrle’s 
recommendation to TRIZ users was to start with a basic TRIZ set and to move later on to 
the more complex resources and ideality-based or substance-based TRIZ tools after more 
experience was obtained (Moehrle, 2005b).  
 
Ilevbare et al. conducted a web-based survey to explore practical insights of TRIZ 
techniques and tool kits (Ilevbare, Probert & Phaal, 2013). The questionnaire used by 40 
participants focused on the specific fields of application, innovation drivers, technology 
and management of businesses. The main outcome of their study was the 
recommendation to reduce complexity, to increase awareness of communication and 
finally to create a more standard usage, so as to optimise the effect of TRIZ techniques 
(Ilevbare, Probert & Phaal, 2013).  
 
Researchers also proposed further developments of the TRIZ techniques. For example, 
Wang et al. combined Althuller’s tools with text mining to identify R&D trends from 
patent documents (Wang, Chang & Kao, 2010). Unlike the majority of the TRIZ 
researchers, Wang et al. did not focus on the contraction matrix. Their research indicated 
that the combination of the evolution patterns of TRIZ and text mining to extract 
technology trends was more efficient than TRIZ in its classic form (Wang, Chang & Kao, 
2010). Vincent et al. proposed a standardised knowledgebase for applications in the 
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biological sector. For this purpose, the international research team provided a patent 
database of biological functions from cell organelle to other biological effects to facilitate 
the use of contradiction matrix (Vincent, Bogatyreva, Pahl, Bogatyrev & Bowyer, 2005). 
Mann discussed how generic matrices could be developed based on a systematic 
programme of patent- and science-based database (Mann, 2005). In order to deal with the 
perceived complexity of TRIZ, some researchers developed further variations of the 
classic form of this methodology. One of such solutions is Advanced Systematic 
Inventive Thinking (Reich, Hatchuel, Shai & Subrahmanian, 2012). 
 
In time, TRIZ was further developed for broader application fields. Researchers adapted 
the TRIZ methodology to non-technological sectors, especially to the service sector (Su, 
Lin & Chiang, 2008; Zhang, Chai & Tan, 2005).  
 
Su et al. developed a TRIZ approach to improve the service quality (Su, Lin & Chiang, 
2008). In addition to the traditional TRIZ process, Su et al. proposed a parameter 
corresponding table which improved the application of contradiction matrix for solutions 
of service problems. Their approach was also adapted by Altuntas & Yener for the 
improvement of healthcare service (Altuntas & Yener, 2012) and by Akay et al. for the 
solution of human factors problems (Akay, Demiray & Kurt, 2008).  
 
Su et al.’s concept was based on a decision tree with 8 stages, including definition of the 
scope of problem, extraction of relevant determinates, development of parameters to 
match the 39 TRIZ contradictions, generation of a feasible solution with support of the 
40 inventive principles linked to the TRIZ parameters and the development of parameters 
criteria (Su, Lin & Chiang, 2008). 
 
TRIZ methodology was adapted for technology forecasting (Slocum & Lundberg, 2001). 
Forecasting a new technology used to take an emotional path in the past. With help of the 
TRIZ methodology, the results based on empirical databases appear more reliable and 
efficient (Slocum & Lundberg, 2001). 
 
Mueller comprehended TRIZ as a framework for the strategic management (Mueller, 
2005). Her management framework was established based on the six categories of TRIZ 
resource tools (Mueller, 2005). 
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Researchers also proposed to improve ergonomics in the agricultural sector by means of 
TRIZ contradiction matrix (Tosetto & Camarotto, 2012). 
 
Beyond the classical process flow, Glaser & Miecznik developed a reverse inventing 
flowchart based on TRIZ to overcome the classical lacks of market research. Their reverse 
inventing process based on TRIZ consists of the steps of situation analysis, abstraction of 
strengths, transformation into searchable queries, comparison with existing knowledge 
bases and evaluation of obtained results (Glaser & Miecznik, 2009). The process was 
successfully tested in a marketing case study for the medical facilities for limb 
prolongations (Glaser & Miecznik, 2009). 
 
Another trend of TRIZ researches was the combination of TRIZ with other management 
tools, e.g. Six Sigma and Lean Manufacturing. Feo & Bar-El came up with an innovative 
design method for Six Sigma. Combining Six Sigma and TRIZ ideality, their solution 
was developed to ensure that new products were created efficiently and at the same time 
met Six Sigma and marketing requirements (De Feo & Bar-El, 2002). 
 
Hipple argued that since the conventional management tools mainly dealt with the 
problem identification in the business process, the enterprises might benefit greatly from 
combining those tools with the problem-solving TRIZ tools. He suggested integrating 
TRIZ tests in the psychological assessment tools for the employee career development 
(Hipple, 2005).  
 
Brad et al. applied the TRIZ tools in the improvement stage of the DMAIC cycle in a 
knowledge management software platform. The researchers used the terminology of 
enhanced sigma-TRIZ to describe the combination of the DMAIC and TRIZ 
methodology (Brad et al., 2009).  
 
Although Six Sigma and TRIZ were both primarily methodologies used for technical 
optimisation in manufacturing sectors, Wang & Chen explored the integration of TRIZ 
methodology in a Lean Six Sigma solution to improve banking services (Wang & Chen, 
2010). Lean Six Sigma was a popular methodology for improvements of business 
opportunities in the aspects of customer satisfaction, costs and process speed for 
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manufacturing (Wang & Chen, 2010). The authors first established a DMAIC Model 
(Define, Measure, Analyse, Improve, Control) for the service industry and subsequently, 
used TRIZ methodology to enhance the traditional Lean Six Sigma techniques (Wang & 
Chen, 2010). The results of their analysis indicated that TRIZ methodology improved the 
effectiveness of the Lean Six Sigma system (Wang & Chen, 2010).  
 
Shirewalker and Okudan (2007) demonstrated the combination of TRIZ and Axiomatic 
Design in the engineering design process in a case study by embedding TRIZ in an 
Axiomatic Design framework (Shirewalker & Okudan, 2007). 
2.2.2  Summary 
TRIZ is a unique knowledge-based problem solving approach (Ilevbare, Probert & Phaal, 
2013; Savranksy, 2000; Domb, Miller, MacGran & Slocum, 1998). While the 
conventional problem solving methods focus on specific solutions for the generic 
problems, TRIZ focuses on the root cause of the problem instead of the problem itself 
(Gadd, 2011). TRIZ transfers a specific problem into a general problem, solves the 
general problem with a set of tools and techniques and subsequently, transfer the general 
solution into a specific solution (Ilevbare, Probert & Phaal, 2013; Gadd, 2011; Savranksy, 
2000).       
 
Over time, TRIZ has evolved to become more effective and overcome some shortages in 
its classic form (Zlotin et al., 2000; Moehrle, 2005a). In the last decades, TRIZ has been 
successfully implemented in various business sectors and proved its advantages compared 
with the conventional trial-and-error methods (Ishida, 2003; Su, Lin & Chiang, 2008; 
Belski, 2009). Previous studies indicate that TRIZ helps to increase the innovation 
efficiency and cost deduction (Knott, 2001).  
 
The current market development of the pharmaceutical industry shows that the 
combination products of liquid medication and injection device are gaining an increasing 
importance. Thus, more attention is paid to the engineering problems for such medical 
devices (auto-injectors). The design of the combination products involves the study of 
technical and biological influence parameters and the interplay of different forces. So far, 
it seems that the application of TRIZ for medical device design in the pharmaceutical 
industry has not yet been dealt with by the academics. Thus, this thesis aims to close this 
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research gap by developing a guideline for TRIZ application in pharmaceutical medical 
device business sector.   
 
Su et al. developed a TRIZ approach to improve the service quality and provided a 
comprehensive description of their TRIZ process (Su, Lin & Chiang, 2008). Later on, 
their approach was adapted by other researchers and led to positive results in further 
application fields (Altuntas & Yener, 2012; Akay, Demiray & Kurt, 2008). Therefore, the 
TRIZ experiments in this thesis is designed based on the framework of Su et al.’s solution, 
with some modifications to meet the requirements for the design tasks of medical devices 
in the pharmaceutical industry. One challenge for the application of a modified Su et al.’s 
framework for the design improvement of auto-injectors is the adaption of the eight stages, 
especially the mapping of requirements on the new combination products, e.g. customer 
satisfaction of EpiPen or quality guidelines with the TRIZ parameters.  
 
The literature review indicates that the majority of previous studies focused on the 
outcome of the applications when measuring the effect of TRIZ (Mao, Zhang & Abourizk, 
2009; Birdi, Leach & Magadley, 2012). For the evaluation of the outcomes, they 
sometimes solely relied on self-assessment of the participants which was influenced by 
the participants’ biases (Birdi, Leach & Magadley, 2012). One alternative method to 
capture the results of the problem solving process is the semi-structured interview as 
conducted by Knott for his study on a TRIZ project at the company Rolls-Roys (Knott, 
2001). This thesis also integrates the method of semi-structured interviews in the case 
study. 
 
However, in order to achieve the above advantages with TRIZ, elaborate prior trainings 
are necessary for a good command of the TRIZ instruments (Sheu & Lee, 2011). 
 
Although Moehrle & Wenzke recognized the importance of team management for the 
problem solving process, like the other researchers, their study focused alone on the 
outcomes of the group work and did not address the process itself (Moehrle & Wenzke, 
2006). This thesis intends to close this gap in research by exploring the group work during 
the problem solving process. 
 
 32 
2.3 Auto-injector  
2.3.1 Research findings  
The term auto-injector is used to describe the application of a drug with a self-
administering medical device as a drug/combination product. One of the well-known 
auto-injectors is the epinephrine auto-injector which is used against allergic reaction e.g. 
nuts, fish or insect stings (Gallagher, Worth, Cunningham-Burley & Sheikh, 2011). 
Gallagher et al. conduct a qualitative study to investigate the performance and the use of 
the auto-injector among teenagers in Scotland (Gallagher, Worth, Cunningham-Burley & 
Sheikh, 2011). In their in-depth interview and focus group study, 26 adolescents and 28 
parents were interviewed for the investigation of under-use of auto-injectors in an 
anaphylactic case. Gallagher et al. found out through their field study, most of the female 
teenager carried the device, but did not use it due to a lack of training or re-training after 
a certain time. Boys did not carry the device with them due to the bulky size of the auto-
injector and therefore would not be able to use the device in emergency cases.  
 
Subsequently, Gallagher et al. proposed an improvement of the organisation of training 
(Gallagher, Worth, Cunningham-Burley & Sheikh, 2011). Till now, needle-free 
demonstration devices are mainly used for patient trainings. However, a clinical study 
indicated that using demonstration devices might compromise the results of patient 
training and that the real devices should be used instead (Gallagher, Worth, Cunningham-
Burley & Sheikh, 2011).  
 
Hawkins et al. proposed a multi-dose auto-injector, similar to those currently provided to 
e.g. diabetes patients, for anaphylactic patients (Hawkins, Weil, Baty, Fitzpatrick & 
Rowell, 2013). However, unlike the diabetes patients who inject up to five times on a 
daily basis, the anaphylactic patients are likely to suffer from an allergic reaction not more 
than a few times in their whole life. Therefore, the concept of Hawkins et al. might still 
need some rethinking to better fit the disease patterns (Hawkins, Weil, Baty, Fitzpatrick 
& Rowell, 2013). 
 
Stecher et al. conducted a study on the needle length of the Epinephrine auto-injector. 
Auto-injectors are designed to administer the formulated drug substance subcutaneously 
(Stecher, Bulloch, Sales, Schaefer & Keahey, 2009). New studies implied that an intra-
muscular injection was faster in reaching the peak in plasma concentration than via 
 33 
subcutaneous injection (Stecher, Bulloch, Sales, Schaefer & Keahey, 2009). Stecher et al. 
conducted an empirical study with the participation of 256 children. The descriptive 
statistics and the regression analyses indicated that the needle length of current auto-
injectors was not adequate to meet the requirements of recommended intra-muscular 
injections. Based on the empirical findings, Stecher et al. suggested extending the needle 
length of the auto-injectors for the administration of epinephrine (Stecher, Bulloch, Sales, 
Schaefer & Keahey, 2009).  
 
Another investigation on auto-injectors for adults and children was conducted in Israel as 
preparation for a new gulf war (Bentur et al., 2006). Benture et al. (2006) investigated the 
atropine auto-injector which was replaced in 1992 with a new device containing both 
substances atropine sulfate and trimedoxime. The results showed, easy understanding and 
simple handling of the self-injecting device, as well as adequate patient trainings, had 
induced a higher self-injecting rate during the Gulf War in 2003. 
 
According to Ramos et al.’s investigation (Ramos, Landy, Tepper, Wein & Schweizer, 
2013) of Alsuma auto-injector by Meridian Medical Technologies, a pre-assembled 
single-use auto-injector was preferred by 95% of the patients. The self-developed 
instruction for use was even preferred by 100% of the 63 recruited patients. According to 
the results of their study, the most essential features of an auto-injector were: ease of use, 
safety and efficacy (Ramos, Landy, Tepper, Wein & Schweizer, 2013). Such 
requirements could only be met with adequate design of the auto-injector and precise and 
simple instruction for use, so as to convince the patients and healthcare professionals to 
use an auto-injector in case of emergency or on a routine basis. In addition, a good 
solution for storage and disposal of the used items was thought to further improve the 
acceptance in the society (Ramos, Landy, Tepper, Wein & Schweizer, 2013). 
 
Despite a well-developed instruction of use, use errors take place from time to time. 
Greenberg and Rivello described in a toxicological journal the EpiPen’s use errors, 
especially injection into hands (Greenberg & Riviello, 2010). They concluded that demo 
devices could be helpful for nurses and medical staff (Greenberg & Riviello, 2010). 
However, trainings with real devices instead of a non-needle demonstration device might 
produce even more positive effects (Gallagher, Worth, Cunningham-Burley & Sheikh, 
2011). 
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Whyte pointed out in his article about the growing utilisation of auto-injectors the 
advantages of auto-injectors compared with pre-filled syringes: there were reportedly 
more than 1 million needle sticks of the syringes every year in the U.S., endorsing the 
request for a new needle protection device like the auto-injectors for routine injections 
(Whyte, 2010). The needle protection system of auto-injectors was designed to have 
hidden needle(s). Furthermore, a survey among patients who received injections on a 
regular basis showed the patients’ preference for injection at home alone instead of having 
to go to the hospital for each routine injection. The home injections could also reduce 
healthcare costs dramatically. In addition, an EU initiative with directive 89/391/EEC and 
2000/54/EC supported the change to a needle protecting medical device system. Currently, 
2/3 of all Biologicals in clinical developments were highly viscous drugs which needed a 
high mechanical force like designed for the auto-injectors to pass through the small needle. 
However, time and design improvements for a precise injection were still needed in order 
to convince the patients (Whyte, 2010). In his final conclusion, Whyte emphasized that 
auto-injectors would be chosen by healthcare professionals as new state of the art in the 
near future (Whyte, 2010). 
 
In spite of the widely accepted design of the EpiPen auto-injector, there were reports on 
random cases of accidental self-injections by the physicians during an allergic attack of 
the patients (Silverberg & Manoach, 2007). Therefore, reducing mechanically caused 
needle sticks was one of the tasks of design improvement of those devices.  
 
To reduce use errors, Sheikh et al. recommended improvements in the following aspects: 
 Healthcare professionals to be trained intensively as the connection between 
industrial manufacturers and patients; 
 Patients to be trained and coached on a regular basis to reduce knowledge gaps in 
extreme physiological situations like anaphylaxis; 
  To enlarge the public awareness of first aid activities with auto-injector 
treatments. 
(Sheikh, Simons, Barbour & Worth, 2012). 
 
Morris et al. conducted a study on measuring training potential and epinephrine stocking 
programme for school nurses in California (Morris, Baker, Belot & Ewards, 2011). 
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California’s law required schools to store EpiPens or equals at school offices and to train 
school nurses to handle the devices. Altogether, 173 school nurses participated at the 
survey designed to investigate the training level of auto-injector usage. The survey results 
showed an inadequate training level of the school nurses. Besides, 73% of the students 
were equipped with epinephrine devices other than EpiPen or no device at all by their 
parents. In case of emergency, those students might need to receive an injection from the 
nurses with an auto-injector they were not familiar with. In such cases, use errors were 
likely to increase (Morris, Baker, Belot & Ewards, 2011). 
 
Brandes et al. investigated bioequivalence of the needle-free systems Sumavel™ 
DosePro™ (needle-free) and the Imitrex STAT dose System (with needle) in a field study 
(Brandes et al., 2009). The results proved bioequivalence of injection in the thigh and the 
abdomen, but no bioequivalence of injection into the arm (Branders et al., 2009). This 
example indicated that pre-filled syringes, safety syringes, auto-injectors and needle-free 
application systems were not exchangeable without clinical trials. Changing method of 
action e.g. rectal gel application vs. an intra-muscular auto-injector would require 
additional clinical trials as well (Lamson et al., 2011). Currently, the research-based 
pharmaceutical industry is in preparation of new guidelines of the FDA which will 
strengthen the demand of usability studies. 
 
To mitigate patients’ different understandings of the auto-injector instruction, Smith 
suggested that a plain language be used to reduce use errors (Smith & Wallace, 2013). 
However, Smith & Wallace’s experiment was conducted in the laboratory, therefore yet 
needed further validation under real-world conditions.  
 
An investigation on practical use of auto-injectors was conducted by Moshiri et al. By 
analysing the effects of various types of auto-injectors, Moshiri et al. found Mark I to be 
the most effective device among all tested auto-injectors. Mark I was deployed as antidote 
against nerve gas agent, e.g. sarin, while a quick injection was considered critical for the 
survival of the patient in case of emergency (Moshiri, Darchini-Maragheh & Balali-Mood, 
2012). 
 
The first auto-injectors were developed by the US Army as antidotes for biological 
weapons (atropine and oximes). The US army arranged trainings on the use of auto-
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injectors for each military member. However, they soon recognised the necessity of 
trainings also for civilians, since incorrect use of medical devices with needles could lead 
to transmission of infectious deceases, e.g. hepatitis B etc. (Ekwueme, Weniger & Chen, 
2002).  
 
Besides the risks of contraction of hepatitis B and human immunodeficiency virus, 
Ekwueme et al. also explored the economic aspect of seven different injection devices in 
the mid-Africa (Ekwueme, Weniger & Chen, 2002). Although from an ethical standpoint, 
every possible step should be taken to prevent any avoidable infections, in order to protect 
the life of the patients and the healthcare workers, financial limitation often constitutes a 
confinement in the developing countries (Ekwueme, Weniger & Chen, 2002). Similarly, 
cost-saving was identified as the key reason that children in Turkey sometimes did not 
receive epinephrine auto-injector or the training which was supposed to facilitate the use 
of the device (Orhan et al., 2011). Orhan et al. (2011) analysed in a case study 10 years’ 
data of epinephrine application and they came to the conclusion, training and 
understanding the handling of auto-injectors was the critical point next to the financial 
costs of those devices for the developing countries. 
 
To enhance better understanding and conscience of auto-injector trainings and the 
training methodology, Litarowsky et al. conducted a training session with inexperienced 
healthcare professionals by measuring their learning curves with self-prepared 
questionnaires (Litarowsky, Murphy & Canham, 2004). The researchers detected a 
positive correlation between the training material and an increased user performance. 
Their findings suggested that video material and the presentation used during the training 
program could reduce the misuse of the EpiPen auto-injector. However, like other similar 
studies, Litarowsky et al. did not provide any follow-up data on the participants’ 
performance after a certain period of time to show the effects of trainings under real-
world conditions and the sustainability of such trainings. 
 
In the current literature, most of the clinical trials with auto-injectors are hidden, probably 
due to concerns of the IP security of the researching business organisations (Oude 
Elberink, van der Heide, Guyatt & Dubois, 2009; Drent, Jakobsdottir, van Wijk, Oostdijk 
& Wit, 2002). Yet sharing findings of the empirical user studies like Drent’s group did 
would be very helpful in mitigating usability errors, so as to benefit the patients (Drent, 
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Jakobsdottir, van Wijk, Oostdijk & Wit, 2002). One useful finding Oude Elberink et al. 
shared with other researchers was that the patients performed better with the auto-
injectors if they were given the choice of the device (Oude Elberink, van der Heide, 
Guyatt & Dubois, 2009). From a practical point of view, it might be more efficient to 
analyse the patients’ needs by means of market researches prior to developing and testing 
the solutions in the clinical studies.  
 
Improved design of medical devices seems to be a key factor for better training results or 
better use of the devices. During an interview, Rylander, CEO of a new start-up company 
for medical devices, revealed his secret of success as understanding the needs of the 
patients by listening to them. Many patients requested the manufacturers to develop new 
glucagon emergency kits which were currently constructed as pre-filled syringes 
(Rylander, 2009). According to Rylander, it was also important to analyse the complaint 
rate of use errors and the errors on the device. In order to meet the patients’ requirements, 
Rylander’s new company combined the old-fashioned drugs in primary packs with newly 
designed secondary packaging (auto-injector) (Rylander, 2009). Also another author 
Renstorm took a similar approach and discussed the option to change primary package 
from glass to co-polymer based syringes (Renstrom, 2008).  
 
On the current market, only a few auto-injectors are easy to use thanks to their well-
developed simple design (Renstrom, 2008). Design improvements are necessary for the 
majority of the devices. A useful instrument for the generation of new ideas for the device 
design might be the problem-solving tool TRIZ. 
 
2.3.2 Summary  
The previous field studies indicated that auto-injectors were widely accepted by the 
patients and the pharmaceutical industry (Gallagher, Worth, Cunningham-Burley & 
Sheikh, 2011; Hawkins, Weil, Baty, Fitzpatrick & Rowell, 2013; Whyte, 2010). 
Compared with pre-filled syringes, the needle protection of auto-injectors was proven to 
be a great advantage in the practice (Whyte, 2010). However, the manufacturers 
understood that the application of such medical devices needed to be further improved 
(Rylander, 2009; Renstrom, 2008). 
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First, the empirical studies showed that certain features of the auto-injectors could cause 
the patients’ psychological declination of the devices (Gallagher, Worth, Cunningham-
Burley & Sheikh, 2011; Stecher, Bulloch, Sales, Schaefer & Keahey, 2009; Hawkins, 
Weil, Baty, Fitzpatrick & Rowell, 2013; Ramos, Landy, Tepper, Wein & Schweizer, 
2013). Therefore, the researchers proposed a number of improvements to the design of 
the existing auto-injectors, in order to encourage the patients to constantly carry the 
devices and to use them in case of emergency. For example, to reduce the bulky size of 
some existing models (Gallagher, Worth, Cunningham-Burley & Sheikh, 2011), to 
modify the needle length (Stecher, Bulloch, Sales, Schaefer & Keahey, 2009), or to design 
the auto-injectors to accommodate multi-doses (Hawkins, Weil, Baty, Fitzpatrick & 
Rowell, 2013). A survey study also showed that the majority of the patients preferred 
single-use auto-injectors to multiple-use devices (Ramos, Landy, Tepper, Wein & 
Schweizer, 2013).  
 
Second, there seems to be a consensus among the researchers that also the social 
acceptance of the auto-injectors greatly depends on the adequate device design, including 
simple instruction for use (Ramos, Landy, Tepper, Wein & Schweizer, 2013). Previous 
field studies clearly indicated that a device design which enabled easy handling of self-
injection could improve patient usage in the practice (Brandes et al., 2009). The assertion 
by Smith & Wallace based on laboratory experiments that plain language would reduce 
use errors of the auto-injectors (Smith & Wallace, 2013) yet needs to be validated in the 
practice.  
 
Third, the researchers related a great number of use errors to a deficiency in the patient 
training. The academics discovered the necessity for such trainings long ago, especially 
for the sake of prevention of contagious diseases (Ekwueme Weniger & Chen, 2002). 
Greenberg & Riviello proposed the use of demo devices for the training of the medical 
staff (Greenberg & Riviello, 2010). Other researchers claimed that the use of real devices 
would produce better training results (Gallagher, Worth, Cunningham-Burley & Sheikh, 
2011). Some empirical studies showed that professionally prepared trainings clearly 
improved the user performance (Litarowsky, Murphy & Canham, 2004). However, none 
of the researchers provided any follow-up information on the participants’ mid-term 
performance after the training, although the sustainable effect of the trainings would be 
of great interest in the practice. 
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Finally, cost level was identified as a key factor for the success of the auto-injectors at 
the market, especially in the developing countries (Orhan et al., 2011). Unfortunately, the 
profit concerns also hindered the device developers and manufacturers from exchanging 
their valuable experiences, so that they could retain their competitive advantages (Oude 
Elberink, van der Heide, Guyatt & Dubois, 2009; Drent, Jakobsdottir, van Wijk, Oostdijk 
& Wit, 2002). 
 
Satisfying the above competing objectives is a complex task. Currently, the researching 
firms of auto-injectors invest large spending on such tasks. In this work, the research shall 
test how problem-solving techniques may affect the results of such undertakings at the 
example of one specific problem-solving technique: TRIZ. 
 
The limited number of pertinent disseminations on auto-injectors indicates that there is a 
demand in this research field. This thesis therefore intends to make a contribution with an 
empirical study. 
2.4 EpiPen 
One example of auto-injectors is the Adrenaline Auto-Injector (AAI) for the emergency 
treatment of anaphylaxis. Anaphylaxis is an acute allergic reaction caused by the release 
of pro-inflammatory mediators from mast cells and basophils in response to an allergen 
that may cause death within very short time (Schwirtz & Seeger, 2012). 
 
EpiPen is one of the most popular AAIs at the global market (Hodges, Clack & Hodges, 
2005; Nguyen Luu et al., 2012). This implies that EpiPen designs are representative for 
this type of medical devices. Contrary to other alternative AAIs, there are numerous 
studies on EpiPens, probably due to its popularity and its long history in the market. In 
consideration of the above, this thesis chose two models of EpiPen for the experiment of 
design improvement with aid of the problem-solving techniques. 
2.4.1 Research findings 
Currently, the medical emergencies of anaphylaxis are commonly treated by adrenaline 
auto-injectors, e.g. the cartridge-based EpiPen (Schwirtz & Seeger, 2012). A longitudinal 
study in the UK indicated that such treatments substantially reduced the frequency and 
severity of further reactions (Ewan & Clark, 2005). 
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Sicherer et al. concluded based on a survey study that many patients were not able to 
administer the life-saving EpiPen correctly. Even some paediatricians were not familiar 
with the functions of the device. Therefore, Sicherer et al. recommended improvement of 
education for the parents and paediatricians on auto-injector use (Sicherer, Forman & 
Noone, 2000).  
 
After being contacted by three schools seeking advice on allergy management, a 
paediatric respiratory service in South Wales carried out an intensive investigation at the 
local schools. The study identified a deficiency in both diagnosis and treatment of severe 
allergy among the school children. In short term, the findings of this study promoted the 
collaborative working between healthcare professionals, school staff, children and their 
parents, including EpiPen training for the school children and their families (Hodges, 
Clack & Hodges, 2005). 
 
In Australia, 20% of the young school children who suffered from anaphylaxis – mainly 
food allergy – were treated with EpiPen (Sanagavarapu, 2012). Sanagavarapu highlighted 
the importance to offer face-to-face trainings to the parents of the young school children, 
as well as to the educators to achieve satisfactory effect in case of emergency treatment 
(Sanagavarapu, 2012).  
 
In Canada, two types of adrenaline auto-injectors were introduced to the market: Twinject 
and EpiPen (Nguyen Luu et al., 2012). Due to the limited uptake and the restrictions on 
applications by school personnel for Twinject, however, EpiPen was clearly favoured by 
the public (Nguyen Luu et al., 2012). During the field study, Nguyen Luu et al. asked the 
school personnel to demonstrate their ability to use the new generation of EpiPen in case 
of anaphylaxis. Their findings of a deficit in EpiPen usage among the school personnel 
suggested that user training and product instruction were the crucial points for the therapy 
success (Nguyen Luu et al., 2012).  
 
Oude Elberink et al. (2009) traced the opinions of insect venom allergic patients with 
reactions limited to the skin on alternative treatments. They found out that although the 
majority of the patients chose the EpiPen therapy, a large number of the patients chose 
the alternative treatment method venom immunotherapy (VIT) because of a higher level 
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of perceived health-related quality of life (HRQL). The main complaint about the EpiPen 
therapy was the cumbersome size of the device, although the treatment itself was 
perceived as comfortable by the patients. A further demand of the patients was to have a 
bigger variety of devices (Oude Elberink, van der Heide, Guyattw & Duboisz, 2009). 
However, according to the current regulations for medical devices, each variant of 
combination product needs its own BLA submission with a lot of regulatory inputs. 
Therefore, a big variety of auto-injectors would probably lead to high expenses which the 
market is not ready to refund.  
 
Simons et al. raised the issue of the dosage of EpiPen auto-injector. When treating 
children weighting 15-30 kg, physicians only had the choice of the classic EpiPen for 
adults and EpiPen Jr for children, while neither of the dosages was optimal. Thus the 
EpiPen could be improved by providing a more flexible dosage (Simons, Gu, Silver & 
Simons, 2002). 
 
The empirical data in Canada indicated that 35% of the adult patients needed more than 
a single shot of EpiPen in an acute situation (Ackaoui, 2011). Ackaoui suggested that 
such patients should always carry two auto-injectors or one with two doses (Twinject). 
However, there were not yet sufficient clinical studies to conclude if the second shot of 
Twinjet could be administered effectively. A further problem with auto-injectors was the 
short expiry date, causing wastes both in costs and pollution. Ackaoui also proposed 
multiple-use auto-injector designs for example with disposable needles to reduce 
pollution (Ackaoui, 2011).  
 
Also Clegg & Richtie detected a lack of training on EpiPen use for the parents and 
teachers of school children in West Lothian (Clegg & Richtie, 2001). To improve this, 
they recommended to the local drug and therapeutics committee: to provide a 
standardised training package including a video demonstration, written material in the 
form of “frequently asked questions”, as well as contact addresses for additional advice; 
to educate the prescribing doctors on EpiPen background and use; to provide trainings to 
school staff on EpiPen use and to use survey study to identify the most prescribing areas 
for EpiPen, so as to organise more targeted training programmes (Clegg & Richtie, 2001). 
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In a recent comparison study of three adrenaline auto-injectors conducted by Schwirtz & 
Seeger, EpiPen showed a higher robustness in quickly and consistently delivering the 
correct dose of adrenaline to the correct tissue layer. However, a higher percentage of 
patients could use the syringe-based alternative auto-injectors correctly, implying that the 
instruction and user training of EpiPen could still be improved. A further weakness of 
EpiPen seemed to be in sustaining mechanical stress (e.g. slight bending of needles) 
(Schwirtz & Seeger, 2010). 
 
In 2001, most families of children who were prescribed adrenaline auto-injectors in 
London were found unable to use the device properly. Three years later, most patient 
families were reported capable of using the device correctly. The improvement was 
mainly achieved by protocoled prescriptions and a follow-up patient training programme 
(Ratnaweera, Trilsbach, Rangasami, Green & Puliyel, 2006). 
 
Based on a survey study conducted in different Canadian provinces, Cicutto et al. 
recommended that legislation be made to oblige schools to EpiPen trainings against 
anaphylaxis. Their findings indicated that in the provinces with legislated environment 
for EpiPen training, the schools made more efforts and the personnel mastered the 
techniques better (Cicutto et al., 2012).  
 
Wong et al. surveyed the primary schools in the London area and found out, with the 
schools’ policy in place, the majority of the staff with responsibility for medicine 
administration knew how to administer EpiPen properly (Wong, Awolowo, Gordon & 
Mo, 2004).  
 
Sclar pointed out that besides the proper injection techniques, also the injection time of 
EpiPen was a critical parameter that might even decide life or death. His field study 
showed that EpiPen produced optimal delivery time of the medicine (Sclar, 2013). 
 
An Australian survey study suggested that almost 10% of anaphylaxis patients were 
expected to experience recurrence. Still, very few patients carried adrenaline auto-
injectors with them. According to the survey results, the main reasons for the patients’ 
declination of the auto-injectors were: fear of needles; fear of adrenaline; preference of 
hospital treatment and the drug being out of date (Mullins, 2003). The preference of 
 43 
hospital treatment might be interpreted as a result of the patients’ perception of carrying 
EpiPen as a decrease of health-related life quality. In other words, the EpiPen design 
could be improved to counteract the patients’ rejection in this aspect.   
2.4.2 Summary  
There seems to be a consensus among researchers that Adrenaline Auto-Injectors (AAIs) 
are one of the most effective therapies against life-threatening acute allergic reactions: 
anaphylaxis (Schwirtz & Seeger, 2012; Ewan & Clark, 2005). 
 
Numerous survey studies were conducted in schools and hospitals among children 
suffering from anaphylaxis. The findings of the various regional studies often indicated a 
deficiency in understanding of the functions of EpiPen by the parents of the children and 
by the school staff (Hodges, Clack & Hodges, 2005; Sanagavarapu, 2012; Nguyen Luu 
et al., 2012; Clegg & Richtie, 2001). Similar deficiency was also observed among adult 
patients (Ackaoui, 2011; Oude Elberink, van der Heide, Guyattw & Duboisz, 2009; 
Ratnaweera, Trilsbach, Rangasami, Green & Puliyel, 2006; Mullins, 2003). 
 
In some cases, the user knowledge was improved greatly by protocoled prescriptions and 
well-organised training programmes. However, follow-up trainings seem necessary, in 
order to achieve sustainable improvements (Ratnaweera, Trilsbach, Rangasami, Green & 
Puliyel, 2006). Also clearer product instructions were expected to improve AAI user skills 
(Nguyen Luu et al., 2012). In this aspect, Clegg & Richtie proposed to produce a 
standardised training package including a video demonstration and written material in the 
form of “frequently asked questions” (Clegg & Richtie, 2001). 
 
A few authors suggest that well-placed school policies on medicine administration or 
even legislation may substantially improve the schools’ performance (Cicutto et al., 2012; 
Wong, Awolowo, Gordon & Mo, 2004). 
 
Although there was a relatively high risk of recurrence, many patients did not carry AAI 
with them (Mullins, 2003; Oude Elberink, van der Heide, Guyattw & Duboisz, 2009). 
The main reasons for the patients’ rejection were thought to be the perceived reduced 
health-related life quality, e.g. due to the bulky size of the device (Oude Elberink, van der 
Heide, Guyattw & Duboisz, 2009), fear of needles or the medicine and the short shelf life 
so that sometimes the drug is found out of date when needed (Mullins, 2003). 
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2.5 Group work 
2.5.1 Research findings 
The term “group work” is used interchangeably with “teamwork” by some authors. In his 
essay, Cooter traced the history of the term “teamwork” and provided a description of the 
development of this concept (Cooter, 2004).  
 
Researchers established different classifications of groups in the past. O’Donnell et al., 
for example, differentiated between “ad hoc groups” and “natural groups”. In their 
opinion, ad hoc groups must go through a phase of entrainment to become natural groups 
(O'Donnell, Arnold & Sutton, 2000). 
 
Group work was often studied in the context of psychodynamic or psychosocial functions 
in groups (Viney, Henry & Campbell, 2001). Cronin et al. pointed out that since groups 
were dynamic entities, it was important to focus on group dynamics instead of group 
statics (Cronin, Weingart & Todorova, 2011). By analysing the management science 
publications of three decades, Goyal et al. analysed the development of social distance 
among economists (Goyal, Van der Leij & Moraga-González, 2006). 
 
Other researchers concentrated on the creation of cause-and-effect models for group work, 
with the aim of generating usable theories on group behaviour and performance 
(Hackman, 2012).  
 
Marrone et al. analysed how boundary-spanning behaviour in groups was caused and how 
such behaviours affected the team work (Marrone, Tesluk & Carson, 2007). 
 
Another prolific field in the terrain of group work research was the cooperative learning 
process (Mustafa, 2010; Bertucci, Conte, Johnson & Johnson, 2010). Mustafa analysed 
the cooperative learning process (Mustafa, 2010). The experiments of Bertucci et al. 
showed that cooperative learning seemed to be more effective than individual learning 
(Bertucci, Conte, Johnson & Johnson, 2010). 
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Many team work researches on learning process were conducted in the education sector, 
especially at the higher education institutions (Gaytan, 2010), but sometimes also in 
primary or secondary schools (Gillies & Robinson, 2012). Such studies often focused on 
the effect of specific education programmes on learning results (Lawrence, 2002). 
 
A survey among college students indicated that although group works was well accepted, 
the majority of students preferred individual assignments to group works due to their 
concerns of certain disadvantages of group work, e.g. free riding of team members (Marks 
& O’Connor, 2013). Laverie et al. focused on how team-based active learning influenced 
the learning orientation of the individual students (Laverie, Madhavaram & McDonald, 
2008). 
 
Napier & Johnson found out that group work satisfaction of the college students were 
substantially influenced by ethical factors, as well as equal level of contributions of the 
group members (Napier & Johnson, 2007). 
 
Group assessment became essential for higher education programme design in the 
modern time, so that meanwhile educators had developed a consensus that education 
needed to be organised in accordance with the students’ skills (Gammie & Matson, 2007). 
Lavy & Yadin studied the effect of team-based peer-reviews on the students learning 
process (Lavy & Yadin, 2010). Furthermore, Ballantine & Larres analysed the link 
between the students’ attitude towards group work and their academic abilities 
(Ballantine & Larres, 2007). 
 
Taylor concludes based on his field study among college students that to promote the 
motivation of group work, group incentive seemed to be more effective than tournament 
or individual incentives (Taylor, 2006). 
 
Group work in high education institutions was also understood as social skill trainings for 
the students – the future management members (Sathe, 2009). Umble et al. conducted 
survey studies among college students to test various hypotheses regarding project team 
processes with competition (Umble, Umble & Artz, 2008). Sathe’s ethnographic study 
suggested that the cohort-based MBA programmes in the United States seemed to 
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improve the cooperative agenda of the students, however, the individualist and 
competitive tendencies remained unchanged (Sathe, 2009).  
 
There were further aspects of group work research on learning process. Espey explored 
the influence of classroom design on the students’ learning attitude and performance 
(Espey, 2008). Head proposed the establishment of a “shared history” to improve the team 
work (Head, 2006). Peek et al. observed the group work of university students from the 
United States and Canada on discussions of accounting ethics (Peek, Peek, Roxas, 
Robichaud & Blanco, 2007). Besides, although many students were aware of theories on 
group work techniques, they seemed to make seldom use of such techniques for their 
learning process (Tabatabaei & Lam, 2013). 
 
In their investigations, Pil & Leana detected a strong link between the team leader and 
the performance of the team members (Pil & Leana, 2009). 
 
Hu addressed the trend of “equal first authors” in the publications of the scientific journals. 
In his opinion, this could cause inefficient teamwork, because the individual research 
contribution was often not properly evaluated (Hu, 2009). Also Acedo et al. analysed the 
tendency of co-authorship, especially in the field of management science, and attempted 
to identify the major factors that caused this tendency (Acedo, Barroso, Casanueva & 
Galán, 2006). 
 
The results of Walker et al.’s experiment could be applicable for the world outside the 
classrooms. During their experiment with team meetings as a tool for team projects, 
Walker et al. discovered an indifference point for the participants. The participants’ 
perception towards team meetings were positive before and negative after the indifferent 
point was reached (Walker, Elson & O'callaghan, 2012). 
 
In management science, group work was often studied in the context of project process. 
Some researchers studied the group work for creative projects. Harrison & Rouse 
concentrated on the dynamics of various internal forces that influenced the group 
coordination (Harrison & Rouse, 2014).  
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Researchers found out that based on the complexity of projects for product development, 
position-based, process-based or outcome-based rewards should be chosen in order to 
maximise the project outcomes (Sarin & Mahajan, 2001). Goby & Lewis emphasized the 
importance of communication in team work for the members of management (Goby & 
Lewis, 2000). 
 
In their work, Kozlowski & Ilgen started with the analysis of cognitive, motivational and 
behavioural team processes and subsequently identified interventions that could align 
team processes, so as to improve team effectiveness (Kozlowski & Ilgen, 2006). 
 
In the contemporary business world, group work was becoming ever more complex. For 
the development of new products, the firms nowadays increasingly set up project teams 
with participants from different disciplines (Sethi, 2000). Levy & Murname underlined 
the necessity of cross-disciplinary learning in group work on robot revolution among 
computer scientists and economist (Levy & Murname, 2014). 
 
Based on their studies on teamwork processes among healthcare workers, Fay et al. 
argued that the multi-disciplinarity had a positive effect on the team performance only 
under restricted circumstances (Fay, Borrill, Amir, Haward & West, 2006). 
 
Sethi proposed a test method to determine the effects of team characteristics and 
contextual influences (Sethi, 2000). 
 
Different team works techniques seemed appropriate for different team styles to achieve 
the best outcome of business projects (Scarfino & Roever, 2009). One of the concepts 
was to classify project teams in the high-tech organisations in traditional, virtual and 
semi-virtual (or hybrid) teams (Webster & Wong, 2008). 
 
Not only did groups often consist of multi-disciplinary members, but also the 
communications between the members sometimes had few opportunities for face-to-face 
contacts. To counteract this challenge, Majchrzak et al. proposed to develop know-how 
collaboration among group members by communicating not only content, but also context 
(Majchrzak, Malhotra & John, 2005). 
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As in today’s world innovation is gaining more importance in most business sectors, 
companies begin to involve customers in their innovation process. One example is the 
on-line brainstorming sites termed "Company-Sponsored Online Co-Creation 
Brainstorming" by researchers. The researchers detected a group work process between 
the peers of the sponsoring companies and the involved customers. However, it seemed 
that the reviewing process of the submitted ideas by the sponsoring companies yet needed 
improvements (Chen, Marsden & Zhang, 2012). 
 
The team transactive memory systems played an important role in group work focusing 
on leveraging the members’ expertise. To measure the effectiveness of team transactive 
memory systems, Lewis developed a 15-item scale (Lewis, 2003). 
 
2.5.2 Summary 
Studies on group work (interchangeably with “teamwork”) have a long history (Cooter, 
2004). Researchers in the past developed various concepts for the classification of groups 
(O'Donnell, Arnold & Sutton, 2000). 
 
Group work was often studied in the context of psychodynamic (Viney, Henry & 
Campbell, 2001; Cronin, Weingart & Todorova, 2011), or psychosocial functions in 
group work (Goyal, Van der Leij & Moraga-González, 2006). While some researchers 
were devoted in the analysis of how individual behaviours affected the team work 
(Marrone, Tesluk & Carson, 2007), others were more interested in the establishment of 
cause-and-effect relationships (Hackman, 2012).  
 
Numerous researches were conducted in the education sector, especially in the higher 
education institutions, often to examine the success of educational programme (Lawrence, 
2002; Sathe, 2009).  
 
Group work also found wide applications in the business world, especially for creative 
projects (Harrison & Rouse, 2014). A central influence factor of such projects seemed to 
be communication in the group, which was essential in aligning group processes and 
improving group effectiveness (Goby & Lewis, 2000; Kozlowski & Ilgen, 2006). 
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To deal with the growing complexity of group work in the contemporary business world, 
the firms nowadays increasingly built up multi-disciplinary project teams (Sethi, 2000). 
However, some researchers claimed that the positive effect of the multi-disciplinarity on 
group performance could only be observed under restricted circumstances (Fay, Borrill, 
Amir, Haward & West, 2006). To counteract the complexity of group work, Majchrzak 
et al. proposed the communication of not only content, but also of context for the know-
how collaboration among group members (Majchrzak, Malhotra & John, 2005). 
 
With the growing importance of innovation in most business sectors, some companies 
involved not only internal personnel, but also customers in their innovation process (Chen, 
Marsden & Zhang, 2012). 
 
Following the trend in the latest development of the business world, this study focuses on 
group work as an innovation process. Two problem-solving techniques are applied in the 
group work process. The group performance is measured in two dimensions: 1) The 
technical solutions as results of the innovation process; and 2) the group work process 
including the analysis of the behaviours of the individual group members and their 
perceptions for the group work. 
 
2.6 Assessment methods of group behaviours 
2.6.1 Research findings 
In preparation of research design for the investigation on how TRIZ affects the group 
work of the innovation activities in terms of group behaviours (process), the assessment 
methods of group behaviour in previous literature are analysed in this part of the literature 
review. 
 
Several studies explored behavioural changes in field of clinical institutions, often by 
means of observations by external researchers and interviews. 
 
Reza et. al. focused on the impact of psycho-educational programme on behavioural 
changes among caregivers of individuals with schizophrenia and mood disorders. They 
findings on the positive effect of the educational programme on family dynamics in 
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favour of the patients were based on external observations using Solomon's experimental 
design (Reza, Shikha, Habibollah & Ali, 2004). 
 
Through observations and perceptions of two external observers, Scherer, Scherer, & 
Campos evaluated the effects of coordinating general team meetings at a psychiatric day 
hospital. Their findings suggested that the intervention of an institutional supervisor could 
improve the efficacy of the meetings, in addition to analysis of the coordinator's 
performance, as well as the organisational dynamics and structure (Scherer, Scherer & 
Campos, 2007). 
In a case study, De Casterlé et. al explored the leadership development in a clinical 
leadership promotion programme. Using mixed methods, they collected with individual 
interviews, focus groups and observation of participants. Based on the empirical findings, 
they developed a framework to describe the leadership development and its impacts on 
the stakeholders (De Casterlé, Willemse, Verschueren & Milisen, 2008). 
 
In order to examine closely group work under pressure, Ren, Kiesler & Fussell conducted 
a case study of a hospital's operating room practices. By means of external observations 
and interviews, they analysed the coping mechanisms and their consequences in case of 
coordination disturbance in group work (Ren, Kiesler & Fussell, 2008). 
 
In order to study team functions in high-risk environments, Kolbe et al. studied sequential 
patterns of the individual behaviours of several medical teams. Subsequently, the external 
observers established a relationship between certain behaviours and results of the group 
work by coding verbal and nonverbal behaviours of the participants and grouping the 
results in high-performing and low-performing. Their conclusion was that a number of 
interactions patterns were expected to lead to higher performance (Kolbe et al., 2014). 
 
Other researchers dedicated their research interest to the complex effect of cognitive or 
coaching process. 
 
With their Problem-Based Learning (PBL) approach for the complex holistic coaching 
process, Jones & Turner explored the colleague students’ behaviours in group work under 
pressure. They collected data through external observations and semi-structured group 
interviews. The focus of their study was the influence of the coach’s role in the outcome 
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of the group work and to establish PBL as a framework for academic research and 
practical application in this special field of coaching in group work (Jones & Turner, 
2006).  
 
The research interest of Larsen et al. was the development of top sport talents with focus 
on the overall environment for the athletes (Larsen, Alfermann, Henriksen & Christensen, 
2013). They closely examined the talent development of some young male soccer players 
in a Danish soccer club in light of the relationship between players and a staff of coaches, 
assistants, and managers. Their means of data collection mainly included interviews, 
participant observations by external observers and analysis of documents. Based on their 
findings, they developed a holistic model with multiple influence factors for the success 
of young sport talents (Larsen, Alfermann, Henriksen, & Christensen, 2013). 
 
Eidimtas’ empirical study on the learning process of Lithuanian fire-fighters was 
organised as a survey study. He found out that the fire-fighters mainly learned from their 
colleagues and their own failures in extreme situations (Eidimtas, 2010).  
 
Camara et al. investigate the relationship between the students’ satisfaction, the individual 
performance and the type of student work groups (with homogeneous or heterogeneous 
performance levels). The group work compilation in their study was conducted by either 
self-selected or randomly selected. Both approaches have biases due to polarisation and 
variability of knowledge of the group members. The group compilation could be 
improved through control of cultural, gender, age or level of education of group 
participants. In practice, however, establishment of such homogeneous groups may not 
always be possible (Camara, Carr & Crota, 2007). The assessment of the group work was 
conducted by external observers. In addition, Camara et al. proposed peer review for the 
evaluation of individual performance of the students (Camara, Carr & Grota, 2007). 
 
Praetorius and Lützhoft scrutinized user needs for dynamic risk management in Vessel 
Traffic Service (VTS). Their means of data collection were study visits and observations 
by external observers, as well as semi-structured interviews. However, the main focus of 
their study was the output, instead of the group dynamics (Praetorius & Lützhöft, 2012). 
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Compared with other studies, Perry Jr et al. took a relatively complex approach for the 
development of a model of team establishment by analysing group work among mid-
career working professionals. The empirical study was constructed as an experiment with 
multiple teams working on similar tasks, with the results reported by the researchers 
through participant observation and interviews. Following this, a survey study was carried 
out with the participants after the above case reports were made available. Subsequently, 
the researchers conducted a qualitative analysis of the survey responses. With their 
research focus on team development, Perry Jr et al. did not follow up on the implications 
for individual performance, although the results suggested an interplay between the 
ongoing assessment and the participants’ behaviours afterwards (Perry Jr, Karney & 
Spencer, 2013). 
 
Bell and Morse (2013) investigated the advantages and disadvantages of the assessment 
approaches inside out which rely on group members’ self-analysis of the individual 
behaviours and outside in which relies on the external observations. In a statistical 
analysis, they compared the quantitative SYMLOG method based on the group members’ 
opinions and the BECM method based on the qualitative assessment by an external 
observer. Their findings confirmed the advantages of SYMLOG by allowing all group 
members to participate in the assessment. Furthermore, Bell and Morse proposed an 
improvement of the SYMLOG method by hybridising it with the BECM method by 
adding external observers to the rating process (Bell & Morse, 2013). 
2.6.2 Summary 
Group dynamics is relatively prolific research field, covering various professional fields 
ranging from medical institutions (Reza, Shikha, Habibollah & Ali, 2004; Scherer, 
Scherer & Campos, 2007; de Casterlé, Willemse, Verschueren & Milisen, 2008; Ren, 
Kiesler & Fussell, 2008; Kolbe et al., 2014) to vessel traffic service (Praetorius & 
Lützhöft, 2012). 
 
Numerous works were organised as empirical studies with different research approaches, 
with participant observation as a frequently used research method (Reza, Shikha, 
Habibollah & Ali, 2004; Scherer, Scherer & Campos, 2007; De Casterlé, Willemse, 
Verschueren & Milisen, 2008; Ren, Kiesler & Fussell, 2008; Kolbe et al., 2014; Jones & 
Turner, 2006; Larsen, Alfermann, Henriksen & Christensen, 2013; Camara, Carr & Grota, 
2007; Praetorius & Lützhöft, 2012; Perry Jr, Karney & Spencer, 2013).  
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Bell and Morse divided the observation methods into two groups according to the 
assessment approaches: inside out which relied on group members’ self-analysis of the 
individual behaviours and outside in which relied on the external observations. In order 
to combine the advantages of both approaches, Bell & Morse proposed to hybridise the 
inside out SYMLOG method with the outside in approach by adding external assessment 
to the classic form of this method (Bell & Morse, 2013). 
 
While most of the assessment methods for observations were developed individually to 
meet the special requirements of the research object, SYMLOG seemed to be universally 
applicable, since its criteria for the assessment of individual behaviours in group were 
independent of the situations. Therefore, this study chose SYMLOG for later assessment 
of the process of group work. 
 
Another frequently used method was interviews, with the variety of individual interviews, 
group interviews, semi-structured interviews, etc. (De Casterlé, Willemse, Verschueren 
& Milisen, 2008; Ren, Kiesler & Fussell, 2008; Jones & Turner, 2006; Larsen, Alfermann, 
Henriksen & Christensen, 2013; Praetorius & Lützhöft, 2012). 
 
Other research methods used in the analysed literature were survey (Eidimtas, 2010; Perry 
Jr, Karney, & Spencer, 2013) and experiment (Reza, Shikha, Habibollah & Ali, 2004; 
Camara, Carr & Grota, 2007). In order to combat the internal validity issues, Reza et al. 
applied Solomon's experimental design (Reza, Shikha, Habibollah & Ali, 2004). 
 
2.7 SYMLOG 
SYMLOG (System for the Multiple Level Observation of Groups) is a method for the 
study of group processes developed by Robert Freed Bales in the later 1970’s (Bell & 
Morse, 2013). The study of the group work process in this thesis is guided by this method 
based on the considerations that: a) SYMLOG was positively evaluated by previous 
researchers especially in the study of social science and psychology; and b) abundant 
descriptions of the application of this method are available in the literature which 
facilitates a good understanding and command of this well-accepted method. 
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2.7.1 Research findings 
One of the latest literature sources related to SYMLOG was Bell and Morse’s discussion 
paper on a comparison study of SYMLOG and BECM (Bell & Morse, 2013). In the 
opinion of Bell and Morse, BECM (also known as “Being, Engaging, Contextualizing 
and Managing”) focused on the external route in the assessment of group work. In the 
BECM method, the group work was rated by an external person. SYMLOG, on the other 
hand, was defined as an inside out methodology whereby group participants themselves 
were responsible for conducting an internal assessment of the group participants (Bell & 
Morse, 2013). However, to the understanding of some other researchers, the group work 
assessment in the SYMLOG methods also needed to be conducted by external persons 
(Marx, 2000).  
 
Since the initiation by Bales, the SYMLOG methodology has been used in various 
contexts for the study of inter-personal relationships in small groups. 
 
By measuring the SYMLOG leadership values instrument before and after skill trainings 
for the managers, the researchers determined the efficacy of the trainings in the three 
bipolar SYMLOG dimensions (Lawrence & Wiswell, 1993).  
 
In the past, SYMLOG found wide applications in family observations. For the clinical 
social workers, Kutner and Kirsch developed a graphic system for the illustration of 
interpersonal relationships based on SYMLOG framework (Kutner & Kirsch, 1985). 
Similarly, Crespi adapted the SYMLOG methodology for the family of origin evaluation 
for family therapists (Crespi, 1993). The method of SYMLOG group observation was 
applied by Herzog and his medical colleagues for family observations on eating disorders 
(Herzog, Kronmüller, Hartmann, Bergmann & Kröger, 2000). Besides, Cashmann et al. 
used the SYMLOG approach to measure the interaction of healthcare professionals in 
interdisciplinary team in proving medical service (Cashman, Reidy, Cody & Lemay, 
2004).  
 
In the narratives of her life story after World War II, Chaitin used the SYMLOG 
framework to describe the family relationships, as well as the interpersonal values of the 
families in the first, second and third generation (Chaitin, 2000).  
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SYMLOG methodology was also used to analyse the gender differences in academic 
researches. Hare et al. used the SYMLOG techniques to compare the behaviours of female 
and male managers in a leadership program, analysing both the self-ratings of the 
managers and the ratings by the co-workers. Quite expectedly, they found out that the 
females managers were more dominant and positive and less task-oriented (Hare, Koenigs 
& Hare, 1997). Schneider et al. combined SYMLOG with Bem Sex Role Inventory (BSRI) 
which consisted of masculinity, femininity and social desirability scales (Schneider, 
Schneider-Düker & Becker-Beck, 2001) to identify the influence of gender on individual 
behaviours. They concluded that the SYMLOG reflected closely the level of individual 
behaviours in the group interaction (Schneider, Schneider-Düker & Becker-Beck, 2001).  
 
Blumberg and Hare (1999) applied the classic form of SYMLOG techniques for their 
investigation of sociometry in organisations. They commented on the advantages and 
disadvantages of the rating process (Blumberg & Hare, 1999). Beyond real life data, Hare 
& Hare simulated group behaviours with SYMLOG under the use of survey data (Hare 
& Paul, 2001). Polley discussed the validation of the adjective rating tool set in the 
SYMLOG environment and offered improvements without clarification of the advantage 
and the application of the improvements (Polley, 1987). 
 
The Scandinavian researcher Eisele compared the performance and decision-making 
process of individuals and in group, using the SYMLOG methodology (Eisele, 2003). 
Especially, he used the rating tools not only for the group investigation, but also for the 
research on individuals (Eisele, 2003).   
 
Isenberg and Ennis compared multidimensional scaling with SYMLOG as a tool for 
personal perception investigations and detected a relatively high correlation of both 
approaches (Isenberg & Ennis, 1981). 
 
In his experiment with 91 young adults using SYMLOG method, Hurley compared self-
rating with group peers. His results showed that the public group peers shifted the 
individual self-estimation towards the average opinions of the other participants of the 
same group (Hurley, 1991). 
 
 56 
In the words of Bell and Morse, SYMLOG has been a well-established quantitative group 
self-analysis tool for over 30 years. This method is often used for the analysis of group 
conflicting, gender work, family observation, face-to-face and computer facing 
communication and proves to be the state of art approach in those cases till this date (Bell 
& Morse, 2013) 
 
2.7.2 Summary  
SYMLOG is a well-recognized tool set with data of over 30 years (Bell & Morse, 2013). 
This method is often used for the analysis of interpersonal relationships in various 
contexts, e.g. management process (Eisele, 2003; Lawrence & Wiswell, 1993), family 
observations (Kutner & Kirsch, 1985; Crespi, 1993), patient observations by healthcare 
professionals (Herzog, Kronmüller, Hartmann, Bergmann & Kröger, 2000), analysis of 
gender differences (Hare, Koenigs & Hare, 1997; Schneider, Schneider-Düker & Becker-
Beck, 2001), or even for narratives involving intensive personal interactions (Chaitin, 
2000). 
 
Some researchers compared SYMLOG with alternative assessment methodologies 
(Schneider, Schneider-Düker & Becker-Beck, 2001; Isenberg & Ennis, 1981). In some 
cases, the researchers detected a relatively strong association between SYMLOG and the 
alternative methods (Isenberg & Ennis, 1981). In other case, the researchers proposed the 
combination of SYMLOG with other methodologies (Schneider, Schneider-Düker & 
Becker-Beck, 2001). 
 
Over time, the academics conducted numerous discussions on the advantages and 
disadvantages of SYMLOG and suggested improvements (Blumberg & Hare, 1999). 
Furthermore, although originally designed to measure interactions in small groups, 
SYMLOG was also applied for the research of individual behaviours (Eisele, 2003).   
 
Although in the original form, SYMLOG is solely based on internal assessment by 
participants in the group consisting of self-rating and group-rating (Bell & Morse, 2013), 
some researchers suggested the inclusion of external assessment by external observers 
(Marx, 2000). One interesting method designed by Hurley was a combination of 
individual internal assessment and public group peers. This process seemed to mitigate 
the gap between self-estimation and external estimation (Hurley, 1991). 
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Altogether, SYMLOG is a well-established quantitative group self-analysis tool and still 
counts as one of the state of art approaches for researches on interpersonal relationships 
in small groups till this date (Bell & Morse, 2013). 
 
Based on the results of the literature review, this thesis chose to apply the SYMLOG 
methodology for the assessment of the group work process, with the research design 
oriented on Hurley’s method using both internal and external assessment.   
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3. Research Design 
As described in Section 1.4, this section is dedicated to the research methodology and 
methods. This involves an introduction of the philosophical worldview, the research 
methodology, the methods for data collection and data assessment, followed by 
discussions on the quality of the research design, the role of researcher and the ethical 
considerations and finally, the research schedule. 
3.1 Philosophical worldview 
The individual philosophy of the researcher may crucially influence how he organises the 
research work, for example how to access the research topic and the research questions. 
Therefore, the philosophical position of the researcher is discussed in this section. 
 
As a natural scientist, the researcher believes that the world with its real developments in 
and around living organism exists sovereignly from its observers. The truth about the real 
world can be best accessed through empirical observations and careful measurements. 
However, due to subjective perceptions, the observations will always be charged with 
biases. This position fits very well to the description of post-positivism by Creswell as 
one of the four main worldviews (Creswell, 2009, pp. 6-7). The post-positivistic position 
is also taken up for this study for the following reasons. 
 
The findings of the literature review indicate that the post-positivist position is shared by 
the majority of the researchers in all pertinent fields for this study. A large part of the 
previous studies analysed in chapter 2 considered the innovation process in the 
pharmaceutical industry, problem-solving techniques and assessment of group work, etc. 
These are organised based on empirical data of observations and experiments. 
 
Based on the above considerations, this research followed the research tradition and 
strongly relied on empirical data based on experiences and observations. 
3.2 Research methodology and methods 
The research methodology is an essential part of the study. According to Creswell, the 
research methodology describes the principles of the researcher’s understanding of how 
the research is to be conducted (Creswell, 2009, pp. 11-12). Creswell distinguishes three 
categories of research methodologies: 
- Quantitative approaches; 
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- Qualitative approaches; and 
-  Mixed approaches. 
(Creswell, 2009, pp. 11-12). 
 
In Creswell’s opinion, the post-positivist researchers tend to take the quantitative 
approaches, which often involve collection and assessment of statistic data, experimental 
inquiries, etc. in access to a research topic (Creswell, 2009, pp. 14-15). 
 
The qualitative approaches are described by Creswell as focusing on the qualitative 
feature of the data related to the participants’ view. The researchers often take up a 
qualitative approach when they observe certain social groups, their development over 
time and their behaviour patterns. The qualitative approaches are suitable for explorative 
researches and are associated with a variety of philosophical positions (Creswell, 2009, pp. 
14-15). 
 
The third category of research methodologies, the mixed methods approaches, is a 
combination of the quantitative and the qualitative approaches (Creswell, 2009, pp. 14-15). 
 
The research focus of this thesis involves both explorative studies and theory building 
based on descriptive statistics. Thus in Creswell’s terms, the methodology of this thesis 
is organised with a mixed method approach.  
 
The structure of the research design is illustrated in the following graphic (Figure 3-1). 
 
 
Figure 3-1  Research design: mixed-method approach 
 
In a first step, the current literature on the key issues of this thesis (the problem-solving 
technique TRIZ, auto-injectors, EpiPen, group work and SYMLOG) is explored by means 
of a literature review. All parts of the literature review are organised as systematic 
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literature review in the style described by Tranfield et al. (see section 2.1). The findings 
of the literature review delivered indications for answers to RQ2 (“How can TRIZ 
techniques be applied for medical device innovation?”) and RQ3 (“How and why do 
TRIZ techniques differentiate themselves from other problem-solving methods, from a 
theoretical perspective?”). This led to the choice of research focus for the research design 
(see chapter 2). 
 
Next, a survey study on the current status of the application of problem-solving tools for 
R&D of medical devices in the pharmaceutical industry is to be conducted in the German 
Rhine-Main region. The main aim of the survey study is to answer RQ1 “Which problem-
solving tools are currently used for R&D of medical devices in the pharmaceutical 
industry?” The survey data shall depict the usage of problem-solving tools in the regional 
pharmaceutical medical device sector. Besides, the survey participants will be asked to 
propose assessment criteria for technical solutions of medical devices as combination 
products for pharmaceutical drug delivery. Subsequently, the proposed criteria will be 
discussed and finalised with a group of experienced experts (expert panel) for further 
rounds of this study (see chapter 4). 
 
Next, a 2x2 experiment is to be carried out on group work for the improvement of auto-
injector design, using problem-solving techniques TRIZ and the alternative technique 
identified by the survey study as the method currently used with the highest frequency. 
During the experiment, two groups of experienced practitioners will be asked to improve 
the design of two EpiPen models. 
 
The efficacy of TRIZ application will be explored both in the aspect of the quality of the 
technical solutions (the outputs) and that of the group work (the process). The results shall 
provide further impulses in pursue of answers to RQ2 (“How can TRIZ techniques be 
applied for medical device innovation?”) and RQ3 (“How and why do TRIZ techniques 
differentiate themselves from other problem-solving methods, from a theoretical 
perspective?”). 
 
The assessment of the technical solutions (the outputs) will be conducted in two steps: a) 
by evaluation of the expert panel based on the criteria determined after the survey study, 
and b) by evaluation of the pen-experienced patients. The assessment of the group work 
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(the process) will be conducted with the SYMLOG method initiated by Bales (see chapter 
6). 
 
Finally, the findings of the literature review, the survey study and the experiment will be 
analysed so that conclusions can be drawn on a theoretical level. 
3.3 Systematic literature review: search plans 
The literature review in this study aims to identify the current status of academic research, 
so as to gain background information and to detect research gaps in the fields of interest. 
The literature review in this thesis is conducted as systematic literature review in the style 
of Tranfield et al. (see section 2.1). The search plans for the key terms in this thesis are 
described in detail in the following sections. 
3.3.1 Search plan: TRIZ 
The focuses in this section of literature review are: 
 To  identify the current status of academic literature and research of TRIZ; 
 To identify the current status of TRIZ application in the pharmaceutical industry; 
 To create a search approach for the main review. 
3.3.1.1 Literature scoping 
The literature scoping was conducted on primary studies and previous literature reviews 
as proposed by Tranfield, Denyer & Smart (2003). The target of the scoping review was 
to identify the quantity of previous literature on TRIZ techniques and to develop a strategy 
for the main search. A scoping review was conducted with the electronic database 
EBSCO collection online database by the University of Gloucestershire on 15.12.2013.   
 
During the scoping search, the search term “TRIZ” was chosen. By selecting only 
disseminations in the English language in academic journals, newspapers, periodical 
reviews and interviews for the timeframe from 1991 till 2013, this led initially to 264 
retrievals.  
3.3.1.2 Search outline 
The EBSCO database was searched by using the following search plan. Subsequently, the 
search results were reduced to the data set considered relevant for this thesis by applying 
the inclusion and exclusion terms (see table 3-1).  
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Database:   The EBSCO database collection including the following databases 
was accessed for the full review. 
eBook Collection (EBSCOhost), Show all News (AP, UPI, etc.), 
Art & Architecture Complete, ATLA Religion Database with 
ATLASerials, Business Source Complete, CINAHL with Full Text, 
Education Research Complete, E-Journals, Environment Complete, 
ERIC, Film & Television Literature Index with Full Text, 
GreenFILE, Hospitality & Tourism Index, Humanities 
International Complete, Library, Information Science & 
Technology Abstracts, MEDLINE, PsycARTICLES, Psychology 
and Behavioral Sciences Collection, PsycINFO, Regional Business 
News, SocINDEX with Full Text, SPORTDiscus with Full Text 
and Teacher Reference Center 
Search term:  “TRIZ” 
Language:  English 
Publication date: 1991 to 2013 
Publication type: Academic journals 
.  
Parameters Inclusion criteria Exclusion criteria 
Timeframe Literature published from 1991 till 
2013 
 
Literature published before 1991 
Business focus Research and development Irrelevant to research and 
development, e.g. banking and 
trading 
Type of literature Academic journals; literature 
reviews; clinical trial reviews 
 
Advertisements, newsletters and 
opinion pieces by  key opinion 
leaders  
Language English Other languages 
Table 3-1:  Inclusion/exclusion criteria: TRIZ 
To explain the choice of the inclusion and exclusion criteria, the single criteria are 
introduced in more details in the following.  
 
Timeframe. The timeframe from 1991 till 2013 was selected for the literature search, in 
order to reflect the focus of current innovation methods for the pharmaceutical industry. 
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Business focus. The focus of the thesis is the application of TRIZ in the research activities 
of the pharmaceutical industry. Therefore, disseminations on application of TRIZ 
techniques for research activities in the pharmaceutical industry are considered pertinent 
to this study. On the contrary, disseminations with focus on special topics e.g. news and 
ad-hoc stock related information are considered non-related to this study and excluded 
from this search. 
 
Type of literature. The academic journals are considered objective evidence and therefore 
included in the literature review. Advertisements and newsletters are considered 
subjective literature and therefore excluded. 
 
Language. The main reason for the choice of language is the limited language knowledge 
of the researcher in German (native language) and English. A search for disseminations 
in German with the above search criteria resulted in no retreaval, therefore, this search 
concentrated on the English language. Since the majority of the pertinent disseminations 
are published in the English language, the focus on the data set in English is considered 
sufficient for this study.  
 
The search plan yielded initially 264 articles in academic journals, news, periodical 
reviews and opinions published between 1991 and 2013. 120 findings were rejected 
because the abstract did not deliver adequate information and the full text was not 
available.  
 
The abstracts of the articles were read for the inclusion/ exclusion decision. According to 
the inclusion and exclusion criteria for this search, 51 literature sources were rejected 
because they were non-academic journals. After reading the abstract of 219 sources, 182 
were rejected, because they focused on special topics e.g. energy storage, banking and 
CAD design features etc., or because they were secondary literature. Altogether, 37 
literature sources remained for the literature review.  
 
By applying the inclusion/ exclusion criteria for a second time, the literature sources were 
further reduced from 37 to 36 academic journals. Two duplicates among the journal 
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publications were identified and subsequently excluded. Finally, 34 sources were 
considered pertinent to this part of literature review. 
3.3.2 Search plan: Auto-injector 
The focus of the literature review in this section is: 
 To identify the current status of academic researches on auto-injectors, and 
 To identify influence factors for the development of auto-injectors in the literature. 
3.3.2.1 Literature scoping 
The literature scoping was conducted on primary studies and previous literature reviews 
as proposed by Tranfield, Denyer & Smart (2003). The target of the scoping review was: 
 To identify and estimate the volume of previous researches on auto-injector 
applications in the pharmaceutical industry 
 To create a search approach for the main review of the auto-injector topics. 
 
The scoping search was conducted at the electronic database EBSCO collection online 
database by the University of Gloucestershire on 17.11.2013. In the scoping review 
process, the EBSCO database search yielded in total 423 articles in academic journals, 
newspapers and periodical reviews in the English language, published between 1959 and 
2013. The search terms “auto” and “injector” were chosen for the search, as the term auto-
injector can be written alternatively as auto-injector, Auto-injector or Auto Injector. Due 
to the focus of this thesis on auto-injectors for drug device combination products, the 
timeframe 1991 till 2013 was selected to reflect this latest development in medical device 
research. This reduced the amount of literature of concern to 409 sources. Special topics 
e.g. news and ad-hoc stock related information were considered non-relevant, thus 
excluded from this search. Together with the focus on the academic journals, the number 
of disseminations was brought further down to 228. 
 
The scoping search identified EpiPen as one of the most widely discussed subjects for 
academic discussions on auto-injectors. EpiPen is also named adrenalin pen or AAI. The 
medical substance in EpiPen is known as Epinephrine, (R)-4-(1-hydroxy-2-(methylamino) 
ethyl) benzene-1,2-diol, or adrenaline (Figure 3-2). A separate section of the literature 
review shall be dedicated to the discussions on EpiPen (see figure 3-2). 
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Figure 3-2 (R)-4-(1-hydroxy-2-(methylamino) ethyl) benzene-1,2-diol. 
 
3.3.2.2 Search outline 
The EBSCO eBook database was searched based on the keywords. According to the 
chosen inclusion and exclusion criteria, the search results were reduced to the data set 
relevant to this thesis. 
Database:   The EBSCO database collection including the following databases 
was accessed for the full review. 
eBook Collection (EBSCOhost), Show all News (AP, UPI, etc.), 
Art & Architecture Complete, ATLA Religion Database with 
ATLASerials, Business Source Complete, CINAHL with Full 
Text, Education Research Complete, E-Journals, Environment 
Complete, ERIC, Film & Television Literature Index with Full 
Text, GreenFILE, Hospitality & Tourism Index, Humanities 
International Complete, Library, Information Science & 
Technology Abstracts, MEDLINE, PsycARTICLES, Psychology 
and Behavioral Sciences Collection, PsycINFO, Regional 
Business News, SocINDEX with Full Text, SPORTDiscus with 
Full Text and Teacher Reference Center 
Search terms:  “auto” AND “injector” 
Language:  English 
Publication date: 1991 to 2013 
Publication type: Academic journals 
 
Inclusion/ exclusion criteria 
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The following exclusion and inclusion criteria were applied for the systematic literature 
review on auto-injectors (table 3-2). 
 
Parameters Inclusion criteria Exclusion criteria 
Medical device 
classification 
Medical devices class II which defines 
auto-injectors  for Biologicals 
(Monoclonal Antibodies) and Biosimilars 
(e.g. Erythropoietin) 
 
Medical devices class I and III 
according to FDA 
Timeframe Literature published from 1991 – 2013 
 
Literature till 1990 
Products New design strategies for auto-injectors as 
combination products for monoclonal 
antibodies; devices with injection volume 
not higher than 2 ml 
 
Application devices with injection 
volume >2ml 
 
Type of 
Literature 
Academic journals and clinical trial 
reviews (primary literature)  
Advertisements, newsletters and 
opinion pieces by  key opinion 
leaders; literature reviews 
(secondary literature) 
 
Focus on  
activities 
Focus on development activities for 
innovative products regardless of the  
markets 
 
Focus on sales & marketing 
activities 
Business sector Patent-protected drugs, Generics, OTC,  
Animal Health care, Biologics, 
Biosimilars 
Non pharmaceutical sectors, e.g. 
chemical oil rig production, printing 
technology, insurances and food 
supply 
 
Language English Other languages 
Table 3-2: Inclusion/exclusion criteria: auto-injector 
 
The choice of the inclusion and exclusion criteria is explained in detail in the following. 
 
Medical device classification. The FDA, one of the world’s most influential regulatory 
institutions for drugs, established three categories for medical devices. The three classes 
of the generic types of devices are defined based on the assessment of its safety, potential 
risks, as well as its influence on the daily routine of the patients. The auto-injectors are 
classified by FDA as Class II medical devices. The intended main application for auto-
injectors is self-injection of Biologicals (patented-protected, e.g. Adalimumab) and 
Biosimilars (patented-free, e.g. Erythropoietin). Therefore, this literature review focuses 
on medical devices defined for Class II by FDA. 
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Timeframe. As discussed in the previous section, the literature search concentrates on the 
disseminations from 1991 to present, so as to focus on the new development of auto-
injectors for drug device combination products e.g. monoclonal antibodies or adrenaline. 
 
The FDA developed guidelines for self-administrating medical devices and combination 
products in the recent years. That means, older innovations may not fit the new rules, 
therefore cannot be in focus of this future-oriented research. In fact, auto-injectors are a 
relatively new segment in the pharmaceutical business. Therefore, the information on 
improvements of state-of-the-art auto-injectors has mainly become publically available 
after 1990. Therefore, the literature after 1990 was chosen to concentrate on the latest 
development in the pharmaceutical industry. 
 
Products. This review focuses on new design innovations for auto-injectors as 
combination products. This includes the feedbacks from patients, as well as the new 
design and handling features of the products.  
 
Large volume devices with more than 2 ml liquid to administrate are not in the focus of 
this review. In the current practice, 2 ml of administered liquid is the maximum for auto-
injectors. Higher volumes are usually administered with other application systems, e.g. 
patch pumps.  
 
Type of literature. The academic journals and clinical trial reviews are considered 
objective evidence and therefore included in the literature review. Advertisements and 
newsletters are considered subjective literature and therefore excluded. 
 
Focus on activities. This search focuses on the research and development activities for 
innovative products. Disseminations with focus on sales and marketing activities are 
excluded, because the special research interests in this prolific research field do not 
concern the focus of this work.  
 
Business sectors. The primary goal is the development of innovative combinations 
products in the pharmaceutical industry. Non-pharmaceutical business sections, e.g. 
chemical oil rig production, printing technology, insurances and food supply, are 
considered non-relevant to this review. 
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Language. The main reason for the choice of language is the limited language knowledge 
of the researcher in German (native language) and English. A search for disseminations 
in the German language with the above search criteria led to 3 retreavals, however the 
full text was not available in the chosen database.  
 
Conventionally, clinical data of the pharmaceutical industry and academic literature on 
pharmaceutical researches are published in the English language. The reason behind this 
is that the two largest health care markets are under control of the US FDA and EU EMA, 
which both request clinical evaluation and the clinical literature review to be conducted 
in English. Also the majority of the pertinent disseminations in the chosen database are 
published in the English language. Therefore, the focus on the data set in English is 
considered sufficient for this study. 
 
The above search plan yielded 228 citations. By employing the inclusion/ exclusion 
criteria, 176 were initially rejected because they focused on application devices with 
injection volume > 2 ml, sales & marketing activities, special business sectors like 
chemical oil rig production, insurance or food supply, or because they were secondary 
literature.  
 
The remaining 52 studies were read for a second time. The full text was read for decision 
on inclusion or exclusion in case the abstract did not deliver sufficient information on the 
content of the disseminations. This led to the rejection of 30 citations due to their focus 
on special business sectors. 
 
In addition, one duplicate was excluded. Finally, 21 sources were found pertinent to this 
literature review. 
 
3.3.3 Search plan: EpiPen 
The focus of the literature review in this section is: 
 To identify the current status of academic researches on EpiPen, and 
 To identify influence factors for the development of the EpiPen system in the 
literature. 
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3.3.3.1 Literature scoping 
The literature scoping was conducted on primary studies as proposed by Tranfield, 
Denyer & Smart (2003). The targets of the scoping review were: 
 To identify and estimate the volume of previous researches on the EpiPen auto-
injector applications in the industry; 
 To summarize subjects of existing literature on relevant issues regarding design 
features, handling and market information of the EpiPen; 
 To create a search approach for the main review of the EpiPen application topics. 
 
The scoping search was conducted with the EBSCO collection online database of the 
University of Gloucestershire on 08.04.2014. The search term “EpiPen” was chosen for 
the search. In the scoping review process, the EBSCO database search yielded initially 
218 articles in academic journals, newspapers and periodical reviews in the English 
language, published between 1980 and 2014. The first literature was published in 1980 
where the early generation of EpiPen was designed as a syringe without the auto-injector 
plastic components. Due to the focus of this thesis on EpiPen as auto-injector for 
adrenaline, the timeframe 2000 till 2014 was selected to reflect this latest development in 
medical device research. The reduced the amount of literature of concern to 205 sources. 
 
Special topics e.g. news and ad-hoc stock related information were considered non-
relevant thus excluded from the search. This brought down the numbers of disseminations 
further to 136. 
3.3.3.2 Search outline 
The EBSCO database was searched based on the keywords. According to the chosen 
inclusion and exclusion criteria, the search results were reduced to the data set considered 
relevant for this thesis. 
Database:   The EBSCO database collection including the following databases 
was accessed for the full review. 
eBook Collection (EBSCOhost), Show all News (AP, UPI, etc.), 
Art & Architecture Complete, ATLA Religion Database with 
ATLASerials, Business Source Complete, CINAHL with Full 
Text, Education Research Complete, E-Journals, Environment 
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Complete, ERIC, Film & Television Literature Index with Full 
Text, GreenFILE, Hospitality & Tourism Index, Humanities 
International Complete, Library, Information Science & 
Technology Abstracts, MEDLINE, PsycARTICLES, Psychology 
and Behavioral Sciences Collection, PsycINFO, Regional 
Business News, SocINDEX with Full Text, SPORTDiscus with 
Full Text and Teacher Reference Center 
Search term:  “EpiPen” 
Publication date: 2000 to 2014 
Publication type: Academic journals 
 
Inclusion/ exclusion criteria 
The following inclusion and exclusion criteria were applied for the systematic literature 
review on EpiPen auto-injectors (see table 3-3). 
 
Parameters Inclusion criteria Exclusion criteria 
Timeframe Literature published from 2000 – 
2014 
Literature till 1999 
   
Type of 
literature 
Academic journals and clinical 
trial reviews 
Literature reviews; advertisements, 
newsletters and opinion pieces by  key 
opinion leaders  
Products EpiPen as auto-injector Non-branded EpiPens, auto-injectors of other 
brands and EpiPen syringes  
Focus on 
activities 
Development activities for 
innovative products 
Sales & marketing activities 
Language English Other languages 
Table 3-3:  Inclusion/exclusion criteria: EpiPen 
 
The choice of the inclusion and exclusion criteria is explained in detail in the following. 
 
Timeframe. As discussed in the previous section, the literature search shall concentrate 
on the EpiPen generations as adrenaline auto-injectors (instead of e.g. syringes in the 
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previous generations). The timeframe from 2000 to present was chosen to reflect this 
concurrent technological stage. 
 
Type of literature. The academic journals and clinical trial reviews are considered 
objective evidence and therefore included in the literature review. Advertisements and 
newsletters are considered subjective literature and therefore excluded. 
 
Products. The subject of this thesis is the EpiPen auto-injectors. The medical devices 
from the earlier generations e.g. the syringes are considered irrelevant to this search and 
therefore excluded. 
 
Focus on activities. This search focuses on the development activities for the innovative 
EpiPen products. Such information serves as foundation for the experiment on technical 
innovation in group work in this study. 
By employing the inclusion/ exclusion criteria, 65 out of 136 sources were rejected, 
because they were not clinical trial reviews, or they were secondary literature reviews or 
did not focus on the EpiPen products. The full text of the remaining 71 journals was read 
for exploration of the content. As a result, 53 citations were rejected because the studies 
did not focus on research and development of EpiPen. The reduced amount of literature 
of concern was 18 sources. 
 
Language. The main reason for the choice of language is the limited language knowledge 
of the researcher in German (native language) and English. A search for disseminations 
in the German language with the above search criteria led to one single retreaval, however 
the full text was not available in the chosen database.  
 
Conventionally, clinical data of the pharmaceutical industry and academic literature on 
pharmaceutical researches are published in the English language. The reason behind this 
is that the two largest health care markets are under control of the US FDA and EU EMA, 
which both request clinical evaluation and the clinical literature review to be conducted 
in English. Also the majority of the pertinent disseminations in the chosen database are 
published in the English language. Therefore, the focus on the data set in English is 
considered sufficient for this study. 
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3.3.4 Search plan: Group work  
The focus of the literature review in this section is: 
 To identify the current status of academic researches on the group work under the 
aspect of problem-solving, and 
 To identify influence factors for the development of group work and problem-
solving in the literature. 
3.3.4.1 Literature scoping 
The literature scoping was conducted on primary studies as proposed by Tranfield et al. 
(Tranfield, Denyer & Smart, 2003). The target of the scoping review was: 
 To identify and estimate the volume of previous researches which focused on 
group work under the aspect of problem-solving process in the current existing 
literature; 
 To summarize research design of previous studies on technical innovation in 
group work. 
 
The scoping search was conducted at the EBSCO business source online database by the 
University of Gloucestershire on 16.11.2014. In the scoping review process with the 
search terms “group work” and “research”, the search yielded 269 articles published 
between 1929 till 2014. Due to the focus of this thesis on the current research findings on 
group work, the timeframe 2000 till 2014 was selected to reflect the latest development 
in the academic studies. This reduced the dataset to 187 sources. The restriction of type 
of literature to academic journals led to the remaining 143 articles. 
3.3.4.2  Search outline 
The EBSCO online database was searched based on the keywords. According to the 
chosen inclusion and exclusion criteria, the search results were reduced to the dataset 
relevant for this thesis. 
Database:  EBSCO business source  
Search terms:  “group work” and “research”  
Language:  English 
Publication date: 2000 to 2014 
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Publication type: Academic journals 
 
Among the 143 located literature sources (see section 3.3.4.1), 91 were rejected because 
the abstract did not deliver adequate information and the full text was not available. As a 
result, the remaining 52 articles were used for this part of the literature review. 
 
Inclusion/ exclusion criteria 
Timeframe. The literature search aims to concentrate on the current approaches and 
findings of investigations on group work. The timeframe from 2000 to present was 
considered adequate for this purpose. 
 
Type of literature. The academic journals and clinical trial reviews are considered 
objective evidence and therefore included in the literature review. Advertisements and 
newsletters are considered subjective literature and therefore excluded. 
 
Language. The main reason for the choice of language is the limited language knowledge 
of the researcher in German (native language) and English. A search for disseminations 
in German with the above search criteria resulted in no retreaval, therefore, this search 
concentrated on the English language. Since literature in this research field is mainly 
published in the English language, the focus on the data set in English is considered 
sufficient for this study. 
 
No further inclusion and exclusion criteria were applied for this systematic literature 
review. 
 
3.3.5 Search plan: Assessment methods of group behaviours  
The focus of the literature review in this section is to explore assessment methods of 
group behaviours in the current literature. 
3.3.5.1 Literature scoping 
The literature scoping was conducted on primary studies as proposed by Tranfield, 
Denyer & Smart (2003). The targets of the scoping review were: 
 To identify and estimate the volume of existing researches on assessment methods 
of group behaviours in the current literature; 
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 To summarize subjects of existing literature on assessment methods of group 
behaviours in the current literature. 
 
The scoping search was conducted at the electronic database EBSCO collection online 
database by the University of Gloucestershire on 15.04.2014. The search terms “group 
dynamics”, “group work performance”, “observations”, “research method” were chosen 
for the search. In the scoping review process, the EBSCO database search yielded initially 
52 articles in academic journals, newspapers and periodical reviews in the English 
language, published between 1952 and 2014. Due to the focus of this thesis on EpiPen as 
auto-injector for adrenaline, the timeframe 2000 till 2014 was selected to reflect this latest 
development. The reduced the amount of literature of concern to 42 sources. 
 
Special topics e.g. news and ad-hoc stock related information were considered non-
relevant thus excluded from this search which brought down the numbers of 
disseminations further to 21. 
3.3.5.2 Search outline 
The EBSCO database was searched based on the keywords. With the chosen inclusion 
and exclusion criteria, the search results were reduced to the data set considered relevant 
to this thesis. 
Database:   The EBSCO database collection including the following databases 
was accessed for the full review. 
eBook Collection (EBSCOhost), Show all News (AP, UPI, etc.), 
Art & Architecture Complete, ATLA Religion Database with 
ATLASerials, Business Source Complete, CINAHL with Full 
Text, Education Research Complete, E-Journals, Environment 
Complete, ERIC, Film & Television Literature Index with Full 
Text, GreenFILE, Hospitality & Tourism Index, Humanities 
International Complete, Library, Information Science & 
Technology Abstracts, MEDLINE, PsycARTICLES, Psychology 
and Behavioral Sciences Collection, PsycINFO, Regional 
Business News, SocINDEX with Full Text, SPORTDiscus with 
Full Text and Teacher Reference Center 
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Search terms: “group dynamics” AND “group work performance” AND 
“observations” AND “research method” 
Publication date: 2000 to 2014 
Publication type: Academic journals 
 
Inclusion/ exclusion criteria 
The following inclusion and exclusion criteria were applied to the systematic literature 
review (see table 3-4). 
 
Parameters Inclusion criteria Exclusion criteria 
Timeframe Literature published from 2000 – 
2014 
Literature till 1999 
   
Type of literature Academic journals and clinical trial 
reviews 
Literature reviews; advertisements, 
newsletters and opinion pieces by  key 
opinion leaders  
Focus on  activities Group behaviours Special medical issues; other technical 
issues that are non-relevant to group 
behaviours 
Language English Other languages 
Table 3-4:  Inclusion/exclusion criteria: group behaviours 
 
The choice of the inclusion and exclusion criteria is explained in detail in the following. 
 
Timeframe. The timeframe from 2000 to present was chosen to reflect the concurrent 
status of knowledge. 
 
Type of literature. The academic journals and clinical trial reviews are considered 
objective evidence and therefore included in the literature review. Advertisements and 
newsletters are considered subjective literature and therefore excluded. 
 
Focus on activities. This search focuses on group behaviours, thus non-relevant issues 
e.g. special medical issues or other technical issues are excluded. 
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By employing the inclusion/ exclusion criteria, 3 out of 21 sources were rejected, because 
they did not focus on group behaviours. The full text of the remaining 18 journals was 
read for exploration of the content. As a result, 6 citations were rejected for the same 
reason.  The literature of concern thus consists of 12 sources. 
 
Language. The main reason for the choice of language is the limited language knowledge 
of the researcher in German (native language) and English. A search for disseminations 
in German with the above search criteria resulted in no retreaval, therefore, this search 
concentrated on the English language. Since literature in this research field is mainly 
published in the English language, the focus on the data set in English is considered 
sufficient for this study. 
 
 
3.3.6 Search plan: SYMLOG 
The focus of the literature review in this section is: 
 To identify the current status of academic researches on the SYMLOG concept 
first published by Bales, and 
 To identify influence factors for the development of SYMLOG in the literature. 
3.3.6.1 Literature scoping 
The literature scoping was conducted on primary studies as proposed by Tranfield et al. 
(Tranfield, Denyer & Smart, 2003). The target of the scoping review was: 
 To identify and estimate the volume of previous researches on the SYMLOG after 
Bales’ initiation of this investigation method for group work; 
 To summarize subjects of existing literature on relevant issues; 
 To create a search approach for the main review. 
 
The scoping search was conducted at the electronic database EBSCO collection online 
database by the University of Gloucestershire on 28.06.2014. In the scoping review 
process with the search term “SYMLOG” initially yielded 266 articles in academic 
journals, newspapers and periodical reviews in the English language, published between 
1974 and 2013. Only academic journals were further investigated. This reduced the 
amount of literature of concern to 172 sources. Furthermore, 137 sources were rejected 
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because the abstract suggested that the focus of the studies was not research on group 
work.  
3.3.6.2 Search outline 
The EBSCO database was searched based on the keywords. According to the chosen 
inclusion and exclusion specifications, the search results were reduced to the data set that 
was relevant for this thesis. 
Database:   EBSCO database 
eBook Collection (EBSCOhost) and Business Source Complete 
Search terms:  “SYMLOG” 
Publication type: Academic journals 
 
Inclusion/ exclusion criteria 
 
Language. The main reason for the choice of language is the limited language knowledge 
of the researcher in German (native language) and English. A search for disseminations 
in the German language with the above search criteria led to 12 retreavals, however the 
full text was not available in the chosen database. Since literature in this research field is 
mainly published in the English language, the focus on the data set in English is 
considered sufficient for this study. 
 
No further inclusion and exclusion criteria were applied for this systematic literature 
review. As a result, 35 disseminations were considered pertinent to this study. 
 
 
3.4 The survey  
The survey study aims mainly at answering RQ1 (“Which problem-solving tools are 
currently used for R&D of medical devices in the pharmaceutical industry?”). 
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The current status of the application of problem-solving tools in the medical device sector 
will be captured by a survey study among practitioners in the Rhine-Main region in 
Germany. The survey is to be contributed by e-mail and paper printouts. 
 
The participants will be asked to describe their experience with problem-solving 
techniques, especially with TRIZ tools, as well as to make proposals for assessment 
criteria of the developed solutions. The questions will be organised as multiple choice 
questions, with the exception of proposals for the quality criteria of the developed 
solutions which will be organised as a qualitative open-end question. 
 
The participants’ answers will be entered in an electronic database. Based on the 
participants’ indications of their previous experience with problem-solving techniques, 
the survey results will be used to identify the most common tools currently applied in the 
medical device sector. The entries made for proposed assessment criteria for the quality 
of medical device solutions will be evaluated for subsequent discussions with the 
acknowledged ‘experts’ (“expert panel”). Finally, the expert panel will determine the 
criteria for the assessment of the experiment in this thesis. 
 
 
 
 
 
 
 
 
 
3.5 The experiment  
3.5.1 Experiment design 
The experiment is constructed to answer RQ2 (“How can TRIZ techniques be applied for 
medical device innovation?”) and RQ3 (“How and why do TRIZ techniques differentiate 
themselves from other problem-solving methods, from a theoretical perspective?” 
The experiment design applied in this study is a two group design with one repetition (2 
x 2 experiment) (see figure 3-3). 
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Group    TRIZ treatment                   Results 
 
 
 
 
  
 
 
Figure 3-3 Experiment design 
 
The 6 participants (P1, P2, …, P6), all volunteers with 5-10 years of practical experiences 
in medical devices design, as well as comparable academic background and experience 
with problem-solving techniques, will be divided into two groups. The allocation of the 
participants aims to control for a similar level of individual professional experience 
including experience with problem-solving tools, academic background, age and gender, 
etc. to ensure comparable groups. 
 
Each group will conduct two experiments, each to improve the design of a different test 
device (auto-injector 1/ auto-injector 2). The test devices used for the experiment will be 
two models of EpiPen auto-injectors. The choice of test devices is explained in chapter 2. 
Since the selection of a group to run exclusively with TRIZ may bias the test results, the 
switched group experimental design is chosen. That means, in course of the experiment, 
each group will act as the test group for one product and the control group for the other. 
While the test group will be asked to fulfil their task by applying the TRIZ techniques, 
the control group will be asked to do the same with the alternative problem-solving 
approach defined by the results of the previous survey study (see test plan in table 3-5). 
This design is expected to reduce the bias caused by the differences between the groups 
in terms of experience and capacities. 
 
Test devices TRIZ group Control group 
Auto-injector 1 P1, P2, P3 P4, P5, P6 
 
 
 
 
Experiment 2 
 
 
 
 
Experiment 1 
A 
B 
A 
B 
Outputs   Process 
Outputs   Process 
Outputs   Process 
Outputs   Process 
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Auto-injector 2 P4, P5, P6 P1, P2, P3 
P…Participant 
Table 3-5 Experiment: test plan 
 
At the beginning of each session of the experiment, the author will give the participating 
group instructions of the experiment steps. This includes an introduction of the test device, 
the problem-solving technique to be used, the background information, and the time limit, 
etc. After this, the researcher will stay in an adjacent room and will not be present for the 
rest of the experiment. All involvement of the author during the experiment will be 
recorded. At the end of each experiment session, the participants will submit the results 
of their group work in writing. The experiment will be video recorded in full length. 
 
3.5.2 TRIZ procedure 
The literature review in chapter 2 suggests that with some modifications, Su et al.’s 
approach for the improvement of service quality is the most suitable TRIZ procedure for 
the experiment in this study (Su, Lin & Chiang, 2008). In consideration of the features of 
research & development processes for medical devices, the initial 8-stage approach by Su 
et al. was modified to a 5-stage TRIZ innovation procedure with the following structure 
(see figure 3-4). 
 
 
Figure 3-4 Research design: 5-stage TRIZ approach 
 
Stage 1: Definition of scope of problem 
1.
•Definition of scope of problem
2.
•Extraction of determinants
3.
•Identification of contradiction parameters
4.
•Identification of inventive principles
5.
•Generation of solutions
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This step of the experiment aims at the definition of the scope of problem for further 
procedures. 
 
Stage 2: Extraction of determinants 
The aim of this step is to extract determinants for the scope of problem based on the 
findings of the previous studies. For this purpose, the findings of literature reviews will 
be analysed, in order to extract the determinants that are considered relevant to design 
and use of the test subjects.  
 
Next, some pen-experienced patients will be involved by means of semi-structured 
interviews. After an extensive introduction of the determinants extracted from the 
literature and the test devices, the patients will be asked to give their opinions on which 
of the determinants derived from the literature need to be improved for each test device 
and which of the determinants they consider essential for auto-injector design in general. 
They will also be given the opportunity to add further determinants for the improvement 
of the test devices. Their inputs will be recorded for further rounds of this research and 
subsequently, made available to both the test and the control groups. 
 
 
 
Stage 3: Identification of contradiction parameters 
At this stage, the appropriate TRIZ inventive principles shall derive from the determinants 
identified in stage 2. This shall be done by means of a parameter-corresponding table as 
proposed by Domb, Miller, MacGran & Slocum (1998) which involves the following 
steps in this research: 
 
1. To finalise determinants for auto-injector design based on findings of stage 2; 
2. To allocate the determinants to the parameters in the TRIZ 39x39 contradiction 
matrix; 
3. To define each parameter as an improving or worsening parameter. 
 
First, a group of six chosen TRIZ/medical device practitioners will be asked to verify the 
determinants detected in stage 2. They will be given the opportunity to add further 
determinants if they feel necessary. 
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With the help of the practitioners, each determinant will be mapped with a parameter in 
the TRIZ 39x39 contradiction matrix. To start this, the author will prepare an initial 
mapping for all verified determinants. The practitioners will be asked to examine the 
proposed mapping results and if they feel necessary, suggest alternative mappings. 
 
Likewise, the author will also propose the specifications if each contradiction parameter 
is an improving or worsening parameter. Similar as in the previous step, the practitioners 
will examine the proposed specifications by analysing the conflict points which prevent 
the ideality from being achieved and if they feel necessary, make corrections. 
 
The choice will be considered valid, if more than 50% of the practitioners consider the 
mapping and specification of a determinant correct. Otherwise, the choice will be 
considered invalid and the determinant(s) will be eliminated from further steps of the 
procedure. 
 
Besides, for each test device, only those determinants related to future improvements in 
opinion of the patients (stage 2) are considered relevant to the further steps of the 
procedure. This implies, for each test device, only the determinants identified by the 
patients for whom a valid mapping and a valid specification is generated will enter the 
further steps of the procedure. In the end, a list of improving and worsening parameters 
will be generated for each test device. 
 
Stage 4: Identification of inventive principles 
The findings of stage 3 will be applied to the TRIZ 39x39 contradiction matrix in order 
to identify the corresponding inventive principles for the improvement of the test devices. 
This is organised as follows. 
 
In the contradiction matrix, each combination of an improving and a worsening parameter 
is mapped with a number of inventive principles which were developed from a previous 
knowledge base. Therefore, the application of the contradiction matrix to the results of 
stage 2, the improving and the worsening parameters for the development of each test 
device, leads to a number of inventive principles.  
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Due to time limitation of the experiment, three inventive principles with the highest 
frequency will be selected for each test device to guide the further TRIZ process. The 
reason for this decision is that a higher frequency implies a higher potential that the 
principles will lead to solutions in the specific cases.  
 
In case fewer than three inventive principles can be identified, or more than three of those 
will have the same highest frequency, the expert panel will be consulted for adding or 
eliminating certain principle(s), in order to keep the number of inventive principles 
constant for the further procedure of the experiment. 
 
Stage 5: Generation of solutions 
The inventive principles identified in stage 4 will be provided in the TRIZ experiment 
sessions. The participants will be asked to generate solutions for device improvements 
based on those principles. 
3.5.3  
3.5.4 The group work 
Immediately after the groups have submitted their solutions at the end of the experiment 
sessions, each group member will receive copies of the SYMLOG Adjective Rating Form 
and be asked to fill out one form for each member (including him-/herself) as evaluation 
of the individual behaviours during the group work (see Appendix XI and XII).  
 
The SYMLOG method was developed in 1960s by Robert Freed Bales based on the 
interaction analysis by Bales in the 1950s (Marx, 2000). The SYMLOG Adjective Rating 
Form describes the behaviour of the participants in a short-term evaluation (Marx, 2000). 
The evaluation of each individual is conducted with a separate rating form. The purpose 
of this instrument is to evaluate the personal attitude and characteristics during the 
experiment. Five choices were possible for the answer of each item: never, seldom, 
sometimes, often and always. 
 
After the forms have been completed, the author will ask the participants to exchange the 
filled out rating forms, so that everyone can review the rating he/she receives from the 
others. The author will also moderate a group discussion for the group members to bring 
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up their opinions on group work. The group discussion will be guided by the following 
questions: 
 
 How do you feel about working in a group? 
 Do you prefer to work in a group or on your own? 
 Did you feel comfortable during the solution-seeking process in the experiment? 
 How would you describe the status of the solution-seeking process in the 
beginning, in the middle and at the end of the session? 
 When was the most innovative moment? 
 Would a moderator, facilitator or a group leader be helpful for the group work? 
 Did you need more time or guidance? 
 
After the discussion, the group members will be requested to fill out the Adjective Rating 
Forms for a second time. Subsequently, the results of two rounds of rating will be assessed 
in respect of personal attitude and characteristics of the participants of the experiment. 
Also the group discussions will be recorded and subsequently assessed for theory building 
on group work. Besides, two independent raters will also fill out the SYMLOG Adjective 
Rating Form for each experiment participant based on the video recordings. 
3.5.5 Assessment of experiment results 
In order to explore the influence of TRIZ tools on problem-solving process in group work, 
the results of the experiment will be analysed in terms of both the outputs and the process: 
 
The outputs. The quality of the technical solutions will be evaluated based on the 
judgment of the expert panel and the patients. The same assessment methods will be 
applied to the test group following TRIZ procedure and the control group using the 
alternative problem-solving method. The following graphic illustrates the experiment 
procedure in terms of the outputs (see figure 3-5). 
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Figure 3-5 Experiment procedure: the outputs 
 
The process. In terms of the process, the interactions among the group members will be 
analysed and interpreted, so as to develop a theoretical understanding of how and why 
TRIZ changes problem-solving processes in group work. The global assessment of 
interactions between the group members is conducted both internally by the group 
members of the experiment and externally, by two independent raters. The following 
graphic illustrates the experiment procedure in terms of the process (see figure 3-6). 
 
Figure 3-6 Experiment procedure: the process 
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3.5.6 Research hypotheses 
There are many possible ways to describe the distinctive characteristics of the TRIZ 
techniques in comparison to other problem-solving tools. In order to answer RQ3 (“How 
and why do TRIZ techniques differentiate themselves from other problem-solving 
methods, from a theoretical perspective?”), three hypotheses were developed to be tested 
through the experiment based on the following considerations. 
 
The findings of the literature review in section 2.2 suggest that the most unique 
characteristic of the TRIZ method is its knowledge-based problem-solving approach 
(Ilevbare, Probert & Phaal, 2013; Savranksy, 2000; Domb et al., 1998). This allows the 
assumption that TRIZ is more efficient than the conventional trial-and-error approach 
when dealing with well-defined technology-driven problems. On the other hand, its 
advantages may diminish when dealing fuzzy problems, e.g. if the problem focuses on 
subjective opinions. 
 
Hypothesis 1: TRIZ is more effective than the conventional problems-solving approach 
when dealing with clearly defined technology-driven problems. 
 
The previous study of Birdi et al. suggests a further difference between TRIZ and the 
conventional problem-solving techniques. According to Birdi et al., the participation in 
TRIZ training leads to higher motivation of the engineers in the technical renovations 
(Birdi, Leach & Magadley, 2012). However, their investigation took the path of self-
assessment of the engineers which was affected by the individual biases of the participants. 
 
This work intends to test Birdi et al.’s assumption by means of SYMLOG Adjective 
Rating Form method, in order to reduce the individual biases in the research process. 
 
Hypothesis 2: TRIZ improves the motivation of the individual participants in the group 
work. 
 
Due to the complexity of its techniques, TRIZ requires elaborate prior trainings and 
special knowledge of the relevant technical issues. Potentially, this could enable the 
individual participants to take greater influence in their special fields and the group might 
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then “automatically” allocate the leadership to the best knowledgeable during the group 
decision-making process. Thus, a final assumption in respect of instinctive features of 
TRIZ was made that TRIZ would promote a clear leadership structure in the group work. 
 
Hypothesis 3: TRIZ promotes a clear leadership structure in the group work. 
 
Altogether, the influence of TRIZ on the outputs and the process of group work may be 
captured with the following 2-dimentional coordinate system (see figure 3-7) for the 
classification of problem solving situations. The dimension “problem definition” 
illustrates if the problem description is clear or fuzzy. The dimension “demand on special 
knowledge” describes the level of special knowledge involved in the problem-solving 
approach  and can be relatively high e.g. in case of TRIZ which requires elaborate prior 
knowledge, or relatively low in case of some conventional problem-solving techniques 
e.g. brainstorming (see figure 3-7). 
 
 
 
Figure 3-7 2-dimensional system for classification of problem-solving situations 
 
The research hypotheses 1 & 2 may be described in the above coordinate system as 
follows.  
 
Hypothesis 1: TRIZ is more effective than the conventional problems-solving approach 
when dealing with clearly defined technology-driven problems. 
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In comparison to the conventional problem-solving techniques, TRIZ requires higher 
level of special knowledge of the participants, both in terms of the relevant technologies 
and the TRIZ instruments. Therefore, innovations for clearly defined technology-driven 
problems by TRIZ are problem-solving situations in quadrant I and solution finding by 
conventional problem-solving techniques are situations in quadrant II. Thus Hypothesis 
1 may be interpreted as “TRIZ is more effective for the problem type in quadrant I than 
the alternative problem-solving technique for the problem type in quadrant II”. 
 
Hypothesis 2: TRIZ improves the motivation of the individual participants in the group 
work. 
 
Due to the higher requirements on the participants’ special knowledge, innovations with 
TRIZ should be referred to as problem-solving situations in quadrant I (if problem is 
clearly defined) or quadrant IV (if problem is fuzzy). Similarly, innovations with the 
alternative conventional problem-solving technique should be referred to as situations in 
quadrant II (if problem is clearly defined) or quadrant III (if problem is fuzzy).  Thus 
Hypothesis 2 may be interpreted as “TRIZ leads to higher motivation of the individual 
participants in group work in problem-solving situations of quadrant I (or IV) than the 
alternative problem-solving technique in situations of quadrant II (or III)”. 
  
Hypothesis 3: TRIZ promotes a clearer leadership structure in the group work. 
 
As discussed above, innovations with TRIZ may be described as problem-solving 
situations in quadrant I (if problem is clearly defined) or quadrant IV (if problem is fuzzy). 
Likewise, problem-solving with the alternative technique are situations in quadrant II (if 
problem is clearly defined) or quadrant III (if problem is fuzzy).  Thus Hypothesis 3 may 
be interpreted as “TRIZ leads to a clearer leadership structure in the group work in 
problem-solving situations of quadrants I (or IV) than the alternative problem-solving 
technique in situations of quadrants II (or III)”. 
 
3.6 Research design quality  
In his book on the research methods for social science, Yin highlighted his major concerns 
of the researcher’s biases and errors in research process, so as to misdirect the research 
findings. To counteract those biases, Yin recommended the following tests: construct 
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validity, internal validity, external validity and reliability to be applied during the case 
study research (Yin, 2009, pp. 141-144).  
 
Construct validity: 
Yin recommends three actions in the data collection stage to identify correct operational 
measures, i.e. use of multiple sources of evidence, establish chain of evidence and the 
review of research report by a third person (Yin, 2009, p. 41). 
 
The evidence used for this study comes from multiple sources: the literature review, the 
survey study, the experiments, the expert interviews, the patient interviews, the individual 
evaluation and the public group peers, as well as the group discussions.  
 
In addition, a chain of evidence is developed as follows throughout this study.  
 
a) The literature review delivered the background information on the key terms of this 
research: TRIZ, auto-injector, EpiPen, group work and SYMLOG.  
 
b) The survey study captures the contemporary status of the application of problem-
solving tools, especially of TRIZ, in the R&D of medical devices in the pharmaceutical 
industry in the Rhine-Main region in Germany. Based on the survey results, the popular 
problem-solving tool in alternative to TRIZ is identified for the experiment. Besides, 
suggestions are made by the survey participants for the assessment criteria of created 
solutions for medical devices. 
  
c) The proposed assessment criteria for the experiment outputs are verified by the medical 
device expert group. This is described as key informants review approach by Yin (2009). 
 
d) The experiment is designed based on the findings of a), including internal and external 
ratings, as well as the group discussions between the two rounds of internal ratings. 
 
e) The assessment of the experiment outputs is conducted based on the results of a), b) 
and c), as well as the patient interviews. 
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f) The assessment of the experiment process is conducted based on the findings of a) and 
d). 
  
Internal validity: 
Internal validity means to establish a causal relationship and to avoid a misinterpretation 
of the investigator’s conclusion on the relationship between different variables (Yin, 2009, 
pp. 141-144). Steps are taken in the research design of this study to increase the internal 
validity. 
 
The causal relationships in the experiment will be cross-examined by independent 
instances. First, the experiment outputs are reviewed by both the expert group and the 
pen-experienced patients. Second, the group work process will be reviewed by the 
individual participants, both before and after the public group peer discussions, as well as 
by two independent raters. Both steps are taken to reduce the biases and misinterpretations 
of one single investigator. In Yin’s terms, the research design addresses rival explanations.  
Another principle advised by Yin in terms of strengthening the internal validity of a 
research program, Pattern matching, is also considered in the research design. This 
includes for example the assessment of the experiment process based on the participants’ 
feedbacks in the Bales’ Adjective Rating Forms.  
 
External validity: 
External validity deals with the generalisation issue of a specific case investigation (Yin, 
2009, pp. 141-144). The generalisation of the results needs can only be verified by 
sufficient repetition of experiments of this study. Due to the limited capacity of this thesis, 
there is a limitation to the external validity of this study.  
 
Reliability: 
The goal is to enable a follow-up research that provides the same results as the previous 
study (Yin, 2009, pp. 141-144). Detailed documentation of the experiment comparable 
with an FDA audit of a medical device development is to be undertaken to record each 
single step. 
 
Following Yin’s recommendation, a research protocol will be written to facilitate the 
follow-up researches in the future. The reason for the protocol is that even the researchers 
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who are not familiar with the research topic will be able to reproduce the experiment 
following the detailed descriptions.  
 
3.7 Researcher’s role and ethical considerations 
The research will comply with the University of Gloucestershire’s Handbook of Research 
Ethics. To specify the most important aspects, the researcher will explain the nature and 
objectives of the study and how the results will be disseminated in advance in a brief 
statement. Free and informed consent will be obtained from all participants on a voluntary 
basis. In addition, the participants are given the opportunity to withdraw their consent at 
any time. 
The data obtained will be stored with precaution and used exclusively for research 
purposes. In addition, the data will be released without any identifying information of the 
participants.  
3.8 Research schedule  
 
(see table 3-7). 
 
Temporal plan is based on 48 months thesis program 
5 months 
4 months 
5 months 
4 months 
DBA501: Research methodology and methods 
DBA502: Action and case research 
DBA503: Systematic literature review 
DBA504: Reflective professional development  
6 months RD-1 draft, rework and submission 
9 months Preparation for research 
 
Literature review 
 
Preparation of experiment and survey study 
 
Pilot study 
 
Identification of determinants and inventive principles for TRIZ procedure 
3 months Improvement of research methods 
2 months Data collection and verification 
 
Distribution and collection of questionnaires; verification by experts and 
patients  
Carrying out 2x2 experiment including internal rating and group discussions 
 
External rating and Experiment assessment by experts and patients  
10 months Data analysis, interpretation, writing up and final submission 
Table 3-6 Research schedule 
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4. Survey study 
4.1 Survey development 
A survey instrument was developed with the aim to answer RQ1 (“Which problem-
solving tools are currently used for R&D of medical devices in the pharmaceutical 
industry?”) In other words, the survey aimed to capture the use of problem-solving 
techniques in various organisation fields and to identify the techniques that are most 
frequently used for R&D of medical devices in the pharmaceutical industry. In addition, 
the participants were intended to be asked to propose assessment criteria of technical 
solutions for medical device design. 
 
In early June 2014, an initial survey was developed and from June to July tested by the 
expert panel for comprehension and completeness. Based on their opinions, some 
redundant questions were eliminated, a few additional questions of interest added and the 
structure of the questionnaire tightened. Besides, a few questions were rephrased for 
better understanding. The improved questionnaire was again distributed to the same 
recipients. The survey design was finalised upon positive feedbacks of the expert panel. 
The final version of the survey has three sections.  
 
The first section of the survey consists of some general information on background of the 
participants, including gender, current position (department) and number of years of 
practical experience in the pharmaceutical industry.  
 
The second section focuses on the participants’ experience with problem-solving 
techniques, including training(s) on problem-solving techniques taken in the past three 
years, frequency of use of problem-solving techniques on the job, the types of problem-
solving tools used on the job and proposals for quality criteria for problem solutions for 
medical devices.  
 
The third section concentrates on the participants’ knowledge of TRIZ, with special 
reference to Ilvebare et al.’s investigation on general benefits of TRIZ in the practice 
(Ilevbare, Probert & Phaal, 2013). This involves TRIZ training(s) taken in the past three 
years, frequency of use of TRIZ as problem-solving techniques on the job, the types of 
TRIZ tools that are known to the participants, as well as the individual opinions on 
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benefits of TRIZ (including the choice that TRIZ applications have “no special benefits 
in problem-solving process”).  
 
The survey was first designed in English and subsequently translated by the author into 
German. Both the English and the German text were validated by the medical device 
expert panel involved in the piloting process. Whenever there were deviations between 
those two texts, the content was closely discussed with the expert panel till a consensus 
was reached that both texts were equal in content. The final version of the survey can be 
found in appendices I and II. 
4.2 Survey distribution 
In early winter 2014, the survey was distributed to staff members in three pharmaceutical 
companies in the Rhine-Main region in Germany.  
 
The questionnaires were handed out as printouts by a supporter (contact person) in each 
participating company who was knowledgeable of the organisation structure. In some 
companies, the medical device business was handled by a stand-alone organisation unit; 
in other cases, such business was treated by a project team with members from various 
business units based on a matrix organisation structure. Only staff members with practical 
R&D experience of medical devices were invited to the survey study. School practicants, 
students and trainees were excluded. Altogether, 125 questionnaires were distributed to 
the above institutions by e-mail or printouts. 
 
The survey was distributed with an accompanying letter which explained the voluntary 
basis of the study and guaranteed the data safety and discretion. The participants were 
asked to submit the questionnaires to the contact person in the company after filling them 
out in their private time. Both the companies and the participants were kept anonymous 
in the responses. The anonymity of participant’s employer to the researcher was 
constructed with reference to the separation between the sponsor and the patients in 
double-blinded clinical studies in the field of pharmaceutical research. 
 
The responses were collected in the succeeding four weeks after the distribution. 
Subsequently, the supporters (contact persons) returned the collected responses to the 
author. 
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4.3 Survey findings 
With 52 returned responses, the return rate of the survey study was 41.6 %. Among the 
participants, 35 were male and 17 female (see table 4-1).  
  
Gender 
Total 
Male Female 
Profession 
R&D 
Count 4 0 4 
% within profession 100.0% 0.0% 100.0% 
% within gender 11.4% 0.0% 7.7% 
% of Total 7.7% 0.0% 7.7% 
Marketing & sales 
Count 1 0 1 
% within profession 100.0% 0.0% 100.0% 
% within gender 2.9% 0.0% 1.9% 
% of Total 1.9% 0.0% 1.9% 
Production Biotech & Chemistry 
Count 0 1 1 
% within profession 0.0% 100.0% 100.0% 
% within gender 0.0% 5.9% 1.9% 
% of Total 0.0% 1.9% 1.9% 
Medical device development 
Count 28 13 41 
% within profession 68.3% 31.7% 100.0% 
% within gender 80.0% 76.5% 78.8% 
% of Total 53.8% 25.0% 78.8% 
Medical device production 
Count 0 2 2 
% within profession 0.0% 100.0% 100.0% 
% within gender 0.0% 11.8% 3.8% 
% of Total 0.0% 3.8% 3.8% 
Others 
Count 2 1 3 
% within profession 66.7% 33.3% 100.0% 
% within gender 5.7% 5.9% 5.8% 
% of Total 3.8% 1.9% 5.8% 
Total 
Count 35 17 52 
% within profession 67.3% 32.7% 100.0% 
% within gender 100.0% 100.0% 100.0% 
% of Total 67.3% 32.7% 100.0% 
Table 4-1 Descriptive statistics of survey study: participants 
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The current medical device departments were established only recently, due to the change 
from small molecules to biologicals drugs in the research-based pharmaceutical business. 
Most of the employees are men, due to the male domination in mechanical and technical 
working fields (many of them coming from the automobile industry). On the other hand, 
the laboratories of the pharmaceutical R&D remain a female domain, as a tradition of the 
pharmaceutical industry with biological-chemical roots (Smith-Doerr, 2004). The gender 
split in this survey study appears to be typical for the medical device development 
departments of the pharmaceutical industry. 
 
Also, 4 of the participants indicated that they worked in R&D, 1 in marketing & sales, 1 
in production Biotech & Chemistry, 41 in medical device development, 2 in medical 
device production and 3 in other professions in the organisation (see table 4-1). 
 
The results of the survey study suggested that the participants had at an average 8 years 
of practical experience in the pharmaceutical industry and 6 years with R&D and/or 
production of medical devices. Out of the 52 participants, 26 took part in trainings on 
problem-solving tools in the last three years, among those 16 had at least 4 days of training 
in total during this period of time.  
 
Among the participants of the survey study, the most frequently used problem-solving 
technique seemed to be brainstorming (making up 96.2% of all participants and 97.6% of 
the participants in the group “medical device development”), followed by mind-mapping 
(63.5% of all participants and 73.2% of the participants in the group “medical device 
development”) and TRIZ (30.8% of all participants and 34.1% of the participants in the 
group “medical device development”). The problem-solving techniques comprised in the 
group “others” were: root cause analysis, DMAIC, strengthening sessions, risk analysis, 
Ishikawa diagram, meta-plan, card sorting/ brain writing and the 5-Why method. 
 
Due to the high frequency of use by the practitioners, brainstorming was chosen to be the 
alternative problem-solving approach for the comparison study in the experiment sessions 
(see table 4-2). 
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Method 1 = Brainstorming 
Method 2 = Mind-mapping 
Method 3 = Trial error experiments 
Method 4 = Lateral thinking 
Method 5 = TRIZ 
Method 6 = Others 
Table 4-2 Frequency of use of problem-solving tools 
 
While 84.6% of the survey participants at least occasionally use some kind of problem-
solving techniques, only 25% of them reported to use TRIZ at a similar frequency (see 
table 4-3). 
 
  Use of problem-solving tools Use of TRIZ 
  never seldom occasionally frequently always never seldom occasionally frequently 
no 
reply 
Count 2 6 20 18 6 22 9 10 3 8 
% of 
Total 
3.8% 11.5% 38.5% 34.6% 11.5% 42.3% 17.3% 19.2% 5.8% 15.4% 
Table 4-3 Use of problem-solving tools vs. use of TRIZ 
 
Altogether, 11 out of 52 participants took part in TRIZ trainings in the last three years 
with a total training duration of 1-3 days. Probably due to the high complexity of the 
methods, only 25% of the participants claimed to be knowledgeable of some concept(s) 
of the TRIZ toolkits (see table 4-4). Besides, only 7 out of 52 participants were familiar 
with more than two TRIZ tools. The participants seemed to be the most acquainted with 
the TRIZ concepts of “39 x 39 contradiction matrix” and “40 inventive principles”. Those 
  
Methods 
Total 
1 2 3 4 5 6 
Profession 
R&D 
Count 4 2 0 0 0 0 4 
% of Total 100.0% 50.0% 0.0% 0.0% 0.0% 0.0% 100.0% 
Marketing & sales 
Count 1 0 1 0 1 0 1 
% of Total 100.0% 0.0% 100.0% 0.0% 100.0% 0.0% 100.0% 
Production 
Biotech & 
Chemistry 
Count 1 0 0 0 0 0 1 
% of Total 100.0% 0.0% 0.0% 0.0% 0.0% 0.0% 100.0% 
Medical device 
development 
Count 40 30 7 2 14 11 41 
% of Total 97.6% 73.2% 17.1% 4.9% 34.1% 26.8% 100.0% 
Medical device 
production 
Count 2 0 0 1 1 0 2 
% of Total 100.0% 0.0% 0.0% 50.0% 50.0% 0.0% 100.0% 
Others 
Count 2 1 1 1 0 0 3 
% of Total 66.7% 33.3% 33.3% 33.3% 0.0% 0.0% 100.0% 
Total 
Count 50 33 9 4 16 11 52 
% of Total 96,2% 63.5% 17.3% 7.7% 30.8% 21.2% 100.0% 
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two concepts are also the main foundation of the TRIZ approach used in the experiment 
sessions of this research (see table 4-4). 
 
  TRIZ concepts* 
  0 1 2 3 4 5 6 7 8 9 10 11 12 
Count 39 8 8 4 3 7 2 3 0 2 1 1 1 
% of 
Total 
75.0% 15.4% 15.4% 7.7% 5.8% 13.5% 3.8% 5.8% 0.0% 3.8% 1.9% 1.9% 1.9% 
 
* TRIZ concepts: 
0= none 
1 = 39 x 39 contradiction matrix 
2= 40 inventive principles 
3= 76 standard solutions 
4= Ideality 
5= Function analysis 
6= Patterns of evolution 
7= Nine windows 
8= Su field analysis 
9= Effects database 
10= Smart little people 
11= ARIZ 
12= S-Curve analysis 
Table 4-4 Participants’ knowledge of TRIZ concepts 
 
The participants provided the following reasons for their favour of the TRIZ methodology 
in their practical work: 
 Methodological approach to innovative problem solving (20) 
 Useful for generating new ideas (12) 
 Applying principles and trends to find creative solutions (7) 
 Rapidity and focus in solution finding (4) 
 Promote team and group work (5) 
 Shrinking systems size without decreasing performance (2) 
 Provides solutions to put the organisation in a competitive position (1). 
There were also three participants who claimed that TRIZ had no special benefits in the 
problem-solving process. 
 
The participants proposed the following criteria for the evaluation of technical solutions 
for medical devices. 
 Patient benefits; 
 Costs (including costs of manpower, development time and production, also if the 
medical insurance will reimburse the costs); 
 Level of innovation (differentiation from existing products); 
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 Feasibility (how well the proposed solution solves the problem; if the 
development and production of the proposed can be implemented without great 
difficulty) and 
 Risks (if the solution will affect user safety). 
4.4 Criteria for assessment of experiment outputs 
In order to determine the criteria for the assessment of experiment outputs, the proposals 
made by the survey participants (see previous section) were discussed with the medical 
device expert panel. As a result, the evaluation of the technical solutions in this research 
was planned to be carried out in two sections:  
i. Expert assessment (to be conducted by the expert panel) and  
ii. Patient assessment (to be conducted by the pen-experienced patients). 
 
The expert assessment consisted of the following three criteria. 
 Feasibility. This criterion assesses if the development and production of the 
proposed solution can be implemented without great difficulty, as well as if the 
solution will raise critical issues e.g. user safety. Obviously, the criteria for 
feasibility of different solutions may vary strongly from each other, therefore 
cannot be completely defined prior to the development of the solutions. The 
assessment of feasibility of the solutions also depends on the previous knowledge 
and experience of the evaluating experts. During the experiment, the participants 
will not be aware of the exact content of this criterion. In other words, the 
requirements of this criterion are fuzzy problems to the participants. 
 Novelty. This aspect describes the level of innovation of the technical solutions. 
The level of novelty is defined as how far the solution differs from the existing 
solutions. As the current solutions are predetermined for the participants, the 
content of this criterion is clearly defined to the participants of the experiment.   
 Costs. This includes the costs for manpower, development time and production.  
The experts’ anticipation of the costs of the developed solutions depends largely 
on their previous knowledge and experience. However, especially when dealing 
with innovative solutions that are not comparable with any existing products, the 
cost anticipation may be rather subjective. Also, which level of costs shall be 
considered appropriate depends largely on the type of solutions, therefore cannot 
be predetermined for the experiment procedure. Thus, the cost requirements on 
the technical solutions are fuzzy problems to the participants. 
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The patient assessment reflects the patient perceptions. The chosen patients will be asked 
to give their opinions on their perceived level of improvement of the technical solutions 
developed in the experiment sessions. The patient assessment is based mainly on the 
patients’ subjective opinions if they like the individual solutions. Obviously, the patients’ 
perceptions are substantially influenced by their experience in the past which are 
unknown to the participants of the experiments. Thus, the requirements of the patients’ 
perceptions are fuzzy problems. 
 
The possible scores range from “0” to “5” for each assessment dimension (“feasibility”, 
“novelty” and “costs” for expert assessment and “patient perception” for patient 
assessment). The content of each score in the assessment dimensions is specified as in the 
following table (see table 4-5). 
 
Assessment  Expert Assessment Patient Assessment 
Criteria Feasibility Novelty Costs Patient perception 
Possible 
scores 
0 not feasible  
1 feasible with great 
difficulty 
2 feasible with difficulty 
3 feasible with efforts 
4 feasible with slight efforts  
5 feasible without efforts 
0 old  
1 improvement 
2 modification 
3 solution transfer 
4 new idea  
5 new technology 
0 unfeasible  
1 very 
expensive  
2 expensive  
3 acceptable  
4 affordable  
5 inexpensive 
0 no improvement at all 
1 unnoticeable improvement  
2 minor improvement  
3 some improvement   
4 noticeable improvement 
5 essential improvement 
Table 4-5 Criteria for assessment of experiment outputs 
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5. Experiment procedure 
5.1 General test procedure 
In winter 2014/2015, six volunteers took part in the experiment as described in section 
3.5. All six persons had 5-10 years of practical experience in medical devices research 
and development, similar academic background and experience with problem-solving 
techniques. The participants were divided into two groups by the author, with the 
consideration that each group should contain a similar level of “total balance” of capacity 
in terms of the group members’ experience with product development and problem-
solving tools, as well as their academic background, age and gender, etc.  
 
During the experiment, both groups were asked to improve the test subjects chosen for 
the experiment. The test devices were two different models of EpiPen auto-injectors. To 
facilitate the technical development process, trainer devices of the test devices were 
provided to the participants. 
 
Test device 1:  EpiPen trainer device 1 (auto-injector 1) 
 
(see figure 5-1). 
 
 
Figure 5-1 Test device 1: EpiPen trainer device 1 
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Test device 2:  EpiPen trainer device 2 (auto-injector 2) 
 
(see figure 5-2). 
 
 
Figure 5-2  Test device 2: EpiPen trainer device 2 
 
Each group was asked to generate ideas for design improvement of the test device in two 
difference sessions. At the beginning of each session, the author gave instructions to the 
group on the problem-solving technique to apply. While the test group was asked to apply 
test procedure 1 (TRIZ techniques as described in 5.2), the control group was asked to 
work with test procedure 2 (brainstorming technique) throughout the session. The test 
plan is demonstrated in the following table (P1, P2, …, P6 stand for the participants 1-6) 
(see table 5-1). 
 
Test devices Test group Control group 
Auto-injector 1 P1, P2, P3 P4, P5, P6 
Auto-injector 2 P4, P5, P6 P1, P2, P3 
Table 5-1 Experiment: test plan 
 
Apart from the test instructions, the participants also received further background 
information (the test procedures and the background information will be addressed with 
more details in section 5.2).  At the end of each experiment session with the duration of 
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60 minutes, the group submitted their solutions in writing in accordance with the test 
instructions. 
 
After the instruction, the author retreated to an adjacent room and stayed there till the end 
of the experiment session. 
 
Immediately after the submission, the author entered the experiment room and distributed 
to each participant three copies of the SYMLOG Adjective Rating Form. The participants 
were asked to fill out one form for each group member including him-/herself as 
evaluation of the individual behaviours during the group work (see appendices X and XI). 
After completion of the forms, the participants were asked to show their ratings to the 
group mates, so that each participant could find out how she/he was rated by the others.  
 
Subsequently, the author moderated a group discussion and asked the participants to bring 
up their opinions on the group work. After this, each participant was again given three 
copies of the Adjective Rating Form and asked to assess the behaviours of the group 
members during the experiment for a second time. 
 
A video recorder was set up before hand, so that the complete experiment sessions 
including the behaviour ratings and the group discussions, as well as all involvement of 
the author, were recorded in full length.  
 
Two independent raters who were knowledgeable of SYMLOG procedures were shown 
the video material afterwards and asked to assess the behaviour of each participant at each 
experiment session by filling out the SYMLOG Adjective Rating Form.  
 
The German language was used for all procedures of the experiment. 
 
5.2 Test procedure 1: the 5-stage TRIZ process 
 
As introduced in section 3.5, the test procedure for the test group was designed as a 5-
stage TRIZ process. This process derives from Su et al.’s approach (Su, Lin & Chiang, 
2008) (see figure 5-3). 
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Figure 5-3  Experiment: 5-stage TRIZ approach 
 
The intension of this procedure is to generate new ideas for medical device innovations 
(drug-device combination products) by applying pre-defined TRIZ techniques. The 
content of the five stages is described in more details in the following. 
 
5.2.1 Stage 1: Definition of scope of problem 
As mentioned in section 5.1, two models of EpiPen auto-injectors were chosen to be the 
test subjects. The EpiPen products were chosen for this study, because they were among 
the oldest marketed drug device combination products and therefore sufficient previous 
studies were made available in academic journals and other publically accessible 
databases. Besides, the author deliberately chose the experiment subjects which were not 
products of his employer to avoid potential conflicts of interest. 
 
The scope of problem for the experiment (ideality in the TRIZ procedure) was thus 
defined as “optimising design of medical devices by finding solutions for problems 
identified by previous studies on example of the test subject”. 
 
 
 
 
1.
•Definition of scope of problem
2.
•Extraction of  determinants
3.
•Identification of contradiction parameters
4.
•Identification of  inventive principles
5.
•Generation of solutions
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5.2.2 Stage 2: Extraction of determinants 
The findings of literature reviews on “auto-injectors” and “EpiPen” were analysed. The 
influence factors considered relevant to design and use of the test subjects were identified 
as determinants for this TRIZ procedure. The results are shown in the following table (see 
table 5-2). 
No. Description 
Authors Citations 
1 
Device 
identification 
(Sicherer, Forman & 
Noone, 2000); (Nguyen 
Luu et al., 2012) 
(Use assessment of self-administered Epinephrine among 
food-allergic children and pediatricians); (Management of 
anaphylaxis in schools:Evaluation of an epinephrine auto-
injector (EpiPen) use by school personnel and comparison of 
two approaches of soliciting participation) 
 
2 
Comprehensive 
instruction of 
use 
(Bentur et al., 2006); 
(Ramos, Landy, 
Tepper, Wein & 
Schweizer, 2013); 
(Smith & Wallace, 
2013); (Nguyen Luu et 
al., 2012) 
(Civilian Adult Self Injections of Atropine – Trimedoxime 
(TMB4) Auto-Injectors); (An Open-Label Trial of a 
Sumatriptan Auto-Injector for Migraine in Patients Currently 
Treated With Subcutaneous Sumatriptan An Open-Label Trial 
of a Sumatriptan Auto-Injector for Migraine in Patients 
Currently Treated With Subcutaneous Sumatriptan); 
(Reducing drug self-injection errors: a randomized trial 
comparing a "standard" versus "plain language" version of 
Patient Instructions for Use); (Management of anaphylaxis in 
schools:Evaluation of an epinephrine auto-injector (EpiPen) 
use by school personnel and comparison of two approaches 
of soliciting participation) 
 
3 
Ease of use (Bentur et al., 2006); 
(Hawkins, Weil, Baty, 
Fitzpatrick & Rowell, 
2013); (Ramos, Landy, 
Tepper, Wein & 
Schweizer, 2013); 
(Rylander, 2009); 
(Renstrom, 2008); 
(Brandes 
 et al., 2009) 
(Civilian Adult Self Injections of Atropine – Trimedoxime 
(TMB4) Auto-Injectors); (Epinephrine autoinjector warning); 
(An Open-Label Trial of a Sumatriptan Auto-Injector for 
Migraine in Patients Currently Treated With Subcutaneous 
Sumatriptan An Open-Label Trial of a Sumatriptan Auto-
Injector for Migraine in Patients Currently Treated With 
Subcutaneous Sumatriptan); (Enject Inc.: Company 
Interview); (Finding right site for drug device); (Needle-free 
subcutaneous sumatriptan (SUMAVEL DOSEPRO): 
bioequivalence and ease of use) 
 
 
4 
Size of device (Gallagher, Worth, 
Cunningham-Burley & 
Sheikh, 2011); (Nguyen 
Luu et al., 2012) 
(Epinephrine auto-injector use in adolescents at risk of 
anaphylaxis:a qualitative study in Scotland, UK); 
(Management of anaphylaxis in schools:Evaluation of an 
epinephrine auto-injector (EpiPen) use by school personnel 
and comparison of two approaches of soliciting 
participation) 
 
5 
Customization 
for target 
groups 
(Oude Elberink, van 
der Heide, Guyatt & 
Dubois, 2009); 
(Rylander, 2009); 
(Renstrom, 2008); 
(Hawkins, Weil, Baty, 
Fitzpatrick & Rowell, 
2013) 
 
(Immunotherapy improves health-related quality of life of 
adult patients with dermal reactions following yellow jacket 
stings); (Enject Inc.: Company Interview); (Finding right site 
for drug device); (Epinephrine autoinjector warning) 
 
6 
Needle length  (Stecher, Bulloch, 
Sales, Schaefer & 
Keahey, 2009); (Sclar, 
2013) 
(Epinephrine Auto-injectors: Is Needle Length Adequate for 
Delivery of Epinephrine Intramuscularly?); (Bioequivalence 
evaluation of epinephrine autoinjectors with attention to 
rapid delivery) 
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No. Description Authors Citations 
7 
Needle 
protection  
(Greenberg & Riviello, 
2010); (Whyte, 2010); 
(Silverberg & 
Manoach, 2007); 
(Nguyen Luu et al., 
2012); (Brandes et al., 
2009) 
(Local effects after inadvertent digital injection with an 
epinephrine auto-injector); (The growing need for auto-
injectors); (Accidental self-administration of epinephrine 
with an auto-injector); (Management of anaphylaxis in 
schools:Evaluation of an epinephrine auto-injector (EpiPen) 
use by school personnel and comparison of two approaches 
of soliciting participation); (Needle-free subcutaneous 
sumatriptan (SUMAVEL DOSEPRO): bioequivalence and ease 
of use) 
8 
Flexibility of 
dose  
(Simons, Gu, Silver & 
Simons, 2002); 
(Ackaoui, 2011) 
(EpiPEN Jr Versus EpiPEN in young children weighing 15 to 30 
kg at risk for anaphylaxis); (Treatment of anaphylaxis EpiPen, 
Twinject, or another autoinjector?) 
9 
Injection time (Stecher, Bulloch, 
Sales, Schaefer & 
Keahey, 2009) 
(Epinephrine Auto-injectors: Is Needle Length Adequate for 
Delivery of Epinephrine Intramuscularly?) 
10 
Marking of 
injection end 
(Schwirtz & Seeger, 
2010); (Schwirtz & 
Seeger, 2012); 
(Nguyen Luu et al., 
2012) 
(Are adrenaline autoinjectors fit for purpose?A pilot study of 
the mechanical and injection performance characteristics of 
a cartridge versus a syringe-based autoinjector); 
(Comparison of the robustness and functionality of three 
adrenaline auto-injectors); (Management of anaphylaxis in 
schools:Evaluation of an epinephrine auto-injector (EpiPen) 
use by school personnel and comparison of two approaches 
of soliciting participation) 
11 
Patient's fear of 
device 
(Gallagher, Worth, 
Cunningham-Burley & 
Sheikh, 2011); 
(Stecher, Bulloch, 
Sales, Schaefer & 
Keahey, 2009); 
(Hawkins, Weil, Baty, 
Fitzpatrick & Rowell, 
2013); (Ramos, Landy, 
Tepper, Wein & 
Schweizer, 2013); 
(Mullins, 2003) 
(Epinephrine auto-injector use in adolescents at risk of 
anaphylaxis:a qualitative study in Scotland, UK); (Epinephrine 
Auto-injectors: Is Needle Length Adequate for Delivery of 
Epinephrine Intramuscularly?); (Epinephrine autoinjector 
warning); (An Open-Label Trial of a Sumatriptan Auto-
Injector for Migraine in Patients Currently Treated With 
Subcutaneous Sumatriptan An Open-Label Trial of a 
Sumatriptan Auto-Injector for Migraine in Patients Currently 
Treated With Subcutaneous Sumatriptan); (Anaphylaxis: risk 
factors for recurrence) 
12 
Adequate 
training - 
trainer, 
participants, 
frequency, 
training device 
etc. 
(Gallagher, Worth, 
Cunningham-Burley & 
Sheikh, 2011); (Bentur 
et al., 2006); 
(Greenberg & Riviello, 
2010); (Sheikh, 
Simons, Barbour & 
Worth, 2012); (Morris, 
Baker, Belot & Ewards, 
2011); (Ekwueme, 
Weniger & Chen, 
2002); (Litarowsky, 
Murphy & Canham, 
2004); (Sicherer, 
Forman & Noone, 
2000); (Hodges, Clack, 
& Hodges, 2005); 
(Sanagavarapu, 2012); 
(Clegg & Richtie, 
2001); (Ratnaweera, 
Trilsbach, Rangasami, 
Green & Puliyel, 2006) 
 
(Epinephrine auto-injector use in adolescents at risk of 
anaphylaxis:a qualitative study in Scotland, UK); (Civilian 
Adult Self Injections of Atropine – Trimedoxime (TMB4) 
Auto-Injectors); (Local effects after inadvertent digital 
injection with an epinephrine auto-injector); (Adrenaline 
auto-injectors for the treatment of anaphylaxis with and 
without cardiovascular collapse in the community); 
(Preparedness for Students and Staff With Anaphylaxis); 
(Model-based estimates of risks of disease transmission and 
economic costs of seven injection devices in sub-Saharan 
Africa); (Evaluation of an Anaphylaxis Training Program for 
Unlicensed Assistive Personnel); (Use assessment of self-
administered Epinephrine among food-allergic children and 
pediatricians); (Severe allergy: an audit and service review); 
(Don´t forget to pack my EpiPen® please: What issues does 
food allergy present for children's starting school?); 
("EpiPen" training: a survey of the provision for parents and 
teachers in West Lothian); (Audit of nurse-led-training for 
epipen in a District General Hospital) 
13 
Shelf life (Ackaoui, 2011); 
(Mullins, 2003.) 
(Treatment of anaphylaxis EpiPen, Twinject, or another 
autoinjector?); (Anaphylaxis: risk factors for recurrence) 
Table 5-2 TRIZ procedure: determinants from literature 
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In the next step, the determinants were verified by three pen-experienced patients. All 
patients had used delivery devices on themselves for more than ten years. Two of the 
patients were female, one male.  
 
First, all 13 determinants from the literature were explained in plain language with 
examples. The patients were given the opportunity to ask questions for comprehension. 
Subsequently, the test devices used for the experiment were verbally introduced, followed 
by demonstration video clips for EpiPen user training in the internet (www.youtube.com). 
The trainer devices were handed out to the patients so that they could test the functions 
and the handling procedure of the devices.  
 
Next, the patients were interviewed in the style of semi-structured interviews (see 
appendix VII).  
 
The results of the patient interviews are summarised in the following. 
 
General essential aspects for auto-injector design 
The patients’ opinions on the determinants from the literature are summarised in the 
following table 5-3. 
No. Description 
Patient 1 Patient 2 Patient 3 Total 
1 Device identification 1 1 1 3 
2 Comprehensive instruction of use 1 1 1 3 
3 Ease of use 1 1 1 3 
4 Size of device 1 1 1 3 
5 Customization for target groups 1 1 1 3 
6 Needle length 1 1 1 3 
7 Needle protection 1 1 1 3 
8 Flexibility of dose  1 1 1 3 
9 Injection time 1 1 1 3 
10 Marking of injection end 1 1 1 3 
11 Patient's fear of device 1 1 1 3 
12 Adequate training  1 1 1 3 
13 Shelf life 1 1 1 3 
 
0 = The patient(s) consider(s) this aspect not essential for auto-injector design 
1 = The patient(s) consider(s) this aspect essential for auto-injector design 
Table 5-3 TRIZ procedure: determinants in patient opinion (general) 
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Since the above determinants were considered by all patients as relevant for the 
development of medical devices, they were chosen for further steps of the TRIZ 
procedure. 
 
Further remarks of the patients were recorded in the following. 
 
1. Device identification 
The device needed to be easily identifiable. Especially in some cases when the patient 
was not in position anymore to apply the device by him-/herself, a helper who was not 
familiar with the device should be able to identify it quickly. 
 
2. Comprehensive instruction of use  
Comprehensive instruction of use was considered important especially for devices with 
relatively frequent updates. Graphics were believed to be more effective than text. 
A senior patient claimed that she expected to receive assistance from medical 
professionals therefore intended to rely on the comprehension of those persons.  
 
3. Ease of use 
Fast reaction time was considered essential for the administration of the medication, since 
this under circumstances could decide life or death. Therefore, the device must be easy to 
operate.  
 
4. Size of device 
While the senior patients tended to be in favour of bigger size of the device, younger, 
especially male patients seemed to prefer more compact designs. The explanation for it 
was that while women had the possibility to carry a larger device in the lady’ handbag, 
men usually had to carry the device in a pocket thus large-sized devices were considered 
bulky. 
 
5. Customization for target groups  
The patients proposed customization for different age groups (for example, larger size for 
the senior, more colourful devices with popping and rocking function for children) and 
gender, etc. One patient proposed different designs for day use and night use. 
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6. Needle length  
The female patients were in favour of longer needles, because they might need the needle 
to pierce through the relatively thick support tights. In their opinion, however, the needles 
should also not be too long, since the length of the needle was associated with patient’s 
fear of device. 
The interviewed male patient preferred shorter needles, mainly because shorter (also 
thinner) needles were supposed to cause less pain during the injection. 
Also the female patients preferred thinner needles due to pain sensitiveness. 
 
7. Needle protection 
All patients considered needle protection as an important function of the auto-injector. 
Especially needle protection designs with hidden needles were preferred, because the 
invisible needle would reduce the patient’s fear of device. 
 
8. Flexibility of dose 
Flexibility of dose was considered by all patients as an advantage. 
 
9. Injection time  
To all the patients, ideally, the injection time should not exceed 10 seconds. The male 
patient would even like to reduce the injection time to 5 seconds.  
 
10. Marking of injection end 
All patients reported that it was difficult to estimate the time used during the injection, 
thus it was always a challenge to judge when the injection was complete and the patient 
could release the device. A signal (acoustic signal or vibrations) at the end of the injection 
was considered an advantage.  
 
11. Patient's fear of device  
Patients often had to overcome their fear before the use of auto-injector. The fear was 
mainly associated with the visible needle, but also with the thoughts that foreign 
substances would enter the body.  
 
 
 
 109 
12. Adequate training - trainer, participants, frequency, training device etc.  
Adequate trainings were considered essential by all interviewed patients. In particular, 
they underlined the importance of training material in their native language, follow-up 
trainings and consideration of the physical conditions of the patient in the training 
programme (e.g. for those who suffer on hearing problems). 
 
13. Shelf life 
Since the type of devices could be expected to be used no more than a few times in the 
patients’ life, all patients believed the shelf life of the device of currently one year needed 
to be extended to 5-10 years. 
 
In addition, one patient mentioned that the device should be robust enough for a daily 
carriage (e.g. in the handbags) over longer period of time. Some improvement proposals 
were made, e.g. plastic rather than glass cartridges be used, or a stronger fitting for the 
cap of the device. 
 
Summarizing the above, all the 13 aspects from the literature were perceived by the 
patients as essential for auto-injector design. Furthermore, they proposed the following 
additional aspects: material of cartridge (plastic instead of glass) and strong fittings (for 
exterior design). 
 
Test device 1 
The results of the interview indicate that all three pen-experienced patients found the 
design of test device 1 adequate in the four aspects device identification, comprehensive 
instruction of use, ease of use and needle protection. All patients perceived the exterior 
design with bright colours adequate for the identification of the device for emergency 
uses. The instruction of use including the illustrations was perceived as comprehensive. 
However, one of the patients suggested that instruction of use for injection by a third 
person be comprised, since in case of emergency the patient might not be in position to 
inject him-/herself, so that a third person had to take over. Also the operation of the device 
was considered easy by all interviewed patients. The needle protection design of the test 
device seemed adequate to all patients, although one of them would like to slightly enlarge 
the safety cap. 
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The patients unanimously agreed that the device needed further improvement in the 
aspects size of device and shelf life of medication. While one patient would like to increase 
the size of the device for the senior, the other two patients proposed to reduce the size. 
One of the patients would like to cut down the size by at least a half. Since any patients 
were most likely to have to use an EpiPen for no more than a few times in their life, all 
patients believed the shelf life of the device needed to be substantially extended. One 
patient proposed changeable interior syringe to extend the lifetime of the secondary 
package. With a standardised secondary package, patients who needed more than one 
type of medical devices, e. g. diabetes patients, only had to carry one large secondary 
package instead of a complete device for each type of medication. 
 
Two out of the three patients felt that the device needed further improvement in the 
aspects customization for target groups, sufficient needle length, flexibility of dose, 
marking of injection end, and adequate training. Especially needs of the senior should be 
taken into account seriously, since the vital functions of their body differed greatly from 
those of other adults. Also the requirements of other age and gender groups should be 
attended to. One patient proposed a device version with a car key chain for men and a 
larger version for ladies’ handbag. One of the patients suggested a longer needle so that 
the needle could pierce through thick cloths like support tights, while another preferred a 
shorter and thinner needle to reduce the pain of the intramuscular injection. To the patients, 
it was necessary that the dose of auto-injectors should become more flexible to suit 
patients in different body weight classes. The patients found it helpful if the injection end 
would be marked with acoustic or visual (e.g. colouration) signals. Two patients 
requested better training opportunities, e.g. training with real devices under supervision 
of medical professionals. 
 
Only one patient considered it necessary to change the device in the aspects injection time 
and patient’s fear of device. The patient would like to reduce the injection time from 
approximately 10 seconds to 5 seconds. However, the other two patients did not consider 
this necessary. Two out of three interviewed patients did not associate the test device with 
patient’s fear thanks to the needle protection design with the hidden needle. However, 
one patient believed alone the thoughts that foreign substance was entering the body 
through the needle – even though an invisible needle – would still cause unease of the 
patients. 
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The results of the patient assessment were summarized in the following table 5-4. 
 
No. Description 
Patient 1 Patient 2 Patient 3 
1 Device identification 0 0 0 
2 Comprehensive instruction of use 0 0 0 
3 Ease of use 0 0 0 
4 Size of device 1 (-) 1 (+) 1 (-) 
5 Customization for target groups 1 (+) 1 (+) 1 (+) 
6 Needle length 1 (+) 0 1 (-) 
7 Needle protection 0 0 0 
8 Flexibility of dose  1 (+) 1 (+) 0 
9 Injection time 0 0 1 (-) 
10 Marking of injection end 1 (+) 1 (+) 0 
11 Patient's fear of device 1 (-) 1 (-) 0 
12 Adequate training  1 (+) 1 (+) 0 
13 Shelf life 1 (+) 1 (+) 1 (+) 
 
0 = The patient(s) consider(s) device improvement in the particular aspect as not necessary 
1 = The patient(s) consider(s) device improvement in the particular aspect necessary 
(+) = The patient(s) want(s) the determinant to increase 
(-) = The patient(s) want(s) the determinant to decrease 
(+/-) = The patients hold different opinions if the determinant should increase or decrease 
Table 5-4 TRIZ procedure: determinants in patient opinion (test device 1) 
 
The determinants were considered relevant for the development of the test device if at 
least 1 patient declared improvements to be necessary. As a result, the following 
determinants were chosen as relevant for further steps of the TRIZ procedure (see table 
5-5). 
 
No. Description 
Patients’ 
opinion 
4 Size of device 3 (+/-) 
5 Customization for target groups 3 (+) 
6 Needle length 2 (+/-) 
8 Flexibility of dose  2 (+) 
9 Injection time 1 (-) 
10 Marking of injection end 2 (+) 
11 Patient's fear of device 2 (-) 
12 Adequate training  2 (+) 
13 Shelf life 3 (+) 
 
(+) = All patients want the determinant to increase 
(-) = All patients want the determinant to decrease 
(+/-) = The patients hold different opinions if the determinant should increase or decrease 
Table 5-5 TRIZ procedure:  relevant determinants for test device 1 
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In addition, one patient asserted that the device ought to be more robust for a daily 
carriage over longer period of time. 
 
Test device 2 
All three patients found improvement necessary for test device 2 in the aspects device 
identification, sufficient needle length, needle protection, patient’s fear of device, 
adequate training and shelf life of medication. All patients suggested a more intensive 
colour scheme for the exterior design. One of the patients proposed in addition a larger 
fond size to visualize the test device as emergency medicinal product. While two patients 
stated that the needle length should be increased so that the needle could pierce through 
thick cloths like support tights, the other patient preferred a shorter and thinner needle so 
that the intramuscular injections could be less painful. To all three patients, the patients’ 
fear of device was mostly associated with the visible needle. Therefore, they proposed 
designs with hidden needles which at the same time could serve as needle protection. All 
patients were native German speakers and suggested that video and training material in 
the German language be provided. Since any patients were likely to use an EpiPen for no 
more than a few times in their life, it was considered a great advantage if its shelf life 
could be extended to 5-10 years.     
 
Two out of the three patients felt that the device needed further improvement in the 
aspects comprehensive instruction of use, size of device, customization for target groups, 
flexibility of dose and marking of injection end. According to the patients, the instruction 
of use should be developed for different age groups to achieve better comprehension of 
the patients. Also the illustration needed to be improved to enable the patient or a third 
person to grasp the device procedure quickly in case of emergency. The size of the auto-
injector should be smaller for younger people and bigger for the senior. Besides, men 
needed smaller pens for the daily carriage, while women could accept larger devices 
because they could easily find a place in a lady’s handbag. Therefore, the patients 
recommended a variety of device designs, e.g. special designs for the senior, the minor 
or the teenagers. Especially devices for the senior could largely reduce the healthcare 
expenses, as currently, the senior were normally obliged to assistance by healthcare 
services, either at home or in a hospital. The dose of the auto-injectors should be more 
flexible to be optimal for patients in different body weight classes. One recommendation 
by the patients was the implementation of multi-use devices in favour of environmental 
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protection which should help to reduce the medication reserve in the device which was 
wasted after the injection, as well as cost reduction. The patients also found it difficult to 
estimate the ongoing injection time, therefore would appreciate a mark for the injection 
end, either as acoustic or visual (e.g. colouration) signals.  
 
Only one patient considered it necessary to change the device in the aspects injection time. 
While the other two patients considered the current injection time adequate, one patient 
would like to have it reduced from approximately 10 seconds to 5 seconds. None of the 
patients thought further improvement necessary in the aspect of ease of use. 
 
The results of the patient verification were shown in the following table 5-6. 
 
No. Description 
Patient 1 Patient 2 Patient 3 
1 Device identification 1 (+) 1 (+) 1 (+) 
2 Comprehensive instruction of use 0 1 (+) 1 (+) 
3 Ease of use 0 0 0 
4 Size of device 0 1 (+) 1 (-) 
5 Customization for target groups 1 (+) 1 (+) 0 
6 Needle length 1 (+) 1 (+) 1 (-) 
7 Needle protection 1 (+) 1 (+) 1 (+) 
8 Flexibility of dose  1 (+) 1 (+) 0 
9 Injection time 0 0 1 (-) 
10 Marking of injection end 1 (+) 1 (+) 0 
11 Patient's fear of device 1 (-) 1 (-) 1 (-) 
12 Adequate training  1 (+) 1 (+) 1 (+) 
13 Shelf life 1 (+) 1 (+) 1 (+) 
 
0 = The patient(s) consider(s) device improvement in the particular aspect as not necessary 
1 = The patient(s) consider(s) device improvement in the particular aspect necessary 
 (+) = The patient(s) want(s) the determinant to increase 
(-) = The patient(s) want(s) the determinant to decrease 
(+/-) = The patients hold different opinions if the determinant should increase or decrease 
Table 5-6 TRIZ procedure: determinants in patient opinion (test device 2) 
 
One patient proposed additional design improvements e.g. to use plastic rather than glass 
for the cartridge, or a stronger fitting for the cap to make the device more robust for a 
daily carriage over longer period of time.  
 
The determinants were considered relevant for the development of the test device if at 
least 1 patient declared improvements to be necessary. As a result, the following 
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determinants were identified as relevant for further steps of the TRIZ procedure (see table 
5-7). 
 
No. Description 
Total 
1 Device identification 3 (+) 
2 Comprehensive instruction of use 2 (+) 
4 Size of device 2 (+/-) 
5 Customization for target groups 2 (+) 
6 Needle length 3 (+/-) 
7 Needle protection 3 (+) 
8 Flexibility of dose  2 (+) 
9 Injection time 1 (-) 
10 Marking of injection end 2 (+) 
11 Patient's fear of device 3 (-) 
12 
Adequate training - trainer, participants, frequency, 
training device etc. 
3 (+) 
13 Shelf life 3 (+) 
 
(+) = All patients want the determinant to increase 
(-) = All patients want the determinant to decrease 
(+/-) = The patients hold different opinions if the determinant should increase or decrease 
Table 5-7 TRIZ procedure:  relevant determinants for test device 2 
The finding of stage 2 were further analysed in stage 3 (see section 5.2.3). 
 
5.2.3 Stage 3: Identification of contradiction parameters 
The aim of this stage is to find the suitable TRIZ contradiction parameters for the later 
generation of the pursued solutions with inventive principles. This was done by means of 
a parameter-corresponding table as proposed by Domb, Miller, MacGran & Slocum 
(1998). This involves the following steps in this research: 
1. To finalise determinants for auto-injector design based on findings of stage 2; 
2. To allocate each determinant to a parameters in the TRIZ 39x39 contradiction 
matrix; 
3. To define each parameter as an improving or worsening parameter. 
 
In early November 2014, six medical device practitioners with TRIZ experience were 
presented with the findings of stage 2. They were asked to scrutinize the 13 determinants 
from the literature, as well as the additional essential aspects for auto-injector 
development material of cartridge (plastic instead of glass), strong fittings (for exterior 
design) proposed by the patients in stage 2. As a result, the practitioners all agreed that 
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the 13 determinants extracted from the literature were important aspects for the 
development of medical devices and should be treated as distinctive determinants for the 
further steps of the TRIZ procedure. Furthermore, the expert panel recommended adding 
a new determinant device robustness to reflect the patient proposals. No further 
determinants were considered necessary by the practitioners. 
 
Next, each of the 14 determinants was to be allocated to a parameter in the TRIZ 39x39 
contradiction matrix. For this purpose, the author produced an initial mapping table (see 
appendix VIII) and handed it out to the practitioners who were subsequently asked the 
following questions: 
1. Do you agree with the proposed mapping (decisions 1)? 
2. In case you agree with the proposal, do you consider the parameter as an 
improving or a worsening parameter (decision 2a)? 
3. In case you disagree with the proposal, with which TRIZ contradiction parameter 
would you map the EpiPen determinant (decision 2b)? 
 
The feedbacks of the six practitioners are summarised in the table 5-8. 
 
Determinants for EpiPen 
use 
TRIZ contradiction 
parameter 
Decision 
1 
Decision 
2a  
Decision 2b  
No. Description No. Description A D I  W Alternative 
1 Device identification 12 Shape 6 x 0 6 x 0   
2 
Comprehensive 
instruction of use 
33 
Ease of operation 
6 x 0 5 x 1 x   
3 
Ease of use 
33 
Ease of operation 
6 x 0 6 x 0   
4 
Size of device 
8 
Volume of stationary 
object 
5 x 
 
1 x 
 
1 x 
 
4 x 
 
1x ease of operation (33; I); 
***1x shape (12; I) 
5 
Customization for 
target groups 35 
Adaptability or 
versatility 
5 x 
 
 1 x 
 
4 x 
 
1 x 
 
1 x shape (12) or ease of 
operation (33; I) 
6 
Needle length 
3 
Length of moving 
object 4 x  2 x 2 x 2 x 
1 x measurement accuracy (28; 
I); 1 x device complexity (36; I) 
or shape (12; I) 
7 
Needle protection  
12 
Shape 
6 x 
 
0 
 
5 x + 
1 x? 
  
0 
  
***1 x device complexity (36; 
I);  
*** 1 x ease of use (33; I) 
8 
Flexibility of dose  
7 
Volume of moving 
object 
5 x 
 
1 x 
  
5 x 
 
 0 
 
1 x device complexity (36; I);  
***1 x ease of operation (33; I) 
or adaptability or versatility 
(35; I) 
Determinants for EpiPen 
use 
TRIZ contradiction 
parameter 
Decision 
1 
Decision 
2a  
Decision 2b  
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No. Description No. Description A D I  W Alternative 
9 
Injection time 
25 
Loss of time 
5 x 
 
 1 x 
 
2 x 
 
3 x 
 
1 x quantity of the substance/ 
the matter (26; I) 
 
10 
Marking of injection 
end 
15 
Duration of action by 
a moving object 
4 x  
 
 1 x 
+ 1 
x? 
 
4 x + 
1 x? 
  
 0 
 
1 x loss of information (24; W) 
or ease of operation (33; I); 
***1 x device complexity (36; 
I)  
11 
Patient's fear of 
device 12 
Shape 
5 x 
 
1 x 
 
4 x + 
1 x? 
 
 0 
 
1 x ease of operation (33; I); 
***1 x adaptability or 
versatility (35; I); 
12 
Adequate training - 
trainer, participants, 
frequency, training 
device etc. 
24 
Loss of information 
3 x 
 
 3 x 
 
2 x 
 
1 x 
 
1 x device complexity (36; I); 
1 x ease of operation (33; I); 
1 x ease of operation (33; I) or 
adaptability or versatility (35; 
I) or device complexity (36; I) 
 
13 
Shelf life 
24 
Loss of information 
1 x  
 
5 x 
 
 0 
 
1 x 
 
4 x stability of the object´s 
composition  (13; I);  
1 x loss of time (25; W) 
14 
Device robustness 
11 
Stress and pressure 
6 x 0 
  
0 
 
6 x 
 
A= agree; D = disagree; I = improving parameter; W = worsening parameter; alternative = alternative TRIZ 
contradiction parameter 
***  Practitioners agrees with the proposed mapping, however proposes further alternative(s) 
(XX; I/W) XX= number of parameter in the TRIZ contradiction matrix; I = improving parameter; W = 
worsening parameter 
?  Practitioners is not sure about the choice 
Table 5-8 TRIZ procedure: parameter mapping by practitioners 
 
In some cases, the practitioners proposed additional parameters to the TRIZ contradiction 
matrix to cover special demands of medical device research and development. In their 
opinion, some of those parameters were irrelevant to the development of medical devices 
thus ought to be eliminated, so that the total number of parameters could be reduced. 
Consequently, also the inventive principles should be modified to better accommodate 
the requirements of medical device development. However, the extension/modification 
of the TRIZ tools would involve extensive background research, including the search of 
pertinent knowledge bases. Due to the limitation of data access and resources of this study, 
such tasks are left to future researchers. 
 
Furthermore, the practitioners suggested that a detailed written guidance for the 
application of TRIZ techniques to medical device development be compiled to specify 
each TRIZ instrument for this special use. This study took the first step for the 
compilation of the guidance by mapping the medical device relevant determinants with 
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the 39 TRIZ parameters in the 39x39 contradiction matrix and consequently with the 
TRIZ inventive principles.  
 
Upon feedbacks of the practitioners, the researcher modified the initial parameter 
mapping according to the following principles. 
 
1. The mapping (decision 1/ decision 2b) was considered valid, when at least 4 out 
of the 6 practitioners agreed with the choice. Otherwise, the mapping was 
considered invalid. 
2. The decision of the parameter as an improving or a worsening parameter (decision 
2a/ decision 2b) was considered valid, when at least 4 out of the 6 practitioners 
agreed with the choice. Otherwise, the mapping was considered invalid. 
 
The results are shown in the table 5-9. 
 
Determinants for EpiPen use TRIZ contradiction parameter 
Mapping I / W  
No. Description No. Description 
1 Device identification 12 Shape Valid I 
2 
Comprehensive instruction of 
use 
33 Ease of operation Valid I 
3 Ease of use 33 Ease of operation Valid I 
4 Size of device 8 Volume of stationary object Valid W 
5 
Customization for target 
groups 
35 Adaptability or versatility Valid I 
6 Needle length 3 Length of moving object Invalid  
7 Needle protection  12 Shape Valid I 
8 Flexibility of dose  7 Volume of moving object Valid I 
9 Injection time 25 Loss of time Invalid  
10 Marking of injection end 15 Duration of action by a moving object Valid I 
11 Patient's fear of device 12 Shape Valid I 
12 
Adequate training - trainer, 
participants, frequency, 
training device etc. 
24 Loss of information Invalid  
13 Shelf life 13 Stability of the object’s composition Valid I 
14 Device robustness* 11 Stress and pressure Valid W 
I = improving parameter; W = worsening parameter 
*Determinant 14 was added based on the patient’s proposal 
Table 5-9 TRIZ procedure: parameter mapping by practitioners (results) 
Thus the relevant parameters for the improvement of the test devices were mapped as 
follows (see table 5-10 and table 5-11). 
 
Test device 1  
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Determinants for device improvement TRIZ contradiction parameters 
W / I 
No. Description No. Description 
4 Size of device 8 Volume of stationary object W 
5 Customization for target groups 35 Adaptability or versatility I 
6 Needle length 3 Invalid  
8 Flexibility of dose  7 Volume of moving object I 
9 Injection time 25 Invalid  
10 Marking of injection end 15 Duration of action by a moving object I 
11 Patient's fear of device 12 Shape I 
12 
Adequate training - trainer, participants, 
frequency, training device etc. 
24 Invalid  
13 Shelf life 13 Stability of the object’s composition I 
14 Device robustness* 11 Stress and pressure W 
I = improving parameter; W = worsening parameter 
*Determinant 14 was added based on the patient’s proposal 
Table 5-10 TRIZ procedure: parameter mapping for test device 1 
 
 
Test device 2  
 
Determinants for device improvement TRIZ contradiction parameters 
W / I 
No. Description No. Description 
1 Device identification 12 Shape I 
2 Comprehensive instruction of use 33 Ease of operation I 
4 Size of device 8 Volume of stationary object W 
5 Customization for target groups 35 Adaptability or versatility I 
6 Needle length 3 Invalid  
7 Needle protection 12 Shape I 
8 Flexibility of dose  7 Volume of moving object I 
9 Injection time 25 Invalid  
10 Marking of injection end 15 Duration of action by a moving object I 
11 Patient's fear of device 12 Shape I 
12 
Adequate training - trainer, participants, 
frequency, training device etc. 
24 Invalid  
13 Shelf life 13 Stability of the object’s composition I 
14 Device robustness* 11 Stress and pressure W 
I = improving parameter; W = worsening parameter 
*Determinant 14 was added based on the patient’s proposal. 
Table 5-11 TRIZ procedure: parameter mapping for test device 2 
 
The relevant contradiction parameters for the improvement of the test devices are 
summarized in the following table (in case several determinants are mapped with the same 
contradiction parameter, the parameter appears more than one time in this table. This is 
because the frequency of the parameters is a part of the solution finding process) (see 
table 5-12). 
Test device 1 Test device 2 
 119 
Improving parameters Worsening parameters Improving parameters Worsening parameters 
No. Description No. Description No. Description No. Description 
35 
Adaptability or 
versatility 
8 
Volume of stationary 
object 
12 
Shape 
8 
Volume of 
stationary object 
7 
Volume of moving 
object 
11 
Stress and pressure 
33 
Ease of operation 
11 
Stress and 
pressure 
15 
Duration of action by a 
moving object 
 
 
35 
Adaptability or 
versatility 
  
12 Shape   12 Shape   
13 
Stability of the object’s 
composition 
 
 
7 
Volume of moving 
object 
 
 
 
 
 
 
15 
Duration of action by 
a moving object 
 
 
    12 Shape   
 
 
 
 
13 
Stability of the 
object’s composition 
 
 
Table 5-12 TRIZ procedure: contradiction parameters for test devices 
 
The content of the parameters is briefly introduced in the following. The description of 
the parameters is oriented on Gadd’s book on TRIZ application for engineers (Gadd, 2011, 
pp. 468-470). 
 
Parameter 7. Volume of a moving object 
This means the space occupied by the object, measured by its length x width x height. In 
the context of medical device design, this can be related for example to the moving 
plunger and the stopper of a cartridge or pre-filled syringe-based system.  
 
Parameter 8. Volume of a stationary object 
Same as parameter 7, this parameter stands for the space occupied by a stationary object, 
measured by its length x width x height. 
 
Parameter 11. Stress and pressure 
Tension or force per unit area, e.g. such induced on a device by daily carriage of the 
patient. 
 
Parameter 12. Shape  
Shape stands for the external appearance of the object and concerns especially the exterior 
design of the auto-injector. Currently, ergonomic aspects play an increasingly important 
role in the device design.  
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Parameter 13. Stability of the object´s compositions 
The stability of object’s compositions describes its wholeness or integrity. The natural 
aging process of formulated drug substances and polymers components, for example, is 
considered decreases in stability. 
 
Parameter 15. Duration of action by a moving object 
This means the time, the object performs the action and can therefore be associated with 
e.g. the injection time of an auto-injector, which is an important technical requirement 
and aspect in the design development, as well as an essential criterion for the product 
release.  
 
Parameter 33. Ease of operation 
Simplicity, e.g. the device operation does not require assistance of a third person; a small 
number of steps in the operation, no need for special tools or accessories etc.  
 
Parameter 35. Adaptability and versatility 
The variety of the device that can be used in multiple ways under different circumstances. 
In other words, specific devices with specific substances (different drugs or formulations) 
with focus on specific patient groups, e.g. suitable ergonomic features. 
 
In the next stage, the contradiction matrix was applied with the above contradiction 
parameters to identify the matching TRIZ inventive principles for the generation of 
solutions.   
5.2.4 Stage 4: Identification of inventive principles 
The scope of problem for the experiment of this study was defined as “optimising design 
of medical devices by finding solutions for problems identified by previous studies on 
example of the test subject” (stage 1). Thus the ideality for the TRIZ procedure in this 
study was defined as design optimisation of the test subject. 
 
The optimisation of auto-injector design usually involves a number of parameters which 
sometimes contradict each other. For example, the patient prefers a sensible mechanic 
construction so that the injection function can be triggered with little force. This can be 
enabled e.g. by a spring with a sufficient volume, so that its stretch and release of power 
in the inner system may lead to the sensible operations as desired. On the other hand, 
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many patients wish the device to be as small as possible, so that the maximum size of the 
spring must be restricted. The original 39x39 TRIZ contradiction matrix with the resulting 
40 inventive principle provides indications for possible optimal solutions in such conflict 
situations. The inventive principles were developed based on a previous knowledge base 
(Gadd, 2011, p. 472).  
 
The findings in stage 3 led to the following constellation of contradiction matrix for test 
device 1 (see table 5-13).    
 
  
Worsening parameter 
 
 8 11 
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35 n. a. 35 16 
7 n. a. 
6  35 
36  37 
15 n. a. 
19  3 
27 
12 
7  2 
35 
34  15 
10  14 
13 
34  28 
35  40 
2  35 
40 
Table 5-13 TRIZ procedure: extracted contradiction matrix for test device 1 
 
Each combination of an improving and a worsening parameter was mapped with a number 
of inventive principles which were developed from a previous knowledge base (see table 
5-14). The combinations (8; 35), (8; 7) and (8; 15) delivered no solutions since no such 
solution patterns could be extracted from the knowledge base. Other combinations led to 
2-4 inventive principles, e. g. (11; 35) were related to the inventive principles 35 and 16; 
(8; 12) was mapped with the inventive principles 7, 2 and 35.  
  
The following table is a summary of the inventive principles identified through the 
applications of TRIZ 39x39 contraction matrix, as well as their frequencies for device 1 
(see table 5-14). 
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Inventive principles  
Frequency 
No. Description 
2 Taking out 2 
3 Local quality 1 
6 Universality 1 
7 Nested Doll 1 
10 Prior action 1 
14 Spheroidality – curvature 1 
15 Dynamics 1 
16 Partial or excessive action 1 
19 Periodic action 1 
27 Cheap short living objects  1 
28 Replace mechanical system 1 
34 Discarding and recovering 2 
35 Parameter change 5 
36 Phase transition 1 
37 Thermal expansion 1 
40 Composite material 2 
Table 5-14 TRIZ procedure: inventive principles for test device 1 
 
Due to the time limit of the experiment, only the three inventive principles with the 
highest frequency were chosen to guide the application of TRIZ approach in the 
experiment, since the higher frequency implied a higher potential that those principles 
could lead to solutions in the specific case. Since the inventive principles 2, 34 and 40 led 
to the same second highest frequency in this step of the TRIZ procedure, after consulting 
the expert panel, the inventive principle 2 taking out and 40 composite material were 
chosen. Thus out of 16 inventive principles, the following 3 were chosen for further TRIZ 
procedure in the experiment: No. 35 parameter change with 5 hits, No. 2 taking out with 
2 hits and No. 40 composite material with 2 hits.  
 
The content of the above inventive principles is introduced briefly in the following. The 
explanation is guided by Gadd’s book on TRIZ application for engineers (Gadd, 2011, 
pp. 140-174). 
 
 No. 2 Taking out  
Taking out may be applied in two forms: to extract the disturbing part and property from, 
e.g. to eliminate or minimize pain during the injection with a medical device; or to extract 
the only necessary part of property of an object, for example to reduce the auto-injector 
to the most necessary parts, e.g. the syringe and the liquid medication.  
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 No. 35 Parameter change 
Parameter change has many different forms, including change of physical state (e.g. to 
gas, liquid or solid), change of concentration or density, change of the degree of flexibility, 
change of the temperature or volume and change of pressure etc.  
 
 No. 40 Composite materials 
This inventive principle stands for the change from uniform material to a composite/ 
multiple-layered structure. This could be, for example, to use different plastic material 
for the internal and the external surface, in order to implement ergonometric features like 
stronger grip for the patient on the outside and to decrease or increase the friction on the 
inside for the injection operations. 
 
Similarly, the findings in stage 3 also delivered the following constellation of 
contradiction matrix for test device 2 (see table 5-15). 
   
  
Worsening parameter 
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7  2 
35 
34  15 
10  14 
33 
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39  31 
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12 
7  2 
35 
34  15 
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7 n. a. 
6  35 
36  37 
15 n. a. 
19  3 
27 
12 
7  2 
35 
34  15 
10  14 
13 
34  28 
35  40 
2  35 
40 
Table 5-15 TRIZ procedure: extracted contradiction matrix for test device 2 
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The following table is a summary of the inventive principles identified by the applications 
of TRIZ 39x39 contraction matrix, as well as their frequencies for device 2 (see table 5-
16). 
 
Inventive principles  
Frequency 
No. Description 
2 Taking out 5 
3 Local quality 1 
4 Asymmetry 1 
6 Universality 1 
7 Nested Doll 3 
10 Prior action 3 
12 Equipotentiality  1 
14 Spheroidality - curvature 3 
15 Dynamics 3 
16 Partial or excessive action 1 
18 Mechanical vibration 1 
19 Periodic action 1 
27 Cheap short living objects  1 
28 Replace mechanical system 1 
31 Porous materials 1 
32 Colour change 1 
34 Discarding and recovering 4 
35 Parameter change 7 
36 Phase transition 1 
37 Thermal expansion 1 
39 Accelerated oxidation 1 
40 Composite material 2 
Table 5-16 TRIZ procedure: inventive principles for test device 2 
 
Again the inventive principles with the three highest frequencies were chosen for the 
TRIZ procedure for test device 2. They were: No. 35 parameter change with 7 hits, No. 
2 taking out with 5 hits and No. 34 discarding and recovering with 4 hits (see table 5-17).  
 
Test device 1 Test device 2 
No. Description No. Description 
35 Parameter change 35 Parameter change 
2 Taking out 2 Taking out 
40 Composite material 34 Discarding and recovering 
Table 5-17 TRIZ procedure: inventive principles for experiment 
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The inventive principles 2 and 35 are already introduced above. In the following, the 
inventive principle 34 is described based on Gadd’s book (Gadd, 2011, pp. 140-174). 
 
 No. 34 discarding and recovering 
Discarding means that objects or parts of objects disappear or change their physical form 
after the completion of their useful function, e.g. bio-needles are absorbed by the body 
after the injection. Recovering stands for restoration of consumable parts of an objection 
during the operation, e.g. self-sharping knifes. 
 
5.2.5 Stage 5: Generation of solutions 
In this final stage, the participants of the test group were provided with the inventive 
principles identified in stage 4. Based on the introduction and the list of the inventive 
principles, the participants were asked to generate solutions for device improvements. 
This stage is organised as experiment sessions with the following steps. 
 
The group was instructed to act as a self-directing working group. Each participant was 
given a pencil and three sheets of paper. No further tools and instrument were allowed.  
 
The first phase of this stage was focused on generation of new ideas based on the chosen 
inventive principles. At the beginning, the participants were give 15 minutes time to note 
down the individual initial ideas. Subsequently, they were given 60 minutes for 
discussions in the group. The participants received a signal 10 minute before the end of 
this phase so that they could take the time to produce a complete written list of their ideas. 
5.3 Test procedure 2: brainstorming 
The results of the survey study identified brainstorming as the problem-solving technique 
used with the highest frequency in the pharmaceutical industry (see section 4.3). Thus 
this method was chosen as the experiment procedure for the control group.  
 
Brainstorming as a method for idea generation was first published by Osborn in 1953. 
Meanwhile, it has become a popular method with a variety of forms for technical 
innovation in different fields (Gobble, 2014).  
 
The brainstorming procedure in this research is organised as follows.  
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Similar as the test group, the control group was given instructions on EpiPen and scope 
of problem for the experiment. However, unlike the test group, they did not receive the 
introduction on the TRIZ inventive principles. 
 
The group was instructed to act as a self-directing working group. Each participant was 
given a pencil and three sheets of paper. No further tools and instrument were allowed.  
 
Initially, the participants were give 15 minutes time to note down his/her initial ideas. 
Subsequently, they were given 60 minutes for discussions in the group. The participants 
received a signal 10 minute before the end of this phase, so that they could produce a 
complete written list of the ideas generated. 
Altogether, the experiment session was organised in a similar style for both groups. The 
only difference was that only the test group received the additional introduction on TRIZ 
inventive principles to be used. 
5.4 Test instructions 
Prior to the experiment sessions, the participants were given the following background 
information. 
5.4.1 EpiPen introduction 
The EpiPen test device to be used in the experiment session was introduced verbally by 
the author, followed by a demonstration video clip for EpiPen user training from the 
internet (www.youtube.com). The trainer device was handed out to the participants so 
that they could test the function and the handling procedure of the device.  
5.4.2 Introduction on scope of problem 
 
The following literature findings on the patient requirements for device improvement 
were made available to all participants as printouts. This information was comprised by 
the author based on the literature review on “auto-injectors” and “EpiPen” and verified 
by the expert panel prior to the start of the experiment (see section 5.2.2).  
 
The participants were given 10 minutes to go through the handouts and to ask questions 
for comprehension. 
Scope of problem for improvement of EpiPen auto-injectors 
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The literature findings are divided in 13 categories. Besides, one additional point was 
added based on the results of patient interviews. Some of the categories have several 
aspects. The problem solutions recommended by the literature are given in brackets 
[recommendation] 
 
 Device identification [differentiation of EpiPen from other devices for use of the 
right device] 
 
1. Comprehensive instruction of use 
 Clear instruction for use [update of instruction for use with additional steps to 
reduce misuse] 
 Instruction of when to apply an EpiPen in the medical guide (anaphylaxis case) 
 
2. Ease of use  
 Convenience for use, carriage and storage in daily Life 
 Backup solution in case of use error (e.g. failure of first injection) [2nd dose 
regimen for 2nd shot, multi-injection delivery devices similar to diabetes pens] 
 
3. Bulky size 
 Device design perceived by patients as bulky and cumbersome [outer shape needs 
to suit into a pocket; new mechanism to activate the device to reduce inner 
mechanical items]  
 
4. Customization for target groups 
 Development of device updates according to customers’ needs on a regular basis 
[new outer shape design and colours for target population] 
 Customisation for gender groups (previous studies indicate that men often only 
carry the EpiPen in risky situations like schools and restaurants, while women 
usually carry their device all the time) 
 Customisation for age groups (e.g. currently EpiPen is not designed for self-
injection by children) 
 
5. Sufficient needle length (for intra-muscular injection) 
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 Needle protection (against accidental sticks) [needle stick prevention] 
 
6. Flexibility of dose 
 E.g. there are EpiPen and EpiPen Jr., however no device suitable for children 
weighting 15-30 kg 
 
7. Injection time 
 Unclear with the current devices, the user has to decide based on his/ her feelings 
 
8. Marking of injection end 
 Currently no indication of administration completion [to develop features to 
reduce delay of indication; support by signs] 
 
9. Patient's fear of device 
 Needle phobia [oral drugs: e.g. antihistamines easier to use; alternative to 
subcutaneous: e.g. sublingual] 
 Psychological barrier associated with the device design  
 Inadequate self-discipline for use and carriage of EpiPen (current design 
associated with fear and panic; fear of using an medical device) 
 
10. Adequate training  
 Training material [new training material: social media, presentation, hand in 
hand practice, trainer device; diabetes based needle and syringe, and storage 
features to be considered] 
 Follow-up trainings [follow-up trainings after initial training; improvement of 
skills by verbal and audio training] 
 Professional trainers [professional training by experts increase confidence for 
transition from care-giver to self-medication management] 
 
11. Short shelf life of medication (70% of all device are destroyed without usage) 
 
12. Device robustness (e.g. for daily carriage, shock resistance) 
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The task for the experiment was defined as “optimising design of medical devices by 
finding solutions for problems identified by previous studies on example of the test 
subject”. Furthermore, the fields of improvements were defined as in the following table. 
This was the result of stage 2 of the 5-stage TRIZ procedure in this study (see table 5-18). 
 
No. Description 
1 Device identification 
2 Comprehensive instruction of use 
3 Ease of use 
4 Bulky size 
5 Customization for target groups 
6 Needle length 
7 Needle protection 
8 Flexibility of dose 
9 Injection time 
10 Marking of injection end 
11 Patient's fear of device 
12 Adequate training  
13 Short shelf life of medication 
14 Device robustness 
Table 5-18 Experiment tasks 
 
5.4.3 Problem-solving techniques 
For the experiment sessions, the test group was asked to use the TRIZ procedure and the 
control group, the brainstorming procedure. 
 
In addition to the EpiPen introduction and the introduction on the scope of problem, the 
test group received a briefing on the TRIZ procedure to be used for the experiment. This 
consisted of an introduction of the three inventive principles to be applied in the session 
(see section 5.2.4). 
 
The control group received the same introduction on the test devices (EpiPen) and the 
scope of problem. Besides, the control group received an introduction on the 
brainstorming procedure for the experiment in this study (see section 5.3). 
5.5 Group work and group discussions 
Immediately after the group work was finished, the group was given an introduction on 
the SYMLOG Adjective Rating Form method. The author went through the form with 
the participants for comprehension.   
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The SYMLOG Adjective Rating Form was handed out to the participants as printouts. 
Each participant was asked to evaluate the behaviour of each group member by filling out 
a form for each person including him-/herself.  
 
Next, the participants were asked to exchange the filled out rating forms with the author. 
The author and the participants reviewed the rating forms altogether. After this, the author 
initiated a group discussion for the group members to bring up their opinions on group 
work guided by the following questions: 
 
 How do you feel about working in a group? 
 Do you prefer to work in a group or on your own? 
 Did you feel comfortable during the solution-seeking process in the experiment? 
 How would you describe the status of the solution-seeking process in the 
beginning, in the middle and at the end of the session? 
 When was the most innovative moment? 
 Would a moderator, facilitator or a group leader be helpful for the group work? 
 Did you need more time or guidance? 
 
Subsequently, the group members filled out the Adjective Rating Forms for each group 
member for a second time. The group discussion was video recorded for later assessment. 
 
In addition, two independent raters evaluated the behaviours of the participants based on 
the video recordings. Each rater filled out the SYMLOG Adjective Rating Form for the 
individual participants in each single experiment session.  
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6. Experiment findings 
6.1 Outputs 
6.1.1 Control group/ test device 1 
The discussion using brainstorming technique was guided by the introduction on the 
scope of problem (see section 5.4.2). Using the background information handout as a 
checklist, the participants proposed the following improvements to the test device with 
reference to all of the 14 technical issues of auto-injectors. 
 
1. Device identification 
Solution: Improvement of secondary package, including: 
 To highlight the emergency use (to emphasize the text ALLERGY and 
EMERGENCY PEN in striking colours and bigger size to differentiate the device 
from other pens for patients and third party users); 
 To increase the colour contrast of the use instruction (instead of the current 
black/grey printing); 
 To use consistent frame for the illustration of all use steps (currently steps 1 & 3 
are framed and step 2 is unframed); 
 To add production information including name and model type of device (this will 
facilitate the patient’s choice of device and reduce the chance of misuse by users, 
especially in light of continuous lifecycle management of the products); 
 To implement electronic audible instruction for use (so that the users can 
playback the instruction at any time and place of their choice). 
 
1. Comprehensive instruction of use 
Solutions:  
 To implement clear introduction of symptoms for anaphylaxis in instruction for 
use; 
 To implement diagnostic device to identify if patient has an anaphylaxis 
conditions e.g. electronic temperature sensors or blood test stripes. 
 
2. Ease of use  
Solutions:  
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 Mechanical or electronic dosage (with 2-3 levels of dosage, similar to the flame 
adjustment lever on a lighter); 
 To integrate the interlock of the device in the dosage adjustment (this could also 
help to reduce the patient’s fear of device); 
 Additional needles (interchangeable similar to a three-coloured pen) that facilitate 
multiple injections; 
 To implement a monitoring window (with marks of dosage to monitor the level 
of available medication in the syringe); 
 New actuator design, e.g. sideways or electronic instead of mechanical actuator 
to reduce the necessary activation force (the force is perceived as too high, 
especially for the patient under physical distress); 
 To implement more ergonomic designs e.g. handhold with nobs (like pencils for 
young pupils); 
 To implement signals (flashing colours, vibrations or screen text) to indicate the 
status of the device (e.g. unlock, unlocked, dosage adjusted, injection proceeding, 
injection completed); 
 Electronic search function (if device misplaced). 
 
3. Size of device 
Solution:  
 To bring down the size of the device with a new actuator design. 
 
4. Customization for target groups 
Solution:  
 Design customization based on gender, age group, body weight and body fat layer. 
The exterior design to be oriented on fashion articles e. g. as key ring for men and 
as necklace for women (similar to emergency necklace).  
 
5. Needle length 
Solution:  
 To implement a lever for the needle length adjustment. 
 
6. Needle protection 
Solution:  
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 To reduced size of needle protection with a new actuator design. 
 
7. Flexibility of dose 
Solution:  
 To implement electronic dosage function. 
 
8. Injection time 
When under physical distress and with injection of adrenaline, the patient’s feeling 
for time may be distorted, therefore an integrated timer was recommended. 
Solution:  
 To implement a timer which signals the end of injection time; 
 To monitor the progress of the injection through an enlarged monitoring window. 
 
9. Marking of injection end  
Solution:  
 To implement signals at the end of injection (flashy colours, vibrations or screen 
text). 
 
10. Patient's fear of device 
Solutions:  
 To reduce the size of device by reducing the size of actuator; 
 To reduce the activation force; 
 To implement friendly and fashionable exterior design. 
 
11. Adequate training  
Solutions: 
 Regular training programmes; 
 Multimedia training material in the native language; 
 Support groups (for patients and family members to exchange practical 
experience). 
 
12. Shelf life 
Solutions: 
 To use refillable cartridge; 
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 To implement exchangeable cartridge and needles; 
 To implement thermal insulation. 
 
13. Device robustness 
Solutions: 
 To use more robust material especially for the cartridge; 
 To implement thermal insulation. 
 
The outputs of the control group with test device 1 are summarized in the following table 
(see table 6-1). 
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No. Device features Improvement ideas 
1 
Device 
identification  
  Improvement of secondary package, including: 
1 To highlight the emergency use 
2 To increase the colour contrast of the use instruction 
3 To use consistent frame for the illustration of all use steps 
4 To add production information including name and model type of device 
5 To implement electronic audible instruction for use 
2 
Comprehensive 
instruction of use 
1 To implement clear introduction of symptoms for anaphylaxis in instruction for use 
2 
To implement diagnostic device to identify if patient has an anaphylaxis conditions e.g. 
electronic temperature sensors or blood test stripes 
3 Ease of use 
1 Mechanical or electronic dosage  (with 2-3 levels of dosage) 
2 To integrate the interlock of the device in the dosage adjustment 
3 Additional needles that facilitate multiple injections 
4 To implement a monitoring window 
5 
New actuator design, e.g. sideways or electronic instead of mechanical actuator to 
reduce the necessary activation force 
6 To implement more ergonomic designs e.g. handhold with nobs 
7 
To implement signals (flashing colours, vibrations or screen text) to indicate the status 
of the device 
8 Electronic search function 
4 Size of device 1 The new actuator design could bring down the size of the device  
5 
Customization 
for target groups 
1 
Design customization based on gender, age group, body weight and body fat layer. The 
exterior design to be oriented towards fashion articles e. g. as key ring for men and as 
necklace for women. 
6 Needle length  1 To implement a lever for the needle length adjustment 
7 
Needle 
protection 
1 Reduced size of needle protection with a new actuator design 
8 
Flexibility of 
doses 
1 Electronic dosage function 
9 Injection time 
1 To implement a timer which signals the end of injection time 
2 To monitor the progress of the injection through the monitoring window 
10 
Marking of 
injection end 
1 To implement signals at the end of injection 
11 
Patient's fear of 
device 
1 To reduce the size of device, e.g. with a new actuator design 
2 To reduce the activation force, e.g. with a new actuator design 
3 To implement friendly and fashionable exterior design 
12 
Adequate 
training  
1 Regular training programmes 
2 Multimedia training material in the native language 
3 Support groups (for patients and family members to exchange practical experience) 
13 Shelf life 
1 To use refillable cartridge 
2 To implement exchangeable cartridge and needles  
3 To implement thermal isolation 
14 
Device 
robustness 
1 To use more robust material especially for the cartridge 
2 To implement thermal isolation 
Table 6-1 Outputs of control group (test device 1) 
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6.1.2 Test group/ test device 1 
The group work of the test group using TRIZ techniques was primarily guided by the 
chosen inventive principles. Each found solution was guided by a single chosen inventive 
principle which sometimes aimed to solve more than one technical issue. 
 
The following solutions were found during the group work. The treated technical issues 
of the test device are put in ( ) and the applied TRIZ inventive principles in [ ]. 
 
Solutions 1. [35 Parameter change - A. Physical state] 
 Compressed gas drive {the injection to be triggered and driven by compressed gas 
instead of the spring force mechanism}. This solution may bring down the size of 
device (4 size of device), facilitate the application (3 ease of use) and reduce 
patient’s fear (11 patient’s fear of device);  
 New delivery form: nasal to brain delivery via powder. This solution may greatly 
improve the convenience for use (3 ease of use) and reduces patient’s fear of the 
application (11 patient’s fear of device). With this solution, the injection device 
becomes obsolete (6 needle length; 7 needle protection; 9 injection time; 10 
marking of injection end). New formulation as more stable (14 robustness) solid 
drug will lead to longer shelf time of the medication (13 shelf life) and a smaller 
device (4 size of device) that may operate with multiple dose/ cartridges (8 
flexibility of dose); 
 New delivery form: solid drug injection into muscle. This may reduce injection 
time (9 injection time). Solid drug is more stable (14 robustness) will lead to 
longer lifetime of the medication (13 shelf life) and a smaller device (4 size of 
device) that may operate with multiple dose/ cartridges (8 flexibility of dose). This 
may facilitate the daily carriage (3 ease of use). 
 
Solutions 2. [35 Parameter change - B. Concentration and density] 
 Micro needle {instead of one single needle, many tiny needles which cause much 
less pain} may reduce the pain of injection (3 ease of use) and reduces patient’s 
fear at the application (11 patient’s fear of device); 
 Formulation change - increase drug concentration to build a smaller device (4 size 
of device) with a small syringe and primary package {possibly a stronger spring 
will be needed or a gas-driven instead of mechanical system shall be used}. This 
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will reduce the duration of injection (9 injection time), which in turn will reduce 
the discomfort of injection (3 ease of use) and reduces patient’s fear (11 patient’s 
fear of device); 
 Formulation change - concentration/density/dosage adjustment depending on the 
target group e. g. gender, age etc. (5 customisation for target groups). 
 
Solutions 3. [35 Parameter change - C. Degree of flexibility] 
 Flip design {elements of the device may be folded in half size like a flip phone}. 
Such design will reduce the device size (4 size of device) and facilitate the daily 
carriage (3 ease of use); 
 Softer plastic material for safety cap – the current cap can be easily removed and 
might loosen unwillingly (14 device robustness); 
 Anti-slip grip {with more flexible material and anti-slip design} may improve the 
user comfort (3 ease of use) and robustness of the device (14 device robustness) 
at the same time; 
 Waterproof material as label protection (14 robustness of device); 
 Softer material for the tip which touches the body during the application may 
increase user comfort (3 ease of use) and reduces patient’s fear (11 patient’s fear 
of device). 
 
Solutions 4. [35 Parameter change - D. Temperature and volume] 
 Temperature detector for refrigeration of drug (13 shelf life) and warming up to 
body temperature before use (3 ease of use); 
 Higher viscosity of drug shortens the injection time (9 injection time) and reduces 
the size of device (4 size of device) and the patient’s tension (11 patient’s fear of 
device); 
 Cooling function with kinetic energy {to transform kinetic energy through 
movements of daily carriage into thermal energy and reduce temperature to 
enhance shelf life}. This prolongs the shelf time of the medication (13 shelf life); 
 Warming up with a built-in chemical reaction to increase temperature before use 
in order to reduce pain by injection (3 ease of use) and to reduce the patient’s 
tension (11 patient’s fear of device). 
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Solutions 5. [35 Parameter change - E. Change of pressure] 
 To reduce activation force with changed mechanism or compressed gas drive - the 
current necessary activation force is perceived as too strong and believed to cause 
patient’s fear of device. This solution is thought to lead to more user comfort (3 
ease of use), a smaller size of the device (4 size of device) and reduced  tension 
of the patient’s (11 patient’s fear of device); 
 To increase pull-off force of blue cap {the current cap can be removed easily thus 
arises concerns that the cap may loosen or fall off unwillingly}. This should make 
the device more robust for the daily transport (14 device robustness). 
 
Solutions 6. [35 Parameter change - F. Change other parameters] 
 Diverse pen designs to match patients’ taste, e.g. toys in form of a giraffe for 
children (3 ease of use; 5 customisation for target groups) and put the patient at 
ease (11 patient’s fear of device); 
 Additional signals {e.g. acoustic function at the end of injection to mark the 
injection end} (10 marking of injection end); 
 Change primary container material from glass to plastic (14 device robustness). 
 
Solutions 7. [40 Composite materials] 
 Additional plastic layer for grip as anti-slip grip to increase user comfort (3 ease 
of use) and robustness for daily transport (14 device robustness); 
 Plastic windows {to monitor injection progress, especially to identify the end of 
injection} (10 marking of injection end); 
 NFC chip for device information (1 device identification; 2 comprehensive 
instruction of use); 
 Audio introduction for device use (1 device identification; 2 comprehensive 
instruction of use); 
 APP for identification of anaphylaxis shock (1 device identification; 2 
comprehensive instruction of use); 
 Muscular tissue detection which adjusts needle length for accurate injection (3 
ease of use; 6 needle length); 
 Different springs in one device for different body weight classes {e.g. one for 
children and one for adults as a possibility for production customisation} (5 
customization for target groups; 8 flexibility of dose); 
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 Other material for device body e.g. alloy to be stronger (14 device robustness) and 
more fashionable designs which match the patient’s taste (5 customisation for 
target group; 11 patent’s fear of device); 
 More robust plastic case (14 device robustness). 
 
Solutions 8. [2 Taking out] 
 Electronic introduction of use, device tells patient what to do which should make 
the introduction for use more comprehensive (1 device identification; 2 
comprehensive instruction of use). 
 
The outputs of the test group with test device 1 are summarized in the table 6-2. 
No. Device features Solution Improvement ideas 
1 
Device 
identification  
7c 1 NFC chip for device information 
7d 2 Audio introduction for device use 
7e 3 APP for identification of anaphylaxis shock 
8 4 Electronic introduction of use 
2 
Comprehensive 
instruction of 
use 
7c 1 NFC chip for device information 
7d 2 Audio introduction for device use 
7e 3 APP for identification of anaphylaxis shock 
8 4 Electronic introduction of use 
3 Ease of use 
1a; 5a 1 Compressed gas drive to trigger injection 
1b 2 New delivery form: nasal to brain as powder 
1c 3 New delivery form: solid drug injection into muscle 
2a 4 Micro needle 
2b; 4b 5 Increased drug concentration 
3a 6 Flip design 
3c; 7a 7 Anti-slip grip 
3e 8 Softer material for device tip 
4a 9 Temperature detector  
4d 10 Built-in chemical reaction to warm up drug 
6a 11 Diversification of pen design 
7f 12 Muscular tissue  
4 Size of device 
1a; 5a 1 Compressed gas drive to trigger injection 
1b 2 New delivery form: nasal to brain as powder 
1c 3 New delivery form: solid drug injection into muscle 
2b; 4b 4 Increased drug concentration 
3a 5 Flip design 
5 
Customization 
for target 
groups 
2c 1 Diversification of concentration/density/dosage 
6a 2 Diversification of pen design 
7g 3 Different springs for each body weight class 
7h 4 Fashionable/robust exterior material 
6 Needle length  
1b 1 New delivery form: nasal to brain as powder 
7f 2 Muscular tissue  
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No. Device features Solution 
Improvement 
ideas 
No. 
7 
Needle 
protection 
1b 1 New delivery form: nasal to brain as powder 
8 
Flexibility of 
doses 
1b 1 New delivery form: nasal to brain as powder 
1c 2 New delivery form: solid drug injection into muscle 
7g 3 Different springs for each body weight class 
9 Injection time 
1b 1 New delivery form: nasal to brain as powder 
1c 2 New delivery form: solid drug injection into muscle 
2b; 4b 3 Increased drug concentration 
10 
Marking of 
injection end 
1b 1 New delivery form: nasal to brain as powder 
6b 2 Acoustic signal at end of injection 
7b 3 Plastic window 
11 
Patient's fear 
of device 
1a; 5a 1 Compressed gas drive to trigger injection 
1b 2 New delivery form: nasal to brain as powder 
2a 3 Micro needle 
2b; 4b 4 Increased drug concentration 
3e 5 Softer material for device tip 
4d 6 Built-in chemical reaction to warm up drug 
6a 7 Diversification of pen design 
7h 8 Fashionable/robust exterior material 
12 
Adequate 
training  
     
13 Shelf life 
1b 1 New delivery form: nasal to brain as powder 
1c 2 New delivery form: solid drug injection into muscle 
4a 3 Temperature detector 
4c 4 Cooling function with kinetic energy  
14 
Device 
robustness 
1b 1 New delivery form: nasal to brain as powder 
1c 2 New delivery form: solid drug injection into muscle 
3b 3 Soft plastic material for safety cap 
3c; 7a 4 Anti-slip grip 
3d 5 Waterproof material as label protection 
5b 6 To increase pull-off force of blue cap 
6c 7 More robust material for primary container 
7h 8 Fashionable/robust exterior material 
7i 9 Robust plastic case 
Table 6-2 Outputs of test group (test device 1) 
 
 
6.1.3 Control group/ test device 2 
Like the control group for test device 1, this group also used the introduction on the scope 
of problem (see section 5.4.2) to lead their discussion. As a result, the following 
improvements with reference to the 14 technical issues of auto-injectors were proposed 
for test device 2. 
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1. Device identification 
 
Solutions: 
 To implement colourful ergonomic designs (e.g. with a handle) to distinguish this 
device from other devices; 
 To implement the text  “EPIPEN = ALLERGY//EMERGENCY USE” in 
noticeable letters (especially for external helpers who might not be familiar with 
the device); 
 To make the plastic case, the cap and the needle tip with brand colour/design; 
 To implement a distinctive new design (a cap to cover needle on top of the needle 
tip). 
 
 
2. Comprehensive instruction of use 
 
Solutions:  
 To implement QR code* (in addition to instruction for use as 5 sec video for third 
persons as quick reference guide); 
 To implement instruction for use with anaphylaxis third person decision tree on 
the plastic case and QR Code video (for third persons to find out if it is a case of 
anaphylaxis); 
 To demonstrate how to hold the auto-injector during the application (add as the 
first point in the instruction for use); 
 To use an arrow to indicate the direction of injection tip. 
*QR-codes on the tertiary packaging are used by some companies for promotion of 
their products. For biopharmaceutical products, QR-code is nowadays commonly 
used for safety instructions. 
 
 
3. Ease of use  
 
Solutions:  
 Eyeglasses case (which can be used for transport of device, so that others will not 
immediately recognize that the user carries the device); 
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 Reset button for 2nd dose (in case the first injection is misused under distress). 
 
 
4. Size of device 
 
Solution:  
 Handle for portability (so that the device can be carried as a pen in the pocket of 
a shirt); 
 To reduce the size with a new design of actuator. 
 
 
5. Customization for target groups 
 
Solution:  
 Age group specific cap design (current design too small for elderly people); 
 Adjustable dosage (based on body weight/muscle structure etc.); 
 Instruction for use for children (e.g. supported by colourful cartoons, electronic 
friends etc.); 
 QR-code video for children; 
 Design/size for children (e.g. small parts big enough not to be swallowed for 
safety reasons); 
 Gender specific device sizes (smaller for men, larger for women and 
distinguishable from other devices e.g. asthma devices); 
 Weight and muscle mass specific needle length. 
 
 
6. Needle length 
 
Solution:  
 Weight and muscle mass specific needle length. 
 
 
7. Needle protection 
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The existing needle protection feature was a robust and reliable system to the 
participants. An improvement was proposed with a new actuator which requires less 
force for the activation. 
 
Solution:  
 Needle cover shield (which hides the needle before and after use); 
 Retractable needle (needle retreats automatically into the inner system of the 
device after use); 
 Bio-needle (needle consist of biological material and dissolves in the body after 
use, similar to biological surgical suture). 
 
 
8. Flexibility of dose 
 
Solution:  
 Multiple dosages (implementation of multiple doses in the device). 
 
 
9. Injection time 
When under physical distress and with injection of adrenaline, the patient’s feeling 
for time may be distorted. Therefore, an integrated timer was recommended. 
 
Solution:  
 Digital timer (which counts the injection time); 
 Audible signal (1st click for the start and 2nd click for the end of injection); 
 Sensorial feedback (e.g. vibration at injection end). 
 
10. Marking of injection end  
 
Solution:  
 Implement of a window (large enough to monitor the drug/plunger); 
 Discolouration of package (after completion of injection, the package changes 
colour). 
 
 144 
11. Patient's fear of device 
 
Solutions:  
 Needle cover shield; 
 Retractable needle; 
 Bio-needle; 
 Follow-up training; 
 Training with real device; 
 Training by medical professionals; 
 Training in school; 
 Training for canteen/restaurant/hotel. 
 
12. Adequate training  
 
Solutions: 
 Follow-up training (once a year); 
 Training with real device (to be filled with sucrose and injected into pad under 
assistance of doctor, not training device without needle); 
 Training by medical professionals; 
 Training in school; 
 Training for canteen/restaurant/hotel (device to be stored in such locations). 
 
13. Shelf life 
 
Solutions: 
 Exchangeable syringe (so that the drug which is the most responsible for   the 
limited shelf life of the device can be renewed); 
 Bring back device (manufacturer helps to exchange the syringe after expiry date). 
 
14. Device robustness 
 No solution was found in this aspect. 
 
The outputs of the control group with test device 2 are summarized in the table 6-3. 
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No. Device features Improvement ideas 
1 
Device 
identification  
1 To implement colourful ergonomic designs 
2 To implement identifying text  in noticeable letters 
3 To use brand colour/design 
4 To implement a distinguishable new design 
2 
Comprehensive 
instruction of use 
1 To implement QR code 
2 
To implement full instruction for use with anaphylaxis third person decision tree on the 
plastic case and QR Code video 
3 To picture how to hold the auto-injector during the application 
4 To use an arrow to show the direction of injection tip 
3 Ease of use 
1 Eyeglasses case 
2 Reset button for 2nd dose 
4 Size of device 
1 Handle for portability 
2 Eyeglasses case 
5 
Customization for 
target groups 
1 Age group specific cap design 
2 Adjustable dosage 
3 Instruction for use for children 
4 QR-code video for children  
5 Design/size for children 
6 Gender specific device sizes 
7 Weight and muscle mass specific needle length 
6 Needle length 1 Weight and muscle mass specific needle length 
7 Needle protection 
1 Needle cover shield 
2 Retractable needle 
3 Bio-needle 
8 Flexibility of doses 1 Multiple dosages 
9 Injection time 
1 Digital timer 
2 Audible signal 
3 Sensorial feedback 
10 
Marking of 
injection end 
1 Implement of a window 
2 Discolouration of package 
11 
Patient's fear of 
device 
1 Needle cover shield 
2 Retractable needle 
3 Bio-needle 
4 Follow-up training 
5 Training with real device 
6 Training by medical professionals 
7 Training in school 
8 Training for canteen/restaurant/hotel 
12 Adequate training  
1 Follow-up training 
2 Training with real device 
3 Training by medical professionals 
4 Training in school 
5 Training for canteen/restaurant/hotel 
13 Shelf life 
1 Exchangeable syringe 
2 Bring back device 
14 Device robustness     
Table 6-3 Outputs of control group (test device 2) 
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6.1.4 Test group/ test device 2 
The problem-solving process of this group was guided by the chosen TRIZ inventive 
principles. In some cases, the group combined various inventive principles to develop 
more complex solutions.  
 
The following ideas were generated by the test group for test device 2. The treated 
technical issues of the test device are put in ( ) and the applied TRIZ inventive principles 
in [ ]. 
Solution 1.  
 To use more intensive colours for labels, instead of black and grey for easier 
identification of the device. [35 Parameter change - F. Other parameters] (1 device 
identification). 
 
Solution 2.  
 To use compressed air to replace the spring in the device [35 Parameter change - 
A. Physical state/ F. Other parameters], in order to reduce the activation force. 
This will on the one hand make the device easier to operate (3 ease of use), on the 
other hand, reduce the size of the device (4 size of device) and in turn the patient’s 
fear (11 patient’s fear of device); 
 In the current design, the relatively big size of the spring due to necessary 
activation force confines the device to a minimum size. By replacing it with a 
compact compressed air system [2 Taking out or extraction - A. Extract disturbing 
objects], the device shall have more freedom in taking on smaller shapes (4 size 
of device) that are more comfortable or convenient to the patients (3 ease of use);  
 The compressed air shall be refillable [34 Discarding and recovering - B. Restore 
consumable parts] which contribute to longer lifetime of the device (13 shelf life). 
 
Solution 3. 
 To implement exchangeable needles [34 Discarding and recovering - B. Restore 
consumable parts]. This will help to extend the useful time of the device (13 shelf 
life); 
 To make the surface of the device, including the fixture e.g. holder for key ring or 
clip, exchangeable accessories of the device [34 Discarding and recovering - B. 
Restore consumable parts] to meet the ergonomic requirements of different 
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patients (3 ease of use; 5 customisation of target groups; 13 shelf life; 14 device 
robustness); 
 To use softer material for the device surface [35 Parameter change - C. Degree of 
flexibility] in order to improve the user comfort (3 ease of use). 
 
Solution 4. 
 To implant the medication under the skin and release the necessary dose with an 
activation device based on magnet, electric impulse etc. [2 Taking out or 
extraction - B. Extract necessary objects]. This will simplify the use of device (3 
ease of use) and reduce the patient’s fear (11 patient’s fear of device). With this 
solution, the needle will become obsolete (6 needle length; 7 needle protection) 
and the injection time and dose will be controlled by the electronic (8 flexibility 
of dose; 9 injection time, 10 marking of injection end). With this design, the device 
is well protected under the skin (14 device robustness); 
 The medication implant should be refillable or exchangeable [34 Discarding and 
recovering - B. Restore consumable parts]. This does not only increase user 
comfort (3 ease of use), but also helps to avoid the patient’s fear (11 patient’s fear 
of device) and extend the lifetime of the device (13 shelf life); 
 Also the batteries for the above systems should be rechargeable or exchangeable 
[34 Discarding and recovering - B. Restore consumable parts] (13 shelf life). 
 
Solution 5. 
 Exchangeable design for the consumable parts - the cartridge and the needle - [34. 
Discarding and recovering - B. Restore consumable parts]. With such designs, the 
life time of the device may be substantially extended (13 shelf life); 
 Refillable cartridges [34 Discarding and recovering - B. Restore consumable parts] 
(13 shelf life); 
 Threaded-coupling to be implemented to facilitate the replacement of the 
consumable parts [2 Taking out or extraction - B. Extract necessary objects] (3 
ease of use; 13 shelf life). 
 
Solution 6.  
 To integrate multiple needles in the device [34 Discarding and recovering - B. 
Restore consumable parts]. This will provide the opportunity for backup 
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injections (3 ease of use) and extend the useful time of the device (13 shelf life). 
Different needle length may be implemented (6 needle length). 
 
Solution 7.  
 To replace the conventional needle with a biological needle which dissolves after 
use [2 Taking out or extraction - A. Extract disturbing objects]. This may reduce 
patient’s fear (11 patient’s fear of device). 
 
Solution 8.  
 To use solid instead of liquid medication [35 Parameter change - A. Physical state]. 
This will largely reduce the injection time (9 injection time) and the pain during 
the injection (3 ease of use), and bring down the size of device (4 size of device). 
Besides, needle or needle protection is no longer needed for this solution (6 needle 
length; 7 needle protection; 10 marking of injection end). Potentially, all the above 
may reduce the patient’s fear (11 patient’s fear of device). 
 
Solution 9.  
 The activation force is perceived as too high. A changed mechanism triggered by 
a sideways button should reduce the activation force [2 Taking out or extraction - 
A. Extract disturbing objects]. This should improve the use comfort (3 ease of 
use), bring down the size of device (4 size of device) and reduce the patient’s fear 
(11 patient’s fear of device). 
Solution 10.  
 To implement a lever to deliver different levels of dosage - similar as the design 
of some lighters [2 Taking out or extraction - B. Extract necessary objects] (8 
flexibility of dose); 
 The safety cap can be eliminated. The function can be maintained as a level of the 
above lever [2 Taking out or extraction - B. Extract necessary objects] (3 ease of 
use; 4 size of device). 
The outputs of the test group with test device 2 are summarized in the table 6-4. 
No. Device features Solution Improvement ideas 
1 Device identification  1 1 Intensive colours for label 
2 Comprehensive instruction of use     
3 Ease of use 
2a; 2b 1 To replace spring by compressed air 
3b 2 Exterior design as exchangeable accessories 
3c 3 Soft exterior material 
 149 
4a 4 Drug implant 
4b 5 Refillable drug implant 
5c 6 Threaded-coupling in pen 
6 7 Multiple needles 
8 8 Solid drug 
9 9 Sideway trigger 
10b 10 Integrated safety catch 
4 Size of device 
2a; 2b 1 To replace spring by compressed air 
8 2 Solid drug 
9 3 Sideway trigger 
10b 4 Integrated safety catch 
5 Customization for target groups 3b 1 Exterior design as exchangeable accessories 
6 Needle length  
4a 1 Drug implant 
6 2 Multiple needles 
8 3 Solid drug 
7  Needle protection  
4a 1 Drug implant 
8 2 Solid drug 
8 Flexibility of doses 
4a 1 Drug implant 
10a 2 Dosage lever 
9 Injection time 
4a 1 Drug implant 
8 2 Solid drug 
10 Marking of injection end 
4a 1 Drug implant 
8 2 Solid drug 
11 Patient's fear of device 
2a; 2b 1 To replace spring by compressed air 
4a 2 Drug implant 
4b 3 Refillable drug implant 
7 4 Biological needle 
8 5 Solid drug 
9 6 Sideway trigger 
12 Adequate training       
13 Shelf life 
2c 1 Refillable compressed air cartridge 
3a 2 Exchangeable needles 
3b 3 Exterior design as exchangeable accessories 
4b 4 Refillable drug implant 
4c 5 Rechargeable or exchangeable battery 
5a 6 Exchangeable consumable parts 
5b 7 Refillable cartridge 
5c 8 Threaded-coupling in pen 
6 9 Multiple needles 
14 Device robustness 3b 1 Exterior design as exchangeable accessories 
Table 6-4 Outputs of test group (test device 2) 
 
6.1.5 Assessment of outputs 
Sessions 1 and 3 were experiment sessions with brainstorming and sessions 2 and 4 with 
TRIZ techniques.  
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The outputs of each experiment session were reviewed by the expert panel. The following 
criteria were applied to the assessment of the individual solutions created during the 
experiment sessions (see section 4.4): 
 
 Feasibility (possible scores: 0 = not feasible; 1 = feasible with great difficulty; 2 
=  feasible with difficulty; 3 = feasible with efforts; 4 = feasible with slight efforts; 
5 = feasible without efforts); 
 
 Novelty (possible scores: 0 = old; 1 = improvement; 2 = modification; 3 = solution 
transfer; 4 = new idea; 5 = new technology); 
 
 Costs (possible scores: 0 = unfeasible; 1 = very expensive; 2 = expensive; 3 = 
acceptable; 4 = affordable; 5 = inexpensive). 
 
In all experiment sessions, numerous ideas were generated as solution to the predefined 
technical problems (see section 5.4.2). During the expert assessment, the members of the 
expert panel evaluated each solution according to the above rating system. The results 
were summarised in detail in appendix XIII. 
 
Parallel to the expert assessment, three ‘pen-experienced’ patients were invited to give 
their opinions on the solutions developed during the experiment sessions. The patients 
were asked to evaluate the improvement ideas generated in the experiment by applying a 
5-point Likert scale defined as follows (see section 4.4). 
 
 0 = no improvement at all; 
 1 = unnoticeable improvement; 
 2 = minor improvement; 
 3 = some improvement; 
 4 = noticeable improvement; 
 5 = essential improvement 
The results of the patient assessment are summarised in detail in appendix XIII. 
While session 1 delivered solutions to all technical issues, session 3 delivered no solution 
in one case. Session 2 failed to deliver solutions to 1 case and session 4 failed in 2 out of 
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the totally 14 technical cases. Thus sessions 2 and 4 using TRIZ exhibit a slightly higher 
rate of missing solutions than sessions 1 and 3 using brainstorming. 
 
The reason of the higher rate of missing solutions of the TRIZ sessions may lie in the 
TRIZ procedure.  On one hand, the TRIZ procedure not only predicted the solutions to 
the technical problems, but also eliminated possible solutions which could contradict the 
solutions to other technical issues, therefore reduced the quantity of solutions. On the 
other hand, only the inventive principles with the highest likelihood of achieving 
successful solutions were introduced in the experiment sessions. Although the chosen 
inventive principles for the experiment were likely to be helpful in solving most of the 
problems, they were not necessarily matched to each single problem. In case the chosen 
principles did not match certain technical problems, there was a higher likelihood that 
TRIZ procedure would fail to deliver any solutions.  
 
In the following, the outputs of session 1 are compared with those of session 2 and session 
3 compared with session 4, as each of the session pairs dealt with the improvement of the 
same test device. The experiment sessions of each session pair is compared in terms of 
total number of generated solutions, as well as the numbers of “top solutions” (see tables 
6-5 and 6-6). 
 
The top solutions are defined as the number of rank 1 and rank 2 solutions to each problem. 
Rank 1 solutions are those with the highest average score of the two sessions in the expert 
or the patient assessment. Similarly, rank 2 solutions are those with the second highest 
score.  
 
In order to restrict the influence of the extremely good performance in some single cases 
in the total evaluation, in each dimension of the assessment, each session is limited to two 
rank 1 & rank 2 solutions in total. That means, in case there are more than two rank 1 
solutions, there will be several rank 1 solutions but no rank 2 solution. In addition, if more 
than two rank 1 solutions are found in the same session, the session will be evaluated with 
two rank 1 solutions. Similarly, if there is one rank 1 solution and several rank 2 solutions, 
the number of rank 2 solutions will be capped so that each session will be evaluated at a 
maximum of one rank 1 solution and one rank 2 solution or two rank 2 solutions. 
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The results of the assessment of the outputs are shown in the table 6-5 and table 6-6.   
 
 
test device 1 Average experts 
Average 
patients 
No. Device features Session Solution 
No. of 
solutions 
Feasibility Novelty Costs sum 
Patient 
perception 
1 
Device 
identification 
1 
Rank 1 
5 
1 0 1 1 1 
Rank 2 1 0 1 0 1 
Rank 
1&2 
2 0 2 1 2 
2 
Rank 1 
4 
0 1 0 2 0 
Rank 2 0 1 0 0 0 
Rank 
1&2 
0 2 0 2 0 
2 
Comprehensive 
instruction of 
use 
1 
Rank 1 
2 
1 1 1 0 1 
Rank 2 0 0 0 0 1 
Rank 
1&2 
1 1 1 0 2 
2 
Rank 1 
4 
2 1 0 2 0 
Rank 2 0 0 1 0 1 
Rank 
1&2 
2 1 1 2 1 
3 Ease of use 
1 
Rank 1 
8 
0 0 0 0 0 
Rank 2 0 0 0 0 0 
Rank 
1&2 
0 0 0 0 0 
2 
Rank 1 
12 
1 2 2 1 2 
Rank 2 1 0 0 1 0 
Rank 
1&2 
2 2 2 2 2 
4 Size of device 
1 
Rank 1 
1 
1 0 0 0 0 
Rank 2 0 0 0 0 0 
Rank 
1&2 
1 0 0 0 0 
2 
Rank 1 
5 
1 2 1 2 1 
Rank 2 0 0 1 0 1 
Rank 
1&2 
1 2 2 2 2 
5 
Customization 
for target 
groups 
1 
Rank 1 
1 
0 0 0 0 1 
Rank 2 0 0 0 0 0 
Rank 
1&2 
0 0 0 0 1 
2 
Rank 1 
4 
2 1 1 2 1 
Rank 2 0 1 1 0 0 
Rank 
1&2 
2 2 2 2 1 
test device 1 Average experts 
Average 
patients 
No. Device features Session Solution 
No. of 
solutions 
Feasibility Novelty Costs sum 
Patient 
perception 
6 Needle length  1 
Rank 1 
1 
1 0 1 1 0 
Rank 2 0 1 0 0 0 
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Rank 
1&2 
1 1 1 1 0 
2 
Rank 1 
2 
0 1 0 1 1 
Rank 2 1 0 1 0 1 
Rank 
1&2 
1 1 1 1 2 
7 
Needle 
protection 
1 
Rank 1 
1 
1 0 1 1 1 
Rank 2 0 1 0 0 0 
Rank 
1&2 
1 1 1 1 1 
2 
Rank 1 
1 
0 1 0 0 0 
Rank 2 1 0 1 1 1 
Rank 
1&2 
1 1 1 1 1 
8 
Flexibility of 
doses 
1 
Rank 1 
1 
1 0 1 0 0 
Rank 2 0 1 0 1 1 
Rank 
1&2 
1 1 1 1 1 
2 
Rank 1 
3 
1 1 2 1 1 
Rank 2 0 1 0 0 0 
Rank 
1&2 
1 2 2 1 1 
9 Injection time 
1 
Rank 1 
2 
1 0 1 1 0 
Rank 2 1 0 1 1 2 
Rank 
1&2 
2 0 2 2 2 
2 
Rank 1 
3 
0 1 0 0 1 
Rank 2 0 1 0 0 1 
Rank 
1&2 
0 2 0 0 2 
10 
Marking of 
injection end 
1 
Rank 1 
1 
0 0 0 0 1 
Rank 2 0 1 1 1 0 
Rank 
1&2 
0 1 1 1 1 
2 
Rank 1 
3 
1 1 1 1 0 
Rank 2 1 0 1 0 2 
Rank 
1&2 
2 1 2 1 2 
11 
Patient's fear 
of device 
1 
Rank 1 
3 
1 0 0 0 2 
Rank 2 0 0 1 0 0 
Rank 
1&2 
1 0 1 0 2 
2 
Rank 1 
8 
0 1 1 1 1 
Rank 2 1 1 1 1 0 
Rank 
1&2 
1 2 2 2 1 
12 
Adequate 
training  
1 
Rank 
1&2 
3           
2               
test device 1 Average experts 
Average 
patients 
No. Device features Session Solution 
No. of 
solutions 
Feasibility Novelty Costs sum 
Patient 
perception 
13 Shelf life 
  Rank 1 
3 
1 0 0 0 0 
1 Rank 2 1 0 1 1 1 
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Rank 
1&2 
2 0 1 1 1 
2 
Rank 1 
4 
0 1 1 1 1 
Rank 2 0 1 0 0 0 
Rank 
1&2 
0 2 1 1 1 
14 
Device 
robustness 
  Rank 1 
3 
0 0 2 0 0 
1 Rank 2 1 0 0 0 1 
  
Rank 
1&2 
1 0 2 0 1 
  Rank 1 
9 
1 1 1 1 1 
2 Rank 2 1 1 1 1 1 
  
Rank 
1&2 
2 2 2 2 2 
  Total  
  Rank 1 
32 
9 1 8 4 7 
1 Rank 2 4 4 5 4 7 
  
Rank 
1&2 
13 5 13 8 14 
  Rank 1 
62 
9 15 10 15 10 
2 Rank 2 6 7 8 4 8 
  
Rank 
1&2 
15 22 18 19 18 
 
Table 6-5 Comparison of outputs: top scores in sessions 1&2 
 
 
test device 2 Average experts Average patients 
No. Device features Session Solution 
No. of 
solutions 
Feasi
bility 
Novelty Costs sum 
Patient 
perception 
1 
Device 
identification  
  Rank 1 
4 
1 1 1 1 1 
3 Rank 2 0 1 1 0 1 
  
Rank 1&2 
 
1 
 
2 
 
2 
 
1 
 
2 
 
  Rank 1 
1 
1 0 0 1 0 
4 Rank 2 0 1 1 0 0 
  
Rank 1&2 
 
1 1 1 1 0 
2 
Comprehensive 
instruction of 
use 
 
3 
Rank 1&2 
 
4           
4               
3 Ease of use 
  Rank 1 
2 
0 0 1 1 2 
3 Rank 2 1 0 0 0 0 
  
Rank 1&2 
 
1 0 1 1 2 
  Rank 1 
10 
1 1 0 0 0 
4 Rank 2 0 1 1 1 0 
  
Rank 1&2 
 
1 2 1 1 0 
test device 2 Average experts Average patients 
No. Device features Session Solution 
No. of 
solutions 
Feasi
bility 
Novelty Costs sum 
Patient 
perception 
4 Size of device 
  Rank 1 
2 
1 0 1 1 1 
3 Rank 2 1 0 1 1 0 
  Rank 1&2 2 0 2 2 1 
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  Rank 1 
4 
1 1 0 0 1 
4 Rank 2 1 1 0 0 0 
  Rank 1&2 2 2 0 0 1 
5 
Customization 
for target 
groups 
  Rank 1 
7 
2 1 2 1 1 
3 Rank 2 0 0 0 1 0 
  Rank 1&2 2 1 2 2 1 
  Rank 1 
1 
0 1 0 1 1 
  Rank 2 0 0 1 0 0 
4 Rank 1&2 0 1 1 1 1 
6 Needle length  
  Rank 1 
1 
0 1 0 1 1 
3 Rank 2 0 0 1 0 0 
  Rank 1&2 0 1 1 1 1 
  Rank 1 
3 
2 0 1 0 0 
4 Rank 2 0 1 0 1 1 
  Rank 1&2 2 1 1 1 1 
7 
Needle 
protection 
  Rank 1 
3 
1 1 1 2 1 
3 Rank 2 1 0 0 0 0 
  Rank 1&2 2 1 1 2 1 
  Rank 1 
2 
0 0 0 0 1 
4 Rank 2 0 1 1 0 0 
  Rank 1&2 0 1 1 0 1 
8 
Flexibility of 
doses 
  Rank 1 
1 
1 0 0 0 1 
3 Rank 2 0 1 1 1 0 
  Rank 1&2 1 1 1 1 1 
  Rank 1 
2 
1 1 1 1 0 
4 Rank 2 0 1 0 0 1 
  Rank 1&2 1 2 1 1 1 
9 Injection time 
  Rank 1 
3 
2 0 1 1 1 
3 Rank 2 0 1 0 1 0 
  Rank 1&2 2 1 1 2 1 
  Rank 1 
2 
0 1 1 0 1 
4 Rank 2 0 0 0 0 0 
  Rank 1&2 0 1 1 0 1 
10 
Marking of 
injection end 
  Rank 1 
2 
1 0 2 1 1 
3 Rank 2 1 1 0 1 0 
  Rank 1&2 2 1 2 2 1 
  Rank 1 
2 
0 1 0 0 0 
4 Rank 2 0 1 0 0 1 
  Rank 1&2 0 2 0 0 1 
11 
Patient's fear of 
device 
  Rank 1 
8 
2 1 2 1 1 
3 Rank 2 0 0 0 1 1 
  Rank 1&2 2 1 2 2 2 
  Rank 1 
6 
0 0 0 0 0 
4 Rank 2 0 1 0 0 0 
  Rank 1&2 0 1 0 0 0 
12 
Adequate 
training  
3 Rank 1&2 5           
4               
test device 2 Average experts Average patients 
No. Device features Session Solution 
No. of 
solutions 
Feasi
bility 
Novelty Costs sum 
Patient 
perception 
13 Shelf life 
  Rank 1 
2 
1 0 1 1 1 
3 Rank 2 0 0 0 0 0 
  Rank 1&2 1 0 1 1 1 
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  Rank 1 
9 
0 1 0 0 0 
4 Rank 2 2 1 1 2 1 
  Rank 1&2 2 2 1 2 1 
14 
Device 
robustness 
3               
4  Rank 1&2 1           
  Total  
  Rank 1 
35 
12 5 12 11 12 
3 Rank 2 4 4 4 6 2 
  Rank 1&2 16 9 16 17 14 
  Total  
  Rank 1 
42 
6 7 4 3 4 
4 Rank 2 3 10 5 5 5 
  Rank 1&2 9 16 8 7 8 
Table 6-6 Comparison of outputs: top of scores sessions 3&4 
 
Comparing the experiment sessions 1 & 2, the test group using TRIZ delivered no solution 
to the problem number 12 “adequate training”. For the remaining 13 problems, the test 
group delivered a higher number of solutions than the control group in 11 cases. Both 
groups delivered the same number of solutions in one case. In the other case, the control 
group delivered a higher number of solutions. 
 
Comparing the experiment sessions 3 & 4, the test group using TRIZ delivered no solution 
to the problem number 2 “comprehensive instruction of use” and number 12 “adequate 
training”, while the control group using brainstorming technique brought no solution to 
problem number 14 “device robustness”. Out of the remaining 11 problems, the test group 
achieved a higher number of solutions in 5 cases, the control group in another 5 cases and 
both groups delivered the same number of solutions in one case. 
 
In both experiment session pairs, the test group achieved a clearly higher number of 
solutions in total than the control group. In the experiment sessions with test device 1, 32 
solutions were developed with brainstorming and 62 solutions with TRIZ techniques. For 
the improvement of test device 2, 35 solutions were developed with brainstorming and 
42 solutions with TRIZ. 
 
The above suggests that potentially, TRIZ generates more solutions to the predefined 
problems than brainstorming. However, there seems to be a weakness in the TRIZ 
procedure when dealing with problems rooted in the patients’ psychology, e.g. 
“comprehensive instruction of use” or “adequate training”, so that the test group failed to 
deliver a solution to the problem “adequate training” in both cases and only in one of both 
sessions solutions to the problem “comprehensive instruction of use”. Such problems may 
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be described as fuzzy problems, since it is difficult to parameterise those problems. In 
case of the problem “adequate training”, the TRIZ expert held different opinions on the 
classification of this problem so that the allocation of the problem to the contradiction 
parameter stayed invalid (see section 5.2.3). 
 
In the following, the performance of the control group and the test group in the session 
pairs are analysed in the dimensions “feasibility”, “novelty”, “costs” and “patient 
perception”. A session was considered to outperform the comparison session if it 
achieved a higher number of rank 1 & rank 2 solutions and an equal number of rank 1 
solutions or higher, or the equal number of rank 1 & rank 2 solutions and a higher number 
of rank 1 solutions. The performances were considered equal, if both sessions achieved 
the same numbers of both rank 1 and rank 2 solutions, or if one session achieved one rank 
1 solution and the other two rank 2 solutions. The performance was not taken into account 
if the comparison session failed to deliver any solution to the specific problem. 
 
In the dimension “feasibility”, out of totally 13 cases, session 1 (control group) achieved 
better results than session 2 (test group) in 6 cases and equal performance in 2 cases. 
Session 2 performed better in the other 5 cases. In the comparison pair with session 3 
(control group) and session 4 (test group), session 3 outperformed session 4 in 5 out of 
11 cases, the results were equal in 4 cases. Session 4 performed better in the other 2 cases. 
 
In the dimension “novelty”, session 2 (test group) outperformed session 1 in 12 out of 13 
cases. In the other case, the performance of both sessions was equal. Also session 4 (test 
group) reached better results than session 3 (control group) in 6 out of 11 cases and equal 
performance in 1 case. Session 3 (control group) performed better in the other 4 cases. 
 
In the dimension “costs”, session 2 (test group) performed better results in 7 out of 13 
cases and in 2 cases equally to session 1 (control group). However, session 3 (control 
group) outperformed session 4 (test group) in 7 out of 11 cases and the performance of 
session 3 (control group) and session 4 (test group) was equal in the other 4 cases. 
 
In the total score, session 2 (test group) outperformed session 1 (control group) in all the 
above assessment dimensions, while session 4 (test group) did clearly better in the 
dimension “novelty” and worse in the other dimensions. 
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The substantial difference between the two experiment procedures in this study was that 
only the test group received the additional indication of TRIZ inventive principles. 
 
The above findings suggest that both brainstorming and TRIZ may lead to good results 
in technical innovation. Measured by the total scores, the experiment sessions using 
brainstorming and TRIZ techniques delivered a similar quality of outputs. However, 
TRIZ seems to have a clear advantage in the dimension “novelty”, while the trend is not 
clear in the other dimensions of expert assessment. 
 
The assessment criterion “novelty” describes the level of innovation of the solutions to 
the predetermined technical problems. Based on the determinants of those clearly defined 
problems, TRIZ inventive principles were selected and provided to the test groups during 
the experiment. The advantage of TRIZ in this dimension indicates that the TRIZ 
inventive principles successfully directed the innovation process into the “shortcuts” to 
the solutions.  
 
Traditionally, the TRIZ inventive principles were developed to solve technology-driven 
problems. The results of the experiment suggest that the positive effect of TRIZ is weaker 
in dealing with soft targets e.g. “adequate training”. 
 
However, the advantage of TRIZ disappeared in the dimensions “feasibility” and “costs” 
of the expert assessment. This criterion “feasibility” describes to what extend the 
proposed solutions can be implemented without great difficulty and the criterion “costs” 
refers to the costs for manpower, development time and production of the proposed 
solutions etc. The assessment criteria in both dimensions could not be fixed prior to the 
determination of the solutions and depend largely on the previous knowledge and 
experience of the evaluating experts (see section 4.4). Therefore, the additional 
information received by the test group on TRIZ inventive principles did not reflect the 
requirements on problems solutions in the above two dimensions, thus it appears only 
logical that TRIZ did not lead to better results. 
 
The patient assessment was conducted based on the patients’ perceptions which were 
strongly influenced by their relevant experience in the past. Since such experiences were 
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largely unknown to others, the requirements of the patients’ perceptions are fuzzy 
problems which were not taken into consideration in the selection of the TRIZ inventive 
principles. This could explain the experiment findings that TRIZ appeared not more 
advantageous than brainstorming in the patient assessment. 
 
In summary, the TRIZ inventive principles improve the opportunity of finding solutions 
to problems with sophisticated technological background by canalising the search in 
certain directions. While brainstorming focuses on the specific problems, TRIZ extracts 
general problems out of the specific problems, or in other words detaches the problems 
from the immediate environment. The inventive principles are proven good solutions in 
the past to the general problems which should be transformed into specific solutions in 
the last stage of the TRIZ procedure (Altshuller, 1999).  
 
The findings of the experiment indicate that the TRIZ inventive principles lead to 
improved innovation results in the clearly defined technology-driven problems. In 
addition, the general solutions can often be “translated” into multiple specific solutions. 
Therefore, TRIZ appears to be especially effective in solving clearly defined technical 
problems which enables distinctive determination of the applicable inventive principles. 
On the other hand, TRIZ seems to have no advantage over brainstorming when dealing 
with fuzzy or non-technical problems. This suggests that TRIZ might not be the 
appropriate instrument for fuzzy problems which cannot be adequately predefined or are 
subject to changing criteria. 
 
6.2 Process 
6.2.1 Rating method 
In accordance with the experiment plan, the following experiment sessions were 
conducted as group work (see table 6-7). 
 
Experiment session Participants Problem-solving 
technique 
Test devices 
1 P4, P5, P6 Brainstorming 1 
2 P1, P2, P3 TRIZ 1 
3 P1, P2, P3 Brainstorming 2 
4 P4, P5, P6 TRIZ 2 
Table 6-7 Organisation of experiment sessions 
 160 
 
The group P1, P2 and P3 consists of two men and one woman. The group P4, P5 and P6 
consists of one man and two women. The age of the participants are similar with the 
average age of each group being between 40-50 years.  
 
During the experiment, all participants sat around a table with similar distance to each 
other. The seats were chosen by the participants themselves and each participant kept the 
same seat in both sessions. 
 
Immediately after the group work for the following experiment sessions, the participants 
were asked to evaluate the behaviours of all group members, including themselves, by 
filling out the SYMLOG Adjective Rating Form.  
 
After reviewing the ratings of the other participants and a subsequent group discussion, 
the participants filled out the forms for a second time. In addition, two independent raters 
filled out the forms for each participant at each session based on the video recording. The 
assessment of the above ratings was conducted in accordance with Bales’ instructions 
(Bales & Cohen, 1979). 
 
The adjectives in the SYMLOG Adjective Rating Form were developed to describe 
behaviours in three dimensions: U-D, P-N and F-B. Each dimension had two ends which 
were qualitatively the opposite of each other (e.g. U is the opposite of D).  
 
Dimension U-D (= Upward – Downward) demonstrated how actively the observed person 
exerted influence on the observed event, ranging from dominant (U) to submissive (D). 
 
Dimension P-N (= Positive – Negative) described if the observed person was friendly (P) 
or unfriendly (N). 
 
Dimension F-B (= Forward – Backward) showed if the observed person was 
instrumentally controlled, in other words, task-oriented (F) or emotionally expressive, in 
other words, oriented by emotions and feelings (B). 
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Each item in the rating form was allocated to a code for a certain type of behaviour in the 
3-dimensional space (see appendices XI and XII). The code was sometimes a single 
direction in the space (U, D, P, N, F and B) and in the other cases a combination of those 
(e.g. UP, UPF). 
 
In the first step, the total score of each direction was calculated. To do this, the scores of 
all relevant items were summed up (for example, in dimension U, the relevant items were 
U, UP, UPF, UF, UNF, UN, UNB, UB and UPB). In other words, the combination items 
counted for each direction in their codes. The result of this step was a total score for each 
direction (U, D, P, N, F and B). 
 
In the next step, the scores of the two opposite directions of each dimension were 
calculated against each other. For example, if U = 7 and F = 20, the result of dimension 
U-F would be 20-7 = 13F (Marx, 2000). 
 
For further analysis of the results, average scores for each individual participant were 
calculated for the ratings before and after the group discussions. Those were then 
compared with the ratings by the independent external raters. 
 
 
 
6.2.2 Control group/ test device 1 
6.2.2.1 Internal ratings: first round 
 
In the first round rating by the participants, all three participants rated each item, however 
in two cases, the participant P5 did not deliver an answer for P6 (see table 6-8). 
 
 
Code 
P4 
by 
P4 
P4 
by 
P5 
P4 
by 
P6 
P4 
Average 
P 
P5 
by 
P4 
P5 
by 
P5 
P5 
by 
P6 
P5 
Average 
P 
P6 
by 
P4 
P6 
by 
P5 
P6 
by 
P6 
P6 
Average 
P 
U 3 3 3 3.00 4 2 3 3.00 4 4 4 4.00 
UP 4 4 3 3.67 4 3 4 3.67 4 4 3 3.67 
UPF 4 3 3 3.33 4 2 2 2.67 4 4 3 3.67 
UF 1 2 0 1.00 0 2 1 1.00 0 3 2 1.67 
UNF 0 0 0 0.00 0 1 0 0.33 0 1 1 0.67 
UN 2 1 0 1.00 3 0 0 1.00 4 2 0 2.00 
UNB 0 1 0 0.33 0 0 0 0.00 0 1 0 0.33 
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UB 3 3 2 2.67 3 2 3 2.67 4 3 1 2.67 
UPB 4 4 3 3.67 4 3 4 3.67 4 4 2 3.33 
P 4 4 4 4.00 4 3 4 3.67 4 4 3 3.67 
PF 3 3 4 3.33 4 3 4 3.67 4   3 3.50 
F 3 3 3 3.00 4 3 4 3.67 4 3 4 3.67 
NF 4 3 2 3.00 3 3 2 2.67 4 3 2 3.00 
N 0 0 0 0.00 0 0 0 0.00 0 0 0 0.00 
NB 0 0 0 0.00 0 0 0 0.00 0 0 0 0.00 
B 0 0 0 0.00 1 1 0 0.67 0 0 0 0.00 
PB 4 3 3 3.33 4 2 3 3.00 4 3 2 3.00 
DP 4 3 4 3.67 4 3 4 3.67 4 3 3 3.33 
DPF 4 3 4 3.67 4 3 4 3.67 4 3 2 3.00 
DF 2 3 2 2.33 3 3 2 2.67 4 4 2 3.33 
DNF 2 2 0 1.33 2 2 0 1.33 3   0 1.50 
DN 1 1 0 0.67 1 1 0 0.67 0 1 0 0.33 
DNB 1 2 0 1.00 0 1 0 0.33 0 1 0 0.33 
DB 1 2 0 1.00 1 2 0 1.00 0 1 0 0.33 
DPB 4 3 2 3.00 3 2 2 2.33 4 2 2 2.67 
D 1 2 0 1.00 1 2 0 1.00 0 1 0 0.33 
Table 6-8 Internal rating 1: experiment session 1 
After completion of the rating, the participants exchanged the rating forms to view the 
results by the other group members, followed by the group discussion. 
 
6.2.2.2 Group discussion 
The group discussion was guided by some predefined questions. 
Q1 How do you feel about working in a group? 
All participants perceived the experience of group work as positive. Two participants 
stated that in the group work, solutions could be developed through discussions based on 
the ideas of all individual members. The other member of the group added that group 
work provided the opportunity for the participants to exchange ideas and to be inspired 
by the others.  
 
Q2 Do you prefer to work in a group or on your own? 
All participants preferred group work, because of the pleasant cooperative atmosphere 
and the opportunity to be inspired by others through exchange of thoughts. 
 
Q3 Did you feel comfortable during the solution-seeking process in the experiment? 
All three participants perceived the group work as pleasant. 
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Q4 How would you describe the status of the solution-seeking process in the 
beginning, in the middle and at the end of the session? 
At the beginning, the group work concentrated on a common understanding of the task 
and the problem-solving approach. In the end, more attention was paid to the time limit 
and the focus was a consensus for the summary of found solutions. In the middle, the 
group work seemed to be more productive, since the tasks were clarified and the time 
pressure was not clearly noticeable. 
 
Q5 When was the most innovative moment? 
There were several innovative moments. In those moments, the new ideas were confirmed 
and/or further developed by the other two group members. 
 
Q6 Would a moderator, facilitator or a group leader be helpful for the group work? 
The group felt that a “democratic” structure without a leader was the best, because each 
member then had the equal opportunity to make a contribution. A moderator was not 
needed, because the participant found that the group members could get to know each 
other better and work more freely without moderation. It was asserted that a similar level 
of capabilities and experience among the participants promoted the group work without 
leadership. 
 
Q7 Did you need more time or guidance? 
To the participants, the time and guidance for the experiment were sufficient. 
 
The participants did not make further assertions. 
6.2.2.3 Internal ratings: second round 
After the group discussion, the participants filled out the SYMLOG Adjective Rating 
Form for a second time. The results are summarised in the following table. All three 
participants rated each item, however in one cases, the participant P5 did not deliver an 
answer for P6 (see table 6-9). 
 
Code 
P4 
by 
P4 
P4 
by 
P5 
P4 
by 
P6 
P4 
Average 
P 
P5 
by 
P4 
P5 
by 
P5 
P5 
by 
P6 
P5 
Average 
P 
P6 
by 
P4 
P6 
by 
P5 
P6 
by 
P6 
P6 
Average 
P 
U 3 3 4 3.33 3 2 2 2.33 4 4 3 3.67 
UP 4 4 4 4.00 4 3 4 3.67 4 4 4 4.00 
 164 
UPF 4 4 2 3.33 4 2 3 3.00 4 4 3 3.67 
UF 0 1 1 0.67 0 1 1 0.67 0 4 2 2.00 
UNF 0 0 0 0.00 0 1 0 0.33 0 0 0 0.00 
UN 2 2 0 1.33 1 1 0 0.67 4 1 0 1.67 
UNB 0 0 0 0.00 0 0 0 0.00 0   0 0.00 
UB 4 3 2 3.00 3 3 3 3.00 3 3 2 2.67 
UPB 3 4 3 3.33 3 3 4 3.33 4 3 3 3.33 
P 4 4 4 4.00 3 3 4 3.33 4 3 4 3.67 
PF 4 4 4 4.00 3 3 4 3.33 3 3 4 3.33 
F 3 3 3 3.00 4 3 3 3.33 4 3 4 3.67 
NF 4 3 2 3.00 4 3 2 3.00 4 4 2 3.33 
N 0 1 0 0.33 0 0 0 0.00 0 0 0 0.00 
NB 0 0 0 0.00 0 0 0 0.00 0 0 0 0.00 
B 1 0 0 0.33 1 0 0 0.33 1 0 0 0.33 
PB 4 3 3 3.33 4 2 3 3.00 4 3 3 3.33 
DP 3 3 4 3.33 4 3 4 3.67 4 3 4 3.67 
DPF 3 3 3 3.00 4 3 4 3.67 4 3 3 3.33 
DF 3 3 3 3.00 4 3 2 3.00 4 3 2 3.00 
DNF 2 1 0 1.00 2 2 0 1.33 3 1 0 1.33 
DN 1 0 0 0.33 0 1 0 0.33 0 0 0 0.00 
DNB 1 1 0 0.67 0 1 0 0.33 0 0 0 0.00 
DB 2 1 0 1.00 0 1 0 0.33 0 1 0 0.33 
DPB 3 3 3 3.00 3 3 3 3.00 3 3 3 3.00 
D 1 1 0 0.67 0 1 0 0.33 0 0 0 0.00 
Table 6-9 Internal rating 1: experiment session 2 
 
Compared to the first round of rating, although the participants made the same ratings in 
most of the cases, some corrections were made by rating the item with 1 score higher or 
lower. In two cases, the correction was more than 1 score. P5 did not provide a score for 
P6 in item PF in the first round and rated this item in the second round with “3”, therefore 
the difference between the two rounds of ratings for this item was “3”.  P4 changed the 
rating for P5 by reducing the score by 2 and cause the change of “-2” of this item. 
 
The change of scores in the second round compared to the first round is shown in the table 
6-10. 
 
Code 
P4 by 
P4 
P4 by 
P5 
P4 by 
P6 
P5 by 
P4 
P5 by 
P5 
P5 by 
P6 
P6 by 
P4 
P6 by 
P5 
P6 by 
P6 
U 0 0 1 -1 0 -1 0 0 -1 
UP 0 0 1 0 0 0 0 0 1 
UPF 0 1 -1 0 0 1 0 0 0 
UF -1 -1 1 0 -1 0 0 1 0 
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UNF 0 0 0 0 0 0 0 -1 -1 
UN 0 1 0 -2 1 0 0 -1 0 
UNB 0 -1 0 0 0 0 0 -1 0 
UB 1 0 0 0 1 0 -1 0 1 
UPB -1 0 0 -1 0 0 0 -1 1 
P 0 0 0 -1 0 0 0 -1 1 
PF 1 1 0 -1 0 0 -1 3 1 
F 0 0 0 0 0 -1 0 0 0 
NF 0 0 0 1 0 0 0 1 0 
N 0 1 0 0 0 0 0 0 0 
NB 0 0 0 0 0 0 0 0 0 
B 1 0 0 0 -1 0 1 0 0 
PB 0 0 0 0 0 0 0 0 1 
DP -1 0 0 0 0 0 0 0 1 
DPF -1 0 -1 0 0 0 0 0 1 
DF 1 0 1 1 0 0 0 -1 0 
DNF 0 -1 0 0 0 0 0 1 0 
DN 0 -1 0 -1 0 0 0 -1 0 
DNB 0 -1 0 0 0 0 0 -1 0 
DB 1 -1 0 -1 -1 0 0 0 0 
DPB -1 0 1 0 1 1 -1 1 1 
D 0 -1 0 -1 -1 0 0 -1 0 
Table 6-10 Internal ratings 1 vs. 2: experiment session 1 
 
6.2.3 Test group/ test device 1 
6.2.3.1 Internal ratings: first round 
 
In the first round rating by the participants, all three participants rated each item, however 
in two cases, the participant P3 did not deliver an answer for P1 (see table 6-11).   
 
Code 
P1 
by 
P1 
P1 
by 
P2 
P1 
by 
P3 
P1 
Average 
P 
P2 
by 
P1 
P2 
by 
P2 
P2 
by 
P3 
P2 
Average 
P 
P3 
by 
P1 
P3 
by 
P2 
P3 
by 
P3 
P3 
Average 
P 
U 3 2   2.50 3 3 3 3.00 3 3 2 2.67 
UP 3 3   3.00 3 3 3 3.00 3 3 3 3.00 
UPF 4 2 3 3.00 3 3 3 3.00 3 3 2 2.67 
UF 2 1 2 1.67 2 2 1 1.67 2 2 1 1.67 
UNF 0 0 1 0.33 1 2 1 1.33 0 1 1 0.67 
UN 0 0 1 0.33 0 0 1 0.33 0 0 1 0.33 
UNB 0 1 1 0.67 1 1 1 1.00 0 1 1 0.67 
UB 3 3 3 3.00 3 2 2 2.33 3 3 2 2.67 
UPB 3 2 3 2.67 4 3 3 3.33 3 2 2 2.33 
P 3 4 3 3.33 3 3 3 3.00 3 4 3 3.33 
PF 3 2 3 2.67 4 3 3 3.33 3 3 2 2.67 
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F 3 3 2 2.67 3 4 3 3.33 3 4 2 3.00 
NF 3 3 2 2.67 2 2 2 2.00 3 2 2 2.33 
N 0 0 1 0.33 0 0 0 0.00 0 0 1 0.33 
NB 0 0 1 0.33 0 0 0 0.00 0 0 0 0.00 
B 0 1 1 0.67 1 1 0 0.67 0 1 1 0.67 
PB 3 3 3 3.00 3 2 3 2.67 4 3 2 3.00 
DP 3 2 2 2.33 3 3 2 2.67 3 2 2 2.33 
DPF 3 3 2 2.67 3 3 3 3.00 3 3 2 2.67 
DF 3 1 2 2.00 3 1 2 2.00 2 1 2 1.67 
DNF 1 0 0 0.33 1 0 0 0.33 1 0 0 0.33 
DN 0 0 0 0.00 0 0 0 0.00 0 0 1 0.33 
DNB 0 0 0 0.00 0 0 0 0.00 0 0 1 0.33 
DB 3 0 0 1.00 3 0 0 1.00 3 1 1 1.67 
DPB 3 2 3 2.67 3 3 3 3.00 4 3 2 3.00 
D 0 1 1 0.67 0 1 1 0.67 0 2 1 1.00 
Table 6-11 Internal ratings 1: experiment session 2 
 
After completion of the rating, the participants exchanged the rating forms to view the 
results by the other group members, followed by the group discussion. 
 
 
6.2.3.2 Group discussion 
The group discussion was guided by the following questions. 
 
Q1 How do you feel about working in a group? 
All participants perceived group work as positive if the atmosphere in the group was good. 
 
Q2 Do you prefer to work in groups or on your own? 
Group work seemed to be effective for the application of TRIZ. Since every participant 
had different interpretations for the inventive principles, the group work was very helpful 
not only for cross-examination of their own ideas, but also for inspiration by the 
interpretations and ideas by the others.  
 
Q3 Did you feel comfortable during the solution-seeking process in the experiment? 
All three participants experience the session as positive and pleasant. 
 
Q4 How would you describe the status of the solution-seeking process in the 
beginning, in the middle and at the end of the session? 
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Due to the clear structure of the inventive principles, no “warming up” was necessary. 
Innovative ideas were generated right from the very beginning of the session. 
 
Q5 When was the most innovative moment? 
There were many moments where innovative ideas were generated, e.g. the giraffe design 
for children. Or as TRIZ led to the specific technical solutions of compressed gas system 
and changed formulation. TRIZ seemed to solve problems not only in short-term, but 
helped in finding out directions for long-term development. 
 
Q6 Would a moderator, facilitator or a group leader be helpful for the group work? 
No leadership or moderation was considered necessary by the group, since TRIZ was 
thought to provide very clear instructions.  
 
Q7 Did you need more time or guidance? 
The time was considered sufficient and no further guidance was needed. 
 
 
The participants did not make further assertions. 
 
 
6.2.3.3 Internal ratings: second round 
 
After the group discussion, the participants filled out the SYMLOG Adjective Rating 
Form for a second time. The results are summarised in table 6-12. 
 
Code 
P1 
by 
P1 
P1 
by 
P2 
P1 
by 
P3 
P1 
Average 
P 
P2 
by 
P1 
P2 
by 
P2 
P2 
by 
P3 
P2 
Average 
P 
P3 
by 
P1 
P3 
by 
P2 
P3 
by 
P3 
P3 
Average 
P 
U 3 2 2 2.33 3 3 3 3.00 3 3 2 2.67 
UP 3 3 3 3.00 3 3 3 3.00 3 3 3 3.00 
UPF 3 3 3 3.00 3 2 3 2.67 3 3 3 3.00 
UF 1 2 1 1.33 1 3 1 1.67 1 3 1 1.67 
UNF 0 1 1 0.67 0 2 2 1.33 0 1 1 0.67 
UN 1 1 1 1.00 1 1 2 1.33 1 1 1 1.00 
UNB 0 1 1 0.67 0 1 1 0.67 1 0 1 0.67 
UB 3 2 3 2.67 3 2 2 2.33 3 3 2 2.67 
UPB 3 2 3 2.67 3 3 3 3.00 3 3 2 2.67 
P 2 3 3 2.67 3 3 3 3.00 3 3 3 3.00 
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PF 3 2 2 2.33 3 3 3 3.00 3 3 2 2.67 
F 3 2 2 2.33 3 3 3 3.00 2 4 2 2.67 
NF 3 3 2 2.67 3 3 2 2.67 1 3 2 2.00 
N 0 0 0 0.00 0 1 0 0.33 0 1 1 0.67 
NB 0 0 0 0.00 1 0 0 0.33 0 0 0 0.00 
B 1 2 0 1.00 2 1 0 1.00 1 1 1 1.00 
PB 3 3 3 3.00 3 2 3 2.67 3 3 2 2.67 
DP 3 2 3 2.67 3 3 2 2.67 3 3 2 2.67 
DPF 3 3 3 3.00 3 3 3 3.00 3 3 2 2.67 
DF 3 1 2 2.00 2 1 3 2.00 3 1 2 2.00 
DNF 1 0 0 0.33 1 0 0 0.33 1 0 1 0.67 
DN 0 0 0 0.00 0 0 0 0.00 0 1 1 0.67 
DNB 0 0 0 0.00 0 0 1 0.33 0 0 1 0.33 
DB 3 0 0 1.00 3 0 1 1.33 3 1 1 1.67 
DPB 3 3 3 3.00 3 3 2 2.67 3 3 3 3.00 
D 0 2 1 1.00 0 1 0 0.33 0 1 1 0.67 
Table 6-12 Internal ratings 2: experiment session 2 
 
 
Compared to the first round of rating, the participants made some corrections by rating 
the items with 1 score higher or lower. In two cases, the correction was more than 1 score. 
In both cases, P3 did not provide a score for P1 in the first round, however rated those 
items in the second round. 
 
The change of scores in the second round compared to the first round is shown in the table 
6-13. 
 
Code 
P1 by 
P1 
P1 by 
P2 
P1 by 
P3 
P2 by 
P1 
P2 by 
P2 
P2 by 
P3 
P3 by 
P1 
P3 by 
P2 
P3 by 
P3 
U 0 0 2 0 0 0 0 0 0 
UP 0 0 3 0 0 0 0 0 0 
UPF -1 1 0 0 -1 0 0 0 1 
UF -1 1 -1 -1 1 0 -1 1 0 
UNF 0 1 0 -1 0 1 0 0 0 
UN 1 1 0 1 1 1 1 1 0 
UNB 0 0 0 -1 0 0 1 -1 0 
UB 0 -1 0 0 0 0 0 0 0 
UPB 0 0 0 -1 0 0 0 1 0 
P -1 -1 0 0 0 0 0 -1 0 
PF 0 0 -1 -1 0 0 0 0 0 
F 0 -1 0 0 -1 0 -1 0 0 
NF 0 0 0 1 1 0 -2 1 0 
N 0 0 -1 0 1 0 0 1 0 
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NB 0 0 -1 1 0 0 0 0 0 
B 1 1 -1 1 0 0 1 0 0 
PB 0 0 0 0 0 0 -1 0 0 
DP 0 0 1 0 0 0 0 1 0 
DPF 0 0 1 0 0 0 0 0 0 
DF 0 0 0 -1 0 1 1 0 0 
DNF 0 0 0 0 0 0 0 0 1 
DN 0 0 0 0 0 0 0 1 0 
DNB 0 0 0 0 0 1 0 0 0 
DB 0 0 0 0 0 1 0 0 0 
DPB 0 1 0 0 0 -1 -1 0 1 
D 0 1 0 0 0 -1 0 -1 0 
Table 6-13 Internal rating 1 vs. 2: experiment session 2 
 
 
 
 
 
 
 
 
 
6.2.4 Control group/ test device 2 
6.2.4.1 Internal ratings: first round 
 
Details of the first round rating by the participants are summarized in table 6-14.  
 
Code 
P1 
by 
P1 
P1 
by 
P2 
P1 
by 
P3 
P1 
Average 
P 
P2 
by 
P1 
P2 
by 
P2 
P2 
by 
P3 
P2 
Average 
P 
P3 
by 
P1 
P3 
by 
P2 
P3 
by 
P3 
P3 
Average 
P 
U 3 3 3 3.00 4 3 3 3.33 2 3 3 2.67 
UP 3 4 4 3.67 4 3 4 3.67 4 4 3 3.67 
UPF 4 3 2 3.00 4 2 3 3.00 3 3 2 2.67 
UF 1 2 1 1.33 2 2 2 2.00 3 3 2 2.67 
UNF 0 1 1 0.67 0 1 2 1.00 0 0 2 0.67 
UN 2 1 1 1.33 1 1 1 1.00 1 1 2 1.33 
UNB 1 1 0 0.67 0 1 0 0.33 1 0 1 0.67 
UB 4 2 2 2.67 3 2 3 2.67 4 3 1 2.67 
UPB 4 2 3 3.00 3 2 4 3.00 4 3 3 3.33 
P 4 3 4 3.67 4 3 4 3.67 4 3 3 3.33 
PF 3 3 3 3.00 4 3 3 3.33 4 3 2 3.00 
F 3 2 3 2.67 3 3 3 3.00 3 3 2 2.67 
NF 4 2 2 2.67 2 3 3 2.67 2 4 3 3.00 
N 0 0 0 0.00 0 0 0 0.00 0 0 1 0.33 
NB 0 0 0 0.00 0 1 0 0.33 0 0 1 0.33 
B 1 2 0 1.00 0 1 0 0.33 3 1 2 2.00 
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PB 3 3 4 3.33 4 2 4 3.33 4 3 3 3.33 
DP 3 3 4 3.33 3 3 3 3.00 4 3 2 3.00 
DPF 3 4 4 3.67 4 3 3 3.33 4 3 3 3.33 
DF 3 1 3 2.33 3 1 3 2.33 3 2 2 2.33 
DNF 3 0 0 1.00 1 1 0 0.67 1 1 0 0.67 
DN 0 0 0 0.00 0 0 0 0.00 0 0 1 0.33 
DNB 0 0 0 0.00 0 1 0 0.33 0 1 0 0.33 
DB 4 0 0 1.33 4 0 0 1.33 3 1 1 1.67 
DPB 4 4 3 3.67 4 4 3 3.67 4 4 2 3.33 
D 0 1 1 0.67 0 2 0 0.67 0 1 1 0.67 
Table 6-14 Internal ratings 1: experiment session 3 
 
After completion of the first round of rating, the participants exchanged the rating forms 
to view the results by the other group members, followed by the group discussion. 
 
 
6.2.4.2 Group discussion 
During the group discussion, the following questions were answered by the participants. 
 
Q1 How do you feel about working in a group? 
All participants found the group work positive, especially with the pleasant relationship 
among the group members. It was also perceived as a benefit that each group member 
could contribute with his own expertise.  
 
Q2 Do you prefer to work in a group or on your own? 
None of the participants seemed to have a clear preference. Two participants found a 
combination of both good, so that each individual could develop his/her own solutions 
first, then cross-examine and combine those ideas in the subsequent group work. 
 
Q3 Did you feel comfortable during the solution-seeking process in the experiment? 
All participants perceived the experiment as pleasant.  
 
Q4 How would you describe the status of the solution-seeking process in the 
beginning, in the middle and at the end of the session? 
In the beginning, it took time to reach a common understanding of the technical issues. 
The discussion was repeated in the middle and at the end of the session, because one 
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participant felt it was necessary to clarify the interconnections of identified solutions. The 
focus on solution finding was stronger in the middle and at the end of the session. 
 
Q5 When was the most innovative moment? 
To all participants the use of QR-code was the most innovative idea. Till this idea came 
across, all proposals were experience-driven as modifications to the existing solutions. 
QR-code suggested the application of a new technology that had not been used in the 
observed field of research and development.  
 
Q6 Would a moderator, facilitator or a group leader be helpful for the group work? 
No hierarchy was considered necessary. At times, some group member appeared more 
dominant, therefore a moderator could be helpful in giving each member the equal 
opportunity to contribute to the group work. 
 
Q7 Did you need more time or guidance? 
More time would be helpful, more guidance was not considered necessary. 
 
The participants did not make further assertions. 
 
6.2.4.3 Internal ratings: second round 
After the group discussion, the participants filled out the SYMLOG Adjective Rating 
Form for a second time. The results are summarised in table 6-15. 
 
Code 
P1 
by 
P1 
P1 
by 
P2 
P1 
by 
P3 
P1 
Average P 
P2 
by 
P1 
P2 
by 
P2 
P2 
by 
P3 
P2 
Average P 
P3 
by 
P1 
P3 
by 
P2 
P3 
by 
P3 
P3 
Average 
P 
U 3 3 3 3.00 3 3 3 3.00 3 3 3 3.00 
UP 4 3 3 3.33 3 3 3 3.00 4 4 3 3.67 
UPF 3 3 3 3.00 4 3 3 3.33 3 3 2 2.67 
UF 0 1 1 0.67 2 2 2 2.00 1 2 1 1.33 
UNF 0 0 1 0.33 0 1 1 0.67 0 0 1 0.33 
UN 1 0 1 0.67 0 1 1 0.67 1 1 1 1.00 
UNB 0 1 1 0.67 1 1 0 0.67 0 1 1 0.67 
UB 4 2 3 3.00 3 3 3 3.00 4 3 2 3.00 
UPB 3 3 3 3.00 3 2 3 2.67 3 3 2 2.67 
P 3 3 3 3.00 3 3 3 3.00 3 4 2 3.00 
PF 3 2 3 2.67 3 3 3 3.00 3 3 3 3.00 
F 4 2 2 2.67 3 3 3 3.00 3 4 3 3.33 
NF 3 3 2 2.67 2 3 3 2.67 3 3 2 2.67 
N 0 0 0 0.00 0 1 0 0.33 0 0 1 0.33 
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NB 0 0 0 0.00 0 0 0 0.00 0 0 1 0.33 
B 0 1 0 0.33 0 1 0 0.33 1 1 2 1.33 
PB 4 3 3 3.33 4 2 3 3.00 4 3 2 3.00 
DP 3 3 3 3.00 3 3 3 3.00 3 3 2 2.67 
DPF 3 3 3 3.00 4 3 3 3.33 3 3 3 3.00 
DF 3 2 2 2.33 3 1 3 2.33 3 2 2 2.33 
DNF 2 0 0 0.67 2 0 0 0.67 1 0 1 0.67 
DN 0 0 0 0.00 0 0 0 0.00 0 0 1 0.33 
DNB 0 0 0 0.00 0 0 0 0.00 0 0 1 0.33 
DB 3 0 0 1.00 3 0 0 1.00 3 0 1 1.33 
DPB 3 4 3 3.33 3 3 3 3.00 3 4 2 3.00 
D 0 2 1 1.00 0 1 0 0.33 0 2 1 1.00 
Table 6-15 Internal ratings 2: experiment session 3 
 
 
Compared to the first round of rating, the participants made some corrections by rating 
the items with 1 score higher or lower. In two cases, the correction was more than 1 score. 
In both cases, P1 reduced the rating for P3 by 2 scores. 
 
The changes of scores in the second round compared to the first round are shown in the 
table 6-16. 
 
 
Code 
P1 by 
P1 
P1 by 
P2 
P1 by 
P3 
P2 by 
P1 
P2 by 
P2 
P2 by 
P3 
P3 by 
P1 
P3 by 
P2 
P3 by 
P3 
U 0 0 0 -1 0 0 1 0 0 
UP 1 -1 -1 -1 0 -1 0 0 0 
UPF -1 0 1 0 1 0 0 0 0 
UF -1 -1 0 0 0 0 -2 -1 -1 
UNF 0 -1 0 0 0 -1 0 0 -1 
UN -1 -1 0 -1 0 0 0 0 -1 
UNB -1 0 1 1 0 0 -1 1 0 
UB 0 0 1 0 1 0 0 0 1 
UPB -1 1 0 0 0 -1 -1 0 -1 
P -1 0 -1 -1 0 -1 -1 1 -1 
PF 0 -1 0 -1 0 0 -1 0 1 
F 1 0 -1 0 0 0 0 1 1 
NF -1 1 0 0 0 0 1 -1 -1 
N 0 0 0 0 1 0 0 0 0 
NB 0 0 0 0 -1 0 0 0 0 
B -1 -1 0 0 0 0 -2 0 0 
PB 1 0 -1 0 0 -1 0 0 -1 
DP 0 0 -1 0 0 0 -1 0 0 
DPF 0 -1 -1 0 0 0 -1 0 0 
 173 
DF 0 1 -1 0 0 0 0 0 0 
DNF -1 0 0 1 -1 0 0 -1 1 
DN 0 0 0 0 0 0 0 0 0 
DNB 0 0 0 0 -1 0 0 -1 1 
DB -1 0 0 -1 0 0 0 -1 0 
DPB -1 0 0 -1 -1 0 -1 0 0 
D 0 1 0 0 -1 0 0 1 0 
Table 6-16 Internal ratings 1 vs. 2: experiment session 3 
 
 
 
 
6.2.5 Test group/ test device 2 
6.2.5.1 Internal ratings: first round 
 
In the first round rating by the participants, all three participants rated each item, however 
in three cases, the participant P5 did not deliver an answer for P4, P5 did not rate himself 
and P5 did not delivered a rating for P6 (see table 6-17). 
 
Code 
P4 
by 
P4 
P4 
by 
P5 
P4 
by 
P6 
P4 
Average 
P 
P5 
by 
P4 
P5 
by 
P5 
P5 
by 
P6 
P5 
Average 
P 
P6 
by 
P4 
P6 
by 
P5 
P6 
by 
P6 
P6 
Average 
P 
U 3 3 3 3.00 4 3 3 3.33 4 4 4 4.00 
UP 3 3 4 3.33 3 3 4 3.33 4 4 4 4.00 
UPF 3 3 2 2.67 3 1 2 2.00 4 4 3 3.67 
UF 1 0 1 0.67 0 1 1 0.67 1   2 1.50 
UNF 0 1 0 0.33 0 0 0 0.00 0 0 0 0.00 
UN 2 2 0 1.33 1 1 0 0.67 3 4 0 2.33 
UNB 0   0 0.00 0 1 0 0.33 0 0 0 0.00 
UB 3 3 3 3.00 3 2 4 3.00 4 3 2 3.00 
UPB 4 4 4 4.00 3 3 4 3.33 4 4 4 4.00 
P 4 3 4 3.67 3 3 4 3.33 4 4 4 4.00 
PF 3 3 4 3.33 3 4 4 3.67 4 4 3 3.67 
F 3 3 3 3.00 4 3 3 3.33 4 4 4 4.00 
NF 3 3 2 2.67 4 3 2 3.00 4 4 2 3.33 
N 0 0 0 0.00 0 1 0 0.33 0 0 0 0.00 
NB 0 0 0 0.00 0 1 0 0.33 0 0 0 0.00 
B 1 1 0 0.67 1   0 0.50 0 0 0 0.00 
PB 3 4 3 3.33 3 2 4 3.00 3 3 2 2.67 
DP 2 3 4 3.00 3 2 4 3.00 4 3 4 3.67 
DPF 3 3 3 3.00 3 2 4 3.00 4 4 3 3.67 
DF 2 3 2 2.33 4 3 3 3.33 4 4 2 3.33 
DNF 2 2 0 1.33 1 2 0 1.00 1 2 0 1.00 
DN 1 0 0 0.33 0 1 0 0.33 0 0 0 0.00 
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DNB 1 1 0 0.67 0 2 0 0.67 0 1 0 0.33 
DB 1 1 0 0.67 0 2 0 0.67 0 1 0 0.33 
DPB 2 1 3 2.00 3 3 3 3.00 4 1 4 3.00 
D 1 0 0 0.33 0 2 0 0.67 0 0 0 0.00 
Table 6-17 Internal rating 1: experiment session 4 
After completion of the rating, the participants exchanged the rating forms to view the 
results by the other group members, followed by the group discussion. 
 
6.2.5.2 Group discussion 
The group discussion was guided by the following questions. 
 
Q1 How do you feel about working in a group? 
Group work was described as positive and pleasant by all participants. Especially for the 
application of TRIZ, group work was considered more effective, as this gave the members 
the opportunity to combine their own ideas with those from the others, or further develop 
the new ideas using the guidance of the TRIZ inventive principles. 
 
Q2 Do you prefer to work in a group or on your own? 
All participants preferred group work than working alone. The main benefits of group 
work were thought to be the mutual supports in terms of supportive inspirations, as well 
as approving and further development of the individual ideas. 
 
Q3 Did you feel comfortable during the solution-seeking process in the experiment? 
The process was perceived by the participants as pleasant. However, the beginning of the 
session involved some difficulties in reaching a common understanding of the content of 
the TRIZ inventive principles. 
 
Q4 How would you describe the status of the solution-seeking process in the 
beginning, in the middle and at the end of the session? 
After the tentative beginning where the participants spent some time on achieving a 
consensus for the content of the inventive principles, new ideas emerged. Most of the 
ideas were generated in the middle of the session. As it approached the end of the session, 
the group focused mainly on finalising the ideas and put the results in writing.  
 
Q5 When was the most innovative moment? 
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The middle part of the group work seemed to be the most innovative during the session.  
  
Q6 Would a moderator, facilitator or a group leader be helpful for the group work? 
Free discussions without formal leadership were stated by the participants to be especially 
helpful. There was no need for a moderator. 
  
Q7 Did you need more time or guidance? 
The participants raised concerns of time during the lengthy discussions on the TRIZ 
techniques at the beginning. However, in the end the time seemed to be sufficient. A prior 
TRIZ refresher training was considered beneficial. 
 
In addition, the participants asserted that compared with their previous experience with 
brainstorming, TRIZ seemed to be more effective for the solution of “hard” technical 
problems. However, brainstorming seemed to be more appropriate for the solution of 
“soft” issues, e.g. instruction for use or training programmes. Besides, in order to produce 
good results, at least one of the group members should have a thorough understanding of 
each relevant technology. 
 
6.2.5.3 Internal ratings: second round 
 
After the group discussion, the participants filled out the SYMLOG Adjective Rating 
Form for a second time. The results are summarised in table 6-18. 
 
 
Code 
P4 by 
P4 
P4 by 
P5 
P4 by 
P6 
P4 
Average P 
P5 by 
P4 
P5 by 
P5 
P5 by 
P6 
P5 
Average P 
P6 by 
P4 
P6 by 
P5 
P6 by 
P6 
P6 Average 
P 
U 3 2 3 2.67 3 1 3 2.33 4 3 4 3.67 
UP 3 4 4 3.67 3 4 4 3.67 4 4 4 4.00 
UPF 3 2 2 2.33 3 2 2 2.33 4 4 4 4.00 
UF 1 1 1 1.00 0 1 1 0.67 1 3 1 1.67 
UNF 0 0 0 0.00 0 1 0 0.33 0 1 0 0.33 
UN 2 1 0 1.00 3 1 0 1.33 4 3 0 2.33 
UNB 0 0 0 0.00 0 1 0 0.33 0 0 0 0.00 
UB 3 3 2 2.67 3 2 3 2.67 3 2 3 2.67 
UPB 4 4 4 4.00 4 3 4 3.67 4 4 3 3.67 
P 4 4 4 4.00 4 3 4 3.67 4 4 4 4.00 
PF 4 4 4 4.00 4 3 4 3.67 4 4 4 4.00 
F 3 4 2 3.00 4 3 3 3.33 4 4 3 3.67 
NF 3 3 2 2.67 4 3 2 3.00 4 3 2 3.00 
N 0 0 0 0.00 0 1 0 0.33 0 1 0 0.33 
NB 0 0 0 0.00 1 0 0 0.33 1 1 0 0.67 
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B 1 1 0 0.67 1 0 0 0.33 1 1 0 0.67 
PB 4 3 3 3.33 4 2 3 3.00 4 3 3 3.33 
DP 3 3 4 3.33 3 2 4 3.00 3 3 3 3.00 
DPF 3 3 3 3.00 3 2 4 3.00 4 4 4 4.00 
DF 3 3 2 2.67 3 3 2 2.67 3 4 2 3.00 
DNF 2 2 1 1.67 2 2 0 1.33 2 2 0 1.33 
DN 0 1 0 0.33 0 0 0 0.00 0 1 0 0.33 
DNB 0 1 0 0.33 0 1 0 0.33 0 0 0 0.00 
DB 0 2 0 0.67 1 2 0 1.00 0 0 0 0.00 
DPB 2 2 3 2.33 3 1 3 2.33 4 2 3 3.00 
D 1 2 0 1.00 0 2 0 0.67 0 0 0 0.00 
Table 6-18 Internal rating 2: experiment session 4 
 
 
Compared to the first round of rating, the participants made some corrections by rating 
the items with 1 score higher or lower. In four cases, the correction was made by 2 scores. 
In a further case, the deviate was “3” because the rating was only given in the second 
round. 
 
The changes of scores in the second round compared to the first round are shown in the 
table 6- 19. 
 
 
 
 
Code 
P4 by 
P4 
P4 by 
P5 
P4 by 
P6 
P4 Average 
P 
P5 by 
P4 
P5 by 
P5 
P5 by 
P6 
P5 Average 
P 
P6 by 
P4 
P6 by 
P5 
P6 by 
P6 
U 0 -1 0 0 -1 -2 0 -1 0 -1 0 
UP 0 1 0 0 0 1 0 0 0 0 0 
UPF 0 -1 0 0 0 1 0 0 0 0 1 
UF 0 1 0 0 0 0 0 0 0 3 -1 
UNF 0 -1 0 0 0 1 0 0 0 1 0 
UN 0 -1 0 0 2 0 0 1 1 -1 0 
UNB 0 0 0 0 0 0 0 0 0 0 0 
UB 0 0 -1 0 0 0 -1 0 -1 -1 1 
UPB 0 0 0 0 1 0 0 0 0 0 -1 
P 0 1 0 0 1 0 0 0 0 0 0 
PF 1 1 0 1 1 -1 0 0 0 0 1 
F 0 1 -1 0 0 0 0 0 0 0 -1 
NF 0 0 0 0 0 0 0 0 0 -1 0 
N 0 0 0 0 0 0 0 0 0 1 0 
NB 0 0 0 0 1 -1 0 0 1 1 0 
B 0 0 0 0 0 0 0 0 1 1 0 
PB 1 -1 0 0 1 0 -1 0 1 0 1 
DP 1 0 0 0 0 0 0 0 -1 0 -1 
DPF 0 0 0 0 0 0 0 0 0 0 1 
DF 1 0 0 0 -1 0 -1 -1 -1 0 0 
DNF 0 0 1 0 1 0 0 0 1 0 0 
DN -1 1 0 0 0 -1 0 0 0 1 0 
DNB -1 0 0 0 0 -1 0 0 0 -1 0 
DB -1 1 0 0 1 0 0 0 0 -1 0 
 177 
DPB 0 1 0 0 0 -2 0 -1 0 1 -1 
D 0 2 0 1 0 0 0 0 0 0 0 
Table 6-19 Internal rating 1 vs. 2: experiment session 4 
 
6.2.6 External rating 
The experiment sessions were also evaluated by two raters based on the video recordings, 
using the SYMLOG Adjective Rating Form.  
 
Prior to the evaluation, the raters reached a consensus on how scores should be given by 
discussing on the standards for different levels of each item in the form. They tested the 
standard with two sample sessions. Subsequently, they conducted the rating 
independently from each other.  
 
The results of the external rating are listed in the table 6-20, table 6-21, table 6-22 and 
table 6-23. 
 
Session 1: Control group/ test device 1 
 
 
 
Code 
P4 by 
Rater 1 
P4 by 
Rater 2 
P4 Average 
 R 
P5 by 
Rater 1 
P5 by 
Rater 2 
P5 Average 
 R 
P6 by 
Rater 1 
P6 by 
Rater 2 
P6 Average 
 R 
U 3 3 3.00 2 3 2.50 4 3 3.50 
UP 4 4 4.00 2 4 3.00 4 3 3.50 
UPF 3 2 2.50 1 2 1.50 4 3 3.50 
UF 1 0 0.50 1 2 1.50 1 2 1.50 
UNF 2 0 1.00 1 0 0.50 1 0 0.50 
UN 2 0 1.00 2 0 1.00 2 0 1.00 
UNB 1 0 0.50 0 0 0.00 0 0 0.00 
UB 3 1 2.00 3 2 2.50 3 2 2.50 
UPB 4 3 3.50 4 3 3.50 4 3 3.50 
P 4 3 3.50 4 3 3.50 4 3 3.50 
PF 3 3 3.00 3 3 3.00 3 3 3.00 
F 2 2 2.00 2 3 2.50 4 3 3.50 
NF 3 2 2.50 4 2 3.00 4 2 3.00 
N 0 0 0.00 1 0 0.50 1 0 0.50 
NB 0 0 0.00 2 0 1.00 0 0 0.00 
B 2 0 1.00 1 0 0.50 0 0 0.00 
PB 4 2 3.00 2 2 2.00 3 2 2.50 
DP 3 2 2.50 4 3 3.50 4 3 3.50 
DPF 4 2 3.00 2 3 2.50 3 3 3.00 
DF 2 2 2.00 1 2 1.50 3 2 2.50 
DNF 1 0 0.50 2 0 1.00 2 0 1.00 
DN 2 0 1.00 1 0 0.50 1 0 0.50 
DNB 1 0 0.50 3 0 1.50 1 0 0.50 
DB 0 0 0.00 2 0 1.00 0 0 0.00 
DPB 3 2 2.50 3 2 2.50 3 3 3.00 
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D 1 0 0.50 3 0 1.50 1 0 0.50 
Table 6-20 External rating: experiment session 1 
Session 2: Test group/ test device 1 
Code 
P1 by 
Rater 1 
P1 by 
Rater 2 
P1 Average 
R 
P2 by 
Rater 1 
P2 by 
Rater 2 
P2 Average 
R 
P3 by 
Rater 1 
P3 by Rater 
2 
P3 Average 
R 
U 1 2 1.50 3 3 3.00 3 3 3.00 
UP 2 3 2.50 4 4 4.00 4 4 4.00 
UPF 2 2 2.00 3 3 3.00 4 3 3.50 
UF 1 0 0.50 2 1 1.50 1 1 1.00 
UNF 0 0 0.00 1 0 0.50 1 0 0.50 
UN 0 0 0.00 0 0 0.00 2 0 1.00 
UNB 0 0 0.00 0 0 0.00 0 0 0.00 
UB 3 2 2.50 2 2 2.00 4 2 3.00 
UPB 2 3 2.50 3 4 3.50 4 3 3.50 
P 3 3 3.00 3 4 3.50 4 4 4.00 
PF 1 3 2.00 4 4 4.00 3 3 3.00 
F 3 2 2.5 2 3 2.5 4 3 3.50 
NF 2 1 1.50 3 2 2.50 3 2 2.50 
N 0 0 0.00 1 0 0.50 1 0 0.50 
NB 0 0 0.00 0 0 0.00 0 0 0.00 
B 0 0 0.00 0 0 0.00 0 0 0.00 
PB 4 2 3.00 2 0 1.00 4 3 3.50 
DP 3 2 2.50 3 4 3.50 3 3 3.00 
DPF 2 2 2.00 4 3 3.50 3 3 3.00 
DF 1 1 1.00 2 2 2.00 2 2 2.00 
DNF 0 0 0.00 0 0 0.00 0 0 0.00 
DN 1 0 0.50 1 0 0.50 1 0 0.50 
DNB 1 0 0.50 0 0 0.00 0 0 0.00 
DB 1 0 0.50 1 0 0.50 0 0 0.00 
DPB 3 2 2.50 3 3 3.00 4 3 3.50 
D 2 0 1.00 0 0 0.00 1 0 0.50 
Table 6-21 External rating: experiment session 2 
 
Session 3: Control group/ test device 2 
Code 
P1 by Rater 
1 
P1 by 
Rater 2 
P1 Average 
R 
P2 by 
Rater 1 
P2 by Rater 
2 
P2 
Average R 
P3  by 
Rater 1 
P3 
byRater 2 
P3 Average 
R 
U 2 2 2.00 3 3 3.00 4 3 3.50 
UP 4 3 3.50 2 4 3.00 4 3 3.50 
UPF 1 1 1.00 1 2 1.50 4 3 3.50 
UF 1 0 0.50 2 1 1.50 1 1 1.00 
UNF 0 0 0.00 0 0 0.00 0 0 0.00 
UN 0 0 0.00 0 0 0.00 3 0 1.50 
UNB 0 0 0.00 0 0 0.00 0 0 0.00 
UB 4 2 3.00 2 2 2.00 4 1 2.50 
UPB 4 2 3.00 3 3 3.00 4 2 3.00 
P 4 3 3.50 4 4 4.00 3 4 3.50 
PF 3 2 2.50 2 4 3.00 3 2 2.50 
F 4 2 3.00 3 3 3.00 4 3 3.50 
NF 3 1 2.00 3 2 2.50 3 3 3.00 
N 1 0 0.50 1 0 0.50 0 0 0.00 
NB 0 0 0.00 0 0 0.00 0 0 0.00 
B 0 0 0.00 0 0 0.00 0 0 0.00 
PB 4 0 2.00 2 2 2.00 4 2 3.00 
DP 3 3 3.00 3 3 3.00 4 2 3.00 
DPF 3 3 3.00 2 4 3.00 3 2 2.50 
DF 2 2 2.00 1 2 1.50 2 2 2.00 
DNF 0 0 0.00 0 0 0.00 1 0 0.50 
DN 0 0 0.00 1 0 0.50 0 0 0.00 
DNB 1 0 0.50 1 0 0.50 0 0 0.00 
DB 1 0 0.50 0 0 0.00 1 0 0.50 
DPB 4 2 3.00 3 2 2.50 4 2 3.00 
D 2 0 1.00 0 0 0.00 1 0 0.50 
Table 6-22 External rating: experiment session 3 
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Session 4: Test group/ test device 2 
Code 
P4 by Rater 
1 
P4 by 
Rater 2 
P4 Average 
R 
P5 by 
Rater 1 
P5 by 
Rater 2 
P5 Average 
R 
P6 by 
Rater 1 
P6 by 
Rater 2 
P6 Average 
R 
U 3 3 3.00 1 3 2.00 4 3 3.50 
UP 2 3 2.50 1 3 2.00 4 4 4.00 
UPF 3 2 2.50 2 2 2.00 4 3 3.50 
UF 2 1 1.50 2 2 2.00 4 2 3.00 
UNF 1 0 0.50 1 0 0.50 3 0 1.50 
UN 1 0 0.50 1 0 0.50 4 0 2.00 
UNB 2 0 1.00 0 0 0.00 1 0 0.50 
UB 3 2 2.50 2 2 2.00 3 2 2.50 
UPB 4 3 3.50 3 3 3.00 4 3 3.50 
P 4 3 3.50 4 3 3.50 3 4 3.50 
PF 2 3 2.50 2 3 2.50 2 3 2.50 
F 3 2 2.50 4 2 3.00 4 3 3.50 
NF 4 2 3.00 3 2 2.50 4 3 3.50 
N 0 0 0.00 0 0 0.00 1 0 0.50 
NB 1 0 0.50 1 0 0.50 2 0 1.00 
B 1 0 0.50 0 0 0.00 1 0 0.50 
PB 4 3 3.50 3 2 2.50 4 2 3.00 
DP 1 3 2.00 4 3 3.50 4 3 3.50 
DPF 2 3 2.50 4 3 3.50 3 3 3.00 
DF 1 2 1.50 2 2 2.00 1 2 1.50 
DNF 0 0 0.00 1 0 0.50 1 0 0.50 
DN 1 0 0.50 0 0 0.00 0 0 0.00 
DNB 2 0 1.00 1 0 0.50 0 0 0.00 
DB 1 0 0.50 2 0 1.00 0 0 0.00 
DPB 3 2 2.50 3 2 2.50 3 3 3.00 
D 1 0 0.50 1 0 0.50 0 0 0.00 
Table 6-23 External rating: experiment session 4 
 
6.2.7 Assessment of process 
6.2.7.1 External rating vs. internal rating 
 
The results of the external ratings are compared with the internal ratings in the following 
graphics. 
 
The x-axis illustrates the dimension P-N (= Positive – Negative) in the SYMLOG 
Adjective Rating method and describes if the observed person is friendly (P) or unfriendly 
(N). The y-axis demonstrates dimension F-B (= Forward – Backward) and shows if the 
observed person is instrumentally controlled (F) or emotionally expressive (B). The size 
of the bubbles represent dimension U-D (= Upward – Downward) and depicts how 
actively the observed person exerts influence on the observed event, ranging from 
dominant (U) to submissive (D). 
 
 
Session 1 (test device 1/ brainstorming) 
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Figure 6-1  Ratings in session 1 (test device 1/ brainstorming) 
 
The behaviour of all participants during this session was perceived as positive (dimension 
P-N), instrumentally controlled (dimension F-B) and active (dimension U-D) by both 
internal and external ratings. 
 
In the second round of internal rating, P6 appeared to be more positive than in the first 
round and was perceived as the friendliest person (highest value in dimension P-N) in the 
group. This opinion was also shared by the external raters. According to the external raters, 
the behaviour of P5 was less positive than the others. However, the group members did 
not seem to have noticed such essential difference in each other’s behaviour in this aspect. 
 
P6 was also perceived as the most task-oriented (dimension F-B) participant of the session 
in all internal and external ratings. Furthermore, while P6 was judged by the group 
members as the leading person (the highest value in dimension U-D), while the external 
raters evaluated P4 as almost as dominant as P6.  
 
(See figure 6-1). 
 
 
Session 2 (test device 1/ TRIZ) 
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Figure 6-2  Ratings in session 2 (test device 1/ TRIZ) 
 
 
Like in session 1, the behaviours of all participants during this session were perceived as 
positive (dimension P-N), instrumentally controlled (dimension F-B) and active 
(dimension U-D) by both internal and external ratings. 
 
In all ratings, all participants illustrated a similar level of friendliness (dimension P-N), 
task-orientation (dimension F-B) and active participation (dimension U-D). 
Exceptionally, according to the external rating, P1 was less positive, less instrumentally 
controlled and less active than the others.  
 
(See figure 6-2). 
 
 
Session 3 (test device 2/ brainstorming) 
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Figure 6-3  Ratings in session 3 (test device 2/ brainstorming) 
 
The participation of all members seemed to have been positive (dimension P-N), 
instrumentally controlled (dimension F-B) and active (dimension U-D) according to the 
internal and external ratings. 
 
In both internal and external rating, P3 was seen as the friendliest (dimension P-N) and 
P2 the most task-oriented (dimension F-B) among all participants. Although to the group 
members, each individual played a similarly active role in the group work, the external 
raters recognised a difference. To them, P3 was clearly more dominant than the others, 
while P1 was hardly active at all.  
 
(See figure 6-3). 
 
Session 4 (test device 2/ TRIZ) 
 
Also in the last session, the behaviour of all participants during this session was perceived 
as positive (dimension P-N), instrumentally controlled (dimension F-B) and active 
(dimension U-D) by both internal and external ratings  
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Figure 6-4  Ratings in session 4 (test device 2/ TRIZ) 
 
In both internal and external ratings, P6 was essentially more positive (dimension P-N), 
more task-oriented (dimension F-B) and more dominant (dimension U-D) than the others.  
 
(See figure 6-4). 
 
 
For each session in each dimension, the participants’ scores were put into ranks. The 
results are shown in table 6-24. 
 
 
 
 
 
No. Session Dimension Participant Rank IR1 Rank IR2 Rank ER 
Rank IR1 
vs. IR2 
Rank IR1 
vs. ER 
Rank IR2 
vs. ER 
1 1 F-B P4 3 3 2 0 1 1 
2 1 F-B P5 2 2 3 0 1 1 
3 1 F-B P6 1 1 1 0 0 0 
4 1 P-N P4 1 1 2 0 1 1 
5 1 P-N P5 3 2 3 1 0 1 
6 1 P-N P6 2 3 1 1 1 2 
7 1 U-D P4 2 2 1 0 1 1 
8 1 U-D P5 3 3 3 0 0 0 
9 1 U-D P6 1 1 2 0 1 1 
10 2 F-B P1 2 3 3 1 1 0 
11 2 F-B P2 1 2 1 1 0 1 
12 2 F-B P3 3 1 2 2 1 1 
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13 2 P-N P1 2 2 3 0 1 1 
14 2 P-N P2 1 3 2 2 1 1 
15 2 P-N P3 3 1 1 2 2 0 
16 2 U-D P1 2 3 3 1 1 0 
17 2 U-D P2 1 2 2 1 1 0 
18 2 U-D P3 3 1 1 2 2 0 
19 3 F-B P1 2 3 3 1 1 0 
20 3 F-B P2 1 1 2 0 1 1 
21 3 F-B P3 3 2 1 1 2 1 
22 3 P-N P1 1 1 2 0 1 1 
23 3 P-N P2 3 3 3 0 0 0 
24 3 P-N P3 2 2 1 0 1 1 
25 3 U-D P1 2 3 3 1 1 0 
26 3 U-D P2 3 2 2 1 1 0 
27 3 U-D P3 1 1 1 0 0 0 
28 4 F-B P4 2 2 3 0 1 1 
29 4 F-B P5 3 2 2 1 1 0 
30 4 F-B P6 1 1 1 0 0 0 
31 4 P-N P4 2 1 3 1 1 2 
32 4 P-N P5 3 2 2 1 1 0 
33 4 P-N P6 1 3 2 2 1 1 
34 4 U-D P4 2 2 2 0 0 0 
35 4 U-D P5 3 3 3 0 0 0 
36 4 U-D P6 1 1 1 0 0 0 
Table 6-24 External rating vs. internal rating in ranks 
 
Comparing with the first round, in 18 out of 36 cases, the ranks remained unchanged, 13 
were modified by one rank and 5 by two ranks in the second round of internal rating. Thus 
it may be said that the participants made moderate corrections to their perceptions after 
the group discussion which disclosed the results of the first round of rating. 
 
In 10 out of 36 cases, the external rating rank was identical with the first round of internal 
rating. Compared with the first round of internal rating, the rank in the external rating was 
different by 1 rank in 23 cases and by 2 ranks in 3 cases.  
 
In 18 out of 36 cases, the external rating rank was identical with the second round of 
internal rating. Compared with the second round of internal rating, the rank in the external 
rating was different by 1 rank in 16 cases and by 2 ranks in 2 cases. 
 
The results of the comparisons between the external rating and the two rounds of internal 
rating indicated that the deviations between the perception of the participants and the 
independent raters were reduced in the second round of internal rating. A possible 
explanation for this effect is that the participants’ perceptions became more objective after 
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publicly viewing the results of the first round of rating. Thus the results of the second 
round of internal rating became closer to the potentially more objective external rating. 
 
 
No. Session Participant Rank IR1 Rank IR2 Rank ER 
Rank IR1 
vs. IR2 
Rank IR1 
vs. ER 
Rank IR2 
vs. ER 
1 1 P4 3 3 2 0 1 1 
2 1 P5 2 2 3 0 1 1 
3 1 P6 1 1 1 0 0 0 
4 3 P1 2 3 3 1 1 0 
5 3 P2 1 1 2 0 1 1 
6 3 P3 3 2 1 1 2 1 
7 2 P1 2 3 3 1 1 0 
8 2 P2 1 2 1 1 0 1 
9 2 P3 3 1 2 2 1 1 
10 4 P4 2 2 3 0 1 1 
11 4 P5 3 2 2 1 1 0 
12 4 P6 1 1 1 0 0 0 
Table 6-25 External rating vs. internal rating in ranks: dimension F-B 
 
 
No. Session Participant Rank IR1 Rank IR2 Rank ER 
Rank IR1 
vs. IR2 
Rank IR1 
vs. ER 
Rank IR2 
vs. ER 
1 1 P4 1 1 2 0 1 1 
2 1 P5 3 2 3 1 0 1 
3 1 P6 2 3 1 1 1 2 
4 3 P1 1 1 2 0 1 1 
5 3 P2 3 3 3 0 0 0 
6 3 P3 2 2 1 0 1 1 
7 2 P1 2 2 3 0 1 1 
8 2 P2 1 3 2 2 1 1 
9 2 P3 3 1 1 2 2 0 
10 4 P4 2 1 3 1 1 2 
11 4 P5 3 2 2 1 1 0 
12 4 P6 1 3 2 2 1 1 
Table 6-26 External rating vs. internal rating in ranks: dimension P-N 
 
 
No. Session Participant Rank IR1 Rank IR2 Rank ER 
Rank IR1 
vs. IR2 
Rank IR1 
vs. ER 
Rank IR2 
vs. ER 
1 1 P4 2 2 1 0 1 1 
2 1 P5 3 3 3 0 0 0 
3 1 P6 1 1 2 0 1 1 
4 3 P1 2 3 3 1 1 0 
5 3 P2 3 2 2 1 1 0 
6 3 P3 1 1 1 0 0 0 
7 2 P1 2 3 3 1 1 0 
8 2 P2 1 2 2 1 1 0 
9 2 P3 3 1 1 2 2 0 
10 4 P4 2 2 2 0 0 0 
11 4 P5 3 3 3 0 0 0 
12 4 P6 1 1 1 0 0 0 
Table 6-27 External rating vs. internal rating in ranks: dimension U-D 
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In the dimension F-B, the first round of internal rating led to the identical ranks as the 
external rating in 3 cases, different by 1 rank in 8 cases and by 2 ranks in 1 out of 12 cases 
in total. Compared with the external rating, the second round of internal rating resulted in 
the identical rank in 5 cases, different by 1 rank in 7 cases and in none of the cases 
different by 2 ranks (see table 6-25). 
 
In the dimension P-N, the first round of internal rating led to the identical ranks as the 
external rating in 2 cases, different by 1 rank in 9 cases and by 2 ranks in 1 out of totally 
12 cases. Compared with the external rating, the second round of internal rating resulted 
in the identical rank in 3 cases, different by 1 rank in 7 cases and different by 2 ranks in 
2 cases (see table 6-26). 
 
In the dimension U-D, the first round of internal rating resulted in the identical ranks as 
the external rating in 5 cases, different by 1 rank in 6 cases and by 2 ranks in 1 out of 
totally 12 cases. Compared with the external rating, the second round of internal rating 
resulted in the identical rank in 10 cases, different by 1 rank in 2 cases and in none of the 
cases different by 2 ranks (see table 6-27). 
 
Dimension Identical Difference by “1” Difference by “2” 
F-B (IR 1 vs. ER) 3 8 1 
F-B (IR 2 vs. ER) 5 7 0 
P-N (IR 1 vs. ER) 2 9 1 
P-N (IR 2 vs. ER) 3 7 2 
U-D (IR 1 vs. ER) 5 6 1 
U-D (IR 2 vs. ER) 10 2 0 
Table 6-28 External rating vs. internal rating in ranks: summary 
 
Summarizing the above, the results of the second round of internal rating lay closer to the 
external rating in all three dimensions in comparison to the first round of rating. 
Furthermore, this development was the strongest in the dimension U-D, moderate in the 
dimension F-B and slight in the dimension P-N (see table 6-28). This suggested that it 
was relatively easy for the participants to adjust their views on the individual contribution, 
however more difficult to change their impression of how friendly each person had been 
to the others during the experiment sessions. It seemed that with some reservation, the 
participants were also ready to modify their opinions on how instrumentally controlled 
the individuals had worked. 
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6.2.7.2 Test group vs. control group 
This section sets out to explore the behaviour of each individual participant at different 
experiment sessions. 
 
 
Figure 6-5 Ratings for participant P1 
 
In all internal and external ratings, Participant P1 seemed to have been more dominant 
during the group work (dimension U-D) in the test session than in the control session. 
However, P1 was observed to be less pleasant to the other group members in the test 
session than in the control session (dimension P-N). In perception the fellow group 
members, the level of task orientation (dimension F-B) in both sessions was almost the 
same, while to the external raters, it was slightly higher in the control session (see figure 
6-5). 
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Figure 6-6 Ratings for participant P2 
 
Also participant P2 appeared to have inserted more active influence on the group work 
(dimension U-D) in the test session than in the control session according to both internal 
and external rating. Although in the observation of the external raters P2 was more 
positive in the test session than in the control session, the group members perceived P2 
as more pleasant in the control session (dimension P-N). The level of task orientation 
(dimension F-B) in both sessions was similar in the internal rating, however the score was 
higher in the test session according the external rating (see figure 6-6). 
 
 
Figure 6-7 Ratings for participant P3 
 
In all internal and external ratings, P3 demonstrated a moderate level of active 
participation at the group work (dimension U-D). According to the external raters, P3 had 
acted more positively in the test session than in the control session (dimension P-N). 
However, only a moderate difference in the behaviour of P3 was observed by the group 
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members in this aspect. Both the internal and the external rating indicated that the level 
of task orientation (dimension F-B) of P3 was similar in both sessions (see figure 6-7). 
 
 
Figure 6-8 Ratings for participant P4 
 
The first round of the internal rating suggested that P4 inserted more influence on the 
group work in the test session (dimension U-D). In the second round of internal rating 
and also in the external rating, P4 was observed with a similar level of active participation 
in both sessions. In both internal and external ratings, P4 appeared to be friendlier in the 
control session than in the test session (dimension P-N). The task orientation (dimension 
F-B) of P4 was perceived as similar in both sessions in the internal ratings and slightly 
higher in the control session according to the external rating (see figure 6-8). 
 
 
 
Figure 6-9 Ratings for participant P5 
 
The first round of the internal rating suggested that P5 inserted more influence on the 
group work (dimension U-D) in the test session; however this relation was reversed in the 
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second round of the internal rating. In the external rating, P5 did not demonstrate any 
dominance in the process. In the external ratings, P5 appeared to be friendlier in the 
control session than in the test session (dimension P-N). However, the group members 
perceived P5 as more positive in the test session than in the control session. The task 
orientation (dimension F-B) of P5 was observed to be similar in both sessions in the 
internal ratings and slightly higher in the control session according to the external rating 
(see figure 6-9). 
 
 
 
Figure 6-10 Ratings for participant P6 
 
Both rounds of internal rating suggested that P6 inserted moderate influence on the group 
work (dimension U-D) in both sessions. In the external rating, however, P6 was observed 
to be much more dominant in the test session than in the control session. According to 
the external ratings, P6 was friendlier in the control session than in the test session 
(dimension P-N). However, the group members perceived P6 as more positive in the test 
session than in the control session. The task orientation (dimension F-B) of P6 was 
observed to be similar in both sessions in both the internal and the external rating (see 
figure 6-10). 
 
 
 
 
The group behaviours in TRIZ and brainstorming sessions during the experiment are 
summarized in the following table (see table 6-29).  
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Participant TRIZ Brainstorming 
P1 internal rating: 
-stronger domination 
-less friendliness 
-similar level of task orientation 
external rating: 
-stronger domination 
-less friendliness 
-lower task orientation 
internal rating: 
-weaker domination 
-more friendliness 
- similar level of task orientation 
external rating: 
-weaker domination 
-more friendliness 
-higher task orientation 
P2 internal rating: 
-stronger domination 
-less friendliness 
-lower task orientation 
external rating: 
-stronger domination 
-more friendliness 
-higher task orientation 
internal rating: 
-weaker domination 
-more friendliness 
-higher task orientation 
external rating: 
-weaker domination 
-less friendliness 
-lower task orientation 
P3 internal rating: 
-stronger domination 
-more friendliness 
-lower task orientation 
external rating: 
-stronger domination 
-more friendliness 
- lower task orientation 
internal rating: 
-weaker domination 
-less friendliness 
-higher task orientation 
external rating: 
- weaker domination 
-less friendliness 
-higher task orientation 
P4 internal rating: 
-stronger domination 
-less friendliness 
-similar level of task orientation 
external rating: 
-stronger domination 
-more friendliness 
-higher task orientation 
internal rating: 
-weaker domination 
-more friendliness 
-similar level of task orientation 
external rating: 
-weaker domination 
-less friendliness 
-lower task orientation 
P5 internal rating: 
-stronger domination 
- more friendliness 
-lower task orientation 
external rating: 
-stronger domination 
-more friendliness 
-lower task orientation 
internal rating: 
-weaker domination 
- less friendliness 
-higher task orientation 
external rating: 
-less friendliness 
-less friendliness 
-higher task orientation 
P6 internal rating: 
-weaker domination 
-less friendliness 
-lower task orientation 
external rating: 
-weaker domination 
-less friendliness 
-lower task orientation 
internal rating: 
-stronger domination 
-more friendliness 
-higher task orientation 
external rating: 
-stronger domination 
-more friendliness 
-higher task orientation 
Table 6-29 Comparison of process: individual behaviours 
 
Altogether, in the dimension F-B, the majority of the participants achieved a lower score 
in the test session than in the control session. In the first round of internal rating, with 4 
out of 6 participants achieved a lower and only one participant a higher score, the average 
score was reduced by 2.1 in the test session. In the second round, with 4 participants 
receiving a clearly lower score (<-1.0) and 2 participants a slightly higher score (<0.4), 
the average was lowered by 1.3. In the external rating, 4 out of 6 participants scored lower 
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and 2 scored higher in the test session compared to the control session. The average score 
decreased by 0.3 (see table 6-30). 
 
Participant 
Internal 
rating 1 
(control) 
Internal 
rating 1 
(test) 
test vs. 
control 
Internal 
rating 2 
(control) 
Internal 
rating 2 
(test) 
test vs. 
control 
External 
rating 
(control) 
External 
rating  
(test) 
test vs. 
control 
P1 4.7 4.0 -0.7 3.3 3.7 0.4 2.0 0.0 -2.0 
P2 5.0 8.0 3.0 7.3 5.3 -2.0 6.0 9.5 3.5 
P3 3.3 3.3 0.0 6.5 5.5 -1.0 6.5 5.5 -1.0 
P4 6.0 3.3 -2.7 6.3 6.5 0.2 4.0 6.5 2.5 
P5 9.0 5.0 -4.0 8.3 6.3 -2.0 2.5 1.0 -1.5 
P6 11.3 3.0 -8.3 9.5 6.3 -3.2 9.5 6.5 -3.0 
average 6.6 4.4 -2.1 6.9 5.6 -1.3 5.1 4.8 -0.3 
Table 6-30 Ratings for participants: dimension F-B 
 
A possible interpretation of the above findings is that the individual behaviour at the 
group work appeared more emotionally expressive with the TRIZ procedure in the 
subjective perception of the participants. However, this tendency seemed much milder in 
the relatively objective observation represented by the external rating. 
 
Also in the dimension P-N, most of the participants achieved a lower score in the test 
session than in the control session. In the first round of internal rating, with 4 out of 6 
participants achieved a lower and 2 participants a higher score, the average score in the 
test session was lower by 1.4. In the second round, with 4 participants receiving a lower 
and only one participant a higher score, the average was lowered by 1.0. In the external 
rating, however, 4 out of 6 participants scored higher in the test session and 2 scored 
lower. The average score increased by 1.3 (see table 6-31). 
 
 
Participant 
Internal 
rating 1 
(control) 
Internal 
rating 1 
(test) 
test vs, 
control 
Internal 
rating 2 
(control) 
Internal 
rating 2 
(test) 
test vs, 
control 
External 
rating 
(control) 
External 
rating  
(test) 
test vs, 
control 
P1 24.0 20.3 -3.7 22.7 20.0 -2.7 21.5 19.5 -2.0 
P2 16.0 21.0 5.0 21.7 18.3 -3.4 21.0 25.0 4.0 
P3 21.3 19.7 -1.6 22.5 26.0 3.5 22.5 26.0 3.5 
P4 24.3 21.3 -3.0 24.7 22.5 -2.2 20.5 22.5 2.0 
P5 16.0 21.7 5.7 24.0 24.0 0.0 16.0 18.0 2.0 
P6 21.7 11.0 -10.7 22.0 21.0 -1.0 22.0 20.0 -2.0 
average 20.6 19.2 -1.4 22.9 22.0 -1.0 20.6 21.8 1.3 
Table 6-31 Ratings for participants: dimension P-N 
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A possible interpretation of the above findings is that the participants using the TRIZ 
techniques acted friendlier to their group mates in the relatively objective observation of 
the external raters. However, in the subjective perception of the group members, the 
participants seemed friendlier in the brainstorming session. One reason for this effect 
could be, since the TRIZ procedure delivered well defined paths, the discussion during 
the test session was more “straightforward” thus leaving such subjective impression. 
 
In the dimension U-D, contrary to the results in the other two dimensions, most of the 
participants achieved a higher score in the test session than in the control session. In the 
first round of internal rating, with 4 out of 6 participants achieved a higher and 2 
participants a lower score, the average score in the test session was higher by 1.4. In the 
second round, with 5 participants receiving a higher and only one participant a lower 
score, the average was higher by 0.8 in the test session. Similarly in the external rating, 5 
out of 6 participants scored higher in the test session leaving the average score of the test 
session surpassing the control session by 0.8 (see table 6-32). 
 
Participant 
Internal 
rating 1 
(control) 
Internal 
rating 1 
(test) 
test vs, 
control 
Internal 
rating 2 
(control) 
Internal 
rating 2 
(test) 
test vs, 
control 
External 
rating 
(control) 
External 
rating  
(test) 
test vs, 
control 
P1 3.3 5.5 2.2 3.3 4.3 1.0 0.0 1.0 1.0 
P2 2.0 8.0 6.0 5.3 6.3 1.0 3.0 4.5 1.5 
P3 4.7 3.3 -1.4 6.5 7.0 0.5 6.5 7.0 0.5 
P4 1.0 4.7 3.7 3.0 6.5 3.5 5.5 6.5 1.0 
P5 -4.0 4.7 8.7 1.0 2.0 1.0 0.5 6.5 6.0 
P6 6.8 -4.0 -10.8 5.0 3.0 -2.0 5.0 0.0 -5.0 
average 2.3 3.7 1.4 4.0 4.9 0.8 3.4 4.3 0.8 
Table 6-32 Ratings for participants: dimension U-D 
 
The above findings suggested that the participants exerted more active influence on the 
process of development and research when using the TRIZ techniques. This activeness 
was confirmed both by the subjective perceptions of the group members in the internal 
rating and by the relatively objective assessment of the external rating. 
 
The findings on group behaviours of totally 6 participants in TRIZ and brainstorming 
sessions during the experiment are summarized in the table 6-33.  
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Dimension TRIZ Brainstorming 
F-B 1st round internal rating: 
1participant with a higher score 
 
2nd round internal rating: 
2 participants with a slightly higher score 
 
External rating: 
2 participants with a higher score 
 
Interpretation: 
 Group work more emotionally 
expressive in subjection perception of 
group members; 
 Tendency much milder in objective 
external rating 
 
1st round internal rating: 
4 participants with a higher score 
 
2nd round internal rating: 
4 participants with a higher score 
 
 
External rating: 
4 participants with a higher score 
 
Interpretation: 
 Group work less emotionally 
expressive in subjection perception of 
group members; 
Tendency much milder in objective 
external rating 
P-N 1st round internal rating: 
2participants with a higher score 
 
2nd round internal rating: 
1 participant with a higher score 
 
External rating: 
4 participants with a higher score 
 
Interpretation: 
 Participants friendlier to group mates 
in objective external rating 
 Participants less friendly to group 
mates in subjective perception of 
group members  
 
1st round internal rating: 
4 participants with a higher score 
 
2nd round internal rating: 
4 participants with a higher score 
 
External rating: 
2 participants with a higher score 
 
Interpretation: 
 Participants less friendly to group 
mates in objective external rating 
 Participants friendlier to group mates 
in subjective perception of group 
members  
 
U-D 1st round internal rating: 
4 participants with a higher score 
 
2nd round internal rating: 
5 participants with a higher score 
 
External rating: 
5 participants with a higher score 
 
Interpretation: 
Participants exerted more active 
influence in objective external rating 
and subjective perception of group 
members 
1st round internal rating: 
2 participants with a higher score 
 
2nd round internal rating: 
1 participant with a higher score  
 
External rating: 
1 participant with a higher score  
 
Interpretation: 
Participants exerted less active influence in 
objective external rating and subjective 
perception of group members 
 
Table 6-33 Comparison of process: summary 
 
6.2.7.3 Group discussion 
During the experiment sessions, a group discussion was conducted between the two 
internal rating rounds (see sections 6.2.2.2, 6.2.3.2, 6.2.4.2 and 6.2.5.2). The discussions 
were guided by the predefined questions. The findings of those are summarised in the 
table 3-34.  
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Question Session 1 (control group/ 
test device 1) 
Session 2 (test group/ 
test device 1) 
Session 3 
(control 
group/ test 
device 2) 
Session 4 (test group/ 
test device 2) 
Q1. How do 
you feel about 
working in a 
group? 
 
Positive. 
Reasons: 
Exchange of ideas; 
inspiration by each other; 
combination of more ideas 
to develop solution.  
Positive if the 
atmosphere in the 
group was good.  
 
Positive, 
especially if 
relationship 
among group 
members is 
pleasant; 
members 
possess 
individual 
expertise. 
 
Positive and pleasant, 
effective for TRIZ 
application. 
Reasons: 
Opportunity for group 
members to combine 
ideas, or further 
develop the new 
ideas. 
Q2. Do you 
prefer to work 
in a group or 
on your own? 
 
Preference for group work. 
Reasons: 
Pleasant cooperative 
atmosphere; opportunity to 
be inspired by others 
through exchange of 
thoughts. 
Preference for group 
work. 
Reasons: 
Cross-examination of 
individual ideas, 
inspiration by the 
interpretations and 
ideas by the others.  
 
Preference for 
combination 
of both. 
Reasons: 
Development 
of individual 
and 
subsequent 
cross-
examination 
and 
combination 
of the ideas in 
group work. 
 
Preference for group 
work. 
Reasons: 
Mutual supports in 
terms of supportive 
inspirations; 
approving and further 
development of the 
individual ideas. 
Q3. Did you 
feel 
comfortable 
during the 
solution-
seeking 
process in the 
experiment? 
Pleasant. 
 
Pleasant. 
 
Pleasant. 
 
Pleasant, in spite of 
difficulties in 
reaching a common 
understanding of the 
content of the TRIZ 
inventive principles at 
the beginning. 
 
 
Q4. How 
would you 
describe the 
status of the 
solution-
seeking 
process in the 
beginning, in 
the middle 
and at the end 
of the 
session? 
 
Beginning: 
Concentration on a common 
understanding of the task 
and the approach to the 
solutions. 
 
Middle: 
Productive (the tasks were 
clarified and the time 
pressure was not clearly 
noticeable). 
 
End: 
Attention to time and 
consensus for summary of 
found solutions.  
 
Beginning: 
No “warming up” was 
necessary (clear 
structure of the 
inventive principles.  
 
Innovative ideas 
generated right from 
the very beginning of 
the session. 
 
Beginning: 
Focus on 
common 
understanding 
of the 
technical 
issues. 
 
Middle & end: 
Focus on 
solution 
finding. 
Beginning: 
Focus on consensus 
for the content of the 
inventive principles. 
 
Middle: 
Most innovative ideas 
generated. 
 
End: 
Focus on finalising 
the ideas and put the 
results in writing.  
 
Q5. When was 
the most 
innovative 
moment? 
 
Several innovative moments 
were experienced. New 
ideas were confirmed 
and/or further developed by 
the other two group 
members. 
As the idea for the 
giraffe design for 
children device was 
generated.  
 
As the idea of 
QR-code 
came across. 
Till then the 
solutions were 
experience-
driven as 
modifications 
to the existing 
solutions.  
 
 
The middle of group 
work.   
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Question Session 1 (control group/ 
test device 1) 
Session 2 (test group/ 
test device 1) 
Session 3 
(control 
group/ test 
device 2) 
Session 4 (test 
group/ test device 2) 
Q6. Would a 
moderator, 
facilitator or 
a group 
leader be 
helpful for the 
group work? 
 
No.  
Reason: 
The group was 
“democratic”, thus each 
member had the equal 
opportunity to make a 
contribution. 
No. 
Reason: 
TRIZ provides very 
clear instructions.   
 
Not in 
general, 
however a 
moderator 
could have 
been helpful 
in giving each 
member the 
equal 
opportunity to 
contribute to 
the group 
work as one 
group member 
appeared 
dominant.  
No. 
 
Q7. Did you 
need more 
time or 
guidance? 
No. 
 
No. 
 
More time but 
no more 
guidance. 
 
No more time needed.  
Prior TRIZ refresher 
training 
recommended. 
Table 6-34 Summary of group discussions 
 
As a whole, group work was experienced as pleasant by the participants in all four 
experiment sessions. The reasons were given as the exchange of ideas with others, 
inspiration by each other and the opportunity to combine ideas from different individuals 
in order to develop better solutions. 
 
Group work was preferred in 3 out of the 4 experiment sessions. In the third session 
guided by brainstorming techniques, a combination of individual work and group work 
was preferred, as the group members asserted that individual work was more efficient in 
generating the initial ideas. After that stage, Group work was thought to be more effective 
in cross-examination and combination of the ideas. 
 
In all experiment sessions, the group work was described as a pleasant experience by all 
participants. This could be a result of the initial good interpersonal relationship previously 
confirmed by the group members. 
 
While the brainstorming sessions seemed to have focused on achieving a common 
understanding of the technical issues, one TRIZ session started with a brief discussion on 
the content of the inventive principles, while the other TRIZ session set out 
straightforward to the innovative development without “warming up”. This indicated that 
TRIZ gave clearer guidance in comparison to brainstorming, however the concept of 
TRIZ was more complicated thus required more prior knowledge and experience.  
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The middle part of the group work was reported to be the most innovative during both 
test and control sessions. The members of a test group and a control group described the 
moments as the most innovative as new ideas that were not experience driven were 
generated. All groups reported that the middle and the end of the sessions were more 
productive, with one brainstorming and one TRIZ team claiming that they paid more 
attention to synthesising the ideas towards the end of the sessions due to the time factor. 
 
According to the participants, a formally defined leadership was not necessary. While the 
members in one brainstorming session stated that the group achieved good results being 
democratic, the participants in the other brainstorming session wished to have a 
moderator because one of the members acted occasionally dominantly and a moderator 
was expected to be able to provide each member an equal opportunity to make a 
contribution. A TRIZ group stated that since TRIZ provided clearly instructions, no 
leadership or moderation would be necessary. 
 
The time for the experiment sessions was sufficient for most of the groups. Only one out 
of the 4 groups wished to have more time. One group in the test session proposed prior 
refresher training for the TRIZ techniques. 
 
It seems that in the experience of the participants, TRIZ led to solutions in shorter time 
thanks to the clear guidance. With the TRIZ techniques, little discussion was necessary 
for the clarification of the technical aims. Adequate prior knowledge of the TRIZ 
procedure was necessary, in order to reach good results. However, compared to 
brainstorming, a good command of the TRIZ procedure took much more efforts due to 
its complexity. 
 
In addition, the participants asserted that TRIZ seemed to be more effective for the 
solution to “hard” technical problems. However, brainstorming might be more 
appropriate for the solution of “soft” issues, e.g. instruction for use or training 
programmes.  
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6.2.7.4 Summary 
The two rounds of internal ratings delivered similar results. Also the external ratings 
showed a similar trend in the assessment of the individual behaviours during the 
experiment sessions. 
 
In dimension Upward – Downward, in both internal and external ratings, the participants 
seemed to exert more active influence on the process of development and research when 
using the TRIZ techniques. 
 
While dominant behaviours of some group members could affect the participation of 
others in the brainstorming sessions, the technical guidance of TRIZ seemed to lead to a 
clearer leadership structure. This was probably because the role allocation in the TRIZ 
group work was related to the special knowledge of the participants.  
 
In general, since it is unlikely that a single member in the group can be the leader in all 
fields of special knowledge that are relevant to the problem solutions, TRIZ practically 
improves  the equal chance for each participant to make a contribution.  
 
The participants also reported that although TRIZ seemed to be more effective for the 
solution of “hard” technical problems, little advantage of this approach was detected 
compared to brainstorming when dealing with “soft” issues, e.g. instruction for use or 
training programmes.  
 
In dimension Forward – Backward, in both subjective perceptions of the participants and 
the more objective observation of the external raters, most of the participants appeared to 
act more emotionally expressive when using the TRIZ procedure.  
 
The above findings may be interpreted as an evidence for the stronger emotional 
involvement of the participants in the TRIZ sessions, as well as a further evidence for the 
improved individual participation at the innovation activities. TRIZ delivered clear 
directions for the development of technical solutions. This seemed to facilitate the 
identification of the participants with the tasks thus they acted more emotionally 
expressive during the TRIZ sessions.  
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In dimension Positive – Negative, the test group members using the TRIZ techniques 
were observed to be friendlier to their group members in the relatively objective 
observation of the external raters. However, the contrary was the subjective perception of 
the group members. The reason behind this phenomenon could be that the group work 
with TRIZ focused more on the task than on the social interactions among the group 
members. Therefore, the friendliness of the participants was not perceived intensively by 
their fellow group members. 
 
The above interpretation is also supported by the group discussions. The group 
discussions revealed that while the brainstorming sessions began with a “warming up” 
phase by searching for a common understanding of the technical issues, with the TRIZ 
techniques, little discussion was necessary for the clarification of the technical aims. 
However, due to the higher complexity of the TRIZ techniques, more preparatory 
trainings were necessary for this problem-solving approach. 
 
Summarising the above, on one hand, the individual role in the group work seems to 
depend on the participant’s pertinent knowledge rather than his/ her personality; on the 
other hand, the group work guided by TRIZ is more “straightforward” and the social 
interactions among group members are reduced while the behaviours among the group 
members remain friendly. Compared to brainstorming, the larger interpersonal distance 
when using TRIZ seems to be more promising for group work which requires strong focus 
on task orientation and less attention on social interactions among the group members, 
for the achievement of solutions to complex technical solutions. 
 
In order to achieve good results, extensive prior trainings on TRIZ applications are 
necessary. Also, TRIZ may be more appropriate for the solution of “hard” technical 
problems than for the “soft” issues like instruction for use or training programmes.  
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7. Discussions of findings and implications 
7.1 Problem-solving tools for R&D of medical devices 
In order to explore the application of problem-solving tools in R&D of medical devices 
in the pharmaceutical industry, a survey study was conducted for this research. The 
participants of the survey study were employees in some big pharmaceutical companies 
in the German Rhine-Main region, with an average of 8 years of practical experience in 
the pharmaceutical industry and 6 years with the development and production of medical 
devices. 
 
The findings suggested that currently, problem-solving techniques found wide application 
in the surveyed companies. Among those, brainstorming was reported to be the most 
frequently used problem-solving technique (96.2%), followed by mind-mapping (63.5%) 
and TRIZ (30.8%). Furthermore, the following problem-solving techniques were reported 
to be used occasionally: root cause analysis, DMAIC, strengthening sessions, risk 
analysis, Ishikawa diagram, Meta-plan, card sorting/ brain writing and the 5-Why method. 
While 84.6% of the survey participants at least occasionally used some kind of problem-
solving techniques, only 25% of them reported to use TRIZ at a similar frequency. 
 
In addition, the employers in the German pharmaceutical industry seemed to provide a 
moderate level of trainings on problem-solving tools to their employees. Out of the 52 
returned answers, 26 reported to have taken part in trainings on problem-solving tools, 
among those 16 had at least totally 4 days of training in the last three years. TRIZ training 
seems to play an important role in such training programmes. The survey showed that 11 
out of 52 participants took TRIZ trainings in the last three years with a total training 
duration of 1-3 days.  
 
The main advantages of the TRIZ methodology were described by the survey participants 
as methodological approach to innovative problem solving, usefulness for generating new 
ideas, application of principles and trends to find creative solutions and promotion of 
team and group work. 
 
The TRIZ methodology was known to most of the practitioners dealing with the 
development of medical device. The best known TRIZ concepts seemed to be “39 x 39 
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contradiction matrix” and “40 inventive principles”. However, due to the complexity of 
the methods, only 25% of the participants claimed to be knowledgeable of some concept(s) 
of the TRIZ toolkits and 13.5% of the participants were familiar with more than 2 TRIZ 
tools.  
 
The above findings of the survey study imply that in order to use TRIZ effectively in the 
technical innovation, the pharmaceutical industry needs yet to provide more TRIZ 
trainings on a more frequent basis. 
 
7.2 Influence of TRIZ on outputs 
The findings in section 6.1.5 indicate several differences in the results of the problem-
solving approaches brainstorming and TRIZ. 
 
First, TRIZ seems to be more effective than brainstorming in solving clearly defined 
technology-driven problems.  
 
The benefits of the TRIZ procedure in this study are the inventive principles which 
improve the opportunity of finding solutions to sophisticated technological problems by 
restricting the search towards the more effective directions. In the TRIZ procedure, the 
specific problems are initially “translated” into a general problem. The solutions to the 
general problem can be extracted from the TRIZ knowledge base. In the final stage, the 
solutions to the general problems are “translated back” to the specific situations 
(Altshuller, 1999). Like several previous studies, the findings of this work supported the 
positive effect of connection to the external knowledge base in the above manner for 
clearly defined technology-driven problems.  
 
The dimension “novelty” of expert assessment represents level of innovation of the 
generated solutions to the predetermined technical problems. With the additional 
information of TRIZ inventive principles, the test groups achieved clearly higher results 
in this dimension than the control groups. In other words, during the experiment, the TRIZ 
inventive principles directed the innovation process into the “shortcuts” to the technical 
solutions. 
Second, TRIZ appears not more effective than brainstorming in solving fuzzy problems, 
including problems with soft targets. 
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A critical step of the TRIZ procedure is the extraction of determinants of contradiction 
parameters, or, the translation of the specific problem into a general problem. Obviously, 
biases in this step will lead to suboptimal solutions. By definition, the features of fuzzy 
problems make it difficult to precisely identify the determinants of the contradiction 
parameters. Therefore, the strength of TRIZ does not lie in the solution of such problems. 
 
The above implications were supported by the experiment results. While the test groups 
achieved clearly better results in the dimension “novelty” for clearly defined requirements 
on technical innovations, the TRIZ techniques showed no advantage in solving fuzzy 
problems in the dimensions “feasibility” and “costs” of the expert assessment, as well as 
in the patient assessment. 
 
Summarising the above, TRIZ is not a panacea or golden solution to all problems. It has 
clear strength when dealing with clearly defined technology-driven problems, however 
might not be the appropriate instrument for fuzzy problems which cannot be adequately 
predefined or are subject to changing criteria. Therefore, the problem-solving technique 
should be chosen based on the characteristics of the problems, so as to achieve the best 
results in the innovation process. 
7.3 Influence of TRIZ on process 
TRIZ is a complex problem-solving approach in comparison to brainstorming, therefore 
demands special knowledge of the users. This difference also has an impact on the process 
of group work. 
 
Unlike the brainstorming techniques which rely largely on the accidental circumstances, 
the TRIZ inventive principles guide the search for the technical solutions specifically into 
the potentially prolific directions. While the personality and experience of the group 
members play an essential role in the group leadership structure for the brainstorming 
process, the complexity of the TRIZ techniques makes the leadership in the group work 
often dependent on special knowledge relevant to the problem solution. Consequently, 
the application of TRIZ leads to a clearer leadership. 
Since it is most likely that each single member in the group is the most knowledgeable in 
some relevant fields, TRIZ practically promotes a more efficient participation of all group 
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members. As a result, the participants exert more active influence on the process of 
development and research when using the TRIZ techniques. 
 
In addition, the guidance of TRIZ in the search process seems to reduce emotional 
reactions among the group members, thus potentially increases the interpersonal distance 
in the group. This suggests, in terms of the process, TRIZ is more appropriate if strong 
focus on the task is considered beneficial for the group work, e.g. when dealing with 
complex technical solutions, and less suitable if the target is highly related to 
interpersonal reactions, e.g. when dealing with psychological topics. 
7.4 Limitations and future research directions 
The limitations of this research as well as possible improvements and some directions for 
future researches are discussed in the following. 
First, this work has been organised as a 2x2 experiment. In order to avoid a systematic 
bias caused by the difference between the groups in terms of their problem-solving 
capacity, the switched group experimental design was chosen, i.e., each group acted as 
the test group in one experiment session and the control group in the other. However, due 
to the rather limited repetitions of the experiment, there is a limitation to the generalisation 
of the study findings. This may be improved by sufficient repetition of the research 
procedure.  
Second, the test and control groups were not perfectly homogenous. Due to the limited 
resources for this study, the groups could not be controlled for age, gender, academic 
background, etc. However, efforts were made to keep up a similar level of “total balance” 
of the group capacities in the above dimensions. 
Third, there might be a learning effect in the second experiment session, since the 
participants might be inspired by their experience in the first session. However, this effect 
was limited due to the different features of the test devices for the comparison sessions. 
Efforts to counteract the bias were made by beginning the experiment with TRIZ in one 
group and with brainstorming with the other group of participants. The learning effect 
could be further reduced with more available resources, in order to increase the internal 
validity by e.g. organising the experiment with Solomon’s four group design. 
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Fourth, the experimental conditions, especially the participants’ awareness of the video 
recording, might have had an impact on their behaviours. This is a typical weakness for 
this kind of participant observation.  
Fifth, the assessment of outputs was conducted with caution and several repetitions. 
However, due to the author’s personal research interest, there might be a remaining bias 
in favour of TRIZ.   
Sixth, the scope of problem in the test procedure was defined based on the findings of a 
systematic literature review. A more extensive scope of problem could be achieved by 
means of exploration of further databases. 
 
Seventh, the TRIZ procedure in this research involves the standard 39x39 contradiction 
matrix and the standard TRIZ inventive principles. A modified contradiction matrix and 
specialised inventive principles could be developed to meet the specific demands of the 
research & development of medical devices in the pharmaceutical industry. However, this 
task would involve extensive exploration of the relevant knowledge bases and could not 
be accomplished within the frame of this work. This may be a direction for future research. 
 
Eighth, this study investigates how the problem definition affects the outputs of the 
technical innovation and how the requirements on special knowledge influence the 
process of group work. A possible direction for future research may also be to investigate 
how the problem definition influences the process of group work. 
 
Ninth, the literature review in this work concentrates on the English language. The main 
reason for the choice of language is the limited language knowledge of the researcher in 
German (native language) and English. A search for disseminations in the German 
language with the above search criteria led to few retreavals, however the full text was 
not available in the chosen database. Therefore, the disseminations in German are not 
included in the review. 
 
Conventionally, clinical data of the pharmaceutical industry and academic literature on 
pharmaceutical researches are published in the English language. The reason behind this 
is that the largest health care markets are under control of the US FDA and EU EMA, 
which both request clinical evaluation and the clinical literature review to be conducted 
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in English. Also the majority of the pertinent disseminations in the chosen database are 
published in the English language. Therefore, the focus on the data set in English is 
considered sufficient for this study. However, the quality of the literature review may be 
improved by including disseminations in further languages. 
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8. Conclusions 
8.1 Most relevant conclusions 
 
Through the experiment in this thesis, conclusions are drawn in seeking answers to the 
research questions. 
 
 
RQ1: Which problem-solving tools are currently used for R&D of medical devices in the 
pharmaceutical industry? 
 
The findings of the survey study indicate that problem-solving tools are frequently used 
in the pharmaceutical industry in the current time. Among those, brainstorming seems to 
be the most frequently used technique, reportedly utilised by 96.2% of all survey 
participants. Another popular problem-solving tool appears to be mind-mapping, used by 
63.5% of the survey participants. Also TRIZ finds applications by 30.8% of the survey 
participants. There are also further problem-solving techniques mentioned to be used by 
the participants in the pharmaceutical industry, however less often, e.g. root cause 
analysis, DMAIC, strengthening sessions, risk analysis, Ishikawa diagram, Meta-plan, 
card sorting/ brain writing and the 5-Why method. 
 
 
RQ2: How can TRIZ techniques be applied for medical device innovation?  
 
This work developed a 5-stage TRIZ procedure for the technical innovation for medical 
devices based on Su et al.’s approach, with some modifications to meet the requirements 
of medical device innovation (Su, Lin & Chiang, 2008).  
 
The modifications made to Su et al’s TRIZ procedure are are summarized in table 8-1. 
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Su et al.’s 8-stage model (Su, Lin & 
Chiang, 2008) 
5-stage TRIZ procedure for medical 
device innovations 
Stage 1: Define the scope of the problem 
- Based on company internal 
knowledgebase 
Stage 1: Definition of scope of problem 
- Based on external knowledgebase 
through systematic literature 
review 
Stage 2: Extract the determinants 
- Based on external literature 
review 
Stage 2: Extraction of  determinants 
- Based on multiple sources, 
including external literature 
review, patient interviews with 
option to add determinants, as 
well as expert panel review with 
option to add determinants 
Stage 3: Develop a parameter 
corresponding table 
- Authors’ proposal  
Stage 3: Identification of contradiction 
parameters 
- Authors’ proposal; 
- Verification and improvement by 
independent TRIZ experts; 
- Verifications by independent 
patients 
Stage 4: Generate the feasible solutions 
through the TRIZ contradiction matrix 
- All inventive principles with more 
than two mappings are selected. 
Stage 4: Identification of  inventive 
principles 
- Frequency of inventive principles 
with scoring model is applied, in 
order to focus on the three most 
beneficial inventive principles.   
Stage 5: Implement feasible solution 
- Prioritization by internal experts 
(management); 
- Fix criteria (time, money, 
resources). 
Stage 5: Generation of solutions 
- Prioritization by external experts 
(expert panel) and independent 
patients;  
- Criteria defined by expert panel 
based on survey findings. 
Stage 6: Are the results effective? - Design loops after initial design;  
- Effective check (feasibility 
testing) after initial production or 
prototyping.  
Stage 7: Identify the next problem - Product technical complaint 
management 
Stage 8: Is the new problem belong to the 
next sector 
- Life cycle management for 
medical device and/or 
combination product 
Table 8-1 Comparison of TRIZ procedure in this thesis with Su et al. (2008) 
 
The TRIZ techniques 39x39 contradiction parameter and 40 inventive principles are 
applied in the above 5-stage procedure for the technical innovation of medical devices. 
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Initially, the specific problems are defined as a number of determinants. In order to 
abstract the general problems out of the specific problems, each determinant is 
subsequently mapped with a parameter (either as an improving or a worsening parameter) 
out of the 39x39 condradiction matrix.  
 
Next, the general solutions to the general problems are identified by looking up the 
inventive principles for the combination of each improving and worsening parameter in 
the 39x39 condradiction matrix. To improve the efficiency of the procedure, only the 
inventive principles with the highest frequency are selected for the further steps as they 
are considered the most beneficial. 
 
In order to transfer the general solutions into specific solutions, the chosen inventive 
principles are provided to the participants to guide their search for improvements. Finally, 
the generated ideas are to be prioritized for the implementation in specific device designs 
(see figure 8-1). 
 
 
 
 
 
Figure 8-1 5-stage procedure with TRIZ framework 
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RQ3: How and why do TRIZ techniques differentiate themselves from other problem-
solving methods, from a theoretical perspective? 
 
The findings of this research suggest several differences between TRIZ techniques and 
the chosen alternative problem-solving method brainstorming. 
 
The results of the experiment in chapter 6 indicate that the TRIZ procedure seeks 
effectively technical solutions after narrowing down the problem field with aid of the 
inventive principles. Aiming at improvement of several technical issues at the same time, 
TRIZ potentially leads to a higher number of solutions to the single problems. This 
suggests that the strength of TRIZ in solving complex technical problems, especially 
when there are trade-offs among the optimal solutions of different partial problems. 
However, the above advantages are not observed for the solution of fuzzy problems. The 
reason behind it is that the fuzziness of the problems worsens the quality of the inventive 
principle so that their advantages diminish when seeking solutions. Hence it may be said 
that the outcomes of the group work with specific problem-solving tools are influenced 
by the type of problem definition.  
 
Basically, no problem-solving approach seems to be a golden solution to all problems. In 
order to achieve the best results of the innovations activities, the problem-solving tools 
should be chosen based on the type of the problems. 
 
Based on the findings in this study, the following 2-dimensional framework was 
developed for the classification of the problems. The dimension “problem definition” 
describes if the problems are clearly defined or fuzzy and the dimension “demand on 
special knowledge” illustrates the level of special knowledge necessary for the generation 
of solutions (see figure 8-3).  
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Figure 8-2 2-dimensional system for classification of problems 
 
While TRIZ was found more effective with the predefined, technology-driven problems 
(TRIZ is more effective for the problem type in quadrant I than brainstorming for the 
problem type in quadrant II), brainstorming performed at a similar level or better with the 
fuzzy problems (the performance of brainstorming for problem type in quadrants III is 
comparable with that of TRIZ for problem type in quadrant IV). Thus research hypothesis 
1 is positively supported by the findings of the experiment. 
 
Hypothesis 1: TRIZ is more effective than the conventional problems-solving approach 
when dealing with clearly defined technology-driven problems. 
 
During the group discussions, the participants reported that contrary to brainstorming, 
there was no “warming up” phase during the TRIZ sessions. This indicates that the 
innovation process with TRIZ has a strong focus on the task. 
 
In general, the analysis of the process of group work leads to the conclusion that the 
participants exert more individual influence when applying TRIZ techniques. That means, 
the problem solving process with TRIZ in situations of quadrant I and IV leads to higher 
motivation of the individual participants in the group work than with brainstorming 
problem-solving tool in situations of quadrant II and III. The reason for this is probably 
that the higher requirements of TRIZ on special knowledge of the participants improve 
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the opportunity of the individual participants to make a contribution, especially those with 
a less dominant personality. Thus, hypothesis 2 is positively supported by the findings of 
the experiment. 
 
Hypothesis 2: TRIZ improves the motivation of the individual participants in the group 
work. 
 
The experimental findings on the process of the group work suggest that there is a clearer 
leadership structure when TRIZ is used for the innovation activities. With brainstorming 
techniques, the leadership in the group depends largely on the personality of the 
participants; hence sometimes the leadership structure is unclear. In group work with 
TRIZ, the leadership is mainly influenced by the special knowledge relevant to the 
problem solutions. The most knowledgeable participant in each pertinent field is the most 
likely to take over the leader role during the process. In short, the problem situations in 
quadrant I and IV when using TRIZ leads to a clearer leadership structure in the group 
work than those in quadrant II and III using brainstorming. Thus research hypothesis 3 is 
positively supported by the findings of the experiment. 
 
Hypothesis 3: TRIZ promotes a clear leadership structure in the group work. 
 
In addition, the larger interpersonal distance in group work with TRIZ allows the 
assumption that TRIZ is more suitable if a strong focus on the task and less on the social 
interactions among the group members are advantageous. 
 
Summarising the above, no problem-solving approach seems to be a golden solution to 
all problems. In order to achieve the optimal results of the innovations activities, the 
problem-solving tools should be chosen based on the type of problems.  
 
8.2 Contribution to knowledge 
This thesis provided the following contributions to knowledge. 
 
First, the effect of the problem-solving tools was explored not only from the perspective 
of the outputs as the majority of previous researchers did in the past, but also from a new 
perspective - the process of group work. The findings of this research provide valuable 
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insights into R&D activities in the pharmaceutical industry in terms of design 
improvement tools for medical devices. 
 
Second, the results of the experiment suggest that the impact of problem-solving tools in 
the innovation activities is related to the type of problems to be solved. A 2-dimensional 
framework was developed for the classification of the problem types. Within this 
theoretical framework, TRIZ is found more suitable for the solution of clearly defined, 
technology-driven problems, especially when the complex task instead of social 
interactions is a necessary part of the group work. 
 
Third, the application of problem-solving tools for R&D of medical devices in the 
pharmaceutical industry was explored. The survey study indicates that problem-solving 
tools are frequently used in the above business sector in the current time. Among those, 
the most frequently used tools are identified as brainstorming, mind-mapping and TRIZ. 
Further problem-solving techniques, e.g. root cause analysis, DMAIC, strengthening 
sessions, risk analysis, Ishikawa diagram, Meta-plan, card sorting/ brain writing and the 
5-Why method also find applications in this field, however less frequently. 
 
Fourth, a specific TRIZ procedure was developed for the research and development of 
medical device in the pharmaceutical industry based on a modified model by Su et al. 
(Su, Lin & Chiang, 2008). This procedure is tailored to meet the requirements of technical 
innovation for medical devices. The detailed description may guide future research in this 
field (see section 5.2). 
 
Fifth, comparison studies on the effect of different problem-solving tools were rare in the 
past. This work proposed a method for the comparison of the different methods, both in 
the aspect of technical solutions and in terms of group behaviours. 
 
Finally, due to the sensitive protection of intellectual property in the pharmaceutical 
industry, the results of field studies in the large pharmaceutical firms can be rarely found 
in the public literature. This study provides valuable insights of the application of 
problem-solving tools in some pharmaceutical firms, as well as how the TRIZ approach 
influences the outputs and the process of the development and research activities in the 
special field of medical devices of the pharmaceutical industry.  
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8.3 Closing note 
This thesis explores the effect of the application of TRIZ approach to the technical 
innovations for R&D of medical devices in the pharmaceutical industry.  
 
The pharmaceutical business is driven by innovation and new technologies. The results 
of the survey study in this research indicates that the modern R&D organisation units 
nowadays have integrated various problem-solving techniques in their innovation process 
in order to improve the overall efficiency. However, it seems that currently, TRIZ is not 
used as frequently as some conventional problem-solving tools e.g. brainstorming and 
mind-mapping.  
The literature review identified TRIZ as a unique knowledge-based problem-solving 
approach (Ilevbare, Probert & Phaal, 2013; Savranksy, 2000; Domb, Miller, MacGran & 
Slocum, 1998) which, unlike the conventional problem solving methods, focuses on the 
root cause of the problem instead of the problem itself (Gadd, 2011). The previous 
implementation of TRIZ techniques in various business sectors clearly indicated the 
advantages of TRIZ compared with the conventional trial-and-error methods (Ishida, 
2003; Su, Lin & Chiang, 2008; Belski, 2009).  
 
In order to test the effect of TRIZ on the technical innovations for R&D of medical 
devices in the pharmaceutical industry, an experiment was carried out with two sample 
medical devices (auto-injectors). During the experiment, two groups of experienced 
practitioners were asked to improve the design of the test devices, alternatively using 
TRIZ and brainstorming. The TRIZ procedure for this study was based on the framework 
of Su et al.’s solution (Su, Lin & Chiang, 2008), with some modifications to meet the 
requirements for the design tasks of medical devices. Although previous researchers 
seemed to have solely concentrated on the technical solutions in their studies on problem-
solving techniques, in this study, the efficacy of TRIZ application was analysed in two 
aspects: the outputs and the process. 
Based on the findings of the literature review, the survey study and the subsequent expert 
and patient interviews, an assessment system was developed to measure the innovative 
group work both in outputs and in process. For the assessment of the group work process, 
behaviours of the individual group members and their perceptions for the group work 
were observed and analysed by using the SYMLOG Adjective rating form method with 
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two rounds of internal ratings and an external rating by two independent raters, 
supplemented by group discussions between the two rounds of internal ratings. 
 
In addition, the results of the experiment indicate that the impact of the problem-solving 
tools is influenced by the type of innovation problems. For the analysis of such influences, 
this research makes a contribution to knowledge by developing a 2-dimensional 
framework to capture the problem types. This framework may be used to guide future 
studies in this field. 
To close, continued efforts are still needed in this challenging research field. A few 
directions for future researches are pointed out by this thesis, including the development 
of a modified contraction matrix and specialised inventive principles, in order to meet the 
specific demands of the research & development for medical devices in the 
pharmaceutical industry.  
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Appendix I  SURVEY-English 
 
A. General Information 
 
1. My gender     male     female 
 
2. My current position is in 
  R&D      marketing & sales  
  Production Biotech & Chemistry   general administration  
  medical device development   medical device production 
  others, which is ______________________________________ 
 
3. Altogether, I have _______ years of practical experience in the pharmaceutical 
industry. 
 
4. Altogether, I have _______ years of practical experience with the development 
of medical devices.  
 
 
B. Experience with problem-solving techniques 
 
1. Altogether, I have taken ___________ days of training(s) on problem-solving 
techniques in the past three years. 
 
2. My job in the pharmaceutical industry now and in the past involves problem-
solving techniques e.g. brain-storming, mind-mapping etc…. 
      never      seldom     occasionally 
    frequently     always 
 
3. My job in the pharmaceutical industry now and in the past involves the 
following problem-solving techniques: 
  brainstorming    mind-mapping   
  trial error experiments  lateral thinking 
 TRIZ 
 Others, which are ____________________________________________ 
 
4. In my opinion, the quality of a problem solution for medical devices in an 
ongoing study shall be judged by its: 
 _____________________________ 
         _____________________________ 
 _____________________________ 
 _____________________________ 
 _____________________________ 
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C.  Experience with TRIZ 
 
1. Altogether, I have taken ___________ days of training(s) on the application of 
TRIZ in the past three years. 
 
2. My job in the pharmaceutical industry now and in the past involves the 
application of TRIZ…. 
 never    seldom     occasionally 
 frequently     always 
 
3. I am especially knowledgeable of the following TRIZ tools: 
            39 x 39 contradiction matrix  40 inventive principles  
 76 standard solutions   ideality 
 function analysis    patterns of evolution 
 nine windows    Su field analysis 
 effects database    smart little people 
 ARIZ     others, namely_____________________ 
 
4. In my opinion, the TRIZ applications have the following benefits (multiple 
choice): 
 A structure approach to innovative problem solving 
 Useful for generating new ideas 
 Applying principles and trends to find creative solutions 
 Fast speed in solution finding 
 Prediction the next big jump in problem solving using trends and nine windows 
 Promotion teamwork 
 Shrinking systems size without decreasing performance 
 Others, namely ______________________________ 
 No special benefits in problem-solving process. 
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Appendix II  SURVEY-German 
 
A. Allgemeine Information 
 
1. Geschlecht     männlich     weiblich 
 
2. Meine jetzige Position ist im Bereich… 
  F&E      Marketing & Vertrieb  
  Produktion Biotech & Chemistry   Allgemeine Verwaltung  
  Medical Device Entwicklung   Medical Device Produktion 
  Sonstiges, nämlich ______________________________________ 
 
3. Insgesamt verfüge ich über _______ Jahre praktische Erfahrungen in der 
Pharmaindustrie.  
 
4. Insgesamt verfüge ich über _______ Jahre praktische Erfahrungen mit der  
Entwicklung von Medical Device.  
 
B. Erfahrungen mit Problemlösungstechniken 
 
1. Insgesamt habe ich an ___________ Tage an die Weiterbildungsmaßnahme(n) 
für Problemlösungstechniken in den letzten drei Tagen teilgenommen. 
 
2. Auf meinem jetzigen bzw. frühere(n) Job(s) in der Pharmaindustrie werden 
Problemlösungstechniken wie z.B. Brainstorming, Mind-Mapping etc. 
eingesetzt…. 
   nie      selten     gelegentlich 
  regelmäßig     immer 
 
3. Auf meinem jetzigen bzw. frühere(n) Job(s) in der Pharmaindustrie werden die 
folgenden Problemlösungstechniken eingesetzt: 
 brainstorming    mind-mapping   
 trial error experiments   lateral thinking 
 TRIZ 
 Sonstige, nämlich ____________________________________________ 
 
4. Meiner Meinung nach, die Güte einer Problemlösung für die Verbesserung 
eines Medical Devices soll nach folgenden Kriterien beurteilt werden: 
 _____________________________ 
 _____________________________ 
 _____________________________ 
 _____________________________ 
 _____________________________ 
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C.  Erfahrungen mit TRIZ 
 
1. Insgesamt habe ich an ___________ Tage an die Weiterbildungsmaßnahme(n) 
für TRIZ Anwendungen in den letzten drei Tagen teilgenommen. 
 
2. Auf meinem jetzigen bzw. frühere(n) Job(s) in der Pharmaindustrie werden 
TRIZ-Anwendungen eingesetzt…. 
       nie      selten     gelegentlich 
  regelmäßig    immer 
 
3. Ich bin besonders erfahren im Umgang mit den folgenden TRIZ-Tools: 
     39 x 39 contradiction matrix  40 inventive principles  
 76 standard solutions   ideality 
 function analysis    patterns of evolution 
 nine windows    Su field analysis 
 effects database    smart little people 
 ARIZ     others, namely ____________________ 
 
4. Meiner Meinung nach haben die TRIZ-Anwendungen die folgenden Vorteile 
(mehrfache Antworte möglich): 
 Ein strukturierter Ansatz für die innovative Problemlösung 
 Hilfreich für die Generierung neuer Ideen 
 Kreative Lösungen generieren durch Anwendung von Prinzipien und Trends 
 Schnelligkeit im Lösungsfindungsprozess 
 Vorzeitige Erkennung vom nächsten großen Sprung in der 
Problemlösungsprozess unter Anwendung von Trends und nine windows 
 Förderung vom Teamwork 
 Einschränkung der Systemgröße ohne die Leistung zu beeinträchtigen 
 Sonstige, nämlich ______________________________ 
 Keine besonderen Vorteile im Problemlösungsprozess. 
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Appendix III SURVEY-ACCOMPANYING LETTER 1 English 
 
Dear colleagues, 
 
For the final thesis of my study of Doctor of Business Administration at the University of 
Gloucestershire (England), I would like to conduct a survey study on the application of 
TRIZ methodology in the pharmaceutical industry. The aim of my survey study is to 
examine the status quo of the application of problem-solving techniques, especially the 
application of TRIZ techniques in the pharmaceutical industry. 
 
I would like to ask you kindly to fill out the attached questionnaire and submit it my 
pigeon hole. In case of any further questions, please do not hesitate to contact me under 
the e-mail address: rene.dathe@hotmail.com 
 
The participation on the survey is on a voluntary basis. I herewith explicitly guarantee 
the anonymity of all data entries made and will use such for my intended doctorate study 
only. No data which might reveal the identity of the participants will be released to any 
third party. 
 
I would like to thank everybody in advance for your support and the timely response. 
 
Yours sincerely, 
René Dathe 
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Appendix IV SURVEY-ACCOMPANYING LETTER 1 German 
 
Liebe Kolleginnen und Kollegen, 
 
im Rahmen meiner Promotionsarbeit für das Studium “Doctor of Business 
Administration” an der University of Gloucestershire (England) möchte ich eine Umfrage 
über die Anwendung  der TRIZ Methodologie in der Pharmaindustrie durchführen. 
Das Ziel dieser Umfrage ist es, den aktuellen Stand der Anwendung von 
Problemlösungstechniken, insbesondere der Anwendung von TRIZ-Techniken, 
festzustellen. 
 
Ich möchte euch bitten, den beigefügten Fragebogen auszufüllen und anschließend in 
mein Postfach einzulegen. Bei Rückfragen bitte ich um Kontaktaufnahme per e-Mail 
unter:  rene.dathe@hotmail.com 
 
Die Teilnahme an diese Umfrage ist freiwillig. Ich garantiere zudem explizit die 
Anonymität aller Datenangaben und werde diese ausschließlich für den Zweck meines 
Promotionsstudiums verwenden. Keine Daten werden an Dritte freigegeben, die den 
Rückschluss auf die Identität der Teilnehmer zulassen.  
 
Ich bedanke mich im Voraus für eure Unterstützung und zeitliche Antwort.  
 
 
Viele Dank und viele Grüße 
René Dathe 
 
  
 234 
Appendix V SURVEY-ACCOMPANYING LETTER 2 English 
 
Dear Sirs, 
 
For the final thesis of my study of Doctor of Business Administration at the University of 
Gloucestershire (England), I would like to conduct a survey study on the application of 
TRIZ methodology in the pharmaceutical industry. The aim of my survey study is to 
examine the status quo of the application of problem-solving techniques, especially the 
application of TRIZ techniques in the pharmaceutical industry. 
 
For the above purpose, I would like to ask you kindly to fill out the attached questionnaire 
and submit it to my e-mail address my rene.dathe@hotmail.com. In case of any further 
questions, please do not hesitate to contact me.  
 
The participation on the survey is on a voluntary basis. I herewith explicitly guarantee 
the anonymity of all data entries made and will use such for my intended doctorate study 
only. No data which might reveal the identity of the participants will be released to any 
third party. 
 
 
I would like to thank everybody in advance for your support and the timely response. 
 
Yours sincerely, 
 
 
René Dathe 
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Appendix VI SURVEY-ACCOMPANYING LETTER 2 German 
 
Sehr geehrte Damen und Herren,  
 
im Rahmen meiner Promtionsarbeit für das Studium “Doctor of Business Administration” 
an der University of Gloucestershire (England) möchte ich eine Umfrage über die 
Anwendung  der TRIZ Methodologie in der Pharmaindustrie durchführen. Das Ziel 
dieser Umfrage ist es, den aktuellen Stand der Anwendung von 
Problemlösungstechniken, insbesondere der Anwendung von TRIZ-Techniken, 
festzustellen. 
 
Ich möchte Sie bitten, den beigefügten Fragebogen auszufüllen und anschließend mir 
zuzumailen (rene.dathe@hotmail.com). Bei Rückfragen selbstverständlich gerne 
jederzeit zur Verfügung. 
 
Die Teilnahme an diese Umfrage ist freiwillig. Ich garantiere zudem explizit die 
Anonymität aller Datenangaben und werde diese ausschließlich für den Zweck meines 
Promotionsstudiums verwenden. Keine Daten werden an Dritte freigegeben, die den 
Rückschluss auf die Identität der Teilnehmer zulassen.  
 
 
Ich bedanke mich im Voraus für Ihre Unterstützung bzw. Ihre zeitliche Antwort.  
 
 
Mit freundlichen Grüßen 
René Dathe 
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Appendix VII SEMI-STRUCTURED PATIENT INTERVIEW 
 
The semi-structured interviews in section 5.2.2 were guided by the following standard 
questions.  
 
1. Do you think any of the following 13 points in general essential for auto-injector design? 
No. Description 
Yes (=1) / no (=0) The needs to be increased 
(=”+”)/ decreased (=”-“) 
1 Device identification   
2 Comprehensive instruction of use   
3 Ease of use   
4 Size of device   
5 Customization for target groups   
6 Needle length   
7 Needle protection   
8 Flexibility of dose    
9 Injection time   
10 Marking of injection end   
11 Patient's fear of device   
12 
Adequate training - trainer, participants, 
frequency, training device etc. 
  
13 Shelf life   
 
2. Are there any further aspects which are in your opinion generally essential for the auto-
injector design? 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
 
3. Do you think test device 1 need improvements in the following 13 points? 
No. Description 
Yes (=1) / no (=0) The needs to be increased 
(=”+”)/ decreased (=”-“) 
1 Device identification   
2 Comprehensive instruction of use   
3 Ease of use   
4 Size of device   
5 Customization for target groups   
6 Needle length   
7 Needle protection   
8 
Flexibility of dose (e.g. for children weighting 
15-30 kg) 
  
9 Injection time   
10 Marking of injection end   
11 Patient's fear of device   
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12 
Adequate training - trainer, participants, 
frequency, training device etc. 
  
13 Shelf life   
 
4. Are there any further aspects you wish to change about test device 1? 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
 
5. Do you think test device 2 need improvements in the following 13 points? 
No. Description 
Yes (=1) / no (=0) The needs to be increased 
(=”+”)/ decreased (=”-“) 
1 Device identification   
2 Comprehensive instruction of use   
3 Ease of use   
4 Size of device   
5 Customization for target groups   
6 Needle length   
7 Needle protection   
8 
Flexibility of dose (e.g. for children weighting 
15-30 kg) 
  
9 Injection time   
10 Marking of injection end   
11 Patient's fear of device   
12 
Adequate training - trainer, participants, 
frequency, training device etc. 
  
13 Shelf life   
 
6. Are there any further aspects you wish to change about the test device 2? 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________ 
______________________________________________________________________  
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Appendix VIII INITIAL MAPPING TABLE FOR TRIZ 
PROCEDURE 
 
Determinants for EpiPen 
use 
TRIZ 
contradiction 
parameter 
Decision 1 Decision 2a  Decision 2b  
No. Description No. Description A D I  W Alternative 
1 
Device 
identification 
12 
Shape 
          
2 
Comprehensive 
instruction of use 
33 
Ease of 
operation 
           
3 
Ease of use 
33 
Ease of 
operation 
          
4 
Size of device 
8 
Volume of 
stationary 
object           
5 
Customization for 
target groups 35 
Adaptability 
or versatility 
          
6 
Sufficient needle 
length (for intra-
muscular injection) 
3 
Length of 
moving 
object 
          
7 
Needle protection 
(against accidental 
sticks) 
12 
Shape 
          
8 
Flexibility of dose 
(e.g. for children 
weighting 15-30 kg) 
7 
Volume of 
moving 
object           
9 
Injection time 
25 
Loss of time 
          
10 
Marking of injection 
end 
15 
Duration of 
action by a 
moving 
object           
11 
Patient's fear of 
device 12 
Shape 
          
12 
Adequate training - 
trainer, 
participants, 
frequency, training 
device etc. 
24 
Loss of 
information 
          
13 
Shelf life 
24 
Loss of 
information 
          
14 
Device robustness 
11 
Stress and 
pressure 
     
A= agree; D = disagree; I = improving parameter; W = worsening parameter; alternative = alternative TRIZ 
contradiction parameter 
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Appendix IX INFORMED CONSENT English 
 
 
Dear participant,  
 
I would like to invite you to take part in my research study at the University of Gloucestershire 
on the efficacy of problem-solving tools for the development of medical devices. The 
participation is on a voluntary basis and you will only be included if you provide your permission. 
The purpose of this study is to examine the efficacy of problem-solving tools for the 
development of medical devices. 
 
I would like to invite you to participate at two experiment sessions for the improvement of auto-
injector design. At the beginning of each session, you will be given clear instruction of the 
problem-solving techniques to be used. During the session you will be requested to generate 
ideas in group for the improvement of the example medical devices by using the described 
problem-solving tools. Subsequently, you will be requested to evaluate the behavior of the 
group members during the sessions. 
 
The sessions will be video recorded for later assessment of your group work. I will keep all 
recording and the assessment private and secret in private premises. I will keep data for five 
years after the study has finished. After five years, I will destroy the data. For the assessment of 
the results, no participant will be identifiable by name. 
 
By taking part in this study, you may help to find out the efficacy of problem-solving tools in the 
pharmaceutical industry. There are no known risks associated with taking part in this study. 
 
If you would like to participate in this study, please read and sign the informed consent 
form and return it to me in person or by e-mail to rene.dathe@hotmail.com.  
 
Many thanks 
 
René Dathe 
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Informed consent form 
 
Title of Project: 
Application of problem-solving techniques to medical device 
innovations 
 
Researcher: 
René Dathe, University of Gloucestershire 
 
 Yes No 
Do you understand that I have asked you to participate in a 
research study? 
  
Have you read and received a copy of the attached information 
letter? 
  
Do you understand the benefits and risks involved in taking 
part in this research study? 
  
Do you understand that you are free contact the researcher to 
take the opportunity to ask questions and discuss this study? 
  
Do you understand that you free to refuse participation, or to 
withdraw from the study at any time, without consequence, and 
that your information will be withdrawn at your request? 
  
Do you understand that I will keep your data confidential?   
Do you understand who will have access to your information?    
 
I wish to take part in this study.  
Printed Name:    ___________________________________________  
Signature:    ___________________________________________  
Date:     ___________________________________________  
Preferred Contact number:  ___________________________________________  
Email:    ___________________________________________ 
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Appendix X INFORMED CONSENT German 
 
 
Liebe Teilnehmerinnen, 
Liebe Teihnehmer, 
 
Ich möchte euch zur Teilnahme an die Studie für mein Forschungsstudium an der University of 
Gloucestershire über die Auswirkung der Problemlösungstools in der Entwicklung der medical 
devices. Die Teilnahme ist freiwillig und setzt voraus, dass ihr die Zustimmung für eure 
Teilnahme ausdrücklich erteilt habt. Das Ziel dieser Studie ist es, die Auswirkung der 
Problemlösungstools für die Entwicklung der medical devices festzustellen. 
 
Ich möchte dich zu zwei Experimenten für die Verbesserung des Autoinjektor-Designs einladen. 
Am Anfang jedes Experiments wirst du klare Anweisungen für die anzuwendenden 
Problemlösungstechniken erhalten. Während des Experiments wirst du aufgefordert, Ideen für 
die Verbesserungen der Beispiel-medical devices mit Hilfe der vorgegebenen 
Problemlösungstechniken in Gruppe zu generieren. Anschließend wirst du aufgefordert, das 
Verhalten anderer Gruppenmitglieder während des Experiments zu bewerten. 
 
Die Experimente werden per Video aufgezeichnet zwecks späterer Auswertung der 
Gruppenarbeit. Ich werde alle Aufzeichnungen bzw. Auswertungen in meinen 
Privaträumlichkeiten vertraulich aufbewahren. Alle Daten werden für fünf Jahre nach dem 
Studienabschluss aufbewahrt. Alle Daten werden nach dieser Aufbewahrungsfrist vernichtet. 
Für die Auswertungen werden die Namen der Teilnehmer nicht erwähnt. 
 
Deine Teilnahme an diese Studie wird dazu beitragen, die Auswirkung der 
Problemlösungstechniken für die Pharmaindustrie festzustellen. Es gibt keine bekannten 
Risiken, die mit der Teilnahme verbunden sind. 
 
Falls du an die Teilnahme der Experimente interessiert bist, bitte lese das beigefügte 
Formular für informierte Zustimmung durch und diese unterschrieben an mich 
persönlich übergeben bzw. an meine e-Mail Adresse verwenden 
(rene.dathe@hotmail.com).  
 
Besten Dank! 
 
René Dathe 
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Formular für informierte Zustimmung 
 
Projektthema: 
Anwendung der Problemlösungstechniken für die Entwicklung der 
medical devices  
 
Forscher: 
René Dathe, University of Gloucestershire 
 
 ja nein 
Hast du verstanden, dass ich dich um die Teilnahme an eine 
Forschungsstudie gebeten habe? 
  
Hast du das beigefügte Infoschreiben gelesen bzw. eine Kopie 
davon erhalten? 
  
Hast du die Vorteile sowie die Risiken, die mit der Teilnahme 
an die Studie verbunden sind, verstanden? 
  
Hast du verstanden dass es dir freisteht, den Forscher zu 
kontaktieren, um mit ihm die Fragen zu klären bzw. über die 
Studie zu diskutieren? 
  
Hast du verstanden dass es dir freisteht, die Teilnahme 
abzulehnen bzw. die Zustimmung an die Studie jederzeit 
folgenlos zu widerrufen und auf deinem Wunsch, all deiner 
Daten zurückgezogen werden können? 
  
Hast du verstanden dass ich deine Daten diskret behandeln 
werde? 
  
Hast du verstanden wer Zugang zu deinen Daten erhalten 
wird?  
  
 
Ich möchte gern an diese Studie teilnehmen.  
Name in Druckschrift:  ___________________________________________  
Unterschrift:    ___________________________________________  
Datum:    ___________________________________________  
Bevorzugte Telefonnummer:  ___________________________________________  
Email:    ___________________________________________ 
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Appendix XI THE SYMLOG ADJECTIVE RATING FORM IN 
ENGLISH 
 
Your Name__________________________  Group _______________________________ 
Name of person described______________   Circle the best choice for each item: 
 
 
(0) (1) (2) (3) (4) 
U active, dominant, talks a lot never rarely sometimes often always 
UP Extroverted, outgoing, positive never rarely sometimes often always 
UPF a purposeful democratic task leader never rarely sometimes often always 
UF an assertive business-like manager never rarely sometimes often always 
UNF 
authoritarian, controlling, 
disapproving 
never rarely sometimes often always 
UN domineering, tough-minded, powerful never rarely sometimes often always 
UNB provocative, egocentric, shows off never rarely sometimes often always 
UB jokes around, expressive, dramatic never rarely sometimes often always 
UPB entertaining, sociable, smiling, warm never rarely sometimes often always 
P friendly, equalitarian never rarely sometimes often always 
PF works cooperatively with others never rarely sometimes often always 
F 
analytical, task-oriented, problem-
solving 
never rarely sometimes often always 
NF legalistic, has to be right never rarely sometimes often always 
N unfriendly, negativistic never rarely sometimes often always 
NB irritable, cynical, won't cooperate never rarely sometimes often always 
B shows feelings and emotions never rarely sometimes often always 
PB affectionate, likable, fun to be with never rarely sometimes often always 
DP 
looks up to others, appreciative, 
trustful 
never rarely sometimes often always 
DPF gentle, willing to accept responsibility never rarely sometimes often always 
DF obedient, works submissively never rarely sometimes often always 
DNF self-punishing, works too hard never rarely sometimes often always 
DN depressed, sad, resentful never rarely sometimes often always 
DNB alienated, quits, withdraws never rarely sometimes often always 
DB afraid to try, doubts own ability never rarely sometimes often always 
DPB quietly happy just to be with others never rarely sometimes often always 
D passive, introverted, says little never rarely sometimes often always 
 
(Bales & Cohen, 1979, p. 393)  
 244 
Appendix XII THE SYMLOG ADJECTIVE RATING FORM IN 
GERMAN 
Name______________________________  Gruppe _______________________________ 
Name der beschriebenen Person________________________________________________   
Machen Sie bei jeder Position einen Kreis um die bestzutreffende Antwort: 
 
 
(0) (1) (2) (3) (4) 
U aktiv, dominant, spricht viel nie selten manchmal häufig immer 
UP 
extravertiert, geht aus sich heraus, 
positiv nie selten manchmal häufig immer 
UPF 
ein zielorientierter, demokratischer 
Leiter in der Aufgabenlösung nie selten manchmal häufig immer 
UF 
ein durchsetzungsfreudiger, 
geschäftsorientierter Manager nie selten manchmal häufig immer 
UNF autoritär, kontrollierend, ablehnend nie selten manchmal häufig immer 
UN dominant, hartnäckig, stark nie selten manchmal häufig immer 
UNB provozierend, eigensinnig, protzend nie selten manchmal häufig immer 
UB witzelt, ausdrucksstark, dramatisch nie selten manchmal häufig immer 
UPB 
unterhaltsam, kontaktfreudig, 
lächelnd, warm nie selten manchmal häufig immer 
P freundlich, partnerschaftlich nie selten manchmal häufig immer 
PF 
kooperativ in der Zusammenarbeit mit 
anderen nie selten manchmal häufig immer 
F 
analytisch, aufgaben- bzw. 
lösungsorientiert nie selten manchmal häufig immer 
NF gewissenhaft, rechthaberisch nie selten manchmal häufig immer 
N unfreundlich, negativistisch nie selten manchmal häufig immer 
NB reizbar, zynisch, unkooperativ nie selten manchmal häufig immer 
B zeigt Gefühle und Emotionen nie selten manchmal häufig immer 
PB 
liebevoll, sympathisch, lustig als 
Gesellschaft nie selten manchmal häufig immer 
DP 
heraufschauend, anerkennend, 
vertrauensvoll nie selten manchmal häufig immer 
DPF nett, verantwortungsbewusst nie selten manchmal häufig immer 
DF gehorsam, unterwürfig in der Arbeit nie selten manchmal häufig immer 
DNF selbstbestrafend, arbeitet zu hart nie selten manchmal häufig immer 
DN depressiv, traurig, zurückweisend nie selten manchmal häufig immer 
DNB entfremdet, resigniert, zurückziehend nie selten manchmal häufig immer 
DB 
gehemmt vor dem Versucht, zweifelt 
an eigener Fähigkeit nie selten manchmal häufig immer 
DPB 
in Stille glücklich darüber, mit anderen 
zusammen zu sein nie selten manchmal häufig immer 
D passiv, introvertiert, spricht wenig nie selten manchmal häufig immer 
English original: (Bales & Cohen, 1979, p. 393) 
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Appendix XIII RESULTS OF OUTPUT ASSESSMENT 
 
EXPERT ASSESSMENT 
 
Experiment session 1 
Control group/ test device 1 Expert 1 Expert 2 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification 
1 4 1 4 9 3 3 4 10 
2 4 1 4 9 4 1 4 9 
3 5 0 4 9 4 0 3 7 
4 4 1 4 9 3 0 5 8 
5 3 4 2 9 5 4 2 11 
2 
Comprehensive 
instruction of use 
1 4 2 3 9 3 4 4 11 
2 1 5 1 7 4 4 3 11 
  
1 2 3 2 7 5 5 2 12 
2 3 2 3 8 4 4 3 11 
3 3 3 3 9 5 4 3 12 
4 3 3 2 8 4 2 5 11 
5 2 4 2 8 3 3 2 8 
6 4 2 3 9 4 4 3 11 
7 2 4 2 8 5 4 2 11 
8 3 4 1 8 4 4 2 10 
4 Size of device 1 3 2 2 7 3 2 2 7 
5 
Customization for 
target groups 
1 5 2 1 8 3 4 3 10 
6 Needle length 1 3 4 3 10 3 5 3 11 
7 Needle protection 1 1 4 2 7 4 3 3 10 
8 Flexibility of doses 1 2 3 2 7 5 4 3 12 
9 Injection time 
1 4 3 3 10 5 4 3 12 
1 5 2 3 10 5 3 4 12 
10 
Marking of injection 
end 
1 2 3 2 7 5 4 3 12 
11 
Patient's fear of 
device 
1 2 4 2 8 3 2 2 7 
2 3 3 3 9 5 2 3 10 
3 5 2 1 8 5 3 3 11 
12 Adequate training 
1 3 0 3 6 5 0 4 9 
2 4 1 3 8 5 0 4 9 
3 2 1 1 4 5 0 3 8 
13 Shelf life 
1 4 0 3 7 3 1 4 8 
2 3 2 4 9 5 2 4 11 
3 4 3 3 10 5 4 3 12 
14 Device robustness 
1 3 3 1 7 4 3 3 10 
2 4 3 3 10 5 4 3 12 
Control group/ test device 1 Expert 3 Average experts 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification 
1 4 1 4 9 3.7 1.7 4.0 9.3 
2 4 0 4 8 4.0 0.7 4.0 8.7 
3 4 0 4 8 4.3 0.0 3.7 8.0 
4 4 1 4 9 3.7 0.7 4.3 8.7 
5 2 1 3 6 3.3 3.0 2.3 8.7 
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2 
Comprehensive 
instruction of use 
1 3 1 3 7 3.3 2.3 3.3 9.0 
2 1 3 3 7 2.0 4.0 2.3 8.3 
3 Ease of use 
1 1 3 1 5 2.7 3.7 1.7 8.0 
2 1 2 1 4 2.7 2.7 2.3 7.7 
3 0 4 0 4 2.7 3.7 2.0 8.3 
4 2 2 2 6 3.0 2.3 3.0 8.3 
5 1 2 1 4 2.0 3.0 1.7 6.7 
6 2 2 2 6 3.3 2.7 2.7 8.7 
7 1 3 1 5 2.7 3.7 1.7 8.0 
8 1 3 1 5 2.7 3.7 1.3 7.7 
4 Size of device 1 2 2 1 5 2.7 2.0 1.7 6.3 
5 
Customization for 
target groups 
1 1 2 2 5 3.0 2.7 2.0 7.7 
6 Needle length 1 1 2 1 4 2.3 3.7 2.3 8.3 
7 Needle protection 1 1 2 1 4 2.0 3.0 2.0 7.0 
8 Flexibility of doses 1 2 3 1 6 3.0 3.3 2.0 8.3 
9 Injection time 
1 2 1 2 5 3.7 2.7 2.7 9.0 
1 3 1 3 7 4.3 2.0 3.3 9.7 
10 
Marking of injection 
end 
1 3 2 2 7 3.3 3.0 2.3 8.7 
11 
Patient's fear of 
device 
1 2 2 1 5 2.3 2.7 1.7 6.7 
2 2 1 2 5 3.3 2.0 2.7 8.0 
3 3 1 2 6 4.3 2.0 2.0 8.3 
12 Adequate training 
1 4 0 4 8 4.0 0.0 3.7 7.7 
2 4 0 4 8 4.3 0.3 3.7 8.3 
3 4 1 4 9 3.7 0.7 2.7 7.0 
13 Shelf life 
1 1 3 1 5 2.7 1.3 2.7 6.7 
2 1 3 1 5 3.0 2.3 3.0 8.3 
3 2 1 1 4 3.7 2.7 2.3 8.7 
14 Device robustness 
1 2 2 2 6 3.0 2.7 2.0 7.7 
2 2 1 2 5 3.7 2.7 2.7 9.0 
 
Experiment session 2 
Test group/test device 1 Expert 1 Expert 2 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification 
1 3 4 2 9 4 5 3 12 
2 3 4 2 9 4 5 3 12 
3 2 5 2 9 4 5 3 12 
4 3 3 4 10 5 5 2 12 
2 
Comprehensive 
instruction of use 
1 3 4 2 9 4 5 3 12 
2 3 4 2 9 4 5 3 12 
3 2 5 2 9 4 5 3 12 
4 3 3 4 10 5 5 2 12 
3 Ease of use 
1 2 5 2 9 4 5 4 13 
2 2 3 1 6 1 5 2 8 
3 3 3 1 7 3 4 3 10 
4 3 4 2 9 3 5 2 10 
5 1 2 1 4 3 2 3 8 
6 3 5 2 10 4 4 3 11 
7 4 3 3 10 4 3 3 10 
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8 5 3 3 11 4 5 3 12 
9 2 4 3 9 4 4 4 12 
10 3 3 2 8 4 4 3 11 
11 4 4 2 10 5 4 4 13 
12 1 5 1 7 4 4 3 11 
4 Size of device 
1 2 5 2 9 4 5 4 13 
2 2 3 1 6 1 5 2 8 
3 3 3 1 7 3 4 3 10 
4 1 2 1 4 3 2 3 8 
5 3 5 2 10 4 4 3 11 
5 
Customisation for 
target groups 
1 1 3 1 5 0 4 1 5 
2 4 4 2 10 5 4 4 13 
3 3 4 3 10 5 4 2 11 
4 4 3 2 9 4 3 3 10 
6 Needle length 
1 2 3 1 6 1 5 2 8 
2 1 5 1 7 4 4 3 11 
7 Needle protection 1 2 3 1 6 1 5 2 8 
8 Flexibility of doses 
1 2 3 1 6 1 5 2 8 
2 3 3 1 7 3 4 3 10 
3 3 4 3 10 5 4 2 11 
9 Injection time 
1 2 3 1 6 1 5 2 8 
2 3 3 1 7 3 4 3 10 
3 1 2 1 4 3 2 3 8 
10 
Marking of injection 
end 
1 2 3 1 6 1 5 2 8 
2 3 2 3 8 5 4 2 11 
3 4 2 4 10 5 3 3 11 
11 
Patient’s fear of 
device 
1 2 5 2 9 4 5 4 13 
2 2 3 1 6 1 5 2 8 
3 3 4 2 9 3 5 2 10 
4 2 4 1 7 3 2 3 8 
5 5 3 3 11 4 5 3 12 
6 3 3 2 8 4 4 3 11 
7 4 4 2 10 5 4 4 13 
8 4 3 2 9 4 3 3 10 
12 Adequate training                    
13 Shelf life 
1 2 3 1 6 1 5 2 8 
2 3 3 1 7 3 4 3 10 
3 2 4 3 9 4 4 4 12 
4 2 5 2 9 2 5 2 9 
14 Device robustness 
1 2 3 1 6 1 5 2 8 
2 3 3 1 7 3 4 3 10 
3 4 2 4 10 4 3 3 10 
4 4 3 3 10 4 3 3 10 
5 5 1 4 10 4 4 3 11 
6 4 3 2 9 4 3 3 10 
7 3 3 2 8 3 3 3 9 
8 4 3 2 9 4 3 3 10 
9 5 2 3 10 5 4 3 12 
Test group/test device 1 Expert 3 Average experts 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification 
1 3 1 2 6 3.3 3.3 2.3 8.9 
2 3 1 2 6 3.3 3.3 2.3 8.9 
3 3 2 2 7 3.0 4.0 2.3 9.3 
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4 2 1 3 6 3.3 3.0 3.0 9.3 
2 
Comprehensive 
instruction of use 
1 3 1 2 6 3.3 3.3 2.3 8.9 
2 3 1 2 6 3.3 3.3 2.3 8.9 
3 3 2 2 7 3.0 4.0 2.3 9.3 
4 2 1 3 6 3.3 3.0 3.0 9.3 
3 Ease of use 
1 1 3 1 5 2.3 4.3 2.3 8.9 
2 1 2 1 4 1.3 3.3 1.3 5.9 
3 2 2 2 6 2.7 3.0 2.0 7.7 
4 1 3 1 5 2.3 4.0 1.7 8.0 
5 2 2 2 6 2.0 2.0 2.0 6.0 
6 1 4 1 6 2.7 4.3 2.0 9.0 
7 4 1 4 9 4.0 2.3 3.3 9.6 
8 2 2 3 7 3.7 3.3 3.0 10.0 
9 2 1 3 6 2.7 3.0 3.3 9.0 
10 1 3 1 5 2.7 3.3 2.0 8.0 
11 1 2 1 4 3.3 3.3 2.3 8.9 
12 1 4 2 7 2.0 4.3 2.0 8.3 
4 Size of device 
1 1 3 1 5 2.3 4.3 2.3 8.9 
2 1 2 1 4 1.3 3.3 1.3 5.9 
3 2 2 2 6 2.7 3.0 2.0 7.7 
4 2 2 2 6 2.0 2.0 2.0 6.0 
5 1 4 1 6 2.7 4.3 2.0 9.0 
5 
Customisation for 
target groups 
1 2 2 2 6 1.0 3.0 1.3 5.3 
2 1 2 1 4 3.3 3.3 2.3 8.9 
3 1 4 1 6 3.0 4.0 2.0 9.0 
4 2 1 3 6 3.3 2.3 2.7 8.3 
6 Needle length 
1 1 2 1 4 1.3 3.3 1.3 5.9 
2 1 4 2 7 2.0 4.3 2.0 8.3 
7 Needle protection 1 1 2 1 4 1.3 3.3 1.3 5.9 
8 Flexibility of doses 
1 1 2 1 4 1.3 3.3 1.3 5.9 
2 2 2 2 6 2.7 3.0 2.0 7.7 
3 1 4 1 6 3.0 4.0 2.0 9.0 
9 Injection time 
1 1 2 1 4 1.3 3.3 1.3 5.9 
2 2 2 2 6 2.7 3.0 2.0 7.7 
3 2 2 2 6 2.0 2.0 2.0 6.0 
10 
Marking of injection 
end 
1 1 2 1 4 1.3 3.3 1.3 5.9 
2 3 2 2 7 3.7 2.7 2.3 8.7 
3 4 2 3 9 4.3 2.3 3.3 9.9 
11 
Patient’s fear of 
device 
1 1 3 1 5 2.3 4.3 2.3 8.9 
2 1 2 1 4 1.3 3.3 1.3 5.9 
3 1 3 1 5 2.3 4.0 1.7 8.0 
4 2 2 2 6 2.3 2.7 2.0 7.0 
5 2 2 3 7 3.7 3.3 3.0 10.0 
6 1 3 1 5 2.7 3.3 2.0 8.0 
7 1 2 1 4 3.3 3.3 2.3 8.9 
8 2 1 3 6 3.3 2.3 2.7 8.3 
12 Adequate training                    
13 Shelf life 
1 1 2 1 4 1.3 3.3 1.3 5.9 
2 2 2 2 6 2.7 3.0 2.0 7.7 
3 2 1 3 6 2.7 3.0 3.3 9.0 
4 1 3 1 5 1.7 4.3 1.7 7.7 
14 Device robustness 
1 1 2 1 4 1.3 3.3 1.3 5.9 
2 2 2 2 6 2.7 3.0 2.0 7.7 
3 3 2 2 7 3.7 2.3 3.0 9.0 
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4 4 1 4 9 4.0 2.3 3.3 9.6 
5 4 1 4 9 4.3 2.0 3.7 10.0 
6 3 1 3 7 3.7 2.3 2.7 8.7 
7 1 2 1 4 2.3 2.7 2.0 7.0 
8 2 1 3 6 3.3 2.3 2.7 8.3 
9 4 1 4 9 4.7 2.3 3.3 10.3 
 
Experiment session 3 
Control group/ test device 2 Expert 1 Expert 2 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification  
1 3 2 3 8 3 3 4 10 
2 5 1 4 10 4 4 3 11 
3 4 3 4 11 4 3 3 10 
4 3 3 3 9 4 4 3 11 
2 
Comprehensive 
instruction of use 
1 4 4 3 11 4 3 3 10 
2 3 5 2 10 3 3 2 8 
3 4 2 4 10 5 3 3 11 
4 4 2 3 9 5 4 3 12 
3 Ease of use 
1 3 3 4 10 3 4 4 11 
2 2 3 3 8 4 4 3 11 
4 Size of device 
1 3 2 4 9 5 4 3 12 
2 3 3 4 10 3 4 4 11 
5 
Customization for 
target groups 
1 4 2 1 7 4 3 3 10 
2 2 3 2 7 4 3 3 10 
3 4 3 3 10 4 3 3 10 
4 4 4 3 11 4 3 3 10 
5 3 3 3 9 4 3 3 10 
6 3 3 3 9 4 3 3 10 
7 1 5 2 8 3 4 3 10 
6 Needle length  1 1 5 2 8 3 4 3 10 
7 Needle protection 
1 4 1 3 8 4 3 3 10 
2 2 3 2 7 4 3 3 10 
3 2 5 1 8 4 4 4 12 
8 Flexibility of doses 1 3 3 2 8 4 4 3 11 
9 Injection time 
1 4 3 2 9 4 4 3 11 
2 3 3 3 9 5 3 3 11 
3 2 4 1 7 5 4 3 12 
10 
Marking of injection 
end 
1 4 2 3 9 4 3 3 10 
2 4 3 3 10 3 3 4 10 
11 
Patient's fear of 
device 
1 4 1 3 8 4 3 3 10 
2 2 3 2 7 4 3 3 10 
3 2 5 1 8 4 4 4 12 
4 4 3 3 10 5 0 4 9 
5 4 4 2 10 5 0 3 8 
6 3 3 3 9 5 0 4 9 
7 4 3 2 9 5 4 2 11 
8 4 3 1 8 1 4 1 6 
12 Adequate training  
1 4 3 3 10 5 0 4 9 
2 4 4 2 10 5 0 3 8 
3 3 3 3 9 5 0 3 8 
4 4 3 2 9 5 1 2 8 
5 4 3 1 8 1 4 1 6 
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13 Shelf life 
1 3 3 2 8 3 3 3 9 
2 4 1 4 9 4 3 4 11 
14 Device robustness                   
Control group/ test device 2 Expert 3 Average experts 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification  
1 4 1 3 8 3.3 2.0 3.3 8.6 
2 4 1 4 9 4.3 2.0 3.7 10.0 
3 2 1 2 5 3.3 2.3 3.0 8.6 
4 2 1 2 5 3.0 2.7 2.7 8.4 
2 
Comprehensive 
instruction of use 
1 3 1 2 6 3.7 2.7 2.7 9.1 
2 3 1 2 6 3.0 3.0 2.0 8.0 
3 3 1 4 8 4.0 2.0 3.7 9.7 
4 4 0 4 8 4.3 2.0 3.3 9.6 
3 Ease of use 
1 4 1 3 8 3.3 2.7 3.7 9.7 
2 1 3 2 6 2.3 3.3 2.7 8.3 
4 Size of device 
1 3 2 2 7 3.7 2.7 3.0 9.4 
2 4 1 3 8 3.3 2.7 3.7 9.7 
5 
Customization for 
target groups 
1 3 1 2 6 3.7 2.0 2.0 7.7 
2 2 2 2 6 2.7 2.7 2.3 7.7 
3 4 1 4 9 4.0 2.3 3.3 9.6 
4 4 1 4 9 4.0 2.7 3.3 10.0 
5 1 2 2 5 2.7 2.7 2.7 8.1 
6 2 2 2 6 3.0 2.7 2.7 8.4 
7 2 4 2 8 2.0 4.3 2.3 8.6 
6 Needle length  1 2 4 2 8 2.0 4.3 2.3 8.6 
7 Needle protection 
1 3 2 3 8 3.7 2.0 3.0 8.7 
2 2 3 1 6 2.7 3.0 2.0 7.7 
3 1 4 1 6 2.3 4.3 2.0 8.6 
8 Flexibility of doses 1 1 3 1 5 2.7 3.3 2.0 8.0 
9 Injection time 
1 2 2 1 5 3.3 3.0 2.0 8.3 
2 2 2 2 6 3.3 2.7 2.7 8.7 
3 2 2 2 6 3.0 3.3 2.0 8.3 
10 
Marking of injection 
end 
1 3 0 3 6 3.7 1.7 3.0 8.4 
2 1 3 2 6 2.7 3.0 3.0 8.7 
11 
Patient's fear of 
device 
1 3 2 3 8 3.7 2.0 3.0 8.7 
2 2 3 1 6 2.7 3.0 2.0 7.7 
3 1 4 1 6 2.3 4.3 2.0 8.6 
4 4 1 4 9 4.3 1.3 3.7 9.3 
5 4 1 4 9 4.3 1.7 3.0 9.0 
6 4 1 4 9 4.0 1.3 3.7 9.0 
7 4 1 4 9 4.3 2.7 2.7 9.7 
8 4 1 3 8 3.0 2.7 1.7 7.4 
12 Adequate training  
1 4 1 4 9 4.3 1.3 3.7 9.3 
2 4 1 4 9 4.3 1.7 3.0 9.0 
3 4 1 4 9 4.0 1.3 3.3 8.6 
4 4 1 4 9 4.3 1.7 2.7 8.7 
5 4 1 3 8 3.0 2.7 1.7 7.4 
13 Shelf life 
1 1 3 2 6 2.3 3.0 2.3 7.6 
2 4 1 5 10 4.0 1.7 4.3 10.0 
14 Device robustness                   
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Test group/test device 2 Expert 1 Expert 2 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification 1 4 3 3 10 5 3 4 12 
2 
Comprehensive 
instruction of use 
                  
    1 2 3 2 7 3 4 2 9 
    2 3 4 3 10 2 4 2 8 
3 Ease of use 
3 4 3 3 10 5 3 4 12 
4 2 5 1 8 2 4 1 7 
5 1 5 1 7 1 5 1 7 
6 4 3 3 10 3 4 2 9 
7 3 3 2 8 4 4 3 11 
8 1 3 2 6 5 3 4 12 
9 3 4 2 9 4 4 3 11 
10 3 3 2 8 4 4 2 10 
4 Size of device 
1 2 3 2 7 3 4 2 9 
2 1 3 2 6 5 3 4 12 
3 3 4 2 9 4 4 3 11 
4 3 3 2 8 4 4 2 10 
5 
Customisation for 
target groups 
1 3 4 3 10 2 4 2 8 
6 Needle length  
1 2 5 1 8 2 4 1 7 
2 3 3 2 8 4 4 3 11 
3 1 3 2 6 5 3 4 12 
7 Needle protection 
1 2 5 1 8 2 4 1 7 
2 1 3 2 6 5 3 4 12 
8 Flexibility of dose 
1 2 5 1 8 2 4 1 7 
2 2 4 3 9 4 4 3 11 
9 Injection time 
1 2 5 1 8 2 4 1 7 
2 1 3 2 6 5 3 4 12 
10 
Marking of injection 
end 
1 2 5 1 8 2 4 1 7 
2 1 3 2 6 5 3 4 12 
11 
Patient's fear of 
device 
1 4 3 3 10 3 4 2 9 
2 2 5 1 8 2 4 1 7 
3 1 3 1 5 1 5 1 7 
4 2 4 2 8 3 4 2 9 
5 1 3 2 6 5 3 4 12 
6 3 4 2 9 4 4 3 11 
12 Adequate training                    
13 Shelf life 
1 2 4 1 7 3 4 2 9 
2 3 3 2 8 5 3 4 12 
3 3 4 3 10 2 4 2 8 
4 2 5 1 8 2 4 1 7 
5 1 5 3 9 1 5 1 7 
6 3 3 1 7 4 3 4 11 
7 3 3 2 8 4 3 4 11 
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8 4 3 3 10 3 4 2 9 
9 3 3 2 8 4 4 3 11 
14 Device robustness 1 3 4 3 10 2 4 2 8 
Test group/test device 2 Expert 3 Average experts 
No. Device features Solution Feasibility Novelty Costs sum Feasibility Novelty Costs sum 
1 Device identification 1 4 1 3 8 4.3 2.3 3.3 9.9 
2 
Comprehensive 
instruction of use 
                  
    1 1 3 1 5 2.0 3.3 1.7 7.0 
    2 2 2 2 6 2.3 3.3 2.3 7.9 
3 Ease of use 
3 2 2 2 6 3.7 2.7 3.0 9.4 
4 1 3 1 5 1.7 4.0 1.0 6.7 
5 1 3 1 5 1.0 4.3 1.0 6.3 
6 1 3 2 6 2.7 3.3 2.3 8.3 
7 0 4 0 4 2.3 3.7 1.7 7.7 
8 1 3 2 6 2.3 3.0 2.7 8.0 
9 1 3 2 6 2.7 3.7 2.3 8.7 
10 1 3 2 6 2.7 3.3 2.0 8.0 
4 Size of device 
1 1 3 1 5 2.0 3.3 1.7 7.0 
2 1 3 2 6 2.3 3.0 2.7 8.0 
3 1 3 2 6 2.7 3.7 2.3 8.7 
4 1 3 2 6 2.7 3.3 2.0 8.0 
5 
Customisation for 
target groups 
1 2 2 2 6 2.3 3.3 2.3 7.9 
6 Needle length  
1 1 3 1 5 1.7 4.0 1.0 6.7 
2 0 4 0 4 2.3 3.7 1.7 7.7 
3 1 3 2 6 2.3 3.0 2.7 8.0 
7 Needle protection 
1 1 3 1 5 1.7 4.0 1.0 6.7 
2 1 3 2 6 2.3 3.0 2.7 8.0 
8 Flexibility of dose 
1 1 3 1 5 1.7 4.0 1.0 6.7 
2 2 2 2 6 2.7 3.3 2.7 8.7 
9 Injection time 
1 1 3 1 5 1.7 4.0 1.0 6.7 
2 1 3 2 6 2.3 3.0 2.7 8.0 
10 
Marking of injection 
end 
1 1 3 1 5 1.7 4.0 1.0 6.7 
2 1 3 2 6 2.3 3.0 2.7 8.0 
11 
Patient's fear of 
device 
1 1 3 1 5 2.7 3.3 2.0 8.0 
2 1 3 1 5 1.7 4.0 1.0 6.7 
3 1 3 1 5 1.0 3.7 1.0 5.7 
4 1 3 1 5 2.0 3.7 1.7 7.4 
5 1 3 2 6 2.3 3.0 2.7 8.0 
6 1 3 2 6 2.7 3.7 2.3 8.7 
12 Adequate training                    
13 Shelf life 
1 1 3 2 6 2.0 3.7 1.7 7.4 
2 1 3 2 6 3.0 3.0 2.7 8.7 
3 2 2 2 6 2.3 3.3 2.3 7.9 
4 1 3 1 5 1.7 4.0 1.0 6.7 
5 1 3 1 5 1.0 4.3 1.7 7.0 
6 1 3 2 6 2.7 3.0 2.3 8.0 
7 2 3 2 7 3.0 3.0 2.7 8.7 
8 1 3 2 6 2.7 3.3 2.3 8.3 
9 0 4 0 4 2.3 3.7 1.7 7.7 
14 Device robustness 1 2 2 2 6 2.3 3.3 2.3 7.9 
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PATIENT ASSESSMENT 
 
Experiment session 1 
Control group/ test device 1 Patient 1 Patient 2 Patient 3 
Average 
patients 
No. Device features Solution 
Patient 
perception 
Patient 
perception 
Patient 
perception 
Patient 
perception 
1 Device identification  
1 4 5 3 4.0 
2 5 5 4 4.7 
3 3 3 1 2.3 
4 4 4 0 2.7 
5 4 1 5 3.3 
2 
Comprehensive 
instruction of use 
1 5 5 3 4.3 
2 5 5 0 3.3 
3 Ease of use 
1 4 4 0 2.7 
2 3 0 0 1.0 
3 4 4 0 2.7 
4 4 1 4 3.0 
5 4 1 1 2.0 
6 4 4 2 3.3 
7 4 3 3 3.3 
8 4 4 0 2.7 
4 Size of device 1 1 2 5 2.7 
5 
Customization for target 
groups 
1 5 5 3 4.3 
6 Needle length  1 2 3 1 2.0 
7 Needle protection 1 4 3 3 3.3 
8 Flexibility of doses 1 4 4 4 4.0 
9 Injection time 
1 5 5 2 4.0 
1 4 4 4 4.0 
10 Marking of injection end 1 5 5 4 4.7 
11 Patient's fear of device 
1 4 1 1 2.0 
2 5 4 4 4.3 
3 5 5 3 4.3 
12 Adequate training  
1 5 3 4 4.0 
2 5 2 4 3.7 
3 4 1 5 3.3 
13 Shelf life 
1 5 1 0 2.0 
2 4 1 3 2.7 
3 5 5 1 3.7 
14 Device robustness 
1 4 3 3 3.3 
2 5 5 1 3.7 
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Experiment session 2 
Test group/test device 1 Patient 1 Patient 2 Patient 3 
Average 
patients 
No. Device features Solution 
Patient 
perception 
Patient 
perception 
Patient 
perception 
Patient 
perception 
1 Device identification 
1 5 0 0 1.7 
2 5 0 0 1.7 
3 4 1 0 1.7 
4 5 1 4 3.3 
2 
Comprehensive 
instruction of use 
1 5 0 0 1.7 
2 5 0 0 1.7 
3 4 1 0 1.7 
4 5 1 4 3.3 
3 Ease of use 
1 3 3 4 3.3 
2 1 1 5 2.3 
3 4 4 5 4.3 
4 4 2 4 3.3 
5 4 5 3 4.0 
6 3 1 2 2.0 
7 4 4 2 3.3 
8 5 4 1 3.3 
9 5 5 0 3.3 
10 3 2 0 1.7 
11 5 5 3 4.3 
12 5 4 0 3.0 
4 Size of device 
1 3 3 4 3.3 
2 1 1 5 2.3 
3 4 4 5 4.3 
4 4 5 3 4.0 
5 3 1 2 2.0 
5 
Customisation for target 
groups 
1 4 5 1 3.3 
2 5 5 3 4.3 
3 5 5 1 3.7 
4 5 5 0 3.3 
6 Needle length 
1 1 1 5 2.3 
2 5 4 0 3.0 
7 Needle protection 1 1 1 5 2.3 
8 Flexibility of doses 
1 1 1 5 2.3 
2 4 4 5 4.3 
3 5 5 1 3.7 
9 Injection time 
1 1 1 5 2.3 
2 4 4 5 4.3 
3 4 5 3 4.0 
10 Marking of injection end 
1 1 1 5 2.3 
2 4 5 3 4.0 
3 4 4 4 4.0 
11 Patient’s fear of device 
1 3 3 4 3.3 
2 1 1 5 2.3 
3 4 2 2 2.7 
4 3 5 1 3.0 
5 5 4 1 3.3 
6 3 2 0 1.7 
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7 5 5 3 4.3 
8 5 5 0 3.3 
12 Adequate training            
13 Shelf life 
1 1 1 5 2.3 
2 4 4 5 4.3 
3 5 5 0 3.3 
4 5 3 1 3.0 
14 Device robustness 
1 1 1 5 2.3 
2 4 4 5 4.3 
3 4 4 3 3.7 
4 4 4 2 3.3 
5 4 4 4 4.0 
6 4 2 3 3.0 
7 2 1 2 1.7 
8 5 5 0 3.3 
9 4 2 2 2.7 
 
Experiment session 3 
Control group/ test device 2 Patient 1 Patient 2 Patient 3 
Average 
patients 
No. Device features Solution 
Patient 
perception 
Patient 
perception 
Patient 
perception 
Patient 
perception 
1 Device identification  
1 5 5 4 4.7 
2 5 5 3 4.3 
3 5 1 3 3.0 
4 5 5 3 4.3 
2 
Comprehensive 
instruction of use 
1 5 1 0 2.0 
2 5 5 0 3.3 
3 5 1 4 3.3 
4 4 1 5 3.3 
3 Ease of use 
1 4 4 3 3.7 
2 5 2 4 3.7 
4 Size of device 
1 5 3 1 3.0 
2 5 2 3 3.3 
5 
Customization for target 
groups 
1 4 4 1 3.0 
2 4 2 0 2.0 
3 4 4 0 2.7 
4 4 4 0 2.7 
5 4 3 2 3.0 
6 4 3 0 2.3 
7 5 5 4 4.7 
6 Needle length  1 5 5 4 4.7 
7 Needle protection 
1 4 4 2 3.3 
2 4 1 2 2.3 
3 0 0 2 0.7 
8 Flexibility of doses 1 4 3 2 3.0 
9 Injection time 
1 4 1 0 1.7 
2 4 4 2 3.3 
3 4 1 2 2.3 
10 Marking of injection end 
1 4 1 4 3.0 
2 5 5 1 3.7 
11 Patient's fear of device 
1 4 4 1 3.0 
2 4 1 1 2.0 
3 0 0 1 0.3 
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4 4 1 3 2.7 
5 4 4 3 3.7 
6 4 4 3 3.7 
7 4 4 3 3.7 
8 5 5 3 4.3 
12 Adequate training  
1 4 1 3 2.7 
2 4 4 2 3.3 
3 4 4 3 3.7 
4 4 4 3 3.7 
5 5 5 3 4.3 
13 Shelf life 
1 4 2 1 2.3 
2 5 5 3 4.3 
14 Device robustness           
 
Experiment session 4 
Test group/test device 2 Patient 1 Patient 2 Patient 3 
Average 
patients 
No. Device features Solution 
Patient 
perception 
Patient 
perception 
Patient 
perception 
Patient 
perception 
1 Device identification 1 4 4 4 4.0 
2 
Comprehensive 
instruction of use 
          
    1 2 1 1 1.3 
    2 4 4 2 3.3 
3 Ease of use 
3 3 3 1 2.3 
4 4 1 0 1.7 
5 4 0 0 1.3 
6 4 1 0 1.7 
7 4 4 0 2.7 
8 4 3 3 3.3 
9 4 2 3 3.0 
10 4 1 1 2.0 
4 Size of device 
1 2 1 1 1.3 
2 4 3 3 3.3 
3 4 2 3 3.0 
4 4 1 1 2.0 
5 
Customisation for target 
groups 
1 4 4 2 3.3 
6 Needle length  
1 4 1 0 1.7 
2 4 4 0 2.7 
3 4 3 3 3.3 
7 Needle protection 
1 4 1 0 1.7 
2 4 3 3 3.3 
8 Flexibility of dose 
1 4 1 0 1.7 
2 4 3 1 2.7 
9 Injection time 
1 4 1 0 1.7 
2 4 3 3 3.3 
10 Marking of injection end 
1 4 1 0 1.7 
2 4 3 3 3.3 
11 Patient's fear of device 1 2 1 3 2.0 
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2 4 1 2 2.3 
3 4 0 0 1.3 
4 1 1 0 0.7 
5 4 3 3 3.3 
6 4 2 2 2.7 
12 Adequate training            
13 Shelf life 
1 4 2 0 2.0 
2 4 3 0 2.3 
3 4 4 2 3.3 
4 4 1 0 1.7 
5 4 1 0 1.7 
6 4 1 0 1.7 
7 4 2 0 2.0 
8 4 1 0 1.7 
9 4 4 0 2.7 
14 Device robustness 1 4 4 2 3.3 
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Appendix IX TRIZ TOOLS AND METHODS 
 
 
This section is intended to provide more details on the TRIZ tools and methods used in 
the 5-stage TRIZ procedure in this thesis. 
 
A key concept in the above-mentioned procedure is “contradiction”. A contradiction in 
the innovation process arises when the attempt to improve one system function leads to 
the deterioration of another system function at the same time. The following are some 
examples of such contradictions: 
- A bigger size of the ventilation fan is thought to increase the cooling effect. 
However, with the same electrical capacity, the heavier weight of the bigger 
fan will reduce the rotation force and in turn reduce the cooling benefit (bigger 
fan to increase cooling effect  higher weight that reduces cooling effect); 
- Especially elderly female patients need longer needles to pierce through the 
tights they wear. However, bigger needle size increases the patients fear of the 
device (langer needle for practical application  small needle size to reduce 
patients’ fear);  
- Medical device patients often prefer a small device for easier daily transport. 
At the same time, they also require a number of sophisticated device functions. 
However, sophisticated device funtions tend to take up more space, which sets 
a limit to the desired small size (bigger device size to accommodate 
sophisticated functions  small size for daily transport). 
 
The basic idea of the contradiction matrix is to improve one system function wihout 
having to compromising the other apparently contradicting function. In order to do so, 
Althuller extracted information out of thousands of patents and identified the solutions to 
each pair of contradictions as inventive principles in the39 x 39 contradiction matrix 
(Ilevbare, Probert & Phaal, 2013). 
 
Below is an overview of the 39 x 39 contradiction matrix.  
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
1 
Weight of 
moving 
object 
 - 
15 
8 
29 
34 
- 
29 
2 
40 
28 
- 
29 
2 
40 
28 
- 
2 
8 
15 
38 
8 
10 
18 
37 
10 
36 
37 
40 
10 
14 
35 
40 
1 
35 
19 
39 
28 
27 
18 
40 
5 
34 
31 
35 
- 
6 
29 
4 
38 
19 
1 
32 
35 
12 
34 
31 
- 
12 
36 
18 
31 
6 
2 
34 
19 
5 
35 
20 
28 
10 
24 
35 
10 
35 
20 
28 
3 
26 
18 
31 
3 
11 
1 
27 
28 
27 
35 
26 
28 
35 
26 
18 
22 
21 
18 
27 
22 
35 
31 
39 
27 
28 
1 
36 
35 
3 
2 
24 
2 
27 
28 
11 
29 
5 
15 
8 
26 
30 
36 
34 
28 
29 
26 
32 
26 
35 
18 
19 
35 
3 
24 
37 
2 
Weight of 
stationary 
object 
-  - 
10 
1 
29 
35 
- 
35 
30 
13 
2 
- 
5 
35 
14 
2 
- 
8 
10 
19 
35  
13 
29 
10 
18 
13 
10 
29 
14 
26 
39 
1 
40 
28 
2 
10 
27 
- 
2 
27 
19 
6 
28 
19 
32 
22 
19 
32 
35 
- 
18 
19 
28 
1 
15 
19 
18 
18 
19 
28 
15 
5 
8 
13 
30 
10 
15 
35 
10 
20 
35 
26 
19 
6 
18 
26 
10 
28 
8 3 
18 
26 
28 
10 
1 
35 
27 
2 
19 
22 
37  
35 
22 
1 
39 
28 
1 9 
6 
13 
1 
32 
2 
27 
18 
11 
19 
15 
29 
1 
10 
26 
39 
25 
28 
17 
15 
2 
26 
35 
1 
28 
15 
35 
3 
Length of 
moving 
object 
8 
15 
29 
34 
-  - 
15 
17 
4 
- 
7 
17 
4 
35 
- 
13 
4 
8 
17 
10 
4 
1 8 
35 
1 
8 
10 
29  
1 
8 
15 
34 
8 
35 
29 
34 
19 - 
10 
15 
19 
32 
8 
35 
24 
- 
1 
35 
7 
2 
35 
39 
4 
29 
23 
10 
1 
24 
 
15 
2 
29 
29 
35 
10 
14 
29 
40 
28 
32 
4 
10 
28 
29 
37 
1 
15 
17 
24 
17 
15 
1 
29 
17  
15 
29 
35 
4 
1 
28 
10 
14 
15 
1 
16 
1 
19 
26 
24 
35 
1 
26 
24 
17 
24 
26 
16 
14 
4 
28 
29 
4 
Length of 
stationary 
object 
- 
35 
28 
40 
29 
-  - 
17 
7 
10 
40 
- 
35 
8 
2 
14 
- 
28 
10 
1 
14 
35 
13 
14 
15 
7 
39 
37 
35 
15 
14 
28 
26 
- 
1 
40 
35 
3 
35 
39 
18 
3 
25 
- - 
12 
8 
6 
28 
10 
28 
24 
35 
24 
26 
30 
29 
14 
- 
15 
29 
28 
32 
28 
3 
2 
32 
10 
1 
18 
- 
15 
17 
27 
2 
25 
3 
1 
35 
1 
26 
26 - 
30 
14 
7 
26 
5 
Area of 
moving 
object 
2 
17 
29 
4 
- 
14 
15 
18 
4 
-  - 
7 
14 
17 
4 
- 
29 
30 
4 
34 
19 
30 
35 
2 
10 
15 
36 
28 
5 
34 
29 
4 
11 
2 
13 
39 
3 
15 
40 
14 
6 
3 
- 
2 
15 
16 
15 
32 
19 
13 
19 
32 
- 
19 
10 
32 
18 
15 
17 
30 
26 
10 
35 
2 
39 
30 
26 
26 
4 
29 
30 
6 
13 
29 
9 
26 
28 
32 
3 
2 
32 
22 
33 
28 
1 
17 
2 
18 
39 
13 
1 
26 
24 
15 
17 
13 
16 
15 
13 
10 
1 
15 
30 
14 
1 
13 
2 
36 
26 
18 
14 
30 
28 
23 
10 
26 
34 
2 
6 
Area of 
stationary 
object 
- 
30 
2 
14 
18 
- 
26 
7 
9 
39 
-  - - - 
1 
18 
35 
36 
10 
15 
36 
37 
- 
2 
38 
40 - 
2 
10 
19 
30 
35 
39 
38 
- - - 
17 
32 
17 
7 
30 
10 
14 
18 
39 
30 
16 
10 
35 
4 
18 
2 
18 
40 
4 
32 
35 
40 
4 
26 
28 
32 
3 
2 
29 
18 
36 
27 
2 
39 
35 
22 
1 
40 
40 
16 
16 
4 
16 
15 
16 
1 
18 
36 
2 
35 
30 
18 
23 
10 
15 
17 
7 
7 
Volume of 
moving 
object 
2 
26 
29 
40 
- 
1 
7 
4 
35 
- 
1 
7 
4 
17 
-  - 
29 
4 
38 
34 
15 
35 
26 
37 
6 
35 
36 
37 
1 
15 
29 
4 
28 
10 
1 
29 
9 
14 
15 
7 
6 
35 
4 
- 
34 
39 
10 
18 
2 
13 
10 
35 - 
35 
6 
13 
18 
7 
15 
13 
16 
36 
39 
34 
10 
2 
22 
2 
6 
34 
10 
29 
30 
7 
14 
1 
40 
11 
26 
28  
25 
28 
2 
16 
22 
21 
27 
35 
17 
2 
40 
1 
29 
1 
40 
15 
13 
30 
12 
10  
15 
29 
26 
1 
29 
26
4 
35 
34 
16 
24 
10 
6 2 
34 
8 
Volume of 
stationary 
object 
- 
35 
10 
19 
14 
19 
14 
35 
8 
2 
14 
- - -  - 
2 
18 
37 
24 
35 
7 
2 
35 
34 
28 
35 
40 
9 
14 
17 
15 
- 
35 
34 
38 
35 
6 
4 
- - - 
30 
6 
- 
10 
39 
35 
34 
- 
35 
16 
32 
18 
35 
3 
2 
35 
16 
- 
35 
10 
25 
34 
39 
19 
30 
18 
35 
4 
35 - 1 - 
1 
31 
2 
17 
26 
- 
35 
37 
10 
2 
9 Speed 
8 
28 
13 
38 
- 
13 
14 
8 
- 
29 
30 
34 
- 
7 
29
9 
34 
-  
13 
28 
15 
19 
6 
18 
38 
40 
35 
15 
18 
34 
28 
33 
1 
18 
8 
3 
26 
14 
3 
19 
35 
5 
- 
28 
30 
36 
2 
10 
13 
19 
8 
15 
35 
38 
- 
19 
35 
38 
2 
14 
20 
19 
35 
10 
13 
28 
38 
13 
26 
- 
10 
19 
29 
38 
11 
35 
27 
28 
28 
32 
1 
24 
10 
28 
32 
25 
1 
28 
35 
23 
2 
24 
35 
21 
35 
13 
8 1 
32 
28 
13 
12 
34 
2 
28 
27 
15 
10 
26 
10 
28 
4 
34 
3 
34 
27 
16 
10 
18 
- 
1
0 
Force 
(Intensity) 
8 
1 
37 
18 
18 
13 
1 
28 
17 
19 
9 
36 
28 
10 
19 
10 
15 
1 
18 
36 
37 
15 
9 
12 
37 
2 
36 
18 
37 
13 
28 
15 
12 
 
18 
21 
11 
10 
35 
40 
34 
35 
10 
14 
27 
35 
10 
14 
27 
19 
2 
- 
35 
10 
21 
- 
19 
17 
10 
1 
16 
36 
37 
19 
35 
18 
37 
14 
15 
8 
35 
40 
5 
- 
10 
37 
36 
14 
29 
18 
36 
3 
35 
13 
21 
35 
10 
23 
24 
28 
29 
37 
36 
1 
35 
40 
18 
13 
3 
36 
24 
15 
37 
18
1 
1 
28 
3 
25 
15 
1 
11 
15 
17 
18 
20 
26 
35 
10 
18 
36 
37 
10 
19 
2 
35 
3 
28 
35 
37 
1
1 
Stress or 
pressure 
10 
36 
37 
40 
13 
29 
10 
18 
35 
10 
36 
35 
1 
14 
16 
10 
15 
36 
28 
10 
15 
36 
37 
6 
35 
10 
35 
24 
6 
35 
36 
36 
35 
21 
 
35 
4 
15 
10 
35 
33 
2 
40 
9 
18 
3 
40 
19 
3 
27 
- 
35 
39 
19 
2 
- 
14 
24 
10 
37 
- 
10 
35 
14 
2 
36 
25 
10 
35 
3 
37 
- 
37 
36 
4 
10 
14 
36 
10 
13 
19 
35 
6 
28 
25 
3 
35 
22 
2 
37 
2 
33 
27 
18 
1 
35 
16  
11 2 35 
19 
1 
35 
2 
36 
37 
35 
24 
 10 
14 
35 
37 
1
2 
Shape 
8 
10 
29 
40 
15 
10 
26 
3 
29 
34 
5 
4 
13 
14 
10 
7 
5 
34 
4 
10 
- 
14 
4 
15 
22 
7 
2 
35 
35 
15 
34 
18 
35 
10 
37 
40 
34 
15 
10 
14 
 
33 
1 
18 
4 
30 
14 
10 
40 
14 
26 
9 
25 
- 
22 
14 
19 
32 
13 
15 
32 
2 
6 
34 
14 
- 
4 
6 
2 
14 
35 
29 
3 
5 
- 
14 
10 
34 
17 
36 
22 
10 
40 
16 
28 
32 
1 
32 
30 
40 
22 
1 
2 
35 
35 
1 
17 
32 
1 
28 
32 
15 
26 
2 
13 
1 
1 
15 
29 
16 
29 
1 
28 
15 
13 
39 
15 
1 
32 
17 
26 
34 
10 
1
3 
Stability of 
the object´s 
composition 
21 
35 
2 
39 
26 
39 
1 
40 
13 
15 
1 
28 
37  
2 
11 
13 
39 
28 
10 
19 
39 
34 
28 
35 
40 
33 
15 
28 
18 
10 
35 
21 
16 
2 
35 
40 
22 
1 
18 
4 
 
17 
9 
15 
13 
27 
10 
35 
39 
3 
35 
23 
35 
1 
32 
32 
3 
27 
15 
13 
19  
27 
4 
29 
18 
32 
35 
27 
31 
14 
2 
39 
6 
2 
14 
30 
40 
- 
35 
27 
15 
32 
35 
- 13 18 
35 
24 
30 
18 
35 
40 
27 
39 
35 
19 
32 
35 
30 
2 
35 
10 
16 
35 
30 
34 
2 
2 
35 
22 
26 
35 
22 
39 
23 
1 
8 
35 
23 
35 
40
3 
 260 
Worsening parameter 
 
 
 
 
Improving parameter 
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L
o
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Q
u
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su
b
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an
ce
 
R
el
ia
b
il
it
y
 
M
ea
su
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m
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A
cc
u
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cy
 
M
u
n
u
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u
ri
n
g
 p
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o
n
  
O
b
je
ct
-a
ff
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d
 h
ar
m
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o
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b
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at
ed
 h
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o
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o
n
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n
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o
f 
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A
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v
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D
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E
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m
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P
ro
d
u
ct
iv
it
y
 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 
1
4 
Strength 
1 
8 
40 
15 
40 
26 
27 
1 
1 
15 
8 
35 
15 
14 
28 
26 
3 
34 
40 
29 
9 
40 
28 
10 
15 
14 
7 
9 
14 
17 
15 
8 
13 
26 
14 
10 
18 
3 
14 
10 
3 
18 
40 
10 
30 
35 
40 
13 
17 
35 
 
27 
3 
26 
- 
30 
10 
40 
35 
19 
19 
35 
10 
35 
10 
26 
35 
28 
35 
35 
28 
31 
40 
- 
29 
3 
28 
10 
29 
10 
27 
11 
3 
3 
27 
16 
3 
27 
18 
35 
37 
1 
15 
35 
22 
2 
11 
3 
10 
32 
32 
40 
28 
2 
27 
11 
3 
15 
3 
32 
2 
13 
28 
27 
3 
15 
40 
15  
29 
35 
10 
14 
1
5 
Duration of 
action by 
moving 
object 
19 
5 
34 
31 
- 
2 
19 
9 
- 
3 
17 
19 
- 
10 
2 
19 
30 
- 
3 
35 
5 
19 
2 
16 
19 
3 
27 
14 
26 
28 
25 
13 
3 
35 
27 
3 
10 
 - 
19 
35 
39 
2 
19 
4 
35 
28 
6 
35 
18 
- 
19 
10 
35 
38 
- 
28 
27 
3 
18 
10 
20 
10 
28 
18 
3 
35 
10 
40 
11 
2 
13 
3 
3 
27 
16 
40 
22 
15 
33 
28 
21 
39 
16 
22 
27 
1  
4 
12 
27 
29 
10 
27 
1 
35 
13 
10 
4 
28 
15 
19 
29 
39 
35 
6 
10 
35 
17 
14 
19 
1
6 
Duration of 
action by 
stationary 
object 
- 
6 
27 
19 
16 
- 
1 
40 
35 
- - - 
35 
34 
38 
- - - - 
39 
35 
3 
23 
- -  
19 
18 
36 
40 
- - - 16 - 
27 
16 
18 
38 
10 
28 
20 
10 
16 
3 
35 
31 
34 
27 
6 
40  
10 
26 
24 
- 
17 
1 
40 
33 
22 
35 
10 
1 1 2 - 
25 
34 
6 
35 
1  
20 
10 
16 
38 
1
7 
Temperature 
36 
22 
6 
38 
22 
35 
32 
15 
19 
9 
15 
19 
3 
3 
35 
39 
18 
35 
38 
34 
39 
40 
18 
35 
6 
4 
2 
28 
36 
30 
35 
10 
3 
21 
35 
39 
19 
2 
14 
22 
19 
32 
1 
35 
32 
10 
30 
22 
40 
19 
13 
39 
19 
18 
36 
40 
 
32 
30 
21 
16 
19 
18 
36 
40 
- 
2 
14 
17 
25 
21 
17 
35 
38 
21 
36 
39 
31 
- 
35 
28 
21 
18 
3 
17 
30 
39 
19 
35 
3 
10 
32 
19 
24 
24 
22 
33 
35 
2 
22 
35
2 
24 
26 
27 
26 
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Use of energy 
by moving 
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12 
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32 
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12 
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18 
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19 
2 
35 
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18 
31 
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23 
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10 
2 
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37 
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16 
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Power 
8 
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38 
31 
19 
26 
17 
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35 
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17 
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13 
38 
35 
6 
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6 
38 
7 
15 
26 
17 
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17 
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Loss of 
substance 
35 
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23 
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10 
23 
2
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Loss of 
information 
10 
24 
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10 
35 
5 
1 
26 
26 
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26 
30 
16 
- 
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22 
26 
32 
- - - - - 10 10 - 19 - - 
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10 
-  
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1 
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23 
15 
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Loss of time 
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20 
37 
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10 
20 
26 
5 
15 
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29 
30 
24 
14 
5 
26 
4 
5 
16 
10 
35 
17 
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34 
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32 
18 
- 
10 
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10 
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17 
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18 
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10 
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32 
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18 
10 
39 
24 
26 
28 
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38 
18 
16 
10 
30 
4 
24 
26 
28 
32 
24 
26 
28 
18 
35 
18 
34 
35 
22 
18 
39 
35 
28 
34 
4 
4 
28 
10 
34 
32 
10 
1 
35 
28 
6 
29 
18 
28 
32 
10 
24 
28 
35 
30 
- 
2
6 
Quantity of 
substance 
35 
6 
18 
31 
27 
26 
18 
35 
29 
35 
14 
18 
- 
15 
14 
19 
2 
18 
40 
4 
15 
20 
29 
- 
35 
29 
34 
28 
35 
14 
3 
10 
36 
14 
3 
35 
14 
15 
2 
17 
40 
14 
35 
34 
10 
3 
35 
34 
10 
3 
35 
31 
3 
17 
39 
- 
34 
29 
16 
18 
3 
35 
31 
35 
7 
18 
25 
6 
3 
10 
24 
24 
28 
35 
35 
38 
18 
16 
 
18 
3 
28 
40 
3 
2 
28 
3 
2 
28 
33 
30 
35 
33 
29 
31 
3 
35 
40 
39 
29 
1 
35 
27 
35 
29 
25 
10 
2 
32 
10 
25 
15 
3 
29 
3 
13 
27 
10 
8 
35 
13 
29 
3 
27 
2
7 
Reliability 
3 
8 
10 
40 
3 
10 
8 
28 
15 
9 
14 
4 
15 
29 
28 
11 
17 
10 
14 
16 
32 
35 
40 
4 
3 
10 
14 
24 
2 
35 
24 
21 
35 
11 
28 
8 
28 
10 
3 
10 
24 
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1 
16 
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11 
28 
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25 
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40 
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10 
11 
32 
13 
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27 
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36 
23 
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26 
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11 
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10 
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29 
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10 
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10 
30 
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28 
40 
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11 
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27 
35 
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40 
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27 
17 
40 
1 
11 
13 
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24 
13 
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1 
27 
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27 
1 
35 
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Worsening parameter 
 
 
 
 
Improving parameter 
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Measurement 
Accuracy 
32 
35 
26 
28 
28 
35 
25 
26 
28 
26 
5 
16 
32 
28 
3 
16 
26 
28 
32 
3 
26 
28 
32 
3 
32 
13 
6 
- 
28 
13 
32 
24 
32 
2 
6 
28 
32 
6 
28 
32 
32 
35 
13 
28 
6 
32 
28 
6 
32 
10 
26 
24 
6 
19 
28 
24 
6 
1 
32 
3 
6 
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- 
3 
6 
32 
26 
32 
27 
10 
16 
31 
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- 
24 
32 
28 
32 
2 
6 
32 
5 
11 
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23 
 - 
28 
24 
22 
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3 
33 
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10 
6 
35 
25 
18 
1 
13 
17 
34 
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32 
13 
11 
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35 
2 
27 
35 
10 
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26 
24 
32 
28 
28 
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10 
34 
10 
34 
28 
32 
2
9 
Munufacturin
g precision 
28 
32 
13 
18 
28 
35 
27 
9 
10 
28 
29 
37 
2 
32 
10 
28 
33 
29 
32 
2 
29 
18 
36 
32 
23 
2 
25 
10 
35 
10 
28 
32 
28 
19 
34 
36 
3 
35 
32 
30 
40 
30 
18 
3 
27 
3 
27 
40 
- 
19 
26 
3 
32 
32 
2 
- 
32 
2 
13 
32 
2 
35 
31 
10 
24 
- 
32 
26 
28 
18 
32 
30 
11 
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1 
-  
26 
28 
10 
36 
4 
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34 
26 
- 
1 
32 
35 
23 
25 
10 
- 
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2 
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26 
28 
18 
23 
10 
18 
32 
39 
3
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harmful 
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22 
21 
27 
39 
2 
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1 
39 
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33 
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39 
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3
1 
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19 
22 
15 
39 
35 
22 
1 
39 
17 
15 
16 
22 
- 
17 
2 
18 
39 
22 
1 
40 
17 
2 
40 
30 
18 
35 
4 
35 
28 
3 
23 
35 
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40 
2 
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Ease of 
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Convenience 
of use 
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7 
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11 
- 
34 
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1 
32 
10 
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Adaptability 
or versatility 
1 
6 
15 
8 
19 
15 
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1 
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2 
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7 
15 
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1 
15 
10 
2 
13 
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15 
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1 
10 
- 
35 
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32 
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- 
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13 
31 
15 
34 
1 
16 
1 
16 
7 
4 
 
15 
29 
37 
28 
1 
27 
34 
35 
35 
28 
6 
37 
3
6 
Device 
complexity 
26 
30 
34 
36 
2 
26 
35 
39 
1 
19 
26 
24 
26 
14 
1 
13 
16 
6 
36 
34 
26 
6 
1 
16 
34 
10 
28 
26 
16 
19 
1 
35 
29 
13 
28 
15 
2 
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17 
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28 
10 
4 
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- 
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2 
28 
29 
- 
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30 
34 
10 
35 
13 
2 
35 
10 
28  
29 
- 
6 
29 
13 
3 
27 
10 
2 
26 
10 
34 
2 
26 
10 
34 
26 
24 
32 
22 
19 
29 
40 
19 
1 
27 
26 
1 
13 
27 
9 
26 
24 
1 
13 
29 
15 
28 
37 
 
15 
10 
37 
28 
15 
1 
24 
12 
17 
28 
3
7 
Difficulty of 
detecting and 
measuring 
27 
26 
28 
13 
6 
13 
28 
1 
16 
17 
26 
24 
26 
2 
13 
18 
17 
2 
39 
30 
16 
29 
1 4 
16 
2 
18 
26 
31 
3 
4 
16 
35 
36 
28 
40 
19 
35 
36 
37 
32 
27 
13 
1 
39 
11 
22 
39 
30 
27 
3 
15 
28 
19 
29 
39 
25 
25 
34 
6 
35 
3 
27 
35 
16 
2 
24 
26 
35 
38 
19 
35 
16 
19 
1 
16 
10 
35 
3 
15 
19 
1 
18 
10 
24 
35 
33 
27 
22 
18 
28 
32 
9 
3 
27 
29 
18 
27 
40 
28 
8 
26 
24 
32 
28 
- 
22 
19 
29 
28 
2 
21 
5 
28 
11 
29 
2 
5 
12 
26 
1 
15 
15 
10 
37 
28 
 
34 
21 
35 
18 
3
8 
Extent of 
automation 
28 
26 
18 
35 
28 
26 
35 
10 
14 
13 
17 
28 
23 
17 
14 
13 
- 
35 
13 
16 
- 
28 
10 
2 
35 
13 
35 
15 
32 
1 
13 
18 
1 
25 
13 
6 
9 
- 
26 
2 
19 
8 
32 
19 
2 
32 
13 
- 
28 
2 
27 
23 
28 
35 
10 
18 
5 
35 
33 
24 
28 
35 
30 
35 
13 
11 
27 
32 
28 
26 
10 
34 
28 
26 
18 
23 
2 
33 
2 
1 
26 
13 
1 
12 
34 
3 
1 
35 
13 
27 
4 
1 
35 
15 
24 
10 
34 
27 
25 
 
5 
12 
35 
26 
3
9 
Productivity 
35 
26 
24 
37 
28 
27 
15 
3 
18 
4 
28 
38 
30 
7 
14 
26 
10 
26 
34 
31 
10 
26 
34 
31 
2  
6 
34 
10 
35 
37 
10 
2 
- 
28 
15 
10 
36 
10 
37 
14 
14 
10  
34 
40 
35 
3 
22 
39 
29 
28 
10 
18 
35 
10 
2 
18 
20 
10 
16 
38 
35 
21 
28 
10 
26 
17 
19 
1 
35 
10 
38 
19 
1 
35 
20 
10 
28 
10 
29 
35 
28 
10 
35 
23 
13 
15 
23 
- 
35 
38 
1 
35 
10 
38 
1 
10 
34 
28 
18 
10 
32 
1 
22 
35 
13 
24 
35 
22 
18 
39 
35 
28 
2 
24 
1 
28 
7 
19 
1 
32 
10 
25 
1 
35 
28 
37 
12 
17 
28 
24 
35 
18 
27 
2 
5 
12 
35 
26 
 
 
(Gadd, 2011, p. 472) 
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Altogether, there are 40 inventive principles which may be looked up in the 39x39 
contradiction matrix as generic solutions to the generic problems described as 
standardised contradictions. The 40 inventive principles are listed in the following table.  
 
1 Segmentation 
2 Talking out 
3 Local quality  
4 Asymmetry 
5 Merging 
6 Universality 
7 Nested doll 
8 Anti-Weight 
9 Prior counteraction 
10 Prior action 
11 Cushion in advance 
12 Equipotentiality 
13 The other way around 
14 Spheroidality – curvature 
15 Dynamics 
16 Partial or excessive action 
17  Another dimension 
18 Mechanical vibration 
19 Periodic action 
20 Continuity of useful action  
21 Rushing through 
22 Blessing in disguise 
23 Feedback 
24 Intermediary 
25  Self-Service 
26 Copying 
27  Cheap short-living objects 
28 Replace mechanical system 
29 Pneumatics and hydraulics 
30 Flexible membranes / thin films 
31 Porous materials 
32 Colour change 
33 Homogeneity 
34 Discarding and recovering 
35 Parameter change 
36 Phase transition 
37 Thermal expansion 
38 Accelerate oxidation 
39 Invert environment 
40 Composite materials 
(E.g. Gadd, 2011, p. 472) 
 
 
In the example of the ventilation fan, the objective of increasing the size without 
increasing the weight of fan may be described in the terminology of the 39x39 
contradiction matrix as “8 volume of stationary object” (improving parameter) and “2 
weight of stationary object” (worsening parameter).  
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By consulting the 39x39 contradictio matrix, the combination of the above parameters 
leads to the inventive principles “5 merging/consolidation”, “35 parameter changes”, “14 
spheroidality curvature” and “2 taking out or extraction”.  
 
a. Inventive principle “5 merging/consolidation” 
This principle stands for merging identical or similar objects or operations, or to produce 
parallel objects or operations. A possible application of this principle is e.g. to increase 
the number of fan blades of the ventilator. 
 
b. Inventive principle “35 parameter changes” 
There are several variations of this inventive principle, including: 
 Change the physical state (e.g. to use cooling air in gas form instead of solid fans). 
 Change the concentration or density (e.g. to decrease the density of the material 
and thus the weight of the fans). 
 Change the degree of flexibility (e.g. to use flexible fan blades out of plastic 
instead of metal). 
 Change the temperature or volume (e.g. to reduce the thickness of the fan blades). 
 Change the pressure (e.g. to produce a vacuum environment to reduce the 
resistance). 
 Change other parameters (e.g. to implement solar cells as additional energy 
source). 
 
c. Inventive principle “14 spheroidality curvature” 
Some example of this principle are, e.g. to implement linear instead of rotary motion of 
the fan blades; to use centrifugal forces in the blade design. 
 
d. Inventive principle “2 taking out or extraction” 
This principle requires that only the necessary parts shall remain in the fan structure (e.g. 
elimination of the decorative housing). 
 
The above explanation of the inventive principle is orientated on Gadd’s interpretation 
(Gadd, 2011, pp. 140-174). 
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In practice, the determination of the improving and worsening parameters, the idea 
generation based on the identified inventive principles, as well as the subsequent 
priorization of the solutions require both experience in the relevant technical fields and 
TRIZ knowledge. This task is often a challenge especially when dealing with complex 
practical problems. 
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Appendix X DRAWINGS OF DESIGN DRAFTS 
 
In some experiments sessions, the paticipants illustrated their innovation ideas in sketches 
of the improved device design. Those drawings are enclosed in the following. 
 
I. TRIZ session - design a 
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II. TRIZ session - design b 
 
 
